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Preface 
Dr Mario Raviglione
At a meeting of stakeholders and donors to the Global TB Programme held in Oslo in 
September 1995, a key discussion point related to the need to monitor progress towards 
global targets set in 1991 by the World Health Assembly. The targets – the popular 70% 
case detection rate and 85% cure rate for new cases of smear-positive pulmonary TB – 
were to be reached by 2000.
At the time of the meeting, no standardized global monitoring system existed. While 
clear definitions of TB cases and treatment outcomes were key components of WHO’s 
then-new global TB strategy – DOTS – the only data available to assess trends in the 
disease came from the epidemiological bulletins of better-of f countries and occasional 
ad-hoc reports from low-income countries following reviews and monitoring missions. 
Since TB is primarily a disease of poor countries, this was not good enough for the 
influential people meeting in Oslo. Their request came loud and clear: WHO should 
start immediately to develop a system that would request all Member States to report 
essential information on TB notifications and treatment outcomes, so that progress – or 
lack of progress – could be monitored and discussed at their next meeting.
Though global targets had been set in 1991, it nevertheless took four years before 
such a system was recognized as a necessity: this was not yet the era of precision, 
accountability, and evidence-based evaluation. Since only a couple of other 
programmes had developed such systems by then, the field of TB was among the 
pioneers in this endeavour.
As a result of the discussions in Oslo, Dr Arata Kochi, then the Director of the Global 
TB Programme, asked me to move quickly to create a global monitoring and evaluation 
system that would satisfy the request.
Exactly 20 years ago, in October 1995, I started setting up a team composed of a 
handful of people charged with globalizing the local recording and reporting system 
recommended within the DOTS strategy. That strategy was based on the model 
programmes that Dr Karel Styblo had developed in several countries where the KNCV 
Tuberculosis Foundation and the Union were implementing modern TB control ef forts.
During several months of intensive work, we created a database and a standard data 
collection form (in paper and electronic formats) that was distributed to all Member 
States. By the summer of 1996, most countries had provided information to WHO 
Headquarters using standardized definitions so that data from one country could 
be compared easily with data from another. For the first time, we could assess global 
progress toward the 2000 targets. The results were presented at the September 1996 
meeting of donors and other stakeholders. They showed that fewer than 20% of all 
cases estimated worldwide were being detected and that the global cure rate was less 
than 80%.
In the following years, our global monitoring and evaluation system for TB evolved 
further, with the inclusion of additional information and more sophisticated analyses. 
For example, our team – led first by Dr Christopher Dye and later by Dr Katherine Floyd 
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– began to monitor the financing of TB control to assess whether Member States were 
investing as required. Later, we integrated data from the drug resistance surveillance 
system to enable us to assess comprehensively all the key indicators needed to monitor 
progress and to identify and correct problems. Our team, under the guidance of Dr 
Philippe Glaziou, developed more precise estimates of the burden of TB, improving 
the methodology to measure incidence, prevalence and mortality. In particular, since 
2006, concerted ef forts have been guided by the WHO Global Task Force on TB Impact 
Measurement, resulting in substantially increased data from national TB prevalence 
surveys and much greater use of mortality data from vital registration systems.
As a result of these ef forts, 20 years later, we are able to judge fairly precisely the 
status of the epidemic and the response of Member States. We can assess where people 
with TB are missing from notification systems; where cure rates remain low and failure 
rates are high; where multidrug- resistant TB is a serious issue; and where domestic 
funding must be complemented by international financing. None of this was possible in 
1995.
We are now entering the era of the Sustainable Development Goals, in which 
paradigm shif ts are expected in all sectors, including health. TB is an infectious disease 
that, despite all progress, claims a number of deaths paralleled only by those from HIV/
AIDS. To end the epidemic (defined as an incidence of fewer than 100 cases per million 
people) by 2035 will require a rapid upgrade of care and managerial standards.
During the next 20 years, we will need to change our mentality and adopt all ef fective 
innovations, including those exploiting digital technology, especially in the realm of 
information management. Novel ways of diagnosing and reporting already exist and 
their adoption will help us evolve further towards interventions that are more user-
friendly, cheaper and more sustainable. If fully adopted, these technologies will not only 
transform the way we handle care and surveillance, but will increase the ef fectiveness of 
managerial and training ef forts for the benefit of those who suf fer from TB.
On the occasion of the publication of this 20th WHO global TB report, which 
coincides with the assessment of the 2015 global TB targets set as part of the Millennium 
Development Goals, I am humbled by the progress in terms of impact and operations 
that we have witnessed in many countries over two decades. The Global Report 
is a testimony to the tireless ef forts of many people worldwide, from National TB 
Programme staf f to community members, from clinicians and nurses to those working 
for non-governmental organizations who have devoted themselves to the noble fight 
against a classic example of a disease of poverty.
Mario Raviglione
Director of the Global TB Programme
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Executive summary 
Background
The year 2015 is a watershed moment in the battle against 
tuberculosis (TB). It marks the deadline for global TB targets 
set in the context of the Millennium Development Goals 
(MDGs), and is a year of transitions: from the MDGs to a new 
era of Sustainable Development Goals (SDGs), and from the 
Stop TB Strategy to the End TB Strategy. It is also two dec-
ades since WHO established a global TB monitoring system; 
since that time, 20 annual rounds of data collection have 
been completed. 
Using data from 205 countries and territories, which 
account for more than 99% of the world’s population, this 
global TB report documents advances in prevention, diag-
nosis and treatment of the disease. It also identifies areas 
where ef forts can be strengthened. 
Main findings and messages
The advances are major: TB mortality has fallen 47% since 
1990, with nearly all of that improvement taking place since 
2000, when the MDGs were set. 
In all, ef fective diagnosis and treatment of TB saved an 
estimated 43 million lives between 2000 and 2014.
The MDG target to halt and reverse TB incidence has 
been achieved on a worldwide basis, in each of the six WHO 
regions and in 16 of the 22 high-burden countries that collec-
tively account for 80% of TB cases. Globally, TB incidence has 
fallen by an average of 1.5% per year since 2000 and is now 
18% lower than the level of 2000.
This year’s report describes higher global totals for new 
TB cases than in previous years, but these reflect increased 
and improved national data rather than any increase in the 
spread of the disease. 
Despite these advances and despite the fact that nearly 
all cases can be cured, TB remains one of the world’s biggest 
threats. 
In 2014, TB killed 1.5 million people (1.1 million HIV-negative 
and 0.4 million HIV-positive). The toll comprised 890 000 
men, 480 000 women and 140 000 children. 
TB now ranks alongside HIV as a leading cause of death 
worldwide. HIV’s death toll in 2014 was estimated at 1.2 
million, which included the 0.4 million TB deaths among HIV-
positive people.1  
Worldwide, 9.6 million people are estimated to have fall-
en ill with TB in 2014: 5.4 million men, 3.2 million women and 
1.0 million children. Globally, 12% of the 9.6 million new TB 
cases in 2014 were HIV-positive.
To reduce this burden, detection and treatment gaps must 
be addressed, funding gaps closed and new tools developed. 
In 2014, 6 million new cases of TB were reported to WHO, 
fewer than two-thirds (63%) of the 9.6 million people esti-
mated to have fallen sick with the disease. This means that 
worldwide, 37% of new cases went undiagnosed or were not 
reported. The quality of care for people in the latter category 
is unknown.
Of the 480 000 cases of multidrug-resistant TB (MDR-TB) 
estimated to have occurred in 2014, only about a quarter of 
these – 123 000 – were detected and reported.
Although the number of HIV-positive TB patients on 
antiretroviral therapy (ART) improved in 2014 to 392  000 
people (equivalent to 77% of notified TB patients known to 
be co-infected with HIV), this number was only one third of 
the estimated 1.2 million people living with HIV who devel-
oped TB in 2014. All HIV-positive TB cases are eligible for ART. 
Funding gaps amounted to US$ 1.4 billion for implemen-
tation of existing interventions in 2015. The most recent 
estimate of the annual funding gap for research and devel-
opment is similar, at about US$ 1.3 billion.
From 2016, the goal is to end the global TB epidemic by 
implementing the End TB Strategy. Adopted by the World 
Health Assembly in May 2014 and with targets linked to 
the newly adopted SDGs, the strategy serves as a blueprint 
for countries to reduce the number of TB deaths by 90% by 
2030 (compared with 2015 levels), cut new cases by 80% and 
ensure that no family is burdened with catastrophic costs 
due to TB. 
1 The cause of TB deaths among HIV-positive people is classified as HIV in 
the International classification of diseases system. 
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Additional highlights from the report
Disease burden and 2015 targets assessment
"" The quantity and quality of data available to estimate TB 
disease burden continue to improve. These include direct 
measurements of mortality in 129 countries and final 
results from 18 national TB prevalence surveys completed 
since 2009, six of them in the past year (Ghana, Indonesia, 
Malawi, Sudan, Zambia and Zimbabwe). 
"" Revised estimates for Indonesia (1 million new cases per 
year, double the previous estimate) explain the upward 
revision to WHO’s global estimates of incident cases com-
pared with those published in 2014. Importantly, however, 
revisions also af fect estimates for previous years and the 
trend in TB incidence globally as well as in Indonesia is still 
downward since around 2000.
"" Of the 9.6 million new TB cases in 2014, 58% were in the 
South-East Asia and Western Pacific regions. 
"" The African Region had 28% of the world’s cases in 2014, 
but the most severe burden relative to population: 281 
cases for every 100  000 people, more than double the 
global average of 133. 
"" India, Indonesia and China had the largest number of 
cases: 23%, 10% and 10% of the global total, respectively. 
"" Globally, TB prevalence in 2015 was 42% lower than in 
1990. The target of halving the rate compared with 1990 
was achieved in three WHO regions – the Region of the 
Americas, the South-East Asia Region and the Western 
Pacific Region – and in nine high-burden countries (Brazil, 
Cambodia, China, Ethiopia, India, Myanmar, the Philip-
pines, Uganda and Viet Nam).
"" The target of halving the TB mortality rate by 2015 com-
pared with 1990 was met in four WHO regions – the Region 
of the Americas, the Eastern Mediterranean Region, the 
South-East Asia Region and the Western Pacific Region – 
and in 11 high-burden countries (Brazil, Cambodia, China, 
Ethiopia, India, Myanmar, Pakistan, the Philippines, Ugan-
da, Viet Nam and Zimbabwe).
"" All three of the 2015 targets (for incidence, prevalence 
and mortality) were met in nine high-burden countries 
– Brazil, Cambodia, China, Ethiopia, India, Myanmar, the 
Philippines, Uganda and Viet Nam.
TB case notifications and treatment outcomes
"" In the 20 years since WHO established a global report-
ing system in 1995, it has received reports of 78 million TB 
cases, 66 million of which were treated successfully. 
"" In 2014, that system measured a marked increase in glob-
al TB notifications for the first time since 2007. The annual 
total of new TB cases, which had been about 5.7 million 
until 2013, rose to slightly more than 6 million in 2014 (an 
increase of 6%). This was mostly due to a 29% increase in 
notifications in India, which followed the introduction of a 
policy of mandatory notification in May 2012, creation of 
a national web-based reporting system in June 2012 and 
intensified ef forts to engage the private health sector. 
India accounted for 27% of global TB notifications in 2014. 
"" Globally, the treatment success rate for people newly 
diagnosed with TB was 86% in 2013, a level that has been 
sustained since 2005. Treatment success rates require 
improvement in the Region of the Americas and the Euro-
pean Region (75% in both regions in 2013).
Drug-resistant TB
"" Globally, an estimated 3.3% of new TB cases and 20% of 
previously treated cases have MDR-TB, a level that has 
changed little in recent years.
"" In 2014, an estimated 190 000 people died of MDR-TB. 
"" More TB patients were tested for drug resistance in 2014 
than ever before. Worldwide, 58% of previously treated 
patients and 12% of new cases were tested, up from 17% 
and 8.5% respectively in 2013. This improvement is partly 
due to the adoption of rapid molecular tests.
"" If all of the TB cases notified in 2014 had been tested for 
drug resistance, an estimated 300 000 would have been 
found to have MDR-TB, with more than half of them (54%) 
occurring in India, China and the Russian Federation. 
"" The number of cases detected (123 000) worldwide repre-
sented just 41% of this global estimate, and only 26% of 
the 480 000 incident cases of MDR-TB estimated to have 
occurred in 2014. Detection gaps were worst in the West-
ern Pacific Region, where the number of cases detected 
was only 19% of the number of notified cases estimated to 
have MDR-TB (the figure for China was 11%).
"" A total of 111 000 people started MDR-TB treatment in 
2014, an increase of 14% compared with 2013.
"" The ratio of patients enrolled in treatment to patients 
newly notified as having MDR-TB or rifampicin-resistant 
TB was 90% globally. The ratio was above 90% in 15 of the 
27 high MDR-TB burden countries as well as in the Euro-
pean Region and the Region of the Americas.
"" Globally, only 50% of MDR-TB patients were successfully 
treated. However, the 2015 treatment success target of 
≥75% for MDR-TB patients was reached by 43 of the 127 
countries and territories that reported outcomes for the 
2012 cohort, including three high MDR-TB burden coun-
tries (Estonia, Ethiopia and Myanmar). 
"" Extensively drug-resistant TB (XDR-TB) had been report-
ed by 105 countries by 2015. An estimated 9.7% of people 
with MDR-TB have XDR-TB. 
Diagnostics and laboratory strengthening
"" The use of the rapid test Xpert MTB/RIF® has expanded 
substantially since 2010, when WHO first recommended 
its use. In all, 4.8 million test cartridges were procured in 
2014 by 116 low- and middle-income countries at conces-
sional prices, up from 550 000 in 2011.
"" By 2015, 69% of countries recommended using Xpert 
MTB/RIF as the initial diagnostic test for people at risk of 
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drug-resistant TB, and 60% recommended it as the initial 
diagnostic test for people living with HIV. 
Addressing the co-epidemics of TB and HIV 
"" In 2014, an estimated 1.2 million (12%) of the 9.6 million 
people who developed TB worldwide were HIV-positive. 
The African Region accounted for 74% of these cases.  
"" The number of people dying from HIV-associated TB 
peaked at 570 000 in 2004 and had fallen to 390 000 in 
2014 (a 32% decrease). 
"" Globally, 51% of notified TB patients had a documented 
HIV test result in 2014, a small increase from 49% in 2013. 
The figure was highest in the African Region, at 79%.
"" The number of people living with HIV who were treated 
with isoniazid preventive therapy reached 933 000 in 
2014, an increase of about 60% compared with 2013. A 
large proportion of these people (59%) were in South 
Africa.
Financing
"" The funding required for a full response to the global TB 
epidemic in low- and middle-income countries is esti-
mated at US$ 8 billion per year in 2015, excluding research 
and development. Projections made in 2013 suggested 
that, by 2015, about US$ 6 billion could be mobilized from 
domestic sources, leaving a balance of US$ 2 billion need-
ed from international donors.
"" Based on self-reporting by countries, funding for TB pre-
vention, diagnosis and treatment reached US$ 6.6 billion 
in 2015, up from US$ 6.2 billion in 2014 and more than dou-
ble the level of 2006 (US$ 3.2 billion).
"" Overall, 87% (US$ 5.8 billion) of the US$ 6.6 billion avail-
able in 2015 is from domestic sources.
"" International donor funding reported by countries to 
WHO has increased since 2006, reaching US$ 0.8 billion in 
2015. 
"" The total amount of international donor funding record-
ed in the creditor reporting system of the Organization for 
Economic Cooperation and Development (OECD) is high-
er: the latest data show total contributions of US$  1  billion 
in 2013. Of this amount, 77% was from the Global Fund. 
The largest country donor was the government of the 
United States of America, which contributed about one 
third of the TB funding channelled via the Global Fund as 
well as bilateral funds of US$  362 million for TB and TB/
HIV in 2013.1 
"" Domestic funding accounts for more than 90% of the 
total funding in 2015 in three country groups: Brazil, the 
Russian Federation, India, China and South Africa (BRICS); 
upper-middle-income countries; and regions outside 
Africa and Asia.
1 Not all of these bilateral funds are captured in the OECD database. For 
example, this does not record flows of funds between OECD countries, 
and funding for TB/HIV may be coded as funding for HIV.
"" International donor funding dominates in the group of 
17 high-burden countries outside BRICS (72% of the total 
funding available in 2015) and in low-income countries 
(81% of the total funding available in 2015).
"" The cost per patient treated for drug-susceptible TB in 
2014 ranged from US$ 100−500 in most countries with a 
high burden of TB. The cost per patient treated for MDR-
TB was typically US$ 5000−10 000.
Research and development
"" In the diagnostics pipeline, tests based on molecular tech-
nologies are the most advanced.
"" A diagnostic platform called the GeneXpert Omni® is 
in development. It is intended for point-of-care testing 
for TB and rifampicin-resistant TB using Xpert MTB/RIF 
cartridges. The device is expected to be smaller, lighter 
and less expensive than currently available platforms for 
point-of-care nucleic acid detection and will come with 
a built-in, 4-hour battery. WHO expects to evaluate the 
platform in 2016.  
"" A next-generation cartridge called Xpert Ultra® is also in 
development. It is intended to replace the Xpert MTB/RIF 
cartridge and could potentially replace conventional cul-
ture as the primary diagnostic tool for TB. 
"" Eight new or repurposed anti-TB drugs are in advanced 
phases of clinical development. For the first time in six 
years, an anti-TB drug candidate (TBA-354) is in Phase I 
testing. 
"" Several new TB treatment regimens for drug-susceptible 
and/or drug-resistant TB are being tested in Phase II or 
Phase III trials; at least two more trials are scheduled to 
start towards the end of 2015 or in early 2016. 
"" WHO has issued interim guidance on the use of bedaqui-
line (in 2013) and delamanid (in 2014).
"" By the end of 2014, 43 countries reported having used 
bedaquiline to treat patients as part of ef forts to expand 
access to treatment for MDR-TB.
"" Recent observational studies of the ef fectiveness of short 
treatment regimens for MDR-TB in Niger and Cameroon 
found that a 12-month regimen was ef fective and well-tol-
erated in patients not previously exposed to second-line 
drugs. At least 16 countries in Africa and Asia have intro-
duced shorter regimens as part of trials or observational 
studies under operational research conditions, and WHO 
will reassess current guidance on their use in 2016. 
"" Fif teen vaccine candidates are in clinical trials. Their 
emphasis has shif ted from children to adolescents and 
adults.
"" New diagnostics, drugs and vaccines will be needed to 
achieve the targets set in the End TB Strategy.
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Box 1.1 Basic facts about TB
TB is an infectious disease caused by the bacillus Mycobacterium tuberculosis. It typically af fects the lungs (pulmonary TB) but can af fect 
other sites as well (extrapulmonary TB). The disease is spread in the air when people who are sick with pulmonary TB expel bacteria, for 
example by coughing. Overall, a relatively small proportion (5–15%) of the estimated 2–3 billion people infected with M. tuberculosis will 
develop TB disease during their lifetime. However, the probability of developing TB is much higher among people infected with HIV. 
The most common method for diagnosing TB worldwide remains sputum smear microscopy (developed more than 100 years ago), in which 
bacteria are observed in sputum samples examined under a microscope. However, developments in TB diagnostics in the last few years 
mean that the use of rapid molecular tests to diagnose TB and drug-resistant TB is increasing, and some countries are phasing out use of 
smear microscopy for diagnostic (as opposed to treatment monitoring) purposes. In countries with more developed laboratory capacity, 
cases of TB are also diagnosed via culture methods (the current reference standard). 
Without treatment, the death rate is high. Studies from the pre-chemotherapy era found that about 70% of people with sputum smear-
positive pulmonary TB died within 10 years, and that this figure was 20% among culture-positive (but smear-negative) cases of pulmonary 
TB.a 
Ef fective drug treatments were first developed in the 1940s. The most ef fective first-line anti-TB drug, rifampicin, became available in 
the 1960s. The currently recommended treatment for new cases of drug-susceptible TB is a six-month regimen of four first-line drugs: 
isoniazid, rifampicin, ethambutol and pyrazinamide. Treatment success rates of 85% or more for new cases are regularly reported to WHO 
by its Member States. Treatment for multidrug-resistant TB (MDR-TB), defined as resistance to isoniazid and rifampicin (the two most 
powerful anti-TB drugs) is longer, and requires more expensive and more toxic drugs. For most patients with MDR-TB, the current regimens 
recommended by WHO last 20 months, and treatment success rates are much lower. 
New TB drugs are now emerging from the pipeline, and combination regimens that include new compounds are being tested in clinical 
trials. There are several TB vaccines in Phase I or Phase II trials. For the time being, however, a vaccine that is ef fective in preventing TB in 
adults remains elusive.
a Tiemersma EW et al. Natural history of tuberculosis: duration and fatality of untreated pulmonary tuberculosis in HIV-negative patients:  
A systematic review. PLoS ONE, 2011, 6(4): e17601. 








Tuberculosis (TB) is a major global health problem. It causes 
ill-health among millions of people each year and ranks 
alongside the human immunodeficiency virus (HIV) as a 
leading cause of death worldwide.1 In 2014, there were an 
estimated 9.6 million new TB cases: 5.4 million among men, 
3.2 million among women and 1.0 million among children. 
There were also 1.5 million TB deaths (1.1 million among 
HIV-negative people and 0.4 million among HIV-positive 
people), of which approximately 890 000 were men, 480 000 
were women and 140 000 were children. The number of TB 
deaths is unacceptably high: with a timely diagnosis and cor-
rect treatment, almost all people with TB can be cured. Basic 
facts about TB are summarized in Box 1.1.
The World Health Organization (WHO) has published 
a global TB report every year since 1997. The main aim of 
these reports is to provide a comprehensive and up-to-date 
assessment of the TB epidemic and progress in prevention, 
diagnosis and treatment of the disease at global, regional 
and country levels, in the context of recommended global TB 
strategies and targets endorsed by WHO’s Member States. 
For the past decade, the focus has been on progress towards 
2015 global targets for reductions in TB disease burden 
set in the context of the Millennium Development Goals 
(MDGs). The targets are that TB incidence should be falling 
(MDG Target 6.c) and that TB prevalence and mortality rates 
should be halved compared with their 1990 levels. The Stop 
TB Strategy,2 developed for the period 2006–2015, has been 
WHO’s recommended approach to achieving these targets 
(Box 1.2). 
With 2015 marking the MDG and global TB target dead-
line, the special emphasis and most important topic of this 
2015 global TB report is an assessment of whether the 2015 
targets have been achieved. This assessment is made for the 
world, for the six WHO regions and for the 22 high-burden 
countries that collectively account for 80% of TB cases. The 
topics covered in the remaining six chapters of the report 
1 In 2014, there were an estimated 1.2 million deaths due to HIV; this 
includes 0.4 million deaths from TB among HIV-positive people. See 
unaids.org.
2 Raviglione M, Uplekar M. WHO’s new Stop TB strategy. The Lancet, 2006; 
367: 952–5.
are: TB case notifications and treatment outcomes; drug-
resistant TB; diagnostics and laboratory strengthening; 
addressing the co-epidemics of TB and HIV; financing; and 
research and development. Since the end of 2015 also marks 
the end of the MDG and Stop TB Strategy eras and the start of 
a post-2015 development framework (2016–2030) of Sustain-
able Development Goals (SDGs)3 and an associated post-2015 
global TB strategy,4 each chapter of the report features con-
tent related to the transition to the new End TB Strategy 
(Box 1.3).
As usual, the 2015 global TB report is based on data col-
lected in annual rounds of global TB data collection from 
countries and territories, including 194 Member States. This 
is done using a web-based system (https://extranet.who.int/
tme), which was opened for reporting in mid-March. In 2015, 
205 countries and territories that account for more than 99% 
of the world’s population and estimated TB cases reported 
data; this included 183 of WHO’s 194 Member States. Data 
about the provision of isoniazid preventive therapy (IPT) 
to people living with HIV and antiretroviral therapy (ART) 
for HIV-positive TB patients, which were collected by the 
HIV department in WHO and the Joint United Nations Pro-
gramme on HIV/AIDS (UNAIDS), were also used. Following 
review and follow-up with countries, the results presented in 
the main part of this report are based on data available on 6 
August 2015. 
The report has four annexes. Annex 1 describes the con-
tents of the global TB database, how data were collected and 
how to access the data. Annex 2 contains country profiles for 
the 22 high-burden countries (profiles for other countries 
are available online5) and Annex 3 contains regional profiles. 
Annex 4 provides detailed data tables for key indicators for 
the most recent year for which data or estimates are avail-
able, for all countries. 
As the 20th in the series, this 2015 global TB report marks 
an important landmark in global TB monitoring by WHO. 
3 http://sustainabledevelopment.un.org/focussdgs.html
4 Uplekar M, Weil D, Lonnroth K, Jaramillo E, Lienhardt C, Dias HM, et al. 
WHO’s new End TB Strategy. The Lancet. 2015;385:1799–801.
5 www.who.int/tb/data.
VISION A TB-free world
GOAL To dramatically reduce the global burden of TB by 2015 in line with the Millennium Development Goals (MDGs) and the Stop TB Partnership targets
OBJECTIVES
n Achieve universal access to high-quality care for all people with TB 
n Reduce the human suf fering and socioeconomic burden associated with TB
n Protect vulnerable populations from TB, TB/HIV and drug-resistant TB
n Support development of new tools and enable their timely and ef fective use
n Protect and promote human rights in TB prevention, care and control
TARGETS 
n MDG 6, Target 6.c: Halt and begin to reverse the incidence of TB by 2015
n Targets linked to the MDGs and endorsed by the Stop TB Partnership:
 — 2015: reduce prevalence of and deaths due to TB by 50% compared with a baseline of 1990
 — 2050: eliminate TB as a public health problem (defined as <1 case per 1 million population per year)
COMPONENTS
1.  Pursue high-quality DOTS expansion and enhancement
a. Secure political commitment, with adequate and sustained financing 
b. Ensure early case detection, and diagnosis through quality-assured bacteriology
c. Provide standardized treatment with supervision, and patient support
d. Ensure ef fective drug supply and management 
e. Monitor and evaluate performance and impact
2.  Address TB/HIV, MDR-TB, and the needs of poor and vulnerable populations
a. Scale up collaborative TB/HIV activities
b. Scale up prevention and management of MDR-TB
c. Address the needs of TB contacts, and of poor and vulnerable populations
3.  Contribute to health system strengthening based on primary health care
a. Help improve health policies, human resource development, financing, supplies, service delivery and information 
b. Strengthen infection control in health services, other congregate settings and households 
c. Upgrade laboratory networks, and implement the Practical Approach to Lung Health 
d. Adapt successful approaches from other fields and sectors, and foster action on the social determinants of health 
4.  Engage all care providers 
a. Involve all public, voluntary, corporate and private providers through public–private mix approaches
b. Promote use of the International Standards for Tuberculosis Care 
5.  Empower people with TB, and communities through partnership
a. Pursue advocacy, communication and social mobilization
b. Foster community participation in TB care, prevention and health promotion 
c. Promote use of the Patients’ Charter for Tuberculosis Care
6.  Enable and promote research 
a. Conduct programme-based operational research 
b. Advocate for and participate in research to develop new diagnostics, drugs and vaccines.
Box 1.2 The Stop TB Strategy at a glance (2006–2015)
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VISION A WORLD FREE OF TB —  zero deaths, disease and suf fering due to TB
GOAL END THE GLOBAL TB EPIDEMIC
INDICATORS
MILESTONES TARGETS
2020 2025 SDG 2030a End TB 2035
Reduction in number of TB deaths 
compared with 2015 (%) 35% 75% 90% 95%
Reduction in TB incidence rate 









TB-af fected families facing catastrophic 
costs due to TB (%) 0 0 0 0
PRINCIPLES
1. Government stewardship and accountability, with monitoring and evaluation
2. Strong coalition with civil society organizations and communities
3. Protection and promotion of human rights, ethics and equity
4. Adaptation of the strategy and targets at country level, with global collaboration
PILLARS AND COMPONENTS
1.  INTEGRATED, PATIENT-CENTRED CARE AND PREVENTION
A. Early diagnosis of TB including universal drug-susceptibility testing, and systematic screening of contacts and high-risk groups 
B. Treatment of all people with TB including drug-resistant TB, and patient support 
C. Collaborative TB/HIV activities, and management of co-morbidities
D. Preventive treatment of persons at high risk, and vaccination against TB
2.  BOLD POLICIES AND SUPPORTIVE SYSTEMS
A. Political commitment with adequate resources for TB care and prevention
B. Engagement of communities, civil society organizations, and public and private care providers
C. Universal health coverage policy, and regulatory frameworks for case notification, vital registration, quality and rational use of 
medicines, and infection control
D. Social protection, poverty alleviation and actions on other determinants of TB
3.  INTENSIFIED RESEARCH AND INNOVATION
A. Discovery, development and rapid uptake of new tools, interventions and strategies
B. Research to optimize implementation and impact, and promote innovations
a Targets linked to the Sustainable Development Goals (SDGs).
Box 1.3 The End TB Strategy at a glance (2016–2035)
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Disease burden and  





The burden of TB disease can be measured in terms of inci-
dence (defined as the number of new and relapse cases of TB 
arising in a given time period, usually one year), prevalence 
(defined as the number of cases of TB at a given point in time) 
and mortality (defined as the number of deaths caused by TB 
in a given time period, usually one year). 
This chapter presents the latest WHO estimates of TB 
incidence, prevalence and mortality between 1990 and 2015. 
Special emphasis is given to assessment of whether 2015 tar-
Key facts and messages
The data available to estimate TB disease burden (incidence, 
prevalence, mortality) continue to improve. In 2014, data from 
vital registration (VR) systems and/or mortality surveys were 
used to estimate TB mortality in 129 countries (up from three 
countries in 2008). There has been substantial progress in the 
implementation of national population-based surveys of the 
prevalence of TB disease since 2008, with 18 surveys (of which 12 
were first-ever national surveys) completed between 2009 and 
August 2015. Of these, results from six surveys were finalized 
in the past year (Ghana, Indonesia, Malawi, Sudan, Zambia, 
Zimbabwe), and additional survey results became available 
for the United Republic of Tanzania. Three additional surveys 
were begun in late 2014 or 2015. Notification data for 2014 were 
reported by 205 countries and territories.
This chapter presents the latest WHO estimates of TB disease 
burden between 1990 and 2015. Special emphasis is given to 
assessment of whether 2015 targets set in the context of the 
Millennium Development Goals (MDGs) were achieved. The 
targets were that incidence should be falling by 2015 (MDG 
target 6c) and that prevalence and mortality rates should be 
halved compared with 1990 levels.
Globally in 2014, there were an estimated 9.6 million incident 
cases of TB: 5.4 million among men, 3.2 million among 
women and 1.0 million among children. The global total is 
a considerable upward revision compared with estimates 
published in 2014, following results from the national 
prevalence survey in Indonesia. It is now estimated that there 
are about 1 million new TB cases per year in Indonesia, twice the 
previously estimated level. 
Globally in 2014, there were an estimated 1.2 million new HIV-
positive TB cases (12% of all TB cases). Almost three-quarters of 
these cases were in the African Region.
Globally in 2014, there were an estimated 1.5 million deaths 
from TB: 1.1 million deaths among people who were HIV-
negative and 390 000 deaths among people who were HIV-
positive.* TB ranks alongside HIV (1.2 million deaths in 2014, 
including the 390 000 TB deaths among HIV-positive people) as 
a leading cause of death worldwide. 
The South-East Asia and Western Pacific Regions collectively 
accounted for 58% of the world’s TB cases in 2014. The African 
Region had 28% of the world’s cases, but the most severe 
burden relative to population (281 incident cases per 100 000 
population on average, more than double the global average 
of 133). India, Indonesia and China had the largest numbers of 
cases (23%, 10% and 10% of the global total, respectively). 
The MDG target of halting and reversing TB incidence by 2015 
was achieved globally, in all six WHO regions and in 16 of the 
22 high TB burden countries (HBCs). The TB incidence rate has 
fallen at an average rate of 1.5% per year since 2000. 
Globally, the TB mortality rate in 2015 was 47% lower than in 
1990: the target of a 50% reduction was almost met. The target 
was achieved in four WHO Regions (the exceptions were the 
African and European regions), and in 11 HBCs. 
Globally, the TB prevalence rate in 2015 was 42% lower than 
in 1990. The target of a 50% reduction was met in three WHO 
regions and in nine HBCs. 
All three 2015 targets were met in the Region of the Americas, 
the South-East Asia Region and the Western Pacific Region, 
and in nine HBCs: Brazil, Cambodia, China, Ethiopia, India, 
Myanmar, the Philippines, Uganda and Viet Nam.
Between 2000 and 2014, TB treatment alone saved 35 million 
lives among HIV-negative people; TB treatment and anti-
retroviral therapy saved an additional 8 million lives among 
HIV-positive people. 
* The underlying cause of TB deaths among HIV-positive people is classified as HIV in the international classification of diseases system.
gets set in the context of the Millennium Development Goals 
(MDGs) were achieved at global level, in the six WHO regions 
and in the 22 high TB burden countries (HBCs) that collective-
ly account for about 80% of the world’s TB cases. The targets 
were that incidence should be falling by 2015 (MDG target 6c) 
and that prevalence and mortality rates should be halved 
compared with their levels in 1990 (Box 2.1).
WHO updates estimates of the burden of disease caused 
by TB annually, using the latest available data and analytical 
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methods.1,2 Since 2006, concerted ef forts have been made 
to improve the available data and methods used, under 
the umbrella of the WHO Global Task Force on TB Impact 
Measurement (Box 2.1). Notification data are consistently 
reported by about 200 countries and territories each year 
(205 in 2014). For this report, direct measurements of TB 
mortality from national or sample vital registration (VR) 
systems were available for 127 countries (up from three 
countries in 2008) and data from mortality surveys were 
available for two countries. Between 2009 and August 2015, 
18 population-based surveys of the prevalence of TB disease 
(of which 12 were first-ever national surveys) were complet-
ed. Of these, results from six surveys were finalized in the 
past year (Ghana, Indonesia, Malawi, Sudan, Zambia, Zim-
babwe), and additional survey results became available for 
the United Republic of Tanzania. These results are reflected 
in prevalence estimates published in this report, and have 
also allowed improvements to estimates of TB incidence and 
mortality. Those for Indonesia in particular have had a major 
impact on global estimates of TB incidence and prevalence. A 
summary of the main updates to available data and methods 
is provided in Box 2.2.
The chapter has five major sections. The first three cover 
estimates of TB incidence, prevalence and mortality in turn, 
including assessment of whether the 2015 target was met. 
The section on TB mortality includes estimates of the lives 
saved through TB treatment (including the additional ben-
efit from antiretroviral therapy for HIV-positive TB patients) 
between 2000 and 2014. The fourth section presents esti-
mates disaggregated by age and sex. The fif th and final 
section explains how WHO will update the current lists of 
HBCs for the post-2015 era. 
2.1  TB incidence 
TB incidence has never been measured at national level 
because this would require long-term studies among large 
cohorts of people (hundreds of thousands), involving high 
costs and challenging logistics. Notifications of TB cases pro-
vide a good proxy indication of TB incidence in countries that 
have both high-performance surveillance systems (for exam-
ple, there is little under-reporting of diagnosed cases) and 
where the quality of and access to health care means that 
few cases are not diagnosed. In the large number of coun-
tries where these criteria are not yet met, better estimates 
of TB incidence can be obtained from an inventory study (an 
inventory study is a survey to quantify the level of under-
reporting of detected TB cases; if certain conditions are met, 
capture-recapture methods can also be used to estimate TB 
1 The online technical appendix is available at www.who.int/tb/data. 
2 It should be highlighted that these updates af fect the entire time-series 
back to 1990. For this reason, estimates presented in this chapter for 
1990−2013 supersede those of previous reports and direct comparisons 
(for example, 2013 estimates in this report and 2013 estimates in the last 
report) are not appropriate. 
incidence).3 To date, such studies have been undertaken in 
only a few countries: examples include Egypt, Iraq, Pakistan 
and Yemen. A recent example, from the Republic of Korea, is 
profiled in Box 2.3.
The ultimate goal is to directly measure TB incidence from 
TB notifications in all countries. This requires a combina-
tion of strengthened surveillance, better quantification of 
under-reporting (i.e. the number of cases that are missed by 
surveillance systems) and universal access to health care. A 
TB surveillance checklist developed by the WHO Global Task 
Force on TB Impact Measurement defines the standards 
that need to be met for notification data to provide a direct 
measure of TB incidence (Box 2.1). By August 2015, a total of 
38 countries including 16 HBCs had completed the checklist 
(Figure 2.1).
Methods currently used by WHO to estimate TB incidence 
can be grouped into four major categories (Figure 2.2). These 
are: 
1. Case notification data combined with expert opinion 
about case detection gaps. Expert opinion, elicited in 
regional workshops or country missions, is used to esti-
mate levels of under-reporting and under-diagnosis. 
Trends are estimated using either mortality data, surveys 
of the annual risk of infection or exponential interpolation 
using estimates of case detection gaps for three years. 
In this report, this method is used for 120 countries that 
accounted for 51% of the estimated global number of inci-
dent cases in 2014. 
2. Results from national TB prevalence surveys. Incidence 
is estimated using prevalence survey results combined 
with either a dynamic model or estimates of the dura-
tion of disease. This method is used for 19 countries that 
accounted for 46% of the estimated global number of 
incident cases in 2014.
3. Notifications in high-income countries adjusted by a 
standard factor to account for under-reporting and 
under-diagnosis. This method is used for 73 countries 
(all high-income countries except the Netherlands and 
the United Kingdom), which accounted for 3% of the esti-
mated global number of incident cases in 2014.
4. Results from inventory/capture-recapture studies. This 
method is used for 5 countries: Egypt, Iraq, the Nether-
lands, the United Kingdom and Yemen. They accounted 
for 0.5% of the estimated global number of incident cases 
in 2014. 
Further details about these methods are provided in the online 
technical appendix1 and in background documents prepared 
for the global review of methods used to produce TB burden 
3 Inventory studies can be used to measure the number of cases that are 
diagnosed but not reported. A guide on inventory studies is available 
at: www.who.int/tb/publications/inventory_studies. 
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Box 2.1 2015 global TB targets assessment 
Background
Global targets for reductions in TB disease burden by 2015 
were set within the context of the United Nations’ Millennium 
Development Goals (MDGs). The targets were that TB incidence 
should be falling, and that TB mortality and prevalence rates 
should be halved by 2015 compared with their level in 1990. The 
targets were adopted at regional and country levels. The Stop TB 
Strategy (2006–2015) developed by WHO had the overall goal of 
achieving these targets (Chapter 1). 
Since 2005, WHO has published estimates of TB incidence, 
prevalence and mortality and an assessment of progress towards 
2015 targets in its annual global TB report. With 2015 marking the 
MDG and global TB target deadline, the special emphasis and most 
important topic of this 2015 global TB report is an assessment of 
whether the 2015 targets were achieved. This assessment is made 
for the world, for the six WHO regions and for the 22 high-burden 
countries (HBCs) that collectively account for 80% of TB cases. It 
is built on the work of the WHO Global Task Force on TB Impact 
Measurement. 
The WHO Global Task Force on TB Impact 
Measurement
The WHO Global Task Force on TB Impact Measurement was 
established in 2006, with the aim of ensuring that assessment of 
whether 2015 targets were met should be as rigorous, robust and 
consensus-based as possible. 
To fulfil this mandate, the Task Force agreed upon three strategic 
areas of work: 
1. Strengthened surveillance in all countries, towards the 
ultimate goal of direct measurement of TB incidence and 
TB mortality using notification and vital registration data, 
respectively;
2. National TB prevalence surveys in 22 global focus countries;
3. Periodic review and updating of methods used to translate 
surveillance and survey data into TB disease burden estimates. 
A wide range of technical, financial and development agencies, 
countries and individual experts have been engaged in the work 
of the Task Force, and full details can be found on the Task Force 
website.a 
The Task Force’s work on strengthened surveillance has covered 
four main topics. These are:
" Development of a TB surveillance checklist of standards 
and benchmarks (with ten core and three supplementary 
standards).b This can be used to systematically assess the 
extent to which a surveillance system meets the standards 
required for notification and vital registration data to 
provide a direct measurement of TB incidence and mortality, 
respectively. By August 2015, 38 countries including 16 HBCs 
had used the checklist (Figure 2.1). 
" Electronic recording and reporting. Case-based electronic 
databases are the reference standard for recording and 
reporting TB surveillance data. A guide was produced in 2011,c 
and ef forts to introduce such systems have been supported. 
" Development of a guide on inventory studies to measure under-
reporting of detected TB cases,d and support to such studies in 
priority countries. One of the main reasons for uncertainty in 
estimates of TB incidence is that in many countries, especially 
those with a large private sector, cases may be detected but 
not reported. An inventory study can be used to quantify the 
number of cases that are detected but not reported to national 
surveillance systems, and serve as a basis for addressing gaps in 
reporting. 
" Expanded use of data from vital registration (VR) systems 
and mortality surveys to produce estimates of the number of 
TB deaths, and contributions to wider ef forts to promote VR 
systems. In this report, estimates of TB mortality are based on 
such data sources for 129 countries (Figure 2.15). 
There has been substantial success in the implementation of 
national TB prevalence surveys. Between 2009 and 2015, 18 
countries including 15/22 global focus countries completed a 
survey and more are scheduled to do so by 2016 (Figure 2.11, 
Figure 2.12). Results from these surveys have provided a large body 
of new evidence about the burden of TB disease (Box 2.2) and also 
have important policy, programmatic and funding implications 
(Box 2.4).
A Task Force subgroup undertook a major review and 
update of methods between June 2008 and October 2009. 
Recommendations were endorsed at a full meeting of the Task 
Force in March 2010. A second thorough and comprehensive 
review of these methods as well as possible alternatives was 
undertaken in 2015, with the purpose of reaching consensus on 
methods to be used for reporting in the 2015 global TB report on 
whether 2015 targets were met. The key recommendation from the 
group of experts was that existing methods should be used – the 
consensus was to “finish the cycle with established methods”.e
Looking forward: TB burden estimates post-2015
The End TB Strategy includes ambitious targets for reductions 
in TB incidence and TB mortality (Chapter 1). During the expert 
review of current methods used to estimate these indicators, 
there was strong agreement that the main goal is to strengthen 
TB surveillance so that TB cases and TB deaths can be directly 
measured using notification and vital registration systems.e 
Therefore, the Task Force strategic area of work related to 
strengthened surveillance needs to be continued. In the interim, 
for countries without high-performance surveillance systems, 
options for improving current methods that were identified 
included the use of new statistical models, use of dynamic models 
(especially for estimation of TB incidence in countries with recent 
prevalence survey data), and implementation of more inventory 
studies to measure under-reporting. It was also agreed that a 
strategic selection of priority countries in which repeat prevalence 
surveys should be done to measure trends is important. 
a www.who.int/tb/advisory_bodies/impact_measurement_taskforce
b www.who.int/tb/publications/standardsandbenchmarks/en/
c Electronic recording and reporting for TB care and control. Geneva, World 
Health Organization, 2011 (WHO/HTM/TB/2011.22). Available at 
www.who.int/tb/publications/electronic_recording_reporting
d Assessing tuberculosis underreporting through inventory studies. Geneva, 





Box 2.2 Updates to estimates of TB disease burden in this report and updates that 
 are anticipated in the near future 
UPDATES IN THIS REPORT
1. New data from national TB prevalence surveys
Between October 2014 and August 2015, final results from 
surveys in Ghana, Indonesia, Malawi, Sudan, the United Republic 
of Tanzania, Zambia and Zimbabwe became available. The size 
of Indonesia’s population and TB burden means that upward 
revisions to estimates based on the prevalence survey af fect global 
estimates of the absolute number of incident cases (although 
importantly, global trends in TB incidence are not af fected and the 
impact on estimates of global TB deaths is small given a relatively 
low case fatality ratio in Indonesia). In the other countries, updated 
estimates are either higher (Ghana, Malawi, United Republic of 
Tanzania, Zambia) or lower (Sudan, Zimbabwe) than previous 
estimates. Post-survey estimates are almost always more precise 
than earlier estimates that were indirectly derived from incidence 
(Figure B2.2.1). 
2.  Newly reported data and updated estimates 
 from other agencies
New VR data were reported to WHO between mid-2014 and 
mid-2015 and some countries made corrections to historical data. 
UNAIDS published updated HIV estimates in August 2014. The 
United Nations Population Division published new estimates in 
July 2015. In most instances, any resulting changes to TB burden 
estimates are well within the uncertainty intervals of previously 
published estimates, and trends are generally consistent. 
For the first time, estimates of TB mortality (HIV-negative) in 
Indonesia could be produced using data from a sample vital 
registration system, af ter adjustment for incomplete coverage 
and ill-defined causes of death. For South Africa, estimates of 
TB mortality (HIV-negative) were obtained from the Institute of 
Health Metrics and Evaluation; these estimates use data from 
the national vital registration system, adjusted for widespread 
miscoding of deaths caused by HIV and TB,a,b and replace previous 
indirect estimates derived from TB incidence and the case fatality 
ratio. 
3. Updated methods for estimating TB burden
In March 2015, the WHO Global Task Force on TB Impact 
Measurement convened an expert group to review methods 
for estimating TB disease burden (see Box 2.1). In general, the 
meeting recommended that current methods should be retained, 
especially for the purposes of reporting on whether 2015 targets 
were met. An exception was methods used to estimate the burden 
of TB disease among children, which have been published by 
WHO since 2013 and which are not relevant to reporting on 2015 
targets. It was recommended that WHO should update methods 
used to estimate TB incidence among children by implementing 
an “ensemble” approach in which estimates derived from case 
notifications adjusted for under-detection and under-reportingc 
are combined with estimates derived from dynamic modelling.d 
An additional recommendation was that HIV-positive TB mortality 
in children should be estimated using a similar approach to that 
used for disaggregating TB/HIV mortality by sex. Estimates of 
childhood TB incidence and mortality presented in this report are 
based on these recommendations.
4. In-depth epidemiological reviews at country level
Estimates for Angola were revised based on discussions with 
experts from the NTP and partners. They should however be 
considered preliminary, pending the findings of an ongoing 
epidemiological review. Estimates for Kazakhstan were updated 
in February 2015 following an in-depth review conducted by WHO 
staf f (headquarters and the Regional Of fice for Europe) in close 
collaboration with the Ministry of Health.
UPDATES ANTICIPATED IN THE NEAR FUTURE
Updates to estimates of disease burden are expected within the 
next year for three countries in which a national TB prevalence 
survey has been recently completed (Uganda, July 2015) or is 
scheduled for completion around the end of 2015 (Bangladesh, 
Mongolia). Estimates of TB incidence may be updated following 
the implementation of inventory studies to measure under-
reporting of detected TB in China, Indonesia, the Philippines, 
Thailand and Viet Nam. An expert review of methods used to 
estimate the burden of MDR-TB is scheduled for 2016.
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FIGURE B2.2.1
Estimates of TB prevalence (all ages, all forms of TB) for 17 countries, before (in 
blue) and af ter (in red) results from national prevalence surveys became available. 
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a The wide uncertainty interval of the post-survey estimate for the United Republic of Tanzania is 
because laboratory challenges meant that it was only possible to directly estimate the prevalence of 
smear-positive (as opposed to bacteriologically confirmed) TB. 
a Murray C, Ortblad K, Guinovart C 
et al. Global, regional, and national 
incidence and mortality for HIV, 
tuberculosis, and malaria during 
1990–2013: a systematic analysis for 
the Global Burden of Disease Study 
2013. Lancet 2014; 384: 1005–70. 
25059949.
b Groenewald P, Nannan N, Bourne D et al. 
Identifying deaths from AIDS in South 
Africa. AIDS 2005; 19: 193–201. 15668545.
c Jenkins H, Tolman A, Yuen C et al. 
Incidence of multidrug-resistant 
tuberculosis disease in children: 
systematic review and global estimates. 
Lancet 2014; 383: 1572–9. 24671080.
d Dodd P, Gardiner E, Coghlan R et al. 
Burden of childhood tuberculosis in 22 
high-burden countries: a mathematical 
modelling study. Lancet Glob Health 2014; 
2: e453–9. 25103518
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n FIGURE 2.1 
Countries that had completed a systematic assessment of TB surveillance using the WHO TB surveillance checklist of 
standards and benchmarks by August 2015
High-burden countries (16)
Other countries (22)
n FIGURE 2.2 
Main method used to estimate TB incidencea
a In the first method, case notification data are combined with expert opinion about  case detection gaps (under-reporting and under-diagnosis), and 
trends are estimated  using either mortality data, repeat surveys of the annual risk of infection or exponential interpolation using estimates of case 
detection gaps for three years. For all high-income countries except the Netherlands and the United Kingdom, notifications are adjusted by a standard 
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estimates that was held 31 March–2 April 2015 (Box 2.1).1,2 
In 2014, there were an estimated 9.6 million incident cases 
of TB (range, 9.1  million–10.0  million)3 globally, equivalent 
to 133 cases per 100  000 population (Table 2.1, Table 2.2). 
The absolute number of incident cases is falling slowly (Fig-
ure 2.3), at an average rate of 1.5% per year 2000−2014 and 
2.1% between 2013 and 2014. The cumulative reduction in the 
TB incidence rate 2000–2014 was 18%. 
Most of the estimated number of cases in 2014 occurred 
in Asia (58%) and the African Region (28%);4 smaller pro-
portions of cases occurred in the Eastern Mediterranean 
Region (8%), the European Region (3%) and the Region of 
the Americas (3%). The 22 HBCs that have been given high-
est priority at the global level since 2000 (listed in Table 2.1 
and Table 2.2) accounted for 83% of all estimated incident 
cases worldwide. The six countries that stand out as having 
the largest number of incident cases in 2014 were India, Indo-
nesia, China, Nigeria, Pakistan and South Africa; these and 
the other five countries that make up the top ten in terms of 
numbers of cases are highlighted in Figure 2.4. India, Indo-
nesia and China alone accounted for a combined total of 43% 
of global cases in 2014. 
The 9.6 million incident TB cases in 2014 included 1.1 mil-
lion–1.3 million (11–13%) among people living with HIV, with 
a best estimate of 1.2 million (12%) (Table 2.1, Table 2.2). The 
proportion of TB cases co-infected with HIV was highest in 
countries in the African Region (Figure 2.5). Overall, 32% of 
TB cases were estimated to be co-infected with HIV in this 
region, which accounted for 74% of TB cases among people 
living with HIV worldwide. In parts of southern Africa, more 
than 50% of TB cases were co-infected with HIV (Figure 2.5).
Following a systematic review of evidence about mortal-
ity caused by MDR-TB undertaken in 2013 and consensus 
about what indicators to use for reporting on the burden of 
MDR-TB,5 this report includes updated global estimates of 
MDR-TB incidence and mortality. The best estimate is that 
there were 480  000 (range, 360  000–600  000) new cases 
of MDR-TB worldwide in 2014 (see also Chapter 4). This total 
includes cases of primary and acquired MDR-TB. 
The number of incident TB cases relative to population 
size (the incidence rate) varies widely among countries 
(Figure 2.6, Figure 2.7). The lowest rates are found predomi-
nantly in high-income countries including most countries in 
western Europe, Canada, the United States of America, Aus-
tralia and New Zealand. In these countries, the incidence rate 
is less than 10 cases per 100  000 population per year. Most 
countries in the Region of the Americas have rates below 50 
per 100 000 population per year and this is the region with 
1 The online technical appendix is available at www.who.int/tb/data. 
2 All background documents are available at www.who.int/tb/
advisory_bodies/impact_measurement_taskforce/meetings/
consultation_april_2015_tb_estimates_subgroup/en/
3 “Range” refers here and elsewhere to the 95% uncertainty interval.
4 Asia refers to the WHO Regions of South-East Asia and the Western 
Pacific.
5 See Box 5.3, Chapter 5 in the 2014 global TB report. 
Box 2.3 Low level of under-reporting of  
 detected TB cases in the Republic  
 of Korea
A national case-based and internet-based TB notification 
system is a key element of the NTP in the Republic of Korea, 
linked to the initiation of response measures including 
outbreak investigations, evaluation of contacts and TB case 
management. The online TB reporting system was established 
in 2000.a 
All TB patients who are treated in public health centres are 
notified to the Korea National TB Surveillance System (KNTSS). 
In 2006, a national survey found that only 67.6% of patients 
diagnosed and treated in the private sector were notified, 
despite a legal framework making notification of TB cases 
mandatory. Since 2008, the coverage of routine TB surveillance 
has been systematically assessed using record-linkage of 
medical records from the National Health Insurance (NHI) 
system and records from the KNTSS database.b National 
identification numbers are used for record-linkage.
Data on levels of under-reporting of TB case notifications in 
2012 and 2013 are presented in Table B2.3.1. Under-reporting 
was defined as failing to report a detected case within 
6 months.
TABLE B2.3.1
Under-reporting of detected TB cases in the  
Republic of Korea
2012 2013
National health insurance system 36 735 33 800
National TB surveillance system 32 515 31 534
Under-reporting 11.5% 6.7%
Under-reporting to the national TB surveillance system was 
found to be lower when cases were diagnosed in general 
hospitals (8%, 2012–2013) compared with private clinics (24%). 
A regulation is being put in place that makes reimbursement 
from the national health insurance system conditional upon 
notification of cases by prescribing physicians, as part of a 
5-year plan for TB elimination (2013–2017). In 2011, the national 
health insurance system covered 90% of medical expenses 
related to TB, and reimbursement coverage is planned to reach 
100% for TB patients in 2016. The new regulation regarding 
conditional reimbursement and the planned increase in 
coverage of health insurance to 100% for TB patients should 
ensure a close to zero level of under-reporting of detected cases 
in the near future.
a WJ Lew, EG Lee, JY Bai et al. An Internet-based surveillance system 
for tuberculosis in Korea. Int J Tuberc Lung Dis, 2006; 10:1241–7.
b YS Park, SJ Hong, YK Boo et al. The national status of tuberculosis 
using nationwide medical records survey of patients with 
tuberculosis in Korea. Tuberc Respir Dis (Seoul), 2012; 73:48–55.
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Estimated epidemiological burden of TB, 2014. Best estimates are followed by the lower and upper bounds of the 95% 
uncertainty interval. Numbers in thousands.a 
POPULATION MORTALITYb HIV-POSITIVE TB MORTALITY PREVALENCE INCIDENCE
HIV-POSITIVE INCIDENT 
TB CASES
Afghanistan 31 628 14 10–18 <0.1 0–0.1 110 56–180 60 53–67 0.3 0.2–0.4
Bangladeshc 159 078 81 59–110 0.2 0.1–0.2 640 340–1 000 360 320–410 0.6 0.4–0.7
Brazil 206 078 5.3 4.9–5.7 2.4 1.8–3.2 110 51–180 90 86–95 16 14–17
Cambodia 15 328 8.9 6.3–12 0.8 0.6–1.0 100 87–120 60 54–66 1.8 1.6–2.0
China 1 369 436 38 37–40 0.7 0.5–0.9 1 200 1 100–1 400 930 860–1 000 13 11–16
DR Congo 74 877 52 38–68 6.3 5.0–7.7 400 210–640 240 220–270 34 27–42
Ethiopia 96 959 32 22–43 5.5 4.4–6.8 190 160–240 200 160–240 19 15–23
India 1 295 292 220 150–350 31 25–38 2 500 1 700–3 500 2 200 2 000–2 300 110 96–120
Indonesia 254 455 100 66–150 22 13–32 1 600 1 300–2 000 1 000 700–1 400 63 41–90
Kenya 44 864 9.4 6.7–12 8.1 6.4–10 120 64–190 110 110–110 40 38–42
Mozambique 27 216 18 12–26 37 29–45 150 80–240 150 120–180 85 65–110
Myanmar 53 437 28 20–37 4.1 3.3–5.1 240 190–310 200 180–220 19 15–24
Nigeria 177 476 170 91–280 78 53–110 590 450–740 570 340–870 100 59–160
Pakistan 185 044 48 11–110 1.3 0.8–1.9 630 530–740 500 370–650 6.4 4.4–8.7
Philippines 99 139 10 9.0–11 <0.1 0–0.1 410 360–470 290 250–320 2.5 2.0–3.2
Russian Federation 143 429 16 15–16 1.1 0.8–1.3 160 70–270 120 110–130 5.5 4.5–6.6
South Africa 53 969 24 22–26 72 58–89 380 210–590 450 400–510 270 240–310
Thailand 67 726 7.4 3.9–12 4.5 2.3–7.4 160 110–220 120 61–190 15 7.8–24
Uganda 37 783 4.5 3.2–6.1 6.4 5.0–8.1 60 33–95 61 53–69 28 24–32
UR Tanzania 51 823 30 13–54 28 15–43 270 110–510 170 80–290 62 29–110
Viet Nam 92 423 17 11–23 1.9 1.3–2.5 180 76–330 130 110–150 7 5.7–8.5
Zimbabwe 15 246 2.3 1.4–3.4 5.2 3.2–7.8 44 24–71 42 29–58 25 17–35
High-burden 
countries 4 552 704 940 790–1 100 320 280–360 10 000 9 200–12 000 8 000 7 500–8 500 930 850–1 000
AFR 963 361 450 350–560 310 270–350 3 200 2 800–3 600 2 700 2 400–3 000 870 790–950
AMR 981 613 17 16–18 6 5.2–6.8 350 270–440 280 270–290 36 34–38
EMR 635 745 88 43–150 3.2 2.6–4.0 1 000 880–1 200 740 610–890 12 10–15
EUR 907 279 33 33–34 3.2 2.7–3.7 440 330–560 340 320–350 20 18–21
SEAR 1 906 087 460 350–570 62 51–74 5 400 4 400–6 500 4 000 3 700–4 400 210 180–240
WPR 1 845 184 88 81–95 4.9 4.2–5.7 2 100 1 900–2 400 1 600 1 500–1 600 31 28–35
Global 7 239 269 1 100 970–1 300 390 350–430 13 000 11 000–14 000 9 600 9 100–10 000 1 200 1 100–1 300
a Numbers for mortality, prevalence and incidence shown to two significant figures. Totals (HBCs, regional and global) are computed prior to rounding.
b Mortality excludes deaths among HIV-positive TB cases. Deaths among HIV-positive TB cases are classified as HIV deaths according to ICD-10 and are 
shown separately in this table. 
c For Bangladesh, a joint reassessment of estimates of TB disease burden will be undertaken following completion of the national TB prevalence survey.
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n TABLE 2.2 
Estimated epidemiological burden of TB, 2014. Best estimates are followed by the lower and upper bounds of the 95% 




TB MORTALITY PREVALENCE INCIDENCE
HIV PREVALENCE IN
INCIDENT TB CASES (%)
Afghanistan 31 628 44 32–57 0.3 0.2–0.3 340 178–555 189 167–212 0.5 0.4–0.7
Bangladeshb 159 078 51 37–68 0.1 0–0.1 404 211–659 227 200–256 0.2 0.1–0.2
Brazil 206 078 2.6 2.4–2.7 1.2 0.9–1.6 52 25–89 44 42–46 17 16–19
Cambodia 15 328 58 41–78 5.3 4.1–6.7 668 565–780 390 353–428 3.0 2.8–3.2
China 1 369 436 2.8 2.7–2.9 <0.1 0–0.1 89 78–102 68 63–73 1.4 1.2–1.7
DR Congo 74 877 69 50–90 8.4 6.7–10 532 282–859 325 295–356 14 11–17
Ethiopia 96 959 33 23–44 5.7 4.6–7.0 200 161–243 207 168–250 9.3 8.2–10
India 1 295 292 17 12–27 2.4 2.0–2.9 195 131–271 167 156–179 5.0 4.5–5.4
Indonesia 254 455 41 26–59 8.5 5.2–13 647 513–797 399 274–546 6.2 5.1–7.5
Kenya 44 864 21 15–28 18 14–22 266 142–427 246 240–252 36 34–38
Mozambique 27 216 67 44–96 134 106–165 554 295–893 551 435–680 57 50–63
Myanmar 53 437 53 38–70 7.7 6.1–9.5 457 352–575 369 334–406 9.7 7.9–12
Nigeria 177 476 97 51–156 44 30–61 330 253–417 322 189–488 18 15–22
Pakistan 185 044 26 6.0–61 0.7 0.4–1.0 341 285–402 270 201–350 1.3 1–1.5
Philippines 99 139 10 9.1–11 <0.1 0–0.1 417 367–471 288 254–324 0.9 0.7–1.1
Russian Federation 143 429 11 11–11 0.7 0.6–0.9 109 49–192 84 76–93 4.6 3.8–5.3
South Africa 53 969 44 41–48 134 107–164 696 390–1 090 834 737–936 61 56–66
Thailand 67 726 11 5.7–18 6.6 3.4–11 236 161–326 171 90–276 13 12–14
Uganda 37 783 12 8.4–16 17 13–21 159 87–253 161 141–183 45 42–48
UR Tanzania 51 823 58 26–104 53 30–84 528 215–979 327 155–561 37 32–42
Viet Nam 92 423 18 12–25 2 1.4–2.7 198 83–362 140 116–167 5.4 5–5.9
Zimbabwe 15 246 15 9.5–22 34 21–51 292 158–465 278 193–379 60 55–65
High-burden 
countries 4 552 704 21 17–24 6.9 6.1–7.8 227 203–253 176 165–188 12 10–13
AFR 963 361 46 36–58 32 28–36 330 288–375 281 250–313 32 28–37
AMR 981 613 1.7 1.6–1.8 0.6 0.5–0.7 36 28–45 28 27–29 13 12–14
EMR 635 745 14 6.8–23 0.5 0.4–0.6 160 139–183 117 96–140 1.7 1.3–2.2
EUR 907 279 3.7 3.6–3.8 0.3 0.3–0.4 48 36–61 37 35–39 5.9 5.4–6.5
SEAR 1 906 087 24 19–30 3.3 2.7–3.9 286 233–343 211 192–232 5.2 4.3–6.1
WPR 1 845 184 4.8 4.4–5.1 0.3 0.2–0.3 116 104–128 85 80–89 2.0 1.8–2.3
Global 7 239 269 16 13–18 5.3 4.8–5.9 174 158–190 133 126–141 12 11–13
a  Mortality excludes deaths among HIV-positive TB cases. Deaths among HIV-positive TB cases are classified as HIV deaths according to ICD-10 and are 
shown separately in this table.
b  For Bangladesh, a joint reassessment of estimates of TB disease burden will be undertaken following completion of the national TB prevalence survey.
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n FIGURE 2.4 
Estimated TB incidence: top-ten countries, 2014. The range shows the lower and upper bounds of the 95% uncertainty 
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n FIGURE 2.3 
Estimated absolute numbers of TB cases and deaths (in millions per year), 1990–2014
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a HIV-associated deaths are classified as HIV deaths according to ICD-10.
the lowest burden of TB on average. Most of the HBCs have 
rates of around 150–300 cases per 100  000 population per 
year (Table 2.2, Figure 2.7); HBCs with markedly lower rates 
in 2014 were Brazil, China and the Russian Federation, while 
rates were above 500 per 100 000 population in Mozambique 
and South Africa. Other countries in the top ten worldwide in 
terms of incidence rates in 2014 are shown in Figure 2.4. 
Globally, the incidence rate was relatively stable from 1990 
up until around 2000, and then started to fall (Figure 2.8), 
achieving the MDG target far ahead of the 2015 deadline. The 
MDG target has also been met in all six WHO regions and in 
16 of the 22 HBCs (Figure 2.9, Figure 2.10, Table 2.3). 
2.2  TB prevalence 
In countries with a relatively high burden of TB (around 100 
cases per 100  000 population or more), the prevalence of 
bacteriologically-confirmed pulmonary TB can be directly 
measured in nationwide population-based surveys using 
sample sizes of around 50 000 people. Survey results can be 
used to produce a national estimate of TB prevalence that 
includes all forms of TB. The cost of a survey usually ranges 
from US$ 1 to  4 million, and comprehensive theoretical 
and practical guidance on survey design, implementation, 
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n TABLE 2.3
2015 targets assessment: global, WHO regions and 22 high-burden countries 
INDICATORS AND 2015 TARGETSa
INDICATOR TB INCIDENCE RATE TB PREVALENCE RATE TB MORTALITY RATE
TARGET INCIDENCE RATE FALLING 50% REDUCTION IN PREVALENCE RATE BY 2015 COMPARED WITH 1990
50% REDUCTION IN MORTALITY RATE 
BY 2015 COMPARED WITH 1990
GLOBAL
Global Met Almost met Almost met
WHO REGION
African (AFR) Met Not met Not met 
Americas (AMR) Met Met Met
Eastern Mediterranean (EMR) Met Not met Met
European (EUR) Met Not met Not met 
South-East Asia (SEAR) Met Met Met
Western Pacific (WPR) Met Met Met
22 HIGH-BURDEN COUNTRIES
AFR DR Congo Not met Not met Not met 
Ethiopia Met Met Met 
Kenya Met Not met Not met 
Mozambique Not met Not met Almost met
Nigeria Not met Not met Not met
South Africa Met Not met Not met 
Uganda Met Met Met
UR Tanzania Met Not met Not met 
Zimbabwe Met Not met Met
AMR Brazil Met Met Met
EMR Afghanistan Not met Not met Not met
Pakistan Not met Not met Met
EUR Russian Federation Met Not met Not met 
SEAR Bangladeshb Not met Not met Not met 
India Met Met Met
Indonesia Met Not met Not met 
Myanmar Met Met Met
Thailand Met Not met Almost met
WPR Cambodia Met Met Met
China Met Met Met
Philippines Met Met Met 
Viet Nam Met Met Met
a Met (green) means that the target was achieved before or by the end of 2015. Not met (orange) means that the target will not be achieved by the end 
of 2015. Almost met (light green) means that the reduction was in the range 40–49%, according to the best estimate. Values for 2015 were based on an 
algorithm that selects the best performing among a family of exponential smoothing via state-space models of the 2005–2014 time-series.
b For Bangladesh, a joint reassessment of estimates of TB disease burden will be undertaken following completion of the national TB prevalence survey.
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n FIGURE 2.5 
Estimated HIV prevalence in new and relapse TB cases, 2014
n FIGURE 2.6 
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n FIGURE 2.7 
Global distribution of estimated TB incidence by rate and absolute number, 2014. The size of each bubble is proportional to 
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analysis and reporting of results is available.1 Repeat surveys 
conducted about every ten years allow trends in disease bur-
den to be assessed. HBCs that have completed repeat surveys 
in the last ten years include Cambodia, China, the Philippines 
and Thailand. Repeat surveys are planned in Myanmar and 
Viet Nam around 2016–2017; a fourth survey is also planned 
in the Philippines in 2016. Countries in which surveys have 
been implemented or are planned in the near future are 
shown in Figure 2.11 and Figure 2.12. In the 1990s and early 
2000s, there was typically no or one survey per year, and all 
the surveys that were done were in Asia. Between 2009 and 
2016, an unprecedented number of national TB prevalence 
surveys have been or will be conducted, in both Africa and 
Asia (Figure 2.12, Box 2.1, Box 2.2). The results and lessons 
learned from one of the most recent surveys, in Indonesia, 
are highlighted in Box 2.4.
1 TB prevalence surveys: a handbook. Geneva, World Health Organization, 
2011 (WHO/HTM/TB/2010.17). Available at www.who.int/tb/advisory_
bodies/impact_measurement_taskforce/resources_documents/
thelimebook/
In low- and medium-burden countries, sample sizes and 
costs for surveys become prohibitively large. If survey data 
are not available, prevalence can be indirectly estimated as 
the product of incidence and the average duration of disease, 
but with considerable uncertainty. 
Details about the methods used to produce estimates of 
TB prevalence are provided in the online technical appen-
dix and in background documents prepared for the global 
review of methods used to produce TB burden estimates that 
was held 31 March–2 April 2015 (Box 2.1).2,3 
There were an estimated 13 million prevalent cases (range, 
11 million–14 million) of TB in 2014 (Table 2.1), equivalent to 
174 cases per 100  000 population (Table 2.2). By the end of 
2015, it is estimated that the prevalence rate will have fallen 
42% globally since 1990, missing the target (Figure 2.8, 
Table  2.3). However, two regions met the target before 2015 
(the Region of the Americas and the Western Pacific Region) 
and the South-East Asia Region reached the target (accord-
2 The online technical appendix is available at www.who.int/tb/data. 
3 All background documents are available at www.who.int/tb/
advisory_bodies/impact_measurement_taskforce/meetings/
consultation_april_2015_tb_estimates_subgroup/en/
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Box 2.4 The 2013/2014 national TB prevalence survey in Indonesia: main results,  
 and policy, programmatic and funding implications
A national survey of the prevalence of TB disease in Indonesia was 
successfully implemented in 2013/2014 under the leadership of 
the National TB Programme and the National Institute of Health 
Research and Development. The main objective of the survey was 
to estimate the prevalence of pulmonary TB (bacteriologically-
confirmed) among the general population aged ≥15 years old.
Methods and main results 
Survey methods from design through implementation, 
analysis and reporting of results followed the international 
recommendations of the WHO Global Task Force on TB Impact 
Measurement.a 
All survey participants were screened for symptoms by interview 
and chest X-ray examination. Participants with any current 
symptom suggestive of TB or radiological lesion(s) in the lung 
were requested to submit two sputum specimens (one spot and 
one early-morning) that were examined by microscopy (AFB) and 
culture (LJ solid media).
A total of 112 350 people of all ages were enumerated, from 156 
clusters around the country. Of these, there were 76 576 eligible 
individuals aged ≥15 years old. All eligible individuals were invited 
to participate in the survey, of whom 67 994 (89%) did so. Of those 
who participated, 15 446 (23%) screened positive and were eligible 
for sputum examination. A total of 426 TB cases were identified by 
the survey (Figure B2.4.1). The excellent participation rate as well 
as other survey indicators (for example, very low levels of missing 
data) show that the survey was implemented to a high standard. 
The TB prevalence rate per 100 000 population aged ≥15 years old 
was estimated to be 257 (95% CI: 210–303) for smear-positive TB, 
and 759 (95% CI: 590−961) for bacteriologically-confirmed TB. Clear 
and consistent age and sex dif ferentials were observed for both 
smear-positive and bacteriologically-confirmed TB, with higher 
rates among men and older age groups (Figure B2.4.2). 
The final survey results were used in combination with other 
sources of information (such as notification data, mortality data 
from a sample vital registration system and previous national 
TB prevalence surveys) to update estimates of the burden of TB 
disease in Indonesia (Figure B2.4.3). Both survey results and these 
updated estimates were discussed and agreed upon in national 
consensus meetings involving all key stakeholders that were held 
in September and October 2014. 
Lessons learned 
The key lessons learned from the survey were: 
1. The burden of TB disease in Indonesia is much higher 
than previously thought.b Revised figures for 2013 are an 
estimated TB incidence rate of 403 (range, 278–550) per 
100 000 population and an estimated prevalence (all forms 
of TB, and including children as well as adults) of 660 (range, 
523–813) per 100 000 population. The 2013/2014 survey has 
provided a more accurate measurement of TB disease burden 
compared with earlier surveys, since unlike previous surveys it 
included systematic chest X-ray screening of the entire survey 
population and bacteriological testing for all those with signs or 
symptoms suggestive of TB. 
2. When analysed alongside results from previous surveys, TB 
incidence is falling, in line with the MDG target for TB. TB 
prevalence and mortality are also falling. In addition, the case 
fatality ratio (the proportion of incident cases that die from TB) 
is estimated at 11%, considerably better than the global average 
of 16%.
3. Overall, only about one third of the estimated 1 million incident 
cases that occur each year are being detected and reported to 
national authorities.
4. The number of TB patients receiving treatment in public 
and private hospitals, without linkage or reporting to the 
national TB programme, was much larger than expected. A 
high proportion of detected cases (about 50%) had not been 
reported. 
5. A high proportion of people with TB had not been detected at 
the time of the survey, showing serious delays in TB diagnosis 
and treatment.
Policy, programmatic and funding implications
The major implications of survey results, some of which require 
high-level policy action, include:
1. TB warrants being one of the top health priorities in Indonesia. 
2. Funding needs for TB prevention, diagnosis and treatment 
are considerably larger than previously thought. Additional 
resources will need to be mobilized at national, provincial and 
district levels.
3. Expansion of health insurance coverage is crucial to support 
high quality TB diagnosis and treatment in public and private 
hospitals (and in the private sector in general), to ensure that 
TB disease does not impose a financial burden on patients and 
their households, and to ensure appropriate cost-recovery for 
care providers.
4. The current policy of mandatory case notification needs to be 
strongly enforced to reduce under-reporting of detected cases. 
This could be facilitated by systems that make it easier for care 
providers to notify cases, such as a user-friendly electronic 
surveillance system, and by incentives for reporting (or 
penalties for not reporting). 
5. Screening and diagnostic tools that have a higher sensitivity 
than current symptom screening and smear microscopy need 
to be introduced or expanded to help reduce the number of 
undetected cases in the community, as well as to reduce the 
possibility of over-diagnosis. Examples include much wider use 
of chest X-ray screening and rapid molecular diagnostics. 
6. Referral mechanisms between health centres and hospitals in 
both the public and private sectors need to be strengthened 
and awareness of TB increased throughout the population and 
among health care workers. These measures will also help to 
reduce the number of undetected cases in the community. 
Conclusions and next steps
The 2013/2014 national survey of the prevalence of TB disease in 
Indonesia is one of the highest quality national TB prevalence 
surveys conducted to date, and the importance of the evidence it 
GLOBAL TUBERCULOSIS REPORT 2015  n  21
FIGURE B2.4.1
Consort diagram of the 2013–2014 national TB prevalence survey in Indonesia
Enumerated population: 112 350
Not eligible to participate: 35 774 (31.8%)
33 206 were less than 15 years old
2 568 were resident for less than 1 month
Did not participate: 8 632 (11.3%)
Negatively screened: 52 498 (77.3%)
Eligible to participate: 76,576 (68.2%)
Positively screened, eligible for sputum examination: 15 446 (22.7%)
Symptom and chest X-ray positive:  4 459 (28.9%)
Symptom positive only:  3 844 (24.9%)
Chest X-ray positive only:  6 743 (43.7%)
Other:   400 (2.6%)
Participated: 67 944 (88.7%)
Did not submit sputum: 305 (2.0%):
174 refused, 131 could not produce sputum
Submitted at least one sputum specimen: 15 141 (98.0%)
Submitted two sputum specimens: 14 568
Submitted only one specimen: 573 
of which 557 were spot specimens and 16 were morning specimens
No laboratory result: 14 (0.1%) Laboratory results were available: 15 127 (99.9%)
All laboratory results 
were normal: 13 836
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FIGURE B2.4.3 
Trends in estimated rates of incidence, prevalence and mortality in Indonesia, 1990–2015. Lef t panel: the incidence rate 
(green) is shown alongside notifications of TB cases (black). Centre and right panels: The horizontal dashed lines represent 
the Stop TB Partnership targets of a 50% reduction in prevalence and mortality rates by 2015 compared with 1990. Shaded 
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has produced is clear. Following wide dissemination of findings, 
results have been used to help develop the national strategic plan 
2015–2020 and the preparation of a Concept Note required for 
financing from the Global Fund. A survey report has been finalized 
and results will be summarized in a paper for a peer-reviewed 
journal. 
a Tuberculosis prevalence surveys: a handbook. Geneva: World Health 
Organization; 2010 (WHO/HTM/TB/2010.17). Available at: http://
www.who.int/tb/advisory_bodies/impact_measurement_taskforce/
resources_documents/thelimebook/en/ 
b Other examples of countries where a survey has shown that the burden 
of TB was higher than previously include Laos PDR (2011), Nigeria (2012), 
Ghana (2013), Malawi (2013) and Zambia (2014).
ing to the best estimate) in 2015 (Figure 2.13).1 TB prevalence 
is falling in all of the other three regions. Among the 22 HBCs, 
nine are assessed to have met the target of a 50% reduction 
from 1990 levels (Figure 2.14, Table 2.3). 
2.3  TB mortality
TB mortality among HIV-negative people can be directly 
measured using data from national VR systems, provided 
that these systems have high coverage and causes of death 
are accurately coded according to the latest revision of the 
International classification of diseases (ICD-10). Sample VR sys-
tems covering representative areas of the country (e.g. as 
in China) provide an interim solution. Mortality surveys can 
also be used to estimate deaths caused by TB. In 2014, most 
countries with a high burden of TB lacked national or sample 
VR systems and few had conducted mortality surveys. In the 
absence of VR systems or mortality surveys, TB mortality 
can be estimated as the product of TB incidence and the case 
fatality rate, or from ecological modelling based on mortali-
ty data from countries with VR systems. TB mortality among 
1 Values for 2015 were estimated using an algorithm that selects the best 
performing among a family of exponential smoothing via state-space 
models of the 2005–2014 time-series.
HIV-positive people is hard to measure even when VR sys-
tems are in place because deaths among HIV-positive people 
are coded as HIV deaths and contributory causes (such as TB) 
are of ten not reliably recorded. For this 2015 report, country-
specific estimates of TB deaths among HIV-positive people 
were produced using the Spectrum sof tware that has been 
used for HIV burden estimates for over a decade. 
Until 2008, WHO estimates of TB mortality used VR data 
for only three countries. This was substantially improved to 
89 countries in 2009; however, most of the data were from 
countries in the European Region and the Region of the 
Americas, which accounted for less than 10% of the world’s 
TB cases. In 2011, the first use of sample VR data from China 
and survey data from India enabled a further major improve-
ment to estimates of TB mortality. For the current report, VR 
data of suf ficient coverage and quality were available for 127 
countries (Figure 2.15) including Indonesia and South Africa 
for the first time (Box 2.2), and survey data were available 
for two countries (India and Viet Nam). The combined total 
of 129 countries accounted for 43% of the estimated number 
of TB deaths globally in 2014. The African Region is the part 
of the world in which there is the greatest need to introduce 
or strengthen a vital registration system in which causes of 
death are classified according to the ICD system. 
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n FIGURE 2.8 
Global trends in estimated rates of TB incidence (1990-2014), and prevalence and mortality rates (1990–2015).  
Lef t: Estimated incidence rate including HIV-positive TB (green) and estimated incidence rate of HIV-positive TB (red).  
Centre and right: The horizontal dashed lines represent the Stop TB Partnership targets of a 50% reduction in prevalence  
and mortality rates by 2015 compared with 1990. Shaded areas represent uncertainty bands. Mortality excludes  








































































n FIGURE 2.9 
Estimated TB incidence rates by WHO region, 1990−2014. Estimated TB incidence rates (green) and estimated incidence 
rates of HIV-positive TB (red). Shaded areas represent uncertainty bands.
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Details about the methods used to produce estimates 
of TB mortality are provided in the online technical appen-
dix and in background documents prepared for the global 
review of methods used to produce TB burden estimates that 
was held 31 March–2 April 2015 (Box 2.1).1,2 
There were an estimated 1.5 million TB deaths in 2014 
(Table 2.1, Figure 2.2): 1.1 million among HIV-negative people 
and 390 000 among HIV-positive people (TB deaths among 
HIV-positive people are classified as HIV deaths in ICD-10).3 
TB ranks alongside HIV as a leading cause of death from an 
infectious disease (Figure 2.16a, Figure 2.16b).4 
1 The online technical appendix is available at www.who.int/tb/data. 
2 All background documents are available at www.who.int/tb/
advisory_bodies/impact_measurement_taskforce/meetings/
consultation_april_2015_tb_estimates_subgroup/en/
3 International statistical classification of diseases and related health problems, 
10th revision (ICD-10), 2nd ed. Geneva: World Health Organization; 2007.
4 WHO Global Health Observatory data repository, available at http://
apps.who.int/gho/data/node.main.GHECOD?lang=en (accessed 27 
August 2015).
Approximately 90% of total TB deaths (among HIV-neg-
ative and HIV-positive people) and 80% of TB deaths among 
HIV-negative people occurred in the African and South-East 
Asia Regions in 2014. India and Nigeria accounted for about 
one third of global TB deaths (both including and excluding 
those among HIV-positive people). 
The number of TB deaths (among HIV-negative people) 
per 100  000 population averaged 16 globally in 2014 (Table 
2.2) and 21 when TB deaths among HIV-positive people are 
included. There is considerable variation among countries 
(Figure 2.17), ranging from <1 TB death per 100 000 popula-
tion (examples include most countries in western Europe, 
Canada, the United States of America, Australia and New 
Zealand) to more than 40 deaths per 100 000 population in 
much of the African Region as well as five HBCs (Afghani-
stan, Bangladesh, Cambodia, Indonesia and Myanmar). 
Globally, the mortality rate (excluding deaths among HIV-
n FIGURE 2.10 
Estimated TB incidence rates, 22 high−burden countries, 1990−2014. Estimated TB incidence rates (green) and estimated 
incidence rates of HIV−positive TB (red). Shaded areas represent uncertainty bands.
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a For Bangladesh, a joint reassessment of estimates of TB disease burden will be 
undertaken following completion of the national TB prevalence survey.
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n FIGURE 2.11
Countries in which national population-based surveys of the prevalence of TB disease have been implemented  
using currently recommended screening and diagnostic methodsa since 1990 or are planned in the near future:  
status in August 2015
a Screening methods include field chest X-ray; culture is used to confirm diagnosis. 
b A country has submitted at least a draf t survey protocol and a budget plan to the WHO Global Task Force for TB Impact Measurement. 
c Countries were implementing field operations in August 2015 or were undertaking data cleaning and analysis. 
d A survey was conducted in accordance with WHO recommendations as outlined in “Tuberculosis prevalence surveys: a handbook (2011)” and at least a 
preliminary report has been published. 
e A repeat national survey is one in which participants were screened with chest X-ray, and culture examination was used to diagnose TB cases. In the 
Philippines, a repeat survey is planned in 2016.
n FIGURE 2.12
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n FIGURE 2.13 
Estimated TB prevalence rates 1990−2015, by WHO region. Shaded areas represent uncertainty bands. The horizontal 
dashed lines represent the Stop TB Partnership target of a 50% reduction in the prevalence rate by 2015 compared with 1990. 
n FIGURE 2.14 
Estimated TB prevalence rates 1990−2015, 22 high−burden countries. Shaded areas represent uncertainty bands. The 
horizontal dashed lines represent the Stop TB Partnership target of a 50% reduction in the prevalence rate by 2015 compared 
with 1990.
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positive people)1 fell 47% between 1990 and 2015, narrowly 
missing the target of a 50% reduction (Figure 2.8, Table 2.3). 
However, two WHO regions met the target about ten years in 
advance of the deadline (the Region of the Americas and the 
Western Pacific Region), and the Eastern Mediterranean and 
South-East Asia Regions reached the target (according to the 
best estimate) by 2015 (Figure 2.18).2 TB mortality has been 
falling rapidly in the European Region since around 2005, 
but not fast enough to reach the target given the increase in 
mortality levels that occurred during the 1990s. In the African 
Region, mortality is falling but only slowly. Among the 22 
HBCs, 11 are assessed to have met the 50% reduction target 
(Figure 2.19, Table 2.3). 
1 Trends in TB mortality rates are restricted to TB deaths among 
HIV-negative people, given that TB deaths among HIV-positive people 
are classified as HIV deaths in ICD-10. 
2 Values for 2015 were estimated using an algorithm that selects the best 
performing among a family of exponential smoothing via state-space 
models of the 2005–2014 time-series.
n TABLE 2.4
Estimated case fatality ratios (CFRs) in the absence of 
treatment 
CATEGORY OF TB CASE CFR (95% UNCERTAINTY INTERVAL)
HIV-negative, not on TB treatment 0.43 (0.28–0.53)
HIV-positive, not on TB treatment or ART 0.78 (0.65–0.94)
n FIGURE 2.15 
Countries (in red) for which TB mortality is estimated using measurements from vital registration systems (n=127)  
and/or mortality surveys (n=2)
2.3.1 Estimated number of lives saved by TB 
treatment, 2000–2014
The actual numbers of TB deaths (presented above) can be 
compared with the number of TB deaths that would have 
occurred in the absence of TB treatment, to give an esti-
mate of the lives saved by TB interventions. The number of 
deaths that would have occurred each year in the absence 
of TB treatment (and without ART provided alongside TB 
treatment for HIV-positive cases) can be conservatively esti-
mated as the number of estimated incident cases (section 
2.1) multiplied by the relevant case fatality ratio (Table 2.4).3 
Estimates are conservative because they do not account for 
the impact of TB control or ART on the level of TB incidence, 
or the indirect, downstream impact of these interventions on 
future levels of infections, cases and deaths. 
Between 2000 and 2014, TB treatment alone saved an 
estimated 35 million lives among HIV-negative people (Table 
2.5). Among HIV-positive people, TB treatment supported by 
ART saved an additional 8.4 million lives. 
2.4  Estimates disaggregated by age and sex
This section presents estimates of TB incidence and TB mor-
tality disaggregated by age and sex. Specifically, estimates 
are shown for men (defined as males aged ≥15 years), women 
3 Further details about methods used to estimate lives saved, including 
CFRs for dif ferent categories of TB case, are provided in the online 
technical appendix, available at www.who.int/tb/data. 
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n FIGURE 2.16a 
Top causes of death worldwide in 2012.a,b Deaths from TB 
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n FIGURE 2.16b 
Estimated number of deaths from HIV/AIDS and TB in 
2014. Deaths from TB among HIV-positive people are shown 
in grey.a,b
a This is the latest year for which estimates for all causes are currently 
available. See WHO Global Health Observatory data repository, 
available at http://apps.who.int/gho/data/node.main.GHECOD 
(accessed 27 August 2015).
b For HIV/AIDS, the latest estimates of the number of deaths in 2012 
that have been published by UNAIDS are available at www.unaids.
org/en/resources/documents/2015/HIV_estimates_with_uncertainty_
bounds_1990-2014. For TB, the estimates for 2012 are those published in 
this report.
c Deaths from TB among HIV-positive people are of ficially classified as 
deaths caused by HIV/AIDS in the International classification of diseases.
a For HIV/AIDS, the latest estimates of the number of deaths in 2014 
that have been published by UNAIDS are available at www.unaids.
org/en/resources/documents/2015/HIV_estimates_with_uncertainty_
bounds_1990-2014. For TB, the estimates for 2014 are those published 
in this report.
b Deaths from TB among HIV-positive people are of ficially classified as 
deaths caused by HIV/AIDS in the International classification of diseases.
HIV/AIDS
TB
0 0.5 1.0 1.5
Millions
n TABLE 2.5
Cumulative number of lives saved by TB and TB/HIV interventions 2000–2014 (in millions), globally and by WHO region. 
Best estimates are followed by 95% uncertainty intervals.
WHO REGION
HIV-NEGATIVE PEOPLE HIV-POSITIVE PEOPLE TOTAL
BEST ESTIMATE UNCERTAINTY INTERVAL BEST ESTIMATE UNCERTAINTY INTERVAL BEST ESTIMATE UNCERTAINTY INTERVAL
AFR 4.2 3.4–5.1 5.9 5.3–6.5 10.1 9.0–11.2
AMR 1.4 1.2–1.5 0.31 0.28–0.33 1.7 1.6–1.8
EMR 2.6 2.1–3.0 0.06 0.056–0.075 2.6 2.2–3.0
EUR 2.1 1.9–2.4 0.13 0.12–0.14 2.3 2.0–2.5
SEA 15.7 13.7–17.7 1.6 1.4–1.8 17.3 15.3–19.3
WPR 9.2 8.3–10.0 0.29 0.27–0.32 9.5 8.6–10.3
Global 35.2 30.9–39.4 8.4 7.6–9.2 43.5 39.2–47.8
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n FIGURE 2.17 
Estimated TB mortality rates excluding TB deaths among HIV−positive people, 2014
n FIGURE 2.18 
Estimated TB mortality rates 1990−2015, by WHO region. Estimated TB mortality excludes TB deaths among HIV-positive 
people. Shaded areas represent uncertainty bands.a The horizontal dashed lines represent the Stop TB Partnership target of a 
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a The width of an uncertainty band narrows as the proportion of regional mortality estimated using vital registration data increases or the quality and 
completeness of the vital registration data improves.
Estimated TB deaths
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n FIGURE 2.19 
Estimated TB mortality rates 1990−2015, 22 high−burden countries. Estimated TB mortality excludes TB deaths among  
HIV-positive people. The horizontal dashed lines represent the Stop TB Partnership target of a 50% reduction in the mortality 
rate by 2015 compared with 1990. Uncertainty is due to adjustments made to the mortality data from vital registration 



















































































































Afghanistan Bangladeshb Brazil Cambodia China
DR Congo Ethiopia India Indonesia Kenya
Mozambique Myanmar Nigeria Pakistan Philippines
Russian Federation South Africa Thailand Uganda UR Tanzania
Viet Nam Zimbabwe
1990 1995 2000 2005 2010 2015 1990 1995 2000 2005 2010 2015 1990 1995 2000 2005 2010 2015
1990 1995 2000 2005 2010 2015 1990 1995 2000 2005 2010 2015
a The width of an uncertainty band narrows as the proportion of regional mortality 
estimated using vital registration data increases or the quality and completeness 
of the vital registration data improves. 
b For Bangladesh, a joint reassessment of estimates of TB disease burden will be 
undertaken following completion of the national TB prevalence survey.
(defined as females aged ≥15 years) and children (defined as 
people aged <15 years). The cut-of f of 15 years is used because 
it is consistent with the age categories for which notifica-
tion data are reported and with the cut-of f used in current 
guidelines to define people eligible to participate in a TB 
prevalence survey.1 Details of the methods used to produce 
disaggregated estimates are provided in the online techni-
cal appendix.2 
1 TB prevalence surveys: a handbook. Geneva: World Health Organization; 
2011 (WHO/HTM/TB/2010.17). Available at www.who.int/tb/advisory_
bodies/impact_measurement_taskforce/resources_documents/
thelimebook
2 The online technical appendix is available at www.who.int/tb/data. 
2.4.1  TB incidence
Estimates of TB incidence among men and women were 
produced by using notification data combined with the 
assumption that the men:women ratio of notified cases 
(1.7 globally)3 was the same as the ratio for incident cases.4 
In 2014, there were an estimated 5.4 million (range, 5.1–5.8 
million) incident cases among men and 3.2 million (range, 
3.0–3.4 million) among women. 
3 See also Table 3.2 in Chapter 3. 
4 Evidence from national prevalence surveys of bacteriologically-positive 
TB consistently show bigger ratios of prevalence to notifications in men 
than women. This means that the implicit assumption made here, that 
there is no sex dif ferential in the detection of incident cases, may not be 
correct. With currently available data, it is not possible to estimate 
male and female case detection ratios for all countries, but if anything 
the estimates presented in this chapter are underestimating the share 
of total TB incidence that is accounted for by men. 
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n FIGURE 2.20 
Global progress in reporting of TB cases among children, 1995–2014.a Lef t panel: Number of notifications of cases among 
children reported to WHO. Right panel: Percentage of case notifications reported to WHO that are age-disaggregated.
n FIGURE 2.21 
Reporting of new and relapse TB case notifications disaggregated by age, 2014
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a Before 2013 childhood case notifications included smear-positive, smear-negative, smear not done and extrapulmonary TB for all new patients. Af ter 
2013 (shown as a gap in the graph) childhood case notification include all new and relapse cases irrespective of case type.
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Box 2.5 Estimating TB incidence among children: challenges, progress  
 to date and next steps
It is well recognized that estimating the incidence of TB in children 
is dif ficult and that published estimates vary.a,b There are at least 
four major reasons for this:
1. TB in children is rarely bacteriologically confirmed. Direct 
examination of sputum smears and tuberculin skin testing both 
suf fer from very poor diagnostic performance. TB in children is 
thus a condition that is usually clinically diagnosed based on a 
combination of signs and symptoms that are not specific to TB. 
Case definitions are inconsistent among countries and within 
countries over time (as a result of changes in medical practice). 
2. Paediatricians who diagnose TB do not always report cases to 
public health authorities. Childhood TB is not usually a public 
health priority and ef fective linkages between NTPs and the 
hospitals and clinics where children are usually diagnosed are 
lacking. Reporting of cases is therefore of ten incomplete and 
not supported by a legal framework.
3. TB cases among children are less likely to be diagnosed in 
countries with a high burden of TB compared with adults. Sick 
children may be evaluated in facilities with little to no capacity 
to diagnose childhood TB, and diagnostic challenges (the low 
specificity of clinical signs and symptoms) translate into low 
access to quality diagnosis and care services. 
4. Dif ferent methods have been used to produce estimates. 
These include a dynamic model and statistical approaches. 
The estimates included in this report are based on combining 
results from a dynamic model,c a statistical approach based 
on a recent study,d and methods previously used by WHOb in a 
statistical ensemble model.e Estimates from the dynamic model 
and statistical approaches using the most updated data for 2014 
were found to be similar. This has contributed to a more robust 
combined estimate compared with those produced using the 
dynamic model or statistical approaches on their own. In turn, this 
means that the uncertainty interval from the ensemble approach 
is narrower than those of estimates produced from each approach 
used on its own. Nonetheless, the uncertainty interval relative to 
the best estimate is about twice as large as the relative uncertainty 
of the overall TB incidence estimate for all ages. 
The lack of overlap between the estimate of childhood TB 
incidence in this report and the one published in the 2014 editionb 
illustrates the dif ficulties in producing such estimates (explained 
above) and limitations in the documentation of uncertainty. 
The estimates in this report use an updated methodological 
approach recommended by the WHO Global Task Force on TB 
Impact Measurement (Box 2.1, Box 2.2). However, even using 
this approach does not allow all sources of uncertainty, such as 
uncertainty due to model specification, to be fully quantified in 
practice.
The variability and lack of stability in recently published estimates 
of TB incidence among children is concerning. Addressing this 
challenge requires much greater commitment from national public 
health authorities to the definition and application of consistent 
case definitions, to ensuring reporting of cases based on a legal 
framework and ensuring that children who are close contacts 
of people with TB are thoroughly investigated using up-to-date 
national recommendations. 
a JA Seddon and D Shingadia. Epidemiology and disease burden of 
tuberculosis in children: a global perspective. Infect Drug Resist, 
7:153–65, null 2014.
b World Health Organization. Global tuberuclosis report 2014. World Health 
Organization, Geneva; 2014. (WHO/HTM/TB/2014.08). See particularly 
Box 2.5 in Chapter 2. 
c PJ Dodd, E Gardiner, R Coghlan, and JA Seddon. Burden of childhood 
tuberculosis in 22 high-burden countries: a mathematical modelling 
study. Lancet Glob Health 2014; 2:e453–9.
d HE Jenkins, AW Tolman, CM Yuen et al. Incidence of multidrug-
resistant tuberculosis disease in children: systematic review and global 
estimates. Lancet, 2014; 383:1572–9.
e For details, see the online technical appendix to this report at www.
who.int/tb/data.
Global progress in reporting of cases among children 
since 1995 (the first year in which such data were requested 
for the 0–14 age group) and since 2005 (when further dis-
aggregation for those aged 0–4 and 5–14 was requested) is 
shown in Figure 2.20. By 2014, reporting of age-disaggre-
gated notification data was almost universal (Figure 2.21). 
In 2014, 359 000 new and relapse cases among children were 
reported, an increase of about 30% compared with 2013. The 
largest increases were in India (about 30 000) and the Phil-
ippines (about 10 000). Cambodia and Myanmar reported 
age-disaggregated data for the first time.
Producing estimates of TB incidence among children is 
challenging (Box 2.5). However, progress is being made, 
based on collaborations established in 2013 between WHO 
and academic groups working on the estimation of TB dis-
ease burden among children, as well as recommendations 
from a global consultation held earlier in 2015 (Box 2.1, Box 
2.2). Methods to estimate TB incidence in children were 
updated for this report compared with those used to pro-
duce estimates published in 2013 and 2014. The updated 
methods involve use of an ensemble approach in which 
results from two independent methods are combined. The 
first method is based on the WHO approach used since 2012, 
with the modification that child-specific case detection 
ratios (as opposed to one ratio for all ages) are used accord-
ing to previously published methods1 that were updated to 
use more recent notification data.2 The second method is a 
1 HE Jenkins, AW Tolman, CM Yuen et al. Incidence of multidrug-resistant 
tuberculosis disease in children: systematic review and global 
estimates. Lancet, 2014; 383:1572–9.
2 This is in line with WHO suggestions documented in 2014. See 
Sismanidis C, Law I, Glaziou P,et al. The burden of tuberculosis disease 
in children. Lancet. 2014; 384(9951):1343. doi: 10.1016/S0140-
6736(14)61810-9.
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n FIGURE 2.22 
The male:female ratios of TB deaths among adults (aged ≥15 years), globally and by WHO region
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n TABLE 2.6
Estimated number of incident cases of TB among children 




OF TB CASE 
NOTIFICATIONS
ESTIMATED TB INCIDENCE
BEST ESTIMATE UNCERTAINTY INTERVAL
AFR 90 523 330 000 290 000–370 000
AMR 10 489 27 000 25 000–29 000
EMR 42 028 80 000 64 000–97 000
EUR 9 898 31 000 28 000–34 000
SEAR 168 310 340 000 310 000–370 000
WPR 37 273 150 000 130 000–170 000
Global 358 521 1 000 000 900 000–1 100 000
dynamic model that uses adult TB prevalence estimates and 
parameters related to the natural history of TB in children. 
Global and regional estimates of TB incidence among chil-
dren using this ensemble approach are shown in Table 2.6. 
The total estimated number of incident cases in 2014 was 
1 million, with a CDR of 36%. The African and South-East Asia 
Regions account for about one third of global cases each. 
2.4.2 TB mortality
To produce estimates of TB deaths among HIV-negative 
adults, mortality data from VR systems disaggregated by 
age and sex were used. Data were available for 113 countries 
(all middle or high-income countries). For countries with-
out VR data, estimates were produced using an imputation 
model that included risk factors known to be associated with 
TB mortality. This model was used to estimate the ratios of 
the male to female and child to adult number of TB deaths. 
TB deaths among HIV-positive people were disaggregated 
by sex and age using the assumption that the male to female 
and children to adult ratios are similar to the corresponding 
ratios of AIDS deaths estimated by UNAIDS.
TB deaths among HIV-negative people 
There were an estimated 700  000 TB deaths among HIV-
negative men and 340  000 among HIV-negative women in 
2014 (Table 2.7). The male: female ratio was also above two in 
all six WHO regions (lef t panel of Figure 2.22). There were an 
additional 81 000 (range, 69 000–93 000) TB deaths among 
HIV-negative children, equivalent to 7% of the total number 
of HIV-negative TB deaths.
TB deaths among HIV-positive people 
There were an estimated 190 000 TB deaths among HIV-pos-
itive men and 140  000 among HIV-positive women in 2014 
n TABLE 2.7
Estimated number of TB deaths among HIV-negative 












AFR 130 000 81 000–170 000 280 000 170 000–400 000
AMR 5 000 4 200–5 800 11 000 9 700–12 000
EMR 26 000 8 600–43 000 55 000 760–110 000
EUR 9 500 7 800–11 000 24 000 22 000–26 000
SEAR 150 000 90 000–210 000 280 000 160 000–400 000
WPR 29 000 21 000–37 000 53 000 43 000–64 000
Global 340 000 270 000–420 000 700 000 530 000–880 000
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(Table 2.8). Most of these deaths were in the African Region, 
where the male:female ratio was close to one (right panel 
of Figure 2.22). The male:female ratio in other regions var-
ied from around 2–4, with best estimates of 2.4–3.5. There 
were an additional 55 000 (range, 50 000–60 000) TB deaths 
among HIV-positive children, equivalent to 14% of the total 
number of HIV-positive TB deaths.
The total number of TB deaths among children (136 000, 
range 115 000–157 000) corresponds to a CFR of 13.6% (com-
pared with 15.5% in adults). 
2.5 HBC lists to be used by WHO in the  
post-2015 era
2.5.1 Background and brief history
The concept of a “high burden country” has become very 
familiar and widely used in the context of TB. The initial 
definition of HBCs in 1998 was based on the burden of TB 
in absolute terms. Its purpose was to allow focused inter-
ventions in the countries responsible for 80% of the global 
burden (measured in terms of the estimated number of inci-
dent cases), since progress in these countries would translate 
into global impact. The concept was subsequently applied to 
TB/HIV (in 2005) and MDR-TB (in 2008). 
The current list of 22 HBCs (featured throughout this 
chapter) has not changed since 2002, and the HBC lists for 
TB/HIV and MDR-TB have not been updated since 2009 and 
2008, respectively.1 With the end of the MDGs and Stop TB 
Strategy in 2015 and the transition to a new era of Sustain-
able Development Goals (SDGs) and the End TB Strategy 
(Chapter 1), 2015 was the ideal year in which to revisit all three 
HBC lists and consider their future. 
1 For the TB/HIV list, see Table 6.1 in Chapter 6. For the MDR-TB list, see 
Table 4.1 in Chapter 4. 
2.5.2 Process used to revisit HBC lists and their use 
post-2015
The process of revisiting HBC lists started with the develop-
ment of a discussion paper by the Global TB Programme in 
WHO. This provided a brief history of the current HBC lists, 
and identified their potential advantages and disadvan-
tages, drawing on input provided from across the WHO TB 
network, by major global technical and financial agencies, 
and by individuals who played a leading role in the original 
establishment and definition of each list. An online survey 
was then conducted in May 2015, focused on elicitation of 
feedback about the advantages and disadvantages of the 
lists, principles and design characteristics related to their use 
post-2015, and which of four “high-level” options for the use 
of lists af ter 2015 was preferred.2 
Based on feedback received on the discussion paper and 
the results of the online survey, a proposal was then pre-
sented for consideration by WHO’s Strategic and Technical 
Advisory Group for TB (STAG-TB) in June 2015. Full details are 
available in the discussion paper prepared for the STAG-TB 
meeting.3 
2.5.3 Proposal presented to STAG-TB, June 2015
The proposal presented at the June 2015 meeting of STAG-TB 
can be summarized as follows: 
"" Three updated lists, for each of TB, MDR-TB and TB/HIV.
"" Each list includes 30 countries, defined as the top 20 in 
terms of absolute numbers of cases, plus the 10 countries 
with the most severe burden in relative terms that do not 
already appear in the top 20 (“20+10”). 
"" Two options for defining the “additional top ten” that have 
a severe burden in relative terms were presented for con-
sideration. The first was to use rates per capita for the TB 
list, and the proportion of TB cases with MDR-TB and TB/
HIV for the other two lists. The second was to use rates 
per capita for all three lists. It was also recognized that for 
the additional top ten, a threshold in terms of a minimum 
number of cases was relevant. The TB list with and with-
out a threshold of 10 000 cases was presented. 
"" A lifetime of five years for all three lists, 2016–2020. 
The STAG-TB recognized the value of HBC lists and endorsed 
the proposal for three “20+10” lists that would have a lifetime 
of five years. It was recommended to use rates per capita 
to define the additional top-ten countries, and to also use a 
2 These were: 1) Discontinue the use of HBC lists; 2) Continue to use three 
HBC lists (TB, MDR-TB, TB/HIV) but update them using the original 
criteria; 3) Continue to use three HBC lists (TB, MDR-TB, TB/HIV) but 
define them using new criteria; 4) Define one HBC list only.
3 World Health Organization. Use of high TB burden country lists in the 
post-2015 era. Geneva: World Health Organization; 2015. (Discussion 
paper). Available at: www.who.int/tb/data. This document was updated 
in August 2015 to reflect the recommendations provided during the 
STAG-TB meeting and to use the latest estimates of disease burden 
prepared for this report.
n TABLE 2.8
Estimated number of TB deaths among HIV-positive adults 












AFR 120 000 110 000–140 000 130 000 94 000–170 000
AMR 1 700 1 500–1 900 3 900 3 200–4 700
EMR 730 550–920 2 000 1 300–2 700
EUR 850 710–980 2 300 1 800–2 800
SEA 13 000 10 000–15 000 45 000 34 000–57 000
WPR 1 300 1 100–1 600 3 300 2 500–4 000
World 140 000 120 000–160 000 190 000 150 000–230 000
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threshold for a minimum number of cases. It was noted that 
countries with high rates but small numbers of cases are best 
included as part of regional HBC lists (if such lists are consid-
ered useful at that level). 
2.5.4 Definition of HBC lists to be used by WHO  
post-2015, and associated next steps
Following the STAG-TB meeting, the Global TB Programme 
finalized the definition of the HBC lists to be used by WHO 
post-2015, as follows: 
"" Three HBC lists, one for each of TB, MDR-TB and TB/HIV.
"" Each list includes 30 countries, defined as the top 20 in 
terms of absolute numbers and an additional ten that 
have the highest rates per capita and that are not already 
part of the top 20.1 For inclusion in the lists on the basis of 
rates, countries must also have a minimum of 10 000 inci-
dent cases per year (for the TB list) or 1000 cases per year 
(for the TB/HIV and MDR-TB lists). 
1 Some countries with the highest numbers in absolute terms also rank in 
the top ten in terms of rates.
"" The estimates of TB disease burden used to define the 
lists are the most up-to-date estimates available in 2015 
i.e. those published in this 2015 global TB report.
"" The lists will have a lifetime of five years, 2016–2020. 
In each list, the resulting list accounts for 86–90% of the 
global number of cases. 
There are two major next steps in 2015. The first is further 
communication by the Global TB Programme to WHO Mem-
ber States, technical partners and funding agencies about the 
final definition of the lists. The second is a meeting to be held 
on 30 November in association with the international confer-
ence on TB and lung diseases (organized by the Union in Cape 
Town, South Africa). This will focus on implementation of the 
End TB Strategy (Chapter 1) with particular attention to the 
30 countries in the new HBC list for TB. Starting in 2016, the 
new lists of 30 HBCs for TB, TB/HIV and MDR-TB will be used 
by WHO, including in the next edition of the global TB report. 
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Key facts and messages
2015 is a landmark year in global monitoring of TB case 
notifications and treatment outcomes by WHO: it is twenty 
years since a system for annual collection of these data from 
all countries was established in 1995. Between 1995 and 2014, 
data compiled via this system show that a cumulative total of 
78 million cases of TB were notified to WHO and 66 million TB 
patients were successfully treated.
In 2014, 6.3 million cases of TB were notified by national 
tuberculosis programmes (NTPs) and reported to WHO: 
just over 6 million individuals were newly diagnosed in 2014 
and 261 000 were previously diagnosed TB patients whose 
treatment regimen was changed. 
In 2014, most notified TB cases were adults. Children (aged 
<15 years) accounted for 6.5% of notified cases, ranging from 
3.4% in the Western Pacific Region to 9.5% in the Eastern 
Mediterranean Region. The male:female ratio of notified cases 
across all age groups was 1.7 globally, ranging from 1.0 in the 
Eastern Mediterranean Region to 2.1 in the Western Pacific 
Region. 
Among pulmonary TB cases, 58% were bacteriologically 
confirmed (as opposed to clinically diagnosed) in 2014; this was 
unchanged from 2013. 
For the first time since 2007, there was a noticeable increase in 
global TB notifications in 2014 (these had stabilized at around 
5.7–5.8 million new and relapse cases for 2007–2013). The 
increase is explained by a 29% increase in notifications in India, 
linked to the introduction of a policy of mandatory notification, 
a new web-based and case-based reporting system that has 
been rolled out nationwide and greater engagement of the 
country’s large private health sector. India accounted for 27% of 
global TB notifications in 2014, followed by China (14%). 
The private health sector, providers of health services in 
the public sector that are not directly linked to NTPs and 
community workers or volunteers can make important 
contributions to the notification and treatment of TB cases. For 
example, 12% of notifications in India were from the private 
sector in 2014, and 55% of notifications in China were from 
public hospitals outside the NTP network. In six of 41 countries 
that reported data, more than 50% of notifications were from 
community referrals in areas where community engagement 
activities were in place.
Globally, notifications of newly diagnosed TB cases in 2014 
represented 63% (95% uncertainty interval, 60–66%) of 
estimated incident cases. The best estimate of the gap between 
notifications of new episodes of TB (new and relapse cases) and 
incident cases was 3.6 million cases. 
Two factors explain gaps between notifications and estimated 
incidence. The first is under-reporting of diagnosed TB cases: 
for example, of cases detected and treated in the private sector. 
The second is under-diagnosis. Reasons for under-diagnosis 
include poor access to health care and failure to detect cases 
when people with TB visit health care facilities. Intensified 
ef forts, such as those already being made in India, are needed 
to ensure that all cases are detected, notified to national 
surveillance systems, and treated according to international 
standards. 
Globally in 2013, the treatment success rate for new cases of TB 
was 86%. Improvement in treatment outcomes is needed in 
the Region of the Americas and the European Region, where 
treatment success rates in 2013 were 75% and 76%, respectively.
The management of latent TB infection (LTBI) is a critical 
component of the new post-2015 End TB Strategy, and WHO 
issued guidance for upper-middle and high-income countries 
with an incidence rate of less than 100 per 100 000 population 
in 2015. In many of these countries, LTBI policies are in place 
and detection and treatment is being provided. However, there 
are also policy-practice gaps that need to be addressed and 
systems for routine recording and reporting of data need to be 
improved.
Routine recording and reporting of the numbers of TB cases 
diagnosed and treated by national TB programmes (NTPs) 
and monitoring of treatment outcomes was one of the five 
components of the global TB strategy (DOTS) launched by 
WHO in the mid-1990s; this remained a core element of its 
successor, the Stop TB Strategy (2006–2015), and is part of 
the new End TB Strategy (Chapter 1). With the standard defi-
nitions of cases and treatment outcomes recommended by 
WHO and associated recording and reporting framework as 
a foundation, the number of people diagnosed and treated 
for TB and associated treatment outcomes is routinely moni-
tored by NTPs in almost all countries, which in turn report 
these data to WHO in annual rounds of global TB data collec-
tion (Chapter 1). 2015 is a landmark year in global monitoring 
of TB case notifications and treatment outcomes by WHO: it 
is twenty years since a system for annual collection of these 
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data from all countries was established in 1995. Between 1995 
and 2014, data compiled via this system show that a cumula-
tive total of 78 million cases of TB were notified to WHO and 
66 million TB patients were successfully treated.1
This chapter has six parts. Section 3.1 summarizes the 
total number of people diagnosed with TB and notified by 
NTPs in 2014; these numbers are also disaggregated by case 
type, age and sex. Section 3.2 presents and discusses the spe-
cific contribution to total case notifications of public–public 
and public–private mix (PPM) initiatives. Section 3.3 high-
lights the role of community engagement in TB detection 
and treatment. Section 3.4 presents trends in notifications 
between 1990 and 2014 and compares these with trends in 
estimated TB incidence. The ratios of notified to estimated 
incident cases (an indicator known as the case detection rate 
or CDR) are provided for selected years. Section 3.5 describes 
the latest data on treatment outcomes (for cases regis-
tered for treatment in 2013) as well as treatment outcomes 
achieved in selected years since 1995. Section 3.6, the final 
part of the chapter, introduces a new topic to the global TB 
report: policy and practices related to treatment of latent TB 
infection (LTBI). This is a core component of the End TB Strat-
egy, which covers the period 2016–2035 (Chapter 1).
3.1  Case notifications in 2014 by type of 
disease, age and sex
Box 3.1 lists the definitions of TB cases recommended by 
WHO as part of an updated recording and reporting frame-
work issued in March 2013,2 and that were used in the 2014 
and 2015 rounds of global TB data collection. These updated 
definitions were necessary to accommodate diagnosis using 
Xpert MTB/RIF and other WHO-endorsed molecular tests 
(Chapter 5), as well as of fering an opportunity to improve 
aspects of the previous (2006) framework, such as inclusion of 
more comprehensive reporting of TB cases among children. 
Notifications of TB cases in 2014 are summarized glob-
ally, for the six WHO regions and for the 22 high TB-burden 
countries (HBCs) in Table 3.1. In 2014, 6.3 million people with 
TB were notified to NTPs and reported to WHO. Of these, 
just over 6 million had a new episode of TB (shown as the 
total of new and relapse cases) and 261 000 had already been 
diagnosed with TB but their treatment was changed to a 
retreatment regimen. 
For the first time since 2007, there was a noticeable 
increase in global TB notifications in 2014, which had previ-
ously stabilized at 5.7–5.8 million new and relapse cases for 
the seven years from 2007–2013 (Figure 3.1). The increase is 
mostly explained by a 29% increase in notifications in India, 
linked to the introduction of a policy of mandatory notifica-
tion, a new web-based and case-based reporting system that 
1 These figures are for new and relapse cases. See Box 3.1 for case 
definitions.
2 Definitions and reporting framework for tuberculosis – 2013 revision. Geneva, 
World Health Organization; 2013 (WHO/HTM/TB/2013.2). Available at: 
www.who.int/tb/publications/definitions.
has been rolled out nationwide, and greater engagement of 
the country’s large private health sector. India accounted for 
27% of global TB notifications in 2014 (Box 3.2, Figure 3.3), up 
from 22% in 2013. The South-East Asia and Western Pacific 
Regions (which include India and China, respectively) togeth-
er accounted for 63% of notifications of new and relapse 
cases globally, and the African Region for 21%. The other 
three regions accounted for relatively small proportions of 
cases. Among pulmonary TB cases, 58% were bacteriologi-
cally confirmed (as opposed to clinically diagnosed) in 2014; 
this was unchanged from 2013. 
In both the Eastern Mediterranean and Western Pacific 
regions, the TB epidemic is a markedly ageing one, with a 
progressive increase in the notification rate with age and a 
peak among those aged ≥65 years old (Figure 3.4). A similar 
pattern is evident in the South-East Asia Region. Elsewhere, 
and most noticeably in the African Region, notification rates 
in 2014 peaked in younger adults. 
Most countries are now able to report notifications dis-
aggregated by both age and sex (Table 3.2). In 2014, adults 
accounted for most of the notified cases. Children (aged <15 
years) accounted for only 6.5% of notifications, although this 
ranged from 3.4% in the Western Pacific Region to 9.5% in 
the Eastern Mediterranean Region. The global male:female 
sex ratio was 1.7, but among HBCs this ratio varied from 0.7 
in Afghanistan to 3.0 in Viet Nam. Variation among coun-
tries in the child:adult and male:female ratios of cases may 
reflect real dif ferences in epidemiology, dif ferential access 
to or use of health care services linked to the NTP, and/or dif-
ferential reporting practices. Evidence from recent national 
TB prevalence surveys shows that the male:female ratio for 
bacteriologically-confirmed TB among adults is typically 
around 2–3 in Asian countries and 1–2 in Africa, and that the 
ratio of prevalent to notified cases is systematically higher 
among men than women (suggesting that women with TB 
have a higher chance of being notified).3,4
3.2  Contribution of public–public and 
public–private mix initiatives to TB case 
notifications and treatment support in 2014
Ensuring proper diagnosis, standardized treatment and 
prompt notification of all TB cases to NTPs requires collabo-
ration with the full range of health care providers. Engaging 
all care providers in TB care and control is component four of 
the Stop TB Strategy and part of pillar two (of three) of the 
post-2015 End TB Strategy (Chapter 1). 
In recent years, many countries have made con siderable 
progress in scaling up PPM initiatives. However, demon-
3 Onozaki I, Law I, Sismanidis C et al. National tuberculosis prevalence 
surveys in Asia 1990–2012: an overview of results and lessons 
learned. Trop Med Int Health 2015; 20(9):1128–1145. doi: 10.1111/tmi.12534. 
Epub 2015 Jun 7.
4 WHO and partners are preparing a paper summarizing results from 
recent prevalence surveys in Africa. It is anticipated that this will be 
published in 2016.
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Box 3.1 WHO definitions of TB cases recommended for use since March 2013 and  
 that were used in the 2014 and 2015 rounds of global TB data collectiona
Bacteriologically confirmed case of TB A patient from whom 
a biological specimen is positive by smear microscopy, culture or 
WHO-approved rapid diagnostic test (such as Xpert MTB/RIF). All 
such cases should be notified, regardless of whether TB treatment 
is started. 
Clinically diagnosed case of TB A patient who does not fulfil the 
criteria for bacteriologically confirmed TB but has been diagnosed 
with active TB by a clinician or other medical practitioner who 
has decided to give the patient a full course of TB treatment. 
This definition includes cases diagnosed on the basis of X-ray 
abnormalities or suggestive histology and extrapulmonary cases 
without laboratory confirmation. Clinically diagnosed cases 
subsequently found to be bacteriologically positive (before or 
af ter starting treatment) should be reclassified as bacteriologically 
confirmed.
Case of pulmonary TB Any bacteriologically confirmed or 
clinically diagnosed case of TB involving the lung parenchyma or 
the tracheobronchial tree. Miliary TB is classified as pulmonary TB 
because there are lesions in the lungs. Tuberculous intra-thoracic 
lymphadenopathy (mediastinal and/or hilar) or tuberculous 
pleural ef fusion, without radiographic abnormalities in the lungs, 
constitute a case of extrapulmonary TB. A patient with both 
pulmonary and extrapulmonary TB should be classified as a case of 
pulmonary TB.
Case of extrapulmonary TB Any bacteriologically confirmed or 
clinically diagnosed case of TB involving organs other than the 
lungs, e.g. abdomen, genitourinary tract, joints and bones, lymph 
nodes, meninges, pleura, skin.
New case of TB A patient who has never been treated for TB or 
has taken anti-TB drugs for less than one month.
Retreatment case of TB A patient who has been treated for one 
month or more with anti-TB drugs in the past. Retreatment cases 
are further classified by the outcome of their most recent course of 
treatment into four categories. 
1. Relapse patients have previously been treated for TB, were 
declared cured or treatment completed at the end of their 
most recent course of treatment, and are now diagnosed with 
a recurrent episode of TB (either a true relapse or a new episode 
of TB caused by reinfection).
2. Treatment af ter failure patients have previously been treated for 
TB and their most recent course of treatment failed i.e. they had 
a positive sputum smear or culture result at month 5 or later 
during treatment. 
3. Treatment af ter loss to follow-up patients have previously been 
treated for TB and were declared ‘lost to follow-up’ at the end of 
their most recent course of treatment. 
4. Other previously treated patients are those who have previously 
been treated for TB but whose outcome af ter their most recent 
course of treatment is unknown or undocumented. 
Case of multidrug-resistant TB (MDR-TB) TB that is resistant to 
two first-line drugs: isoniazid and rifampicin. For most patients 
diagnosed with MDR-TB, WHO recommends treatment for 20 
months with a regimen that includes second-line anti-TB drugs.
Case of rifampicin-resistant TB (RR-TB) A patient with TB that 
is resistant to rifampicin detected using phenotypic or genotypic 
methods, with or without resistance to other anti-TB drugs. It 
includes any resistance to rifampicin, whether mono-resistance, 
multidrug resistance, polydrug resistance or extensive drug 
resistance.
a Definitions and reporting framework for tuberculosis – 2013 revision. Geneva, 
World Health Organization, 2013 (WHO/HTM/TB/2013.2). Available at 
www.who.int/tb/publications/definitions.
n FIGURE 3.1 
Global trends in absolute number of notified TB cases (black) and estimated TB incidence (green), 1990−2014.  
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Afghanistan 32 712 31 746 966 14 737 8 573 7 227 1 209 65
Bangladesh 196 797 191 166 5 631 106 767 42 832 37 406 2 989 863 309 72
Brazil 81 512 73 970 7 542 41 120 17 801 9 479 3 602 1 488 480 70
Cambodia 43 738 43 059 679 12 168 11 286 18 310 445 709 141 51
China 826 155 819 283 6 872 235 704 526 106 32 348 25 125 33
DR Congo 116 894 115 795 1 099 75 631 13 494 19 566 4 298 1 892 914 84
Ethiopia 119 592 119 592 40 087 41 575 37 930 49
India 1 683 915 1 609 547 74 368 754 268 343 032 275 502 124 679 112 066 66
Indonesia 324 539 322 806 1 733 193 321 101 991 19 653 6 449 1 391 1 66
Kenya 89 294 88 025 1 269 34 997 30 872 14 640 3 569 2 947 1 000 53
Mozambique 58 270 57 773 497 24 430 23 455 6 276 1 542 2 070 50
Myanmar 141 957 138 352 3 605 42 608 70 305 16 108 5 276 3 650 405 39
Nigeria 91 354 86 464 4 890 49 825 29 460 4 764 2 415 0 64
Pakistan 316 577 308 417 8 160 122 537 120 350 57 463 7 420 426 221 52
Philippines 267 436 243 379 24 057 92 991 139 950 4 161 6 277 41
Russian Federation 136 168 102 340 33 828 37 296 40 894 8 763 7 982 6 753 652 49
South Africa 318 193 306 166 12 027 155 473 106 482 33 522 7 430 2 693 566 60
Thailand 71 618 67 722 3 896 34 394 21 115 10 244 1 969 0 0 63
Uganda 46 171 44 187 1 984 26 079 11 854 4 180 1 499 468 107 69
UR Tanzania 63 151 61 571 1 580 23 583 23 380 13 600 1 008 51
Viet Nam 102 087 100 349 1 738 49 938 25 179 18 118 7 114 69
Zimbabwe 32 016 29 653 2 363 11 224 13 151 3 909 1 369 49
High-burden 
countries 5 160 146 4 961 362 198 784 2 179 178 1 763 137 653 169 223 666 137 416 4 796 56
AFR 1 342 400 1 300 852 41 548 635 560 399 155 212 057 39 782 11 217 3 081 62
AMR 228 476 215 243 13 233 127 864 40 746 32 501 10 193 2 918 1 021 76
EMR 465 677 453 393 12 284 183 630 151 696 103 959 12 368 866 874 56
EUR 321 421 266 058 55 363 112 416 76 759 39 175 23 935 11 483 2 290 61
SEAR 2 580 605 2 482 074 98 531 1 188 654 632 418 389 819 152 498 117 970 715 64
WPR 1 375 572 1 335 816 39 756 449 845 734 179 103 085 44 354 3 037 1 316 40
Global 6 314 151 6 053 436 260 715 2 697 969 2 034 953 880 596 283 130 147 491 9 297 58
Blank cells indicate data not reported.
a New and relapse includes cases for which the treatment history is unknown.
strating progress in terms of the contribution of non-NTP 
public and private sector providers to total case notifications 
requires systematic recording of the source of referral and 
place of TB treatment locally, and reporting and analysis of 
aggregated data nationally. In many countries, data related 
to the contribution of private sector providers are still not 
collected or reported through routine monitoring systems, 
although there are excellent examples of how this can be 
done (Box 3.2). 
The available data show that the approach to and contri-
bution of PPM varies across countries, and is related to the 
number and type of health care providers. Table 3.3a shows 
ten prominent examples of countries (including HBCs) where 
public-public mix interventions contributed between 11% 
and 55% of total notifications in 2014. Table 3.3b presents 
ten prominent examples of countries (including HBCs) where 
public-private mix interventions contributed between 12% 
and 46% of total case notifications. 
Box 3.2 Substantial increases in TB notifications in India 2013–2014 – the role of  
 mandatory notification and e-health interventions
The number of new and relapse TB cases notified in India reached 
1.61 million in 2014, a 29% increase compared with 1.24 million 
in 2013 (Figure B3.2). This substantial increase is due to better 
reporting of detected cases to national authorities (as opposed to 
an increase in the underlying TB incidence), which can be explained 
by three major factors:
" The introduction of a policy of mandatory notification of TB 
cases in May 2012;a 
" The launch of a new web-based system (Nikshay) for case-
based notification by the Central TB Division (CTD) and the 
National Informatics Centre in June 2012;b 
" Increased and intensified ef forts to engage with the 
private sector by the Revised National Tuberculosis Control 
Programme (RNTCP), which have been facilitated by Nikshay. 
(DOT), patient transfers, and contact tracing, as well as 
demographic and clinical details of the individual TB patient such 
as age, sex, HIV status, bacteriology and drug-susceptibility test 
results, and treatment outcomes. This has allowed the RNTCP 
to generate reports consistent with updated definitions of case 
definitions and treatment outcomes recommended by WHO since 
2013 (Box 3.1). This includes age and sex-disaggregated data for 
all new and relapse cases, which could not be produced using the 
old reporting system. The CTD uses five variables to avoid entry 
of duplicate records in Nikshay. The greater granularity of the 
data being recorded in Nikshay is also allowing better forecasting 
of TB drug requirements for children and adults, and provides 
information on the nutritional status of patients. 
To support the introduction and implementation of Nikshay, 
online videos in English and Hindi were used to train frontline 
workers, and mobile-phone short messaging services (SMS) were 
used to ensure regular contact of users with programme managers 
at all levels. Managers can now receive reports on case-finding, 
sputum conversion and treatment outcome via SMS. Patients – 
half of whom have a mobile number entered in the system – also 
benefit from SMS reminders for visits related to follow-up of 
treatment. Traditional paper-based and aggregated quarterly 
reporting will be phased out in 2016, and reporting will be entirely 
through Nikshay.
In the next phase of Nikshay’s development, the aim is to capture 
geospatial data to enable spatial surveillance, and to use and 
record bar-codes on medication boxes for drug supply chain and 
inventory management. Linking up with other electronic services 
may also allow electronic payments to patients and providers, and 
access to the national unique identification number (Aadhaar)d 
and related social support schemes for TB patients. 
The cities of Mumbai, Patna and Mehsana already provide good 
examples of how digital technologies are helping the RNTCP to 
reach out to providers who are involved in TB care but who have 
previously been outside the reach of national surveillance. In these 
settings, private providers can phone call centres free of charge to 
ensure free anti-TB medications for their patients. Patients receive 
“e-vouchers” for standardized medications, which they can redeem 
at no charge at private chemists. Call centres also issue reminders 
to patients for follow-up visits via telephone calls and SMS. This 
digital system is linked with the RNTCP, so that programme staf f 
receive alerts and can take actions as necessary. Incentives for 
notification are paid to providers electronically, as are payments 
for laboratory tests. e-Learning tools have also been introduced to 
facilitate the dissemination of the ‘Standards for TB Care in India’, 
and e-Learning techniques have also been useful for rapid, large-
scale training of staf f on the use of the call centres.
a http://pib.nic.in/newsite/erelease.aspx?relid=83486
b http://nikshay.gov.in/AboutNikshay.htm
c Satyanarayana S, Nair SA, Chadha SS, et al. From where are tuberculosis 
patients accessing treatment in India? Results from a cross-sectional 
community based survey of 30 districts. PLoS One 2011; 6: e24160
d https://resident.uidai.net.in/
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FIGURE B3.2 



















Mandatory notification was introduced in recognition of the fact 
that while the private sector provides treatment for approximately 
50% of TB patients,c most of these cases were not being reported 
to the RNTCP. 
Nikshay was introduced as part of ef forts to facilitate reporting of 
TB cases, including those treated in the private sector. The system 
is available for reporting of cases by both public and private health 
care facilities. It is accessible via android-based smartphones and a 
web-portal, both of which facilitate the process of notifying cases. 
Since its rollout nationwide by the end of 2012, reporting from 
the private sector has grown and data quality has improved. By 
June 2015, more than 4.6 million TB patients had been reported by 
over 40 000 public and over 90 000 private health care facilities, 
with about 5 000 TB cases being added to the system each day. 
Nikshay has also eliminated the time previously taken to transmit 
laboratory results to treatment sites and peripheral units. 
Nikshay captures data that are important for both programme 
management and clinical care. These include details of who 
notified a TB case, who provides direct observation of treatment 
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n FIGURE 3.2 
Case notification and estimated TB incidence rates by WHO region, 1990−2014. Regional trends in case notification  
rates (new and relapse cases, all forms) (black) and estimated TB incidence rates (green). Shaded areas represent  
uncertainty bands.
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In China, a large proportion of people with TB seek 
care from public hospitals, and various models of hospital 
engage ment exist. In 2014, public hospitals contributed 55% 
of all notified TB cases. A web-based system for reporting 
of communicable diseases has played a key role in ensuring 
that TB cases detected in public hospitals outside the NTP 
network are notified. Medical college hospitals in India, 
speciality lung hospitals and general hospitals in Indonesia, 
hospitals owned by social security organizations in Peru 
and other Latin American countries, and the hospitals of 
health insurance organizations in Egypt are other examples 
of public health care providers that are making important 
contributions to TB case notifications. In 2014, public sector 
medical college hospitals in India alone reported 176 000 
TB cases. Given that health centres and hospitals are of ten 
managed by dif ferent departments within ministries of 
health and that ministries such as those for education, social 
welfare, defence or justice can also be involved in providing 
health services, implementing public-public mix approaches 
is essential in many parts of the world.
Public-private mix approaches are necessary in coun-
tries with a large private sector, including most HBCs in the 
South-East Asia and Western Pacific regions and an increas-
ing number of countries in the African Region, where the 
private medical sector is growing rapidly. The steep rise in 
TB case notifications from private sector care providers in 
India between 2013 and 2014 (from 85 000 to 195 000 in 2014) 
is particularly impressive. Further details are provided in 
Box 3.2. A large increase of more than 30% in notifications 
from the private sector in Pakistan between 2013 and 2014 is 
also a notable achievement. Both countries have made con-
certed ef forts to increase notifications of detected cases by 
the private sector, and these are now paying of f. 
The private health sector in Africa is of ten considered 
insignificant in terms of its contribution to provision of TB 
care. Data from Kenya, Malawi and Nigeria show that this 
is not always the case. In 2014 as in 2013, almost one in five 
cases notified in Malawi was reported by a private care 
provider, even though TB drugs are generally not available 
in private pharmacies (unlike in Kenya and Nigeria). Most 
of the contributions to TB case notifications in Malawi are 
referrals of people with TB signs and symptoms to the pub-
lic sector by the front-line, community-based private health 
care providers. These of ten include clinical of ficers, nurses 
and traditional healers. Engaging such front-line care pro-
viders, including drug shops and pharmacies, facilitates 
early case detection. The Malawi example should prompt 
other countries that have not previously considered PPM to 
be of importance to revisit their strategies. In all settings, 
PPM interventions should also be designed to help not only 
detection of TB cases, but also early detection by providers 
where care is of ten sought first. 
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n FIGURE 3.3 
Case notification and estimated TB incidence rates, 22 high-burden countries, 1990−2014. Trends in case notification  





















































































































1990 1995 2000 2005 2010 2015 1990 1995 2000 2005 2010 2015 1990 1995 2000 2005 2010 2015
1990 1995 2000 2005 2010 2015 1990 1995 2000 2005 2010 2015
Afghanistan Bangladesha Brazil Cambodia China
DR Congo Ethiopia India Indonesia Kenya
Mozambique Myanmar Nigeria Pakistan Philippines
Russian Federation South Africa Thailand Uganda UR Tanzania
Viet Nam Zimbabwe
a For Bangladesh, a joint reassessment of estimates of TB disease burden will be 
undertaken following completion of the national TB prevalence survey.
n FIGURE 3.4
Regional TB notification rates by age, 2014a
a Countries not reporting cases in these categories are excluded.  
Cases included make up 87% of reported cases and exclude the 





























3.3 Community contributions to TB 
notifications and treatment support
Despite the best ef forts of health systems, about one third of 
people who develop TB globally are still either not diagnosed, 
or their cases are not reported (see section 3.5). Dif ficulty in 
accessing health facilities is one of the reasons why people 
with TB may not be diagnosed, and can also have a negative 
impact on treatment adherence. Access to health care can 
be af fected by social and political factors (such as stigma 
and discrimination, and the availability of cross-border ser-
vices for migrants), and economic barriers (for example, 
the cost of transport). The role of community engagement 
in contributing to TB prevention, diagnosis and treatment, 
especially where people with TB have poor access to formal 
health services, is therefore well-recognized. Fostering such 
community participation has been an explicit component of 
the Stop TB Strategy and a “strong coalition with civil society 
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n TABLE 3.2 











Afghanistan* 4 454 18 856 7 227 19 0.7
Bangladesh* 6 262 180 743 0 3.3 1.5
Brazil 2 368 71 602 0 3.2 2.1
Cambodia 12 050 31 009 28 1.2
China 4 164 815 119 0 0.5 2.3
DR Congo* 3 438 71 901 292 4.6 1.3
Ethiopia* 15 917 103 675 0 13 1.2
India 95 709 1 513 838 5.9 1.9
Indonesia 23 170 299 636 0 7.2 1.4
Kenya 8 448 80 846 0 9.5 1.5
Mozambique – –
Myanmar 36 301 101 987 64 26 1.6
Nigeria 5 463 85 891 0 6.0 1.5
Pakistan 27 245 281 172 0 8.8 1.0
Philippines 12 191 46 965 38 422 21 1.8
Russian 
Federation 3 195 98 433 712 3.1 2.3
South Africa 31 977 274 189 0 10 1.3
Thailand* 119 34 275 0 0.3 2.5
Uganda 3 316 40 871 7.5 1.8
UR Tanzania 6 463 55 108 0 10 1.5
Viet Nam* 144 49 785 0.3 3.0
Zimbabwe 2 290 27 363 7.7 1.3
High-burden 
countries 304 684 4 283 264 46 717 6.6 1.7
AFR 90 523 963 808 2 298 8.6 1.4
AMR 10 489 198 350 1 935 5.0 1.7
EMR 42 028 399 043 7 945 9.5 1.0
EUR 9 898 250 946 719 3.8 2.0
SEAR 168 310 2 248 065 19 394 7.0 1.8
WPR 37 273 1 063 252 38 422 3.4 2.1
Global 358 521 5 123 464 70 713 6.5 1.7
Blank cells indicate data that could not be reported for the age categories 
shown.
–  indicates values that cannot be calculated.
* New cases only.
TABLE 3.3a
Contribution of public-public mixa to notifications of  
TB cases in selected countries, 2014
COUNTRY
NUMBER OF  
TB CASES NOTIFIED 
BY NON-NTP PUBLIC 
SECTOR CARE 
PROVIDERS 
TOTAL NUMBER  






TO TOTAL CASE 
NOTIFICATIONS (%) 
China 458 356 826 155 55
Côte d’Ivoire 2 279 23 750 9.5
Egypt 1 375 7 467 18
El Salvador 1 016 2 220 46
India 189 857 1 683 915 11
Indonesia 57 586 324 539 18
Iraq 2 748 8 341 33
Peru 8 164 31 461 26
Sri Lanka 4 457 9 473 47
Yemen 3 390 9 693 35
a Includes all contributions from non-NTP providers of care in the public 
sector, including public hospitals, public medical colleges, prisons/
detention centres, military facilities, railways and public health 
insurance organizations.
TABLE 3.3b
Contribution of public-private mixa to notifications of  
TB cases in selected countries, 2014
COUNTRY
NUMBER OF  
TB CASES NOTIFIED 
BY PRIVATE SECTOR 
CARE PROVIDERS
TOTAL NUMBER  







Bangladesh 22 960 196 797 12
Ethiopia 16 876 119 592 14
India 194 992 1 683 915 12
Iran 3 093 10 395 30
Iraq 3 803 8 341 46
Kenya 18 200 89 294 20
Malawi 3 500 17 723 20
Myanmar 25 978 141 957 18
Nigeria 13 031 91 354 14
Pakistan 55 254 316 577 17
a Private sector providers include private individual and institutional 
providers, corporate/business sector providers, mission hospitals, 
nongovernmental organizations and faith-based organizations.
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organizations and communities” is one of the four principles 
underpinning the End TB Strategy (Chapter 1). Establishing 
and strengthening collaboration with nongovernmental 
and other civil society organizations to scale up community-
based TB activities, and enhancing their role in the design 
and implementation of national TB strategic plans, are 
important. 
Accurate monitoring of the contributions of communities 
to TB notifications and treatment support requires standard 
definitions of key concepts and indicators, and standard-
ized systems for recording and reporting of data. These were 
developed in 2013 and are shown in Box 3.3. Data for the 
three core indicators were collected for the first time in 2013, 
with a focus on 13 countries in the African and South-East 
Asia regions that were known to be recording and report-
ing such information. In 2014, data collection was expanded 
and 22 countries from the same two regions reported data. 
Based on these two years of experience, data collection was 
expanded in the 2015 round of global TB data collection to 
cover the European, Eastern Mediterranean and Western 
Pacific regions. Following consultations with WHO staf f in 
Regional and Country Of fices, a total of 69 countries were 
targeted for reporting of data. Of these, 41 reported data for 
at least one of the three core indicators; 34 (83%) reported 
data on the percentage of TB patients who received treat-
ment support in the community, and 30 (73%) reported data 
on the percentage of TB notifications that originated from 
community referrals. 
A summary of the contribution of communities to TB 
notifications and treatment support is provided in Table 
Box 3.3 Definitions of key terms and indicators used to monitor  
 community engagement
Community-based TB activities. These cover a wide range 
of activities that contribute to the detection, referral and 
treatment of people with drug-susceptible, drug-resistant and 
HIV-associated TB. They are conducted outside the premises of 
formal health facilities (e.g. hospitals, health centres and clinics) 
in community-based structures (e.g. schools, places of worship, 
congregate settings, markets) and homesteads. Community 
health workers and community volunteers carry out community-
based TB activities, depending on the national and local context. 
Community health workers. These are people with some 
formal education who have been given training to contribute to 
community-based health services, including TB prevention and 
patient care and support. Their profile, roles and responsibilities 
vary greatly among countries, and their time is of ten compensated 
by incentives in kind or in cash.
Community volunteers. These are people who have been 
systematically sensitized about TB prevention and care, either 
through a short, specific training scheme or through repeated, 
regular contact sessions with professional health workers.
Core indicators for routine monitoring of community-based TB 
activities
In 2013, three core indicators were defined and agreed by WHO 
and partners. These are:
1. Percentage of TB notifications from community referrals. This 
indicator measures the proportion of notified TB patients (all 
forms of TB) who were referred by a community health worker 
or community volunteer.
2. Percentage of registered TB patients who received treatment support 
in the community. This indicator measures the proportion 
of TB patients who were supported during treatment by a 
community health worker or community volunteer.
3. Percentage of registered TB patients who received treatment 
support in the community who were successfully treated. This 
indicator measures the proportion of TB patients who received 
treatment support from a community health worker or 
community volunteer during their TB treatment and who were 
successfully treated. 
3.4. About one third (14/41) of countries reported nationwide 
coverage of community engagement in case notification, 
and 41% (17/41) reported nationwide coverage of community-
based treatment support. In areas where community-based 
referral activities were in place, the percentage of notified 
TB patients accounted for by community referrals ranged 
from 2% in Myanmar and Sri Lanka to 73% in Cambodia. The 
proportion of TB patients receiving community-based treat-
ment support ranged from 2% in Malaysia, Romania and 
Sierra Leone to 100% in Kenya, Pakistan and Tajikistan. 
Reporting of the treatment success rate among TB 
patients who received treatment support in the commu-
nity has continued to be a challenge. Among the 41 countries 
that reported data related to community engagement, only 
26 (41%) reported information for this indicator. Even in 
these countries, there are concerns with the accuracy of the 
reported data. For example, while the general tendency was 
for treatment outcomes to improve between 2013 and 2014 
among patients receiving treatment support from a com-
munity volunteer or community health worker, there were 
large year-to-year changes in some countries that appeared 
implausible. Intensified ef forts are needed to improve the 
accuracy of data for this indicator, and/or to revisit its status 
as a core indicator. For example, it may be more appropriate 
to assess this indicator as part of a periodic evaluation, rather 
than through routine reporting. This is being considered by 
WHO as part of wider ef forts to develop expanded guidance 
on community engagement. 
It is also important to note that there are countries in 
which community-based TB activities are a routine com-
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Box 3.4 The ENGAGE-TB approach: progress and highlights to date
The ENGAGE-TB approach aims to integrate community-based TB activities into the work of nongovernmental organizations and other 
civil society organizations that were previously not engaged in TB prevention, diagnosis and treatment. Pilot projects were started in 
2012 with funding from the Bristol-Myers Squibb Foundation Secure the Future in five countries: the Democratic Republic of the Congo, 
Ethiopia, Kenya, South Africa and the United Republic of Tanzania. In Ethiopia, TB activities were integrated into maternal and child health 
activities and cervical cancer screening. In Kenya, they were integrated into maternal and child health activities and livelihood initiatives. In 
the other three countries, they were integrated into HIV programmes. 
By the end of 2014, the total population covered by the pilot projects had reached 8 million and 24 previously unengaged nongovernmental 
organizations had started to implement community-based TB activities. In pilot areas, community referrals of people with signs and 
symptoms suggestive of TB contributed 5–68% of notified TB patients in 2013 and 2014, and 20–89% of all TB patients had benefited from 
community-based treatment support during the same period. 
ponent of TB services, but where it is not yet possible to 
quantify this contribution. For example, Zimbabwe has 
recently finalized revisions to its national monitoring and 
evaluation system and will be able to report data on commu-
nity contributions starting in 2016. In the near future, it is also 
anticipated that Malawi will incorporate routine reporting of 
community contributions within the existing monitoring and 
evaluation system. 
In addition to improving the documentation and report-
ing of community-based TB activities, ef forts to engage 
nongovernmental organizations that have previously not 
been involved in TB prevention, diagnosis and treatment 
have continued using the ENGAGE-TB approach.1 In addition 
to five focus countries (the Democratic Republic of the Con-
go, Ethiopia, Kenya, South Africa and the United Republic 
of Tanzania), five additional countries have now integrated 
the ENGAGE-TB approach into their national strategies and 
mobilized funding for its implementation. These are Burkina 
Faso, Côte d’Ivoire, Malawi, Namibia and Zimbabwe. Pro-
gress made to date in the original five countries is described 
in Box 3.4. 
3.4  Trends in case notifications 1990–2014 and 
estimates of the case detection rate
Globally, the number of TB cases newly diagnosed and noti-
fied per 100 000 population remained relatively stable 
between 1990 and 2000, rose sharply between 2000 and 
2008, and then fell slowly from 2009 to 2013 (Figure 3.1). In 
terms of absolute numbers, there was an increase from 1995 
to 2000, a more pronounced increase from 2000 to 2008 
and then very little change from 2008 to 2013 (Figure 3.1). 
Between 2013 and 2014, these patterns changed, with a clear 
upward increase in terms of rates and absolute numbers. 
This change is driven by an increase in the South-East Asia 
Region (Figure 3.2), which itself reflects the large increase 
in notifications (of 366 000 cases) in India between 2013 and 
2014 (Figure 3.3, Box 3.2). 
1 http://www.who.int/tb/people_and_communities/en/
Globally and in all WHO regions, a clear gap exists 
between the numbers of notified cases and the estimated 
numbers of incident cases. However, this gap has narrowed 
in the last 15 years, especially in the Eastern Mediterranean 
and Western Pacific regions and to a lesser extent in the 
South-East Asia Region (Figure 3.2). Trends in the 22 HBCs 
are shown in Figure 3.3; for other countries these trends are 
illustrated in country profiles that are available online.2
The case detection rate (CDR)3 for TB is an indicator that 
is included within the Millennium Development Goals (MDG)
framework. For a given country and year, the CDR is calculat-
ed as the number of new and relapse TB cases (see Box 3.1 for 
definitions) that were notified by NTPs (Table 3.1), divided by 
the estimated number of incident cases of TB that year. The 
CDR is expressed as a percentage; it gives an approximate4 
indication of the proportion of all incident TB cases that are 
actually diagnosed and reported to NTPs or national surveil-
lance systems. 
The best estimate of the CDR for all forms of TB globally 
in 2014 was 63% (range, 60–66%), up from 48–52% in 2005 
and 36–40% in 1995 – the year in which the DOTS strategy 
began to be introduced and expanded (Table 3.5).5 The best 
estimate of the global gap between notifications (of new epi-
sodes of TB i.e. new and relapse cases) and incident cases in 
2014 was 3.6 million cases. 
At regional level, the highest CDRs in 2014 were estimat-
ed to be in the Region of the Americas (best estimate 77%; 
range, 75–81%), the Western Pacific Region (best estimate 
85%; range, 81–90%) and the European Region (best esti-
mate 79%; range, 75–83%). The other regions had estimated 
CDRs of 43–75%, with best estimates in the range 48−62%. 
2 www.who.int/tb/data
3 The CDR is actually a ratio rather than a rate, but the term ‘rate’ has 
become standard terminology in the context of this indicator.
4 It is approximate because of uncertainty in the underlying incidence of 
TB and because notified cases are not necessarily a subset of incident 
cases that occurred in the same year; see Chapter 2 for further 
discussion.
5 The ranges represent 95% uncertainty intervals. There is uncertainty in 
estimates of the CDR because of uncertainty in estimates of TB 
incidence (the denominator).
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TABLE 3.4
Community contributions to TB case notifications and treatment support for TB patients (all forms) in 41 countries,a 
2013–2014. Data are for the basic management units (BMUs) that reported data.
COUNTRIES
CONTRIBUTION TO TB NOTIFICATIONS, 2014 CONTRIBUTION TO TREATMENT ADHERENCE SUPPORT, 2013
TOTAL TB NOTIFICATIONS (ALL FORMS) FROM 
COMMUNITY REFERRALS IN 2014
GEOGRAPHIC 
COVERAGE OF DATA 
REPORTING BY BMUs
TB PATIENTS (ALL FORMS) WHO RECEIVED 
TREATMENT ADHERENCE SUPPORT IN THE 
COMMUNITY IN 2013
GEOGRAPHIC 
COVERAGE OF DATA 
REPORTING BY BMUsNUMBER
% OF BMU 
NOTIFICATIONS NUMBER % OF ALL TB PATIENTS
Afghanistan 1 088 7 661/722 1 089 13 336/722
Bangladesh 79 477 61 478/880 Not available
Botswana Not available 5 316 63 27/27
Bulgaria 229 15 22/22 Not available
Burkina Faso 299 5 86/86 1 569 39 30/86
Burundi 796 11 17/17 1 335 18 17/17
Cambodia 14 115 73 43/93 Not available
Côte d’Ivoire 8 165 36 151/184 7 785 29 134/184
DR Congo 12 649 57 95/516 7 202 49 95/516
Eritrea 102 4 69/69 Not available
Ethiopia 14 399 38 364/957 11 314 22 760/957
Georgia 28 82 3/77 Not available
Ghana 326 16 49/216 11 392 73 216/216
Guineab 1 307 11 55/465 1 307 12 55/465
India 19 713 3 1 200/3 394 726 069 52 3 394/3 394
Indonesia 8 707 11 47/511 4 218 14 27/511
Kenya 3 535 9 798/3 320 78 813 100 3 046/3 320
Lesotho Not available 9 649 90 17/34
Madagascar 5 914 52 72/215 382 5 72/215
Malaysia Not available 84 2 15/146
Mongolia 351 8 32/32 731 16 32/32
Mozambiqueb 2 868 5 323/323 5 656 11 251/323
Myanmar 1 304 2 171/354 1 605 5 165/354
Namibia Not available 6 463 63 31/34
Nepal 457 3 75/75 363 19 5/75
Nigeria Not available 55 995 56 774/774
Pakistan Not available 231 557 100 1 137/1 306
Republic of Moldova Not available 3 308 78 57/57
Romania Not available 320 2 177/177
Rwanda 1 188 20 515/515 2 889 48 515/515
Sao Tome and Principe 109 69 1/1 Not available
Senegal 1 011 10 76/76 891 7 76/76
Sierra Leone 3 065 40 170/170 187 2 170/170
South Africac 928 0.3 Not available Not available
Sri Lanka 85 2 26/26 1 637 18 26/26
Tajikistan 883 14 109/109 6 495 100 109/109
Timor-Leste Not available 244 7 18/18
Uganda Not available 26 044 55 117/117
UR Tanzania 10 416 18 168/168 49 412 75 168/168
Uzbekistanb 7 191 64 4 278/4 516 20 812 96 4 433/4 516
Viet Nam Not available 100 721 99 815/815
a Twenty-eight countries did not submit data for either indicator: Algeria, Angola, Armenia, Azerbaijan, Benin, Bhutan, Cameroon, Cape Verde, Central 
African Republic, Chad, Congo, Gabon, Gambia, Guinea-Bissau, Kiribati, Liberia, Malawi, Mali, Mauritania, Niger, Philippines, Sudan, Swaziland, 
Thailand, Togo, Turkey, Zambia and Zimbabwe.      
b The proportion of patients receiving treatment support in the community was calculated using the total cohort (all BMUs) of TB patients starting 
treatment in 2013 as the denominator. Data disaggregated by BMU were not reported.      
c The proportion of notifications that came from community referrals was calculated using the total cohort (all BMUs) of TB patients notified in 2014 as 
the denominator. Data disaggregated by BMU were not reported.      
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n TABLE 3.5 
Estimates of the case detection rate for new and relapse cases %, 1995–2014.a Best estimates are followed by the lower and 
upper bounds of the 95% uncertainty interval
1995 2000 2005 2010 2014
Afghanistan – – 19 18–21 47 44–51 53 48–59 53 47–60
Bangladesh 21 20–23 26 24–28 38 36–41 45 41–50 53 47–60
Brazil 79 73–85 73 67–80 84 79–90 82 78–86 82 78–86
Cambodia 24 22–26 27 25–30 52 49–56 65 59–70 72 66–80
China 33 31–35 33 31–35 75 71–79 87 81–94 88 82–95
DR Congo 31 29–33 39 36–42 53 50–56 53 49–57 48 43–52
Ethiopia 11 9.3–13 33 27–40 48 41–57 66 55–80 60 49–73
India 59 56–61 49 47–51 48 47–50 59 55–62 74 70–80
Indonesia 4 2.9–5.8 8.9 6.5–13 26 19–37 30 22–44 32 23–46
Kenya 62 60–64 72 70–74 81 79–82 82 80–84 80 78–82
Mozambique 23 18–32 23 17–31 30 25–36 33 27–40 39 31–49
Myanmar 10 9.3–11 16 14–17 53 50–56 66 61–72 70 64–78
Nigeria 4.3 3.4–5.7 6.5 4.9–9.1 13 11–18 16 11–24 15 10–26
Pakistan 3.9 3.3–4.6 2.9 2.4–3.6 34 29–40 56 45–73 62 48–83
Philippines 42 39–46 42 38–46 47 44–51 58 52–65 85 76–97
Russian Federation 60 56–64 75 70–80 65 62–69 84 77–92 85 77–94
South Africa 59 53–67 58 51–65 60 53–68 73 65–82 68 61–77
Thailand 41 26–78 23 14–43 39 24–74 56 34–100 59 36–110
Uganda 23 19–27 30 25–37 48 43–55 62 55–70 72 64–83
UR Tanzania 28 16–62 32 20–61 31 20–54 31 20–58 36 21–77
Viet Nam 34 30–38 57 50–65 64 58–71 71 61–84 77 65–94
Zimbabwe 61 44–92 67 54–86 66 54–83 76 59–100 70 51–100
High-burden countries 34 33–36 35 33–36 48 46–50 57 54–60 62 58–66
AFR 28 26–30 34 32–37 44 41–47 50 46–55 48 43–54
AMR 69 66–72 71 68–74 76 74–79 76 73–79 77 75–81
EMR 22 19–24 23 20–27 44 39–50 58 50–69 61 51–75
EUR 58 57–60 65 63–67 69 67–72 80 76–84 79 75–83
SEAR 38 35–42 35 32–39 43 39–46 52 47–57 62 56–68
WPR 36 35–38 38 36–40 69 66–71 79 75–83 85 81–90
Global 37 36–39 38 36–40 50 48–52 58 55–61 63 60–66
–  indicates values that cannot be calculated.
a  Estimates for all years are recalculated as new information becomes available and techniques are refined, so they may dif fer from those published 
previously. The lower and upper bounds are defined as the 2.5th and 97.5th centiles of outcome distributions produced in simulations.
All regions have improved their estimated CDRs since the 
mid-1990s, with improvements particularly evident since 
2000. Among the 22 HBCs, the highest rates of case detec-
tion in 2014 (>80%) were estimated to be in Brazil, China, the 
Philippines and the Russian Federation. The lowest rates, 
with best estimates of 50% or less, were in the Democratic 
Republic of the Congo, Indonesia, Mozambique, Nigeria and 
the United Republic of Tanzania. 
There are two major reasons for a gap between notifica-
tions and estimated incidence. The first is underreporting 
of diagnosed TB cases, for example because private sector 
providers fail to notify cases. This is one of the reasons for a 
relatively low CDR in Indonesia (see also Box 2.4, Chapter 2). 
The second is under-diagnosis of people with TB for reasons 
such as poor access to health care and failure to recognize TB 
signs and symptoms and test for TB when people do present 
to health care facilities. A good example is Nigeria, where 
the 2012 national TB prevalence survey suggested that this is 
a major reason for the low CDR.1 It should also be acknowl-
edged that the estimates of TB incidence are uncertain, and 
the gap between the estimated number of incident cases and 
1 World Health Organization. Global tuberculosis report 2014. Geneva: 
World Health Organization; 2014 (WHO/HTM/TB/2014.08). See 
pp10–11.
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the number of notifications could be under- or over-stated. 
Intensified ef forts are needed to ensure that all cases 
are detected, notified to national surveillance systems, 
and treated according to international standards. Progress 
towards the goal of universal health coverage, implementa-
tion of PPM initiatives such as those described in section 3.2, 
and ensuring that there is an ef fective regulatory framework 
that includes mandatory notification of cases are all essential 
to reduce underreporting and under-diagnosis, and con-
stitute part of the End TB Strategy (Chapter 1). The current 
status of progress towards universal health coverage from a 
financing perspective is discussed further in Chapter 7.
3.5  Treatment outcomes
The definitions of TB treatment outcomes for new and 
relapse cases of TB that are recommended by WHO as part 
of an updated recording and reporting framework issued 
in March 2013, and used in the 2015 round of global TB data 
collection, are shown in Box 3.5.1 Most of these cases (97% 
globally) have drug-susceptible TB, but in some parts of the 
world, especially countries of the former Soviet Union, more 
than 20% of new and relapse cases have MDR-TB (Chapter 4). 
Universal access to drug susceptibility testing, as called for in 
the End TB Strategy (Chapter 1), is required to ensure that all 
people with TB receive appropriate treatment. 
Data on treatment outcomes for new and relapse cases of 
1 Treatment outcomes for people diagnosed with rifampicin-resistant 
and MDR-TB are presented in Chapter 4. 
TB are shown for the world, the six WHO regions and the 22 
HBCs in Table 3.6 and Figure 3.5. Globally, the treatment suc-
cess rate for the 5.4 million new and relapse cases that were 
treated in the 2013 cohort was 86%. It is impressive that as 
the size of the global treatment cohort grew from 1.0 million 
in 1995 to 4.2 million in 2005 and 5.4 million in 2013, the treat-
ment success rate first improved and has subsequently been 
sustained at a high level. 
Among the six WHO regions, the highest treatment 
success rates were in the Western Pacific Region, the South-
East Asia Region and the Eastern Mediterranean Region. 
The treatment success rate was 79% in the African Region. 
The lowest treatment success rates were in the Region of 
the Americas and the European Region (both 75%). In the 
Region of the Americas, treatment outcomes would prob-
ably be considerably improved if the number of patients in 
the “not evaluated” category could be reduced. In the Euro-
pean Region, rates of treatment failure, death and loss to 
follow-up, as well as the proportion of patients without a 
documented treatment outcome, all need to be reduced. 
One explanation for the poor outcomes in this region may be 
that the proportion of new and relapse cases that have drug-
resistant TB is high (Chapter 4). All cases need to be tested 
for susceptibility to first-line drugs, and those with rifampic-
in-resistant and MDR-TB enrolled on second-line rather than 
first-line regimens. 
Most of the 22 HBCs have reached or exceeded a treat-
ment success rate of 85%. Improvements are still needed in 
Box 3.5 Definitions of treatment outcomes for new and relapse cases recommended  
 for use since March 2013 and that were used in the 2014 and 2015 rounds of  
 global TB data collectiona
Cured A pulmonary TB patient with bacteriologically-confirmed 
TB at the beginning of treatment who was smear- or culture-
negative in the last month of treatment and on at least one 
previous occasion. 
Completed treatment A TB patient who completed treatment 
without evidence of failure but with no record to show that sputum 
smear or culture results in the last month of treatment and on at 
least one previous occasion were negative, either because tests 
were not done or because results are unavailable. 
Died A TB patient who died from any cause during treatment.
Failed A TB patient whose sputum smear or culture is positive at 
month five or later during treatment.
Lost to follow-up A TB patient who did not start treatment or 
whose treatment was interrupted for two consecutive months or 
more.
Not evaluated A TB patient for whom no treatment outcome 
is assigned. This includes cases ‘transferred out’ to another 
treatment unit as well as cases for whom the treatment outcome is 
unknown to the reporting unit.
Successfully treated A patient who was cured or who completed 
treatment.
Cohort A group of patients in whom TB has been diagnosed, and 
who were registered for treatment during a specified time period 
(e.g. the cohort of new cases registered in the calendar year 2012). 
This group forms the denominator for calculating treatment 
outcomes. The sum of the patients included in the above treatment 
outcome categories should equal the number of cases registered. 
It should be highlighted that in the new definitions recommended 
since March 2013 any patient found to have drug-resistant 
TB and placed on second-line treatment should be removed 
from the drug-susceptible TB outcome cohort. This means that 
management of the standard TB register and of the second-line 
TB treatment register needs to be coordinated to ensure proper 
accounting of the outcomes of treatment (see also Chapter 4).
a Definitions and reporting framework for tuberculosis – 2013 revision. Geneva, 
World Health Organization, 2013 (WHO/HTM/TB/2013.2). Available at 
www.who.int/tb/publications/definitions.
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a. Treatment success (%)
1995 2000 2005 2010 2011 2012 2013
Afghanistan – 85 90 86 88 88 88
Bangladesh 71 81 90 91 91 92 93
Brazil 17 71 72 72 73 72 72
Cambodia 91 91 91 89 94 94 93
China 93 93 92 95 95 95 95
DR Congo 74 78 85 89 87 88 87
Ethiopia 61 80 78 77 89 91 89
India 25 34 87 89 89 88 88
Indonesia 91 87 89 89 88 86 88
Kenya 75 80 81 86 87 86 86
Mozambiqueb 39 75 79 85 – 87 88
Myanmar 67 82 83 88 88 89 87
Nigeria 49 79 75 81 85 86 86
Pakistan 70 74 82 90 92 91 93
Philippines 60 88 89 90 87 88 90
Russian 
Federation 65 68 67 66 65 69 68
South Africa 58 63 69 53 77 77 78
Thailand 64 69 71 83 82 81 81
Uganda 44 63 73 68 73 77 75
UR Tanzania 73 78 83 89 88 90 91
Viet Nam 89 92 92 92 93 91 89
Zimbabwe 53 69 66 76 80 81 80
High-burden 
countries 53 67 85 86 88 88 88
AFR 60 71 74 73 79 81 79
AMR 50 76 75 73 75 75 75
EMR 79 81 82 88 89 87 91
EUR 67 75 77 74 73 76 75
SEAR 33 50 87 89 89 88 88
WPR 80 90 90 92 93 92 92
Global 57 69 84 84 87 86 86
n TABLE 3.6 
Treatment success for all new and relapsea cases (%) and cohort size (thousands), 1995–2013
Blank cells indicate data not reported.
– indicates values that cannot be calculated.
a  Cohorts before 2012 include new cases only. For the 2012 and 2013 cohorts, 14 and 16 high-burden countries respectively included both new and relapse 
cases, as recommended in the revised recording and reporting framework issued by WHO in 2013 (see Definitions and reporting framework for 
tuberculosis 2013 revision. Geneva, World Health Organization, 2013 (WHO/HTM/TB/2013.2). Available at www.who.int/tb/publications/definitions.
b  Treatment outcomes in Mozambique are for new pulmonary bacteriologically-confirmed cases only. Introduction of monitoring of outcomes for other 
cases was started in 2015.
b. Cohort size (thousands)
1995 2000 2005 2010 2011 2012 2013
Afghanistan 3.1 10 26 26 29 31
Bangladesh 11 38 119 150 148 165 184
Brazil 46 34 78 78 71 75 77
Cambodia 4.4 15 34 40 37 38 36
China 131 214 788 877 856 885 842
DR Congo 16 36 65 109 92 105 112
Ethiopia 5.1 30 39 152 91 45 44
India 265 349 1 071 1 229 1 209 1 288 1 244
Indonesia 3 52 244 296 314 329 326
Kenya 6.5 28 98 90 82 98 81
Mozambique 11 13 18 20 21 23
Myanmar 7.9 17 73 127 135 137 136
Nigeria 9.5 16 35 78 84 90 92
Pakistan 0.8 4.1 117 256 255 111 289
Philippines 90 50 81 162 190 214 216
Russian 
Federation 0.05 3.6 74 94 89 90 83
South Africa 28 86 259 338 292 328 321
Thailand 20 23 49 48 49 58 66
Uganda 15 14 21 40 43 26 45
UR Tanzania 20 24 59 59 59 62 64
Viet Nam 38 53 55 88 89 104 102
Zimbabwe 9.7 14 43 46 40 38 35
High-burden 
countries 739 1 119 3 430 4 403 4 252 4 337 4 475
AFR 178 365 886 1 220 1 103 1 142 1 165
AMR 129 111 187 200 191 202 201
EMR 46 64 226 386 391 242 432
EUR 34 42 221 255 244 251 241
SEAR 318 512 1 639 1 980 1 986 2 114 2 101
WPR 296 360 1 030 1 240 1 233 1 344 1 298
Global 1 001 1 453 4 188 5 280 5 146 5 295 5 437
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Box 3.6 Outcomes of TB treatment by HIV statusa
Brazil, the Russian Federation, South Africa, Thailand, Ugan-
da and Zimbabwe. 
Treatment outcomes in 2013 were worse among HIV-
positive TB patients compared with HIV-negative TB patients 
(Box 3.6). Further ef forts are needed to narrow this gap. 
3.6  Detection and treatment of latent TB 
infection
Latent TB infection (LTBI) is defined as the presence of 
immune responses to Mycobacterium tuberculosis antigens 
without clinical evidence of active TB. Most people with 
LTBI have no signs or symptoms of TB disease and are not 
infectious. However, they are at risk of developing active 
TB disease and becoming infectious. The lifetime risk of TB 
disease for a person with documented LTBI is estimated at 
5–15%, with the majority of cases occurring within the first 
five years af ter initial infection.1 
The risk of LTBI reactivation can be reduced by preven-
tive treatment. WHO has issued global recommendations 
on the treatment of LTBI for people living with HIV and for 
1 Getahun H, Matteelli A, Chaisson RE, Raviglione M. Latent Mycobacte-
rium tuberculosis infection. New Engl J Med. 2015;372(22):2127–35.
In the 2015 round of global TB data collection, 140 countries 
reported treatment outcomes for the 2013 patient cohort that 
were disaggregated by HIV status. This was an increase from 133 
countries that reported such data for 2012. These 140 countries 
included 22 of the 41 high TB/HIV burden countries (listed in 
Table 6.1 of Chapter 6) and collectively accounted for 71% (n= 
397 000) of the HIV-positive TB patients reported by NTPs in 2013, 
similar to the level of 2012 (70%). 
Overall, the treatment success rate in 2013 was worse for HIV-
positive TB patients (73%) compared with HIV-negative TB patients 
(88%), similar to levels in 2012 (Figure B3.6). The dif ference was 
smaller in the African region (75% and 84%, respectively). There 
were large dif ferences in the European and Eastern Mediterranean 
Regions, where the treatment success rates among HIV-positive TB 
patients were only 47% and 60% respectively, compared with 80% 
and 91% among HIV-negative patients. The treatment success rate 
in the European Region were much worse than in 2012 (47% versus 
57%), mainly reflecting data for Ukraine. This country accounted 
for 80% of the HIV-positive TB patients for whom treatment 
outcomes in 2013 were reported, but did not report data in 2012. 
More encouragingly, the treatment success rate for HIV-positive TB 
patients in the Western Pacific Region was substantially better in 
2013 compared with 2012 (73% vs 57%).
Globally, the proportion of TB patients who died during treatment 
remained more than three times higher among HIV-positive TB 
patients (11% versus 3.5%). In the African Region, HIV-positive 
TB patients were almost twice as likely to die compared with 
HIV-negative TB patients (9.8% versus 5.1%). Dif ferentials were 
larger in the European Region (21% versus 6.6%) and the Eastern 
children aged less than 5 years old who are close contacts 
of a TB case.2,3 Most recently, WHO has issued guidelines on 
the management of LTBI that are targeted at upper-middle 
and high-income countries with an estimated incidence rate 
of less than 100 per 100 000 population.4 In these countries, 
systematic testing and treatment of LTBI is recommended 
for a wider range of risk groups: people living with HIV, adult 
as well as child contacts of pulmonary TB cases, patients with 
silicosis, patients initiating anti-tumour necrosis factor (TNF) 
treatment, patients on dialysis, and transplant patients 
(Table 3.7). 
The management of LTBI is a critical component of the 
new post-2015 End TB Strategy (Chapter 1), and is one of the 
interventions that can help countries to achieve the ambi-
2 World Health Organization. Guidelines for intensified tuberculosis 
case-finding and isoniazid preventive therapy for people living with HIV in 
resource-constrained settings. Geneva: World Health Organization; 2011.
3 World Health Organization. Recommendations for investigating contacts of 
persons with infectious tuberculosis in low- and middle income countries. 
Geneva: World Health Organization; 2012.
4 World Health Organization. Guidelines on the management of latent 
tuberculosis infection. Geneva: World Health Organization; 2015. 
Available at: http://www.who.int/tb/publications/ltbi_document_page/
en/
Mediterranean Region (17% versus 1.8%). The proportion of 
patients categorized as lost to follow-up, who may also have died 
of TB, was also higher for those who were HIV-positive (6.5% versus 
4.6%), similar to levels in 2012. The proportion of HIV-positive TB 
patients for whom the treatment outcome was not evaluated 
was relatively similar globally (8.1% compared with 7.6% of HIV-
negative TB patients), although there was a noticeable drop in the 
Western Pacific Region (from 30% of patients in 2012 to 12% in 
2013). This is the main explanation for the large improvement in the 
treatment success rate for HIV-positive TB patients in this region.
a Countries with no treatment outcome data for HIV-positive TB patients 
were excluded from the analysis.
FIGURE B3.6 
Outcomes of TB treatment by HIV status, 2013
























GLOBAL TUBERCULOSIS REPORT 2015  n  51
n FIGURE 3.5
Treatment outcomes for new and relapse cases, 2013, 
globally, for the six WHO regions and 22 high-burden 
countries
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a Treatment outcomes are for new cases only.
b Treatment outcomes in Mozambique are for new pulmonary 
bacteriologically-confirmed cases only. Introduction of monitoring of 
outcomes for other cases was started in 2015.
tious targets of a 90% reduction in the TB incidence rate and 
a 95% reduction in TB deaths by 2035, compared with 2015 
levels. LTBI management can also contribute to TB elimina-
tion, especially in low TB incidence settings. In this context, 
country preparedness for the programmatic implementation 
of LTBI management (including addressing well-recognized 
challenges such as treatment adherence) is of growing pri-
ority and importance. A two-pronged approach is required, 
in which: (1) treatment for LTBI is provided in all countries to 
people living with HIV and children aged less than 5 years 
old who are household or close contacts of a TB case; and 
(2) treatment for LTBI is provided to additional risk groups in 
upper-middle and high-income countries with an incidence 
rate of less than 100 per 100 000 population. 
Data on the treatment of LTBI among people living with 
HIV are already collected routinely, with data presented in 
this report (Chapter 6). In 2014 and 2015, WHO expanded 
data collection related to LTBI through discussions during 
regional meetings of NTP managers (or their equivalent) 
and other national stakeholders in four WHO regions, and 
by conducting a special survey of existing policy and prac-
tices in upper-middle income and high-income countries 
with an incidence rate of less than 100 per 100 000 popula-
tion (shown in Figure 3.6). The main results are summarized 
below. 
n TABLE 3.7
WHO recommendations for the management of latent TB infection, by country group 
COUNTRY GROUP AT RISK POPULATIONS TESTING ALGORITHM TREATMENT OPTIONS
High-income and upper middle-
income countries with an estimated 
TB incidence rate of less than 100 
per 100 000 population
Strongly recommended for the 
following risk groups:
1) People living with HIV; 
2) Adults and children who are 
household or close contacts of 
pulmonary TB cases;
3) Clinical indications – patients 
with silicosis; patients initiating 
anti-TNF treatment; patients on 
dialysis; transplant patients. 
Exclude active TB using TB 
investigations.
A positive IGRA or TST test result is 
required to diagnose LTBI.
6 months daily isoniazid 
9 months daily isoniazid
3 months weekly rifapentine plus 
isoniazid
3 to 4 months daily isoniazid plus 
rifampicin
3 to 4 months  daily rifampicin
Resource-limited and other middle-
income countries with an estimated 
TB incidence rate of more than 100 
per 100 000 population
1) People living with HIV;
2) Children under 5 years of age 
who are household contacts of 
a TB case.
Exclude active TB using TB 
investigations. An LTBI test is not 
required prior to LTBI treatment, 
but is encouraged for people living 
with HIV.
IGRA should not replace TST.
6 months daily isoniazid
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n FIGURE 3.6
The 113 upper-middle-income and high-income countries with an estimated incidence rate of less than 100 per 100 000 
population that are the primary audience for 2015 WHO guidelines on the management of latent TB infection
n FIGURE 3.7
Reported policies and practices for latent TB infection 
(LTBI) in upper-middle-income and high-income countries 
with an estimated incidence rate of less than 100 per 
100 000 population, four WHO regionsa
a Two countries in the African Region (Algeria and Seychelles) were 
included in the survey, both of which reported that they had national 
policies on LTBI and were providing LTBI testing and treatment for 
people living with HIV and/or children who are close contacts of TB 
cases. One country in the South-East Asia Region (Maldives) was invited 
to participate in the survey but no response was received.
National policy on LTBI exists
Testing and treatment for LTBI being provided for people living 
with HIV, and/or children who are close contacts of TB cases.
WHO region


















3.6.1  Results from a survey of LTBI policy and practice 
in upper-middle and high-income countries 
with an incidence rate of less than 100 per 
100 000 population
Data were reported by 74 (69%) of the 108 countries invited 
to participate in the survey.1 Among these countries, 76% 
(56/74) had a national policy on LTBI but a higher number 
(68/74, 92%) were providing testing for LTBI and preventive 
treatment for people living with HIV and/or children who 
were contacts of TB cases. This demonstrates a gap between 
policy and practice, which existed in three of four WHO 
regions (Figure 3.7). Systematic testing and treatment for 
LTBI in other risk groups for whom it is recommended was 
reported by only a few countries. 
Testing for LTBI and exclusion of active TB
Of the 68 countries implementing systematic testing and 
treatment of LTBI in at least one at-risk population, 30 (44%) 
relied only on the tuberculin skin test (TST); the other 38 
countries used both TST and interferon-gamma release 
assays (IGRAs) to test for LTBI.2 TST was the only test used in 
most countries in the Eastern Mediterranean Region (70%, 
7/10) and the Americas (73%, 11/15). Both tests were common-
1 Five countries or territories with very small populations and numbers of 
TB cases were not included in the survey: Bermuda, Monaco, San 
Marino, Turks and Caicos Islands, US Virgin Islands.
2 In the remaining six countries, specific at-risk populations were not 
identified. 
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ly used in the European Region (81%, 25/31). Shortages of TST 
were reported by 34 countries. 
To exclude active TB prior to starting treatment for LTBI, 
most countries (62%, 42/68) used a combination of clinical 
screening for TB symptoms and a chest X-ray; this is consist-
ent with WHO recommendations. A further 24 countries 
used these methods but supplemented them with addition-
al diagnostic tests including smear microscopy, culture, and 
molecular testing. The remaining country used only clinical 
symptoms to exclude active TB. 
Treatment regimens
In just over half of the 68 countries (35/68, 51%), the only 
option for LTBI treatment was a daily regimen of isoniazid 
for six or nine months. Rifamycin-containing regimens were 
used in other countries, but to date the shortest and simplest 
regimen (a weekly dose of rifapentine plus isoniazid for 12 
weeks) had been adopted by only five of these countries.
Recording and reporting 
Recording and reporting gaps were evident in many coun-
tries. Of the 40 countries providing testing and treatment 
for LTBI for people living with HIV, only 21 had a system for 
recording and reporting data. Of the 53 countries providing 
LTBI to children aged less than five who were household or 
close contacts of TB cases, 33 had a system for recording or 
reporting data. A monitoring and evaluation framework for 
LTBI is being developed by WHO and is expected to be avail-
able in 2016.
Key messages and conclusions 
Overall, the survey shows that intensified ef forts are need-
ed to ensure that national LTBI policies are in place, as a 
foundation for programmatic management of LTBI using 
standardised approaches. Such policies should prioritize and 
target population groups with the highest risk of progres-
sion to active disease in whom the benefits of preventive 
treatment outweigh the potential risks. Ef forts are needed 
to promote the use of short treatment regimens, such as 
weekly rifapentine plus isoniazid for 12 weeks, which would 
have potential benefits in terms of acceptability, adherence, 
and tolerability compared to the standard isoniazid regi-
men. Systems for routine collection and analysis of data are 
required in all countries and shortages in the supply of TST 
must be addressed. 








Key facts and messages 
Drug-resistant TB poses a major threat to control of TB 
worldwide. By the end of 2014, data on anti-TB drug resistance 
were available for 153 countries, accounting for more than 95% 
of the world’s population and estimated TB cases. Eighty of 
these countries have continuous surveillance systems, while 
the others rely on epidemiological surveys. 
In 2014, the first-ever drug resistance surveys were completed 
in the Democratic People’s Republic of Korea (North 
Hwanghae Province), Iraq, Papua New Guinea (four provinces), 
Turkmenistan and Ukraine; repeat surveys were completed 
in Iran, Lesotho, Morocco and Senegal. In mid-2015, drug 
resistance surveys were ongoing in 13 countries. These included 
the first nationwide surveys in the Democratic Republic of the 
Congo, India and Sudan.
Globally, an estimated 3.3% (95% CI: 2.2–4.4%) of new cases 
and 20% (95%CI: 14–27%) of previously treated cases have 
MDR-TB; these levels have remained virtually unchanged in 
recent years. In 2014, there were an estimated 480 000 (range: 
360 000–600 000) new cases of MDR-TB worldwide, and 
approximately 190 000 (range: 120 000–260 000) deaths from 
MDR-TB. Among patients with pulmonary TB who were notified 
in 2014, an estimated 300 000 (range: 220 000–370 000) had 
MDR-TB. More than half of these patients were in India, China 
and the Russian Federation. 
Extensively drug-resistant TB (XDR-TB) has been reported by 
105 countries. On average, an estimated 9.7% (95% CI: 7.4–12%) 
of people with MDR-TB have XDR-TB.
There was major progress in coverage of drug susceptibility 
testing (DST) between 2013 and 2014. Worldwide, 12% of new 
bacteriologically-confirmed TB cases and 58% of previously 
treated TB patients were tested for drug resistance in 2014, 
up from 8.5% and 17% respectively in 2013 (representing 
proportional increases of 43% and 223%, respectively). 
Coverage was highest in the European Region (97% of new cases). 
In the South-East Asia and Western Pacific regions combined, 
two-thirds of previously treated cases underwent testing. 
Globally in 2014, 123 000 patients with MDR -TB or rifampicin-
resistant tuberculosis (RR-TB) were notified, of whom about 75% 
lived in the European Region, India, South Africa or China. This 
was equivalent to 41% of the 300 000 notified TB patients who 
were estimated to have MDR-TB in 2014. The number of notified 
MDR/RR-TB cases in 2014 was almost the same as in 2013. A 
major diagnostic gap has therefore persisted, and was worst in 
the Western Pacific Region where detected cases represented 
19% of estimated cases. The figure for China was 11%. 
People with MDR-TB or RR-TB are eligible for second-line 
treatment with MDR-TB regimens. A total of 111 000 people 
were started on MDR-TB treatment in 2014, an increase of 14% 
compared with 2013. The ratio of enrolled to notified MDR/
RR-TB cases was 90% globally, and >90% in 15 high MDR-TB 
burden countries as well as the European Region and the 
Region of Americas. The ratio was <60% in 3 high MDR-TB 
burden countries: China (49%), Myanmar (44%) and Nigeria 
(53%). 
The 2015 treatment success target of ≥75% for MDR-TB patients 
was reached by 43 of the 127 countries and territories that 
reported outcomes for the 2012 cohort. Only three high MDR-TB 
burden countries (Estonia, Ethiopia, and Myanmar) achieved a 
treatment success rate of ≥75%. Globally, only 50% of patients 
on MDR-TB treatment were successfully treated, largely due to 
high rates of mortality and loss to follow-up. 
Despite progress in responding to the challenge of drug-
resistant TB, serious detection and treatment gaps remain. 
Intensified ef forts to close these gaps are urgently required.
Drug-resistant TB continues to threaten global TB control 
and remains a major public health concern in many coun-
tries. The first part of this chapter (section 4.1) summarizes 
the progress made in the global coverage of surveillance of 
anti-TB drug resistance, using the most recent data gathered 
from epidemiological surveys and continuous surveillance 
systems, with a focus on multidrug-resistant TB (MDR-TB)1 
and extensively drug-resistant TB (XDR-TB).2 The second part 
1 Defined as resistance to at least rifampicin and isoniazid, the two most 
powerful first-line anti-TB drugs.
2 XDR-TB is defined as MDR-TB plus resistance to at least one 
fluoroquinolone and a second-line injectable.
of this chapter presents an assessment of global and national 
progress in diagnosing and treating rifampicin-resistant (RR-
TB) and MDR-TB (section 4.2). 
4.1  Surveillance of drug-resistant TB
4.1.1  Progress in the coverage of drug resistance 
surveillance
Since the launch of the Global Project on Anti-tuberculosis 
Drug Resistance Surveillance in 1994, data on drug resist-
ance have been systematically collected and analysed from 
153 countries worldwide (79% of 194 WHO Member States). 
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This number includes 80 countries that have continuous 
surveillance systems based on routine diagnostic drug sus-
ceptibility testing (DST) of all TB patients, and 73 countries 
that rely on epidemiological surveys of representative sam-
ples of patients. Over the past two decades, all 22 high TB 
and/or 27 high MDR-TB burden countries (for a total of 36 
countries) have either established a continuous surveillance 
system or conducted at least one survey to monitor drug 
resistance. Progress towards achieving global coverage of 
drug resistance surveillance data is shown in Figure 4.1.
Continuous surveillance for MDR-TB, based on routine 
DST of TB patients and systematic collection and analysis 
of data, is the most ef fective approach to monitor trends 
in drug resistance. The number of countries that can rely 
on data generated by continuous surveillance systems is 
increasing, following major ef forts to scale up the avail-
ability of culture and DST services. In the past two years, an 
additional 10 countries established high quality continuous 
surveillance systems to monitor drug resistance in new and 
previously treated TB cases. Several countries of the eastern 
European and central Asian regions, where proportions of 
MDR-TB among TB cases are the highest, have established 
high quality surveillance systems to monitor drug resistance. 
These are Belarus, Estonia, Georgia, Kazakhstan, Latvia, 
Lithuania, the Russian Federation (at subnational level) and 
Tajikistan. 
Surveys conducted every five years represent the most 
common approach to investigating the burden of drug 
resistance in resource-limited settings where routine DST 
is not accessible to all TB patients, due to lack of laboratory 
capacity or resources. In 2014, the first-ever drug resistance 
surveys were completed in the Democratic People’s Repub-
lic of Korea (North Hwanghae Province), Iraq, Papua New 
Guinea (four provinces), Turkmenistan and Ukraine; repeat 
surveys were completed in Iran, Lesotho, Morocco and Sen-
egal.
Of the 36 high TB and/or MDR-TB burden countries, 
26 have generated drug resistance data through epide-
miological surveys. Nearly half of these (14 countries) have 
conducted surveys recently, between 2010 and 2014. These 
are Afghanistan (Central region), Azerbaijan, Bangladesh, 
Kyrgyzstan, Myanmar, Nigeria, Pakistan, the Philippines, 
Tajikistan, Thailand, Uganda, Ukraine, Uzbekistan and 
Viet Nam. Three countries have not completed a survey since 
the mid-1990s: the Democratic Republic of the Congo, Kenya 
and Zimbabwe. However, a national survey is currently being 
implemented in all three of these countries.
Six high TB and/or MDR-TB burden countries (Afghani-
stan, Brazil, the Democratic Republic of the Congo, India, 
Indonesia and the Russian Federation) still rely on drug 
resistance surveillance data gathered from sub-national are-
as only. This situation will improve in the near future. In 2014, 
Brazil launched a large nationwide sentinel system to moni-
tor drug resistance. The Democratic Republic of the Congo 
and India are currently conducting national surveys, and in 
Indonesia the first-ever nationwide drug resistance survey is 
n FIGURE 4.1
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scheduled for implementation in 2016. The remaining coun-
tries should consider conducting nationwide drug resistance 
surveys in the short term to better understand the burden of 
MDR-TB and to guide the planning of diagnostic, treatment 
and care services.
In mid-2015, drug resistance surveys were ongoing in 13 
countries. These included the first-ever nationwide surveys 
in the Democratic Republic of the Congo, India and Sudan; 
and repeat surveys in Bolivia, China, Côte d’Ivoire, Kenya, 
Namibia, Romania, Rwanda, Venezuela, South Africa and 
Zimbabwe.
Central and Francophone Africa remain the parts of the 
world where drug resistance surveillance data are most 
lacking, largely as a result of weak laboratory infrastructure. 
These countries should consider conducting drug resistance 
surveys using Xpert MTB/RIF to at least obtain a nationally 
representative estimate of the proportion of TB patients with 
rifampicin resistance.
4.1.2  Percentage of new and previously treated TB 
cases that have MDR-TB
Globally in 2014, there were an estimated 3.3% (95% CI: 2.2–
4.4%) of new cases and 20% (95%CI: 14–27%) of previously 
treated cases with MDR-TB (Table 4.1). These estimates are 
essentially unchanged from those published in recent global 
TB reports.
The proportions of new and previously treated TB cases 
with MDR-TB at the country level are shown in Figure 4.2 and 
Figure 4.3, and for the 27 high MDR-TB burden countries also 
in Table 4.1. Eastern European and central Asian countries 
continue to have the highest levels of MDR-TB. Among new 
cases, the proportions with MDR-TB were highest in Belarus, 
Estonia, Kazakhstan, Kyrgyzstan, the Republic of Moldova, 
the Russian Federation, Ukraine and Uzbekistan. Among 
previously treated TB cases, the proportions with MDR-TB 
were highest in Belarus, Estonia, Kazakhstan, Kyrgyzstan, 
the Republic of Moldova, Tajikistan, Ukraine and Uzbeki-
stan. In the Russian Federation, even though the average 
proportion of previously treated cases with MDR-TB does not 
exceed 50%, the proportion is well above 50% in several Fed-
eral Subjects.
Levels of drug resistance among new cases remain low 
(<3%) in many parts of the world, including in almost all 
countries in the Region of the Americas; most African coun-
tries where drug resistance surveys have been conducted; 
most of the South-East Asia Region; most of western Europe; 
and several countries in the Western Pacific Region.
4.1.3  Estimated global incidence of MDR-TB and 
estimated number of MDR-TB cases among 
notified TB patients in 2014
Data compiled from surveys and continuous surveillance of 
drug resistance among TB patients can be used to estimate 
the total number of incident cases of MDR-TB worldwide and 
the total number of deaths from MDR-TB in 2014. Methods 
n TABLE 4.1
Estimated proportion of TB cases that have MDR-TB, 
globally and for 27 high MDR-TB burden countries and 
WHO regions
ESTIMATED 
















Armenia 9.4 7.0–12 43 38–49
Azerbaijan 13 10–16 28 22–37
Bangladesh 1.4 0.7–2.5 29 24–34
Belarus 34 32–36 69 66–72
Bulgaria 2.3 1.3–3.8 23 17–31
China 5.7 4.5–7.0 26 22–30
DR Congob 2.2 0.3–4.1 11 6.2–16
Estonia 19 14–27 62 42–79
Ethiopia 1.6 0.9–2.8 12 5.6–21
Georgia 12 10–13 39 35-44
India 2.2 1.9–2.6 15 11–19
Indonesia 1.9 1.4–2.5 12 8.1–17
Kazakhstan 26 25–27 58 57–59
Kyrgyzstan 26 23–31 55 52–58
Latvia 8.2 5.8–11 30 21–40
Lithuania 14 12–16 49 43–55
Myanmar 5.0 3.1–6.8 27 15–39
Nigeria 2.9 2.1–4.0 14 10–19
Pakistan 3.7 2.5–5.0 18 13–23
Philippines 2.0 1.4–2.7 21 16–29
Republic of Moldova 24 21–26 62 59–65
Russian Federation 19 14–25 49 40–59
South Africa 1.8 1.4–2.3 6.7 5.4–8.2
Tajikistan 8.1 6.9–9.4 52 47–57
Ukraine 22 20–24 56 50–61
Uzbekistan 23 18–30 62 53–71
Viet Nam 4.0 2.5–5.4 23 17–30
High MDR-TB 
burden countries 3.8 2.2–5.4 22 13–31
AFR 2.1 0.5–3.7 11 6.7–16
AMR 2.4 1.3–3.5 11 6.5–16
EMR 3.2 2.3–4.1 18 12–25
EUR 15 10–20 48 43–53
SEAR 2.2 1.9–2.6 16 14–18
WPR 4.4 2.5–6.3 22 18–25
Global 3.3 2.2–4.4 20 14–27
a Best estimates are for the latest available year. 
b The estimates for DR Congo are indirect estimates based on data from 
countries in the same epidemiological region.
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a Figures are based on the most recent year for which data have been reported, which varies among countries. Data reported before the year 2000 are 
not shown.
n FIGURE 4.3











a  Figures are based on the most recent year for which data have been reported, which varies among countries. Data reported before the year 2000 are 
not shown. In six countries or territories, the high percentages of previously treated cases with MDR-TB refer to only a small number (1–8) of notified TB 
cases. These are: Bahrain; Belize; Bonaire, Saint Eustatius and Saba; Cyprus; Israel; and Sao Tomé and Principe.
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used to produce these estimates are described in detail in 
an online technical appendix (available at www.who.int/tb/
data).
The number of incident cases includes cases among noti-
fied TB patients, cases among people diagnosed with TB 
that were not notified to national TB programmes (NTPs) in 
whom a diagnosis of MDR-TB was missed, and cases among 
people not diagnosed with TB at all. Globally in 2014, there 
were an estimated 480 000 (range: 360 000–600 000) inci-
dent cases of MDR-TB. This number is essentially unchanged 
from those published in recent global TB reports, despite 
an upward revision to global estimates of the burden of TB 
following results from the 2013/2014 national TB prevalence 
survey in Indonesia (which indicated that there are about 
1 million rather than 0.5 million incident TB cases per year 
in this country; see Chapter 2). The explanation is that the 
upward revision to the estimated number of incident cases 
of MDR-TB in Indonesia (equivalent to approximately 12 000 
extra cases) has been compensated for by reductions in the 
reported numbers of previously treated cases in several high 
MDR-TB burden countries (for example, India); this category 
of case (especially those not defined as relapse cases) has an 
important influence on estimates of the total number of inci-
dent cases of MDR-TB.1 There were approximately 190  000 
(range: 120 000–260 000) deaths from MDR-TB in 2014, com-
parable to estimates published in recent global TB reports. 
Data compiled from surveys and continuous surveil-
lance of drug resistance among TB patients also allow the 
production of global as well as country-specific estimates 
of the number of MDR-TB cases among notified TB patients 
with pulmonary TB. These are the MDR-TB cases that could be 
detected if all notified patients were tested for drug resistance 
to rifampicin and isoniazid using WHO-recommended diagnos-
tic tests. Globally, in 2014 there were an estimated 300  000 
(range: 220 000–370 000) MDR-TB cases among notified 
TB patients; this is unchanged from the estimate for 2013.2 
Of the 300 000 cases, 53% were among new cases and 47% 
were among previously treated cases. Of note, the increased 
number of TB cases notified in India between 2013 and 2014 
(Chapter 3) and the higher proportions of MDR-TB detect-
ed in Ukraine in the latest survey of drug resistance were 
counter-balanced by lower numbers of new TB cases noti-
fied in China, the Russian Federation and Ukraine and lower 
numbers of previously treated TB cases notified in India and 
1 The number of incident cases of MDR-TB is estimated as the sum of the 
number of cases in three distinct groups. These are (i) new cases of TB; 
(ii) relapse cases and (iii) all previously treated cases of TB, excluding 
those in the relapse category. A review of methods used by WHO to 
estimate MDR-TB incidence and mortality is scheduled for 2016. In line 
with retaining current methods for the 2015 targets assessment, 
methods to estimate the burden of MDR-TB have not been changed this 
year (see also Chapter 2, particularly Box 2.1 and Box 2.2). Further 
details about the methods used to estimate the burden of MDR-TB are 
provided in the online technical appendix, available at www.who.int/
tb/data
2 WHO. Global tuberculosis report 2014. Geneva: World Health 
Organization; 2014 (WHO/HTM/TB/2014.08).
several Eastern European countries. Country-specific esti-
mates are discussed in section 4.2.
Given the increasing use of molecular diagnostics that 
detect RR-TB (Chapter 5), their growing importance in detec-
tion of TB patients with RR-TB (section 4.2) and the fact that 
the recommended treatment for people with RR-TB is the 
same as for those with MDR-TB, monitoring and evaluation 
of the response to drug-resistant TB requires more atten-
tion to and emphasis on the underlying burden of RR-TB. The 
burden of rifampicin resistance is presented in Box 4.1 and 
compared with that of MDR-TB.
4.1.4  Resistance to second-line drugs
XDR-TB, defined as MDR-TB plus resistance to at least one 
fluoroquinolone and a second-line injectable, had been 
reported by 105 countries globally by the end of 2014. A total 
of 83 countries and five territories reported representative 
data from continuous surveillance or surveys regarding the 
proportion of MDR-TB cases that had XDR-TB. Combining 
their data, the average proportion of MDR-TB cases with 
XDR-TB was 9.7% (95% CI: 7.4–12%), similar to estimates for 
previous years (9.0% in 2013 and 9.6% in 2012). Fourteen of 
these countries reported ≥10 XDR-TB cases in the most recent 
year for which data were available. Among those countries, 
the proportion of MDR-TB cases with XDR-TB was highest in 
Belarus (29% in 2014), Georgia (15% in 2014), Latvia (19% in 
2014) and Lithuania (25% in 2013). Among the 36 high TB and/
or MDR-TB burden countries, 23 have surveillance data on 
second-line drug resistance but only eight have established a 
national continuous surveillance system for second-line drug 
resistance among patients with MDR-TB. Increased ef forts 
should be made to ensure that all patients diagnosed with 
MDR-TB undergo testing for susceptibility to fluoroquinolo-
nes and injectable agents, and that results are recorded and 
reported. 
The proportion of MDR-TB cases with resistance to any 
fluoroquinolone for which testing was done, including 
ofloxacin, levofloxacin and moxifloxacin, was 21% (95% CI: 
8.3–34%). 
4.2  Management of drug-resistant TB 
4.2.1  Coverage of drug susceptibility testing (DST)
Targets included in the Global Plan to Stop TB 2011–2015 call 
for 20% of all new bacteriologically-confirmed TB cases (i.e. 
those considered to be at high risk for MDR-TB) as well as 
all previously treated cases to undergo DST to first-line TB 
drugs.3 According to WHO recommendations, all patients 
with MDR-TB should undergo testing for susceptibility to 
fluoroquinolones and second-line injectable agents, to 
determine if they have XDR-TB.
There was major progress in DST coverage between 2013 
3 The Global Plan to Stop TB 2011–2015: transforming the fight towards 
elimination of tuberculosis. Geneva: World Health Organization; 2010 
(WHO/HTM/STB/2010.2).
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and 2014 (Figure 4.4a, Figure 4.5). Globally in 2014, 12% of 
the 2.7 million new bacteriologically-confirmed TB cases and 
58% of the 0.7 million previously treated TB patients were 
tested for drug resistance in 2014, up from 8.9% and 17% 
respectively in 2013. This represents proportional increases 
in DST coverage of 43% and 223% among new and previously 
treated cases, respectively.1 
Coverage was highest in the European Region, where 97% 
of new cases were tested in 2014 (Table 4.2). In the South-
East Asia and Western Pacific regions combined, two-thirds 
of previously treated cases underwent testing, reflecting 
relatively better access to DST in these regions. Levels of test-
ing remained below 5% among new cases in the South-East 
Asia and Eastern Mediterranean regions, while there was a 
substantial increase in testing coverage among new bacte-
riologically confirmed cases in the African Region (from 0.9% 
in 2013 to 6.4% in 2014). Testing coverage among previously 
treated cases also improved considerably in most regions, 
notably from 5.8% to 67% in the South-East Asia Region 
(driven largely by improved reporting from India) and from 
9.6% to 33% in the African Region. 
Among the 27 high MDR-TB burden countries – which 
account for >85% of estimated MDR-TB cases in the world 
– the proportion of TB patients who were tested for drug sus-
ceptibility in 2014 varied markedly (Table 4.2). In nine of the 
12 European countries that reported data, testing was done 
for ≥95% of new cases; three of these countries reported 
universal coverage among previously treated cases. Among 
1 These figures are based on data reported by 160 (73%) countries and 
territories for new TB cases and by 157 (72%) countries and territories 
for previously treated cases.
Box 4.1 Monitoring and evaluation of progress in the response to drug-resistant TB:  
 the increasing importance of rifampicin-resistant TB (RR-TB)
Following the rollout of molecular tests for the detection of M. 
tuberculosis and rifampicin resistance (line probe assays and 
Xpert MTB/RIF) (Chapter 5), the Global TB Programme in WHO 
has collected and reported notifications of drug-resistant TB 
that combine rifampicin-resistant TB (RR-TB) and MDR-TB since 
2013. All RR-TB and/or MDR-TB cases detected by either rapid 
molecular diagnostics or conventional DST are reported as cases 
of drug-resistant TB. Furthermore, in accordance with WHO 
recommendations to enrol all patients diagnosed with RR-TB on 
an MDR-TB drug regimen,a treatment enrolment and treatment 
outcomes of patients receiving MDR-TB treatment have been 
reported for all patients diagnosed with RR-TB, including those 
that did not have MDR-TB. 
To date, estimates of the burden of drug-resistant TB at global, 
regional and country levels have focused on MDR-TB. The number 
of cases with MDR-TB will be slightly lower than the combined 
number of cases with MDR-TB or RR-TB (that is not MDR-TB). 
This means that when the burden of MDR-TB is used as the 
denominator for estimating detection and treatment coverage, 
the values for both indicators will be slightly overstated.
For these reasons, it is becoming increasingly important to 
estimate the combined burden of MDR-TB and RR-TB. In 2014, 
the global proportion of TB cases with MDR-TB, irrespective of 
treatment history, was 7.7% (95%CI: 4.6–10.8%), with an estimated 
number of MDR-TB cases among notified pulmonary TB patients 
of 300 000. In the same year, the global proportion of TB cases 
with RR-TB was 8.8% (95%CI: 6.2–11.3%), meaning that there were 
approximately 40 000 additional cases of RR-TB that were not 
MDR-TB. In future global TB reports, greater emphasis will be given 
to estimates of the combined burden of MDR-TB and RR-TB when 
assessing global, regional and national progress in the detection 
and treatment of drug-resistant TB.
a Companion Handbook to the WHO Guidelines for the Programmatic 
Management of Drug-Resistant Tuberculosis. Geneva: World Health 
Organization; 2014 (WHO/HTM/TB/2014.11). http://apps.who.int/
iris/bitstream/10665/130918/1/9789241548809_eng.pdf.
n FIGURE 4.4
DST coverage among new cases and enrolment on MDR-TB 
treatment, compared with the targets in the Global Plan to 
Stop TB, 2011–2015. Lines indicate the planned targets, blue 
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the high MDR-TB burden countries outside Europe, testing 
among new cases was highest in Myanmar (24%) and China 
(19%). Among previously treated cases, testing coverage was 
higher overall, and reached 96% in Viet Nam, 88% in Indo-
nesia and 75% in the Democratic Republic of the Congo. In 
South Africa, the equivalent of 69% of all notified TB cases 
were tested, although DST data were not available separate-
ly for new and previously treated cases.
Among MDR-TB patients notified in 2014, only 24% had 
DST performed for both fluoroquinolones and second-line 
injectable drugs. Coverage was lowest in the European 
Region, likely as a result of incomplete reporting of DST 
results from laboratories.
Evidence of progress in DST coverage notwithstanding, 
diagnostic DST must be further expanded, especially given 
the call for universal DST in the post-2015 End TB Strategy 
(Chapter 1). This requires continued strengthening of labo-
ratory capacity and wider uptake of new rapid diagnostics 
(see Chapter 5), as well as increased deployment of informa-
tion and communication technologies (ICT) to improve the 
completeness of reporting from laboratory and treatment 
centres. 
4.2.2  Notification of RR-TB and MDR-TB cases 
Globally, 123 000 cases of MDR-TB or RR-TB, who are eligi-
ble for treatment with MDR-TB regimens, were notified to 
WHO in 2014. India, the Russian Federation and South Africa 
accounted for almost half of the total (Table 4.3). These 123 
000 cases represented 41% of the estimated 300 000 (range, 
220 000–370 000) MDR-TB cases among pulmonary TB 
patients that were notified in 2014 (Figure 4.6),1 and 26% of 
the estimated 480  000 (range: 360 000−600 000) incident 
MDR-TB cases in the world in 2014. 
The number of MDR/RR-TB cases reported for 2014 was 
nearly identical to the latest figure for 2013. In this context, 
it should be highlighted that the data available at the time of 
preparation of this report show that the number of MDR/RR-
TB cases detected globally in 2013 was lower than previously 
published,2 following a downward correction to numbers 
originally reported for India. Increases in the number of 
detected cases did however occur between 2013 and 2014 in 
India (23 162 to 25 748), China (4 183 to 5 807), the Russian Fed-
eration (13 521 to 15 585), and Myanmar (1 984 to 3 495). There 
were reductions between 2013 and 2014 in the Philippines, 
South Africa, Ukraine, Uzbekistan and several other coun-
tries (Figure 4.7). The reasons for the apparent stagnation in 
detection, given increasing DST coverage, are not clear and 
should be investigated as a matter of priority. A comparison 
of the number of Xpert MTB/RIF cartridges procured and the 
number of MDR/RR-TB cases detected in eight countries is 
provided in Box 4.2.
The number of notified MDR/RR-TB cases as a proportion 
of the estimated number of MDR-TB cases among pulmo-
nary TB patients ranged from 19% in the Western Pacific 
Region to 80% in the African Region. In Kazakhstan, South 
1 When compared with the estimate of all MDR/RR-TB cases (not just the 
MDR-TB cases), this value would decrease to 36% (see also Box 4.1). 
2 The number published in the 2014 global TB report was 136 000 in 2013.
n FIGURE 4.5 
DST coverage in previously treated TB cases, globally and for WHO regions, 2009–2014.a Numbers of cases tested are 
shown for each bar.
a DST is for rifampicin only or for both rifampicin and isoniazid.
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n TABLE 4.2 
DST coverage among TB and MDR-TB cases, globally and for 27 high MDR-TB burden countries and WHO regions, 2014
NEW BACTERIOLOGICALLY CONFIRMED 
CASES RETREATMENT CASES CONFIRMED MDR–TB CASES
NUMBER WITH DSTa 
RESULTS
% OF CASES WITH 
DST RESULT
NUMBER WITH DSTa 
RESULTS
% OF CASES WITH 
DST RESULT
NUMBER WITH DSTb 
RESULTS
% OF CASES WITH 
DST RESULT
Armenia 343 96 50 17 100 100
Azerbaijan 2 059 >100 3 901 >100 840 100
Bangladesh 12 573 12 4 959 51 182 19
Belarus 1 990 97 877 84 1 251 100
Bulgaria 639 80 101 45 36 97
China 45 664 19 17 210 54 –
DR Congo 545 0.7 6 135 75 41 19
Estonia 175 >100 29 71 47 96
Ethiopia 2 405 6 7 682 – 25 15
Georgia 1 700 95 634 61 357 93
India 12 795 1.7 214 209 69 3 572 25
Indonesia 1 058 0.5 8 445 88 229 35
Kazakhstan 9 597 >100 6 377 >100 –
Kyrgyzstan – – –
Latvia 483 99 107 86 70 100
Lithuania 968 >100 294 100 232 86
Myanmar 10 295 24 15 166 >100 –
Nigeria – – –
Pakistan 361 0 11 685 72 2 380 98
Philippines 4 415 4.7 20 196 67 868 80
Republic of Moldova 1 764 99 831 61 277 31
Russian Federation 31 250 84 13 925 28 –
South Africa – – 3 416 42
Tajikistan 2 432 100 800 64 371 100
Ukraine 13 833 97 9 707 69 –
Uzbekistan 11 956 >100 5 888 77 927 29
Viet Nam 2 756 5.5 8 511 96 246 78
High MDR–TB burden countries 172 056 8.6 357 719 64 15 467 22
AFR 40 940 6.4 31 952 33 3 898 35
AMR 30 531 24 8 724 32 606 20
EMR 8 404 4.6 13 703 52 2 465 78
EUR 108 569 97 48 234 52 5 294 14
SEAR 45 056 3.8 247 336 67 4 610 27
WPR 92 801 21 54 560 62 2 251 30
Global 326 301 12 404 509 58 19 124 24
Blank cells indicate data not reported.       
– indicates values that cannot be calculated.       
The percentages may exceed 100% as a result of the inclusion of extrapulmonary patients among cases tested or inadequate linkages between laboratory 
and clinical registers.       
a DST is for rifampicin only or for both rifampicin and isoniazid.      
b DST for a fluoroquinolone and a second-line injectable drug.      
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TABLE 4.3
Estimated MDR-TB cases in 2014, notified cases of rifampicin-resistant TB and MDR-TB and enrolments on MDR-TB 
treatment in 2014, and treatment outcome reporting for 2012 cohort, globally and for 27 high MDR-TB burden countries 
and WHO regions
ESTIMATED MDR-TB AMONG NOTIFIED 
PULMONARY TB CASES, 2014
NOTIFIED MDR/RR-TB CASES, 
2014
CASES ENROLLED ON MDR-
TB TREATMENT, 2014
MDR-TB CASES REPORTED 
WITH TREATMENT OUTCOME 
DATA, 2012 COHORT
BEST 









Armenia 160 140–190 111 69 120 >100 115 >100
Azerbaijan 1 300 1 100–1 500 1 007 77 814 81 373 63
Bangladesh 4 800 3 400–6 200 994 21 945 95 505 98
Belarus 1 700 1 600–1 800 1 282 75 1 903 >100 2 502 >100
Bulgaria 72 53–91 44 61 29 66 44 90
China 52 000 42 000–61 000 5 807 11 2 846 49 1 906 63
DR Congo 2 800 980–4 500 442 16 436 99 134 >100
Estonia 62 48–75 50 81 48 96 50 81
Ethiopia 1 300 700–2 300 503 39 557 >100 271 95
Georgia 640 590–700 441 69 501 >100 623 >100
India 71 000 57 000–85 000 25 748 36 24 073 93 9 874 80
Indonesia 6 800 5 200–8 400 1 812 27 1 284 71 432 >100
Kazakhstan 4 900 4 800–5 000 5 877 >100 7 315 >100 7 213 95
Kyrgyzstan 2 000 1 800–2 100 1 267 63 1 157 91 775 81
Latvia 84 66–100 71 85 70 99 90 82
Lithuania 300 270–340 279 93 271 97 219 81
Myanmar 9 000 6 500–12 000 3 495 39 1 537 44 443 57
Nigeria 3 300 2 500–4 200 798 24 423 53 154 >100
Pakistan 12 000 8 800–15 000 3 243 27 2 662 82 858 54
Philippines 11 000 8 600–13 000 3 000 27 2 680 89 1 798 >100
Republic of Moldova 1 500 1 400–1 600 925 62 930 >100 856 96
Russian Federation 39 000 33 000–45 000 15 585 40 21 904 >100 16 021 >100
South Africa 6 200 5 100–7 300 18 734 >100 11 538 62 8 084 52
Tajikistan 880 810–950 902 >100 804 89 535 77
Ukraine 13 000 12 000–14 000 7 735 60 8 201 >100 5 556 80
Uzbekistan 7 000 6 100–7 900 4 955 71 3 665 74 1 491 86
Viet Nam 5 100 3 900–6 300 2 198 43 1 532 70 713 >100
High MDR-TB burden countries 260 000 180 000–330 000 107 305 41 98 245 92 61 635 87
AFR 32 000 15 000–49 000 25 531 80 17 352 68 10 246 56
AMR 7 000 4 700–9 300 3 745 54 3 568 95 2 866 97
EMR 15 000 12 000–19 000 4 348 29 3 423 79 1 271 57
EUR 72 000 62 000–81 000 42 293 59 49 074 >100 37 638 >100
SEAR 99 000 90 000–110 000 33 264 34 28 536 86 11 566 77
WPR 71 000 47 000–94 000 13 437 19 8 850 66 6 176 >100
Global 300 000 220 000–370 000 122 618 41 110 803 90 69 763 86
a Notified cases of MDR/RR-TB in 2014 as a percentage of the best estimate of MDR-TB cases among all cases of pulmonary TB in the same year. The 
percentage may exceed 100% if estimates of the number of MDR-TB are too conservative and if linkage between the clinical and laboratory registers is 
inadequate. Percentages shown are slightly higher than what would be expected if an estimate for all RR-TB cases (rather than MDR-TB) was used as a 
denominator (see also Box 4.1).
b The percentage of MDR-TB cases originally notified in 2012 with outcomes reported. The percentage may exceed 100% as a result of updated 
information about MDR-TB cases in 2012, inadequate linkages between notification systems for TB and MDR-TB, the inclusion of RR-TB cases in the 
numerator who were not confirmed MDR-TB, and the inclusion in the treatment cohort of cases of MDR-TB from a year prior to 2012.   
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Africa, and Tajikistan the figure was above 100% (Table 4.3), 
indicating either repeated reporting of cases when informa-
tion systems are based on laboratory results without linkage 
to patient registers, and/or that estimates of MDR-TB are too 
conservative (for example, because drug resistance surveil-
lance data have become outdated).
Box 4.2 The roll-out of rapid TB diagnostics compared with changes in the  
 number of cases of MDR/RR-TB notified by national TB programmes
Global progress in the detection of drug-resistant TB should be 
related to the roll-out of molecular diagnostics such as Xpert 
MTB/RIF and line probe assays (LPAs).a However, as use of these 
technologies expands, the number of tests required to detect 
one case may increase. This is because initial use of the test 
is likely to focus on groups with a higher risk of having MDR/
RR-TB (such as previously treated TB patients), in line with policy 
recommendations,b and then broaden to cover people at lower 
risk for drug-resistance (such as patients being evaluated for TB). 
Variation among countries is also expected given dif ferences in the 
prevalence of MDR/RR-TB (for example, the prevalence of MDR-TB 
is much higher in Ukraine compared with Bangladesh).
The relationship between annual procurements of Xpert MTB/RIF 
cartridges and notifications of MDR/RR-TB cases for 8 high MDR-TB 
burden countries is shown in Figure B4.2.1. These countries are 
among the major users of Xpert globally (each having procured 
42 000–82 000 cartridges in 2014) and Xpert is of ten the leading 
FIGURE B4.2.1 
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diagnostic test for drug resistance that is in use. Although there 
was substantial variation in the number of MDR/RR-TB cases 
reported for every 100 Xpert cartridges procured, the ratio tended 
to decrease over time in all countries. 
It was striking that sharp falls in the number of MDR/RR-TB cases 
detected for every 100 Xpert cartridges procured in Ethiopia and 
the Philippines between 2013 and 2014 occurred alongside an 
absolute reduction in the total number of reported MDR/RR-TB 
cases. The reasons for this are not well understood. Possible 
explanations include issues with reporting of cases, as opposed to 
actual levels of testing or laboratory results, and lag times between 
orders and actual use of tests. 
a For further details about these technologies, see Chapter 5.
b Xpert MTB/RIF implementation manual: technical and operational 
“how-to”; practical considerations. Geneva: World Health 
Organization; 2014 (WHO/HTM/TB/2014.1). http://apps.who.int/iris/
bitstream/10665/112469/1/9789241506700_eng.pdf.
4.2.3  Enrolment of notified RR-TB and MDR-TB cases 
on treatment
The number of patients enrolled globally on MDR-TB treat-
ment was 111 000 in 2014, up from 97 000 in 2013. There was a 
13% increase in enrolments between 2013 and 2014 in the 27 
high MDR-TB burden countries, with increments exceeding 
1000 patients in India, Pakistan, the Russian Federation and 
Uzbekistan. 
Globally, the number of patients starting second-line 
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n FIGURE 4.6









MDR-TB treatment was 90% of those notified with MDR/
RR-TB in 2014 (Table 4.3). The ratio was over 90% in 15 high 
MDR-TB burden countries, the European Region and the 
Region of Americas. The ratio was lowest in the Western 
Pacific (66%) and African (68%) regions.
In eight high MDR-TB burden countries, enrolments out-
stripped notifications of MDR/RR-TB (Figure 4.7). This may be 
caused by empirical treatment of TB patients considered at 
risk of having MDR-TB but for whom a laboratory-confirmed 
diagnosis was missing, incomplete reporting of laboratory 
data, or enrolment of “waiting lists” of people with MDR-
TB who were detected before 2014. In contrast, the ratio 
of enrolled to diagnosed cases was under 60% in 3 high 
MDR-TB burden countries in 2014, and below 50% in China 
(49%) and Myanmar (44%). These low ratios show that pro-
gress in detection is far outstripping capacity to provide 
treatment but may also reflect weaknesses in data collection 
systems. 
Overall, while the number of patients being enrolled on 
treatment for MDR-TB continues to increase, progress falls 
far short of Global Plan targets (Figure 4.4b, Table 4.3). Get-
ting closer to the Global Plan targets requires intensification 
of ef forts in many countries, but particularly China and the 
Russian Federation. These two countries rank second and 
third globally in terms of estimated numbers of cases, while 
levels of detection and treatment coverage remain relatively 
low. Continued support to NTPs through updated guidance, 
as well as direct technical assistance provided through the 
mechanisms of the Regional Green Light Committees and 
the Global Drug-resistant TB Initiative (www.stoptb.org/wg/
mdrtb/), is expected to improve global detection and treat-
ment of drug-resistant TB.
In 2014, 49 countries and territories reported treating peo-
ple with XDR−TB (Figure  4.8). Globally, 4 044 patients with 
XDR-TB were enrolled on treatment (higher than the level of 
3 284 in 2013). Most of the cases in 2014 were notified from 
India (1 262, up from 392 in 2013), Ukraine (657), South Africa 
(562), Belarus (431), and Kazakhstan (318).
4.2.4   Accelerating the scale-up of detection and 
enrolment on treatment for people with  
drug-resistant TB: the role of models of care 
and non-NTP providers
In many countries, one of the reasons for inadequate access 
to diagnosis and treatment of drug-resistant TB is that 
the network for the programmatic management of drug-
resistant TB (PMDT) is too centralized. Hospital-based 
models of care, which are still dominant in many countries, 
are a barrier to the expansion of PMDT because they depend 
on hospitals or referral centres. Greater use of ambulatory 
care as part of decentralized PMDT services is necessary to 
expand access. However, national policies and practices vary 
and hospitalization is still the predominant model of care in 
many countries. 
Among the 27 high MDR-TB burden countries, the Demo-
cratic Republic of the Congo reported the lowest level of 
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n FIGURE 4.7 
MDR−TB cases and additional rifampicin−resistant TB cases detected (red) compared with TB cases enrolled on MDR−TB 



























































































































































Belarus Bulgaria China DR Congo
Estonia Ethiopia Georgia India
Indonesia Kazakhstan Kyrgyzstan Latvia
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Globala
2009 2010 2011 2012 2013 2014
a The global total of MDR/RR-TB cases detected in 2013 (123 001) is lower than previously published in the 2014 Global TB Report (136 412) following revisions 
to data reported by India.
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hospitalization (5% of MDR-TB patients), followed by Myan-
mar (10%). In contrast, hospitalization for 100% of MDR-TB 
patients in 2014 (at least for part of their treatment) was 
reported by 10 high MDR-TB countries, including two of the 
top three MDR-TB burden countries: China and the Russian 
Federation. In a further six high MDR-TB burden countries, 
at least 90% of MDR-TB patients were hospitalized. When 
MDR-TB patients are hospitalized the duration of stay was 
relatively short in Indonesia, at five days, and ranged from 
30–60 days in five other countries (Bangladesh, China, 
Estonia, Ethiopia, Myanmar). In the other 15 countries that 
reported data, the average length of stay was 160 days.
The number of visits to a health facility af ter diagnosis of 
MDR-TB also varied markedly, from less than 30 (Bangladesh, 
Estonia, Myanmar, and South Africa) to over 700 (Armenia, 
Georgia, Indonesia, Russian Federation and Ukraine). The 
involvement of all relevant non-NTP health care providers is 
important to scale up PMDT and improve access to services. 
Unfortunately, reliable data on these activities are of ten not 
collected by NTPs. In 2014, only nine high MDR-TB burden 
countries provided information on the numbers of patients 
started on MDR-TB treatment by non-NTP health care pro-
viders. The Philippines, Latvia and Kyrgyzstan reported that 
22%, 14% and 11% respectively of MDR-TB cases were treated 
by non-NTP providers, while figures of 1−5% were reported 
to be treated in the private sector in Myanmar, Viet Nam and 
four Eastern European countries: Armenia, Republic of Mol-
dova, Ukraine and Uzbekistan.
n FIGURE 4.8 









In 2014, only 39 countries (including 13 of the 27 high 
MDR-TB burden countries) reported that palliative and end-
of-life care were provided within the scope of their NTPs. This 
finding attests to the huge unmet need for such services, 
which should be delivered alongside proper infection control 
measures (since most of these patients remain a source of 
infection).
4.2.5  Treatment outcomes for patients with 
MDR-TB and XDR-TB
The Global Plan included a target that all countries should 
report outcomes for all notified MDR-TB cases by 2015. A total 
of 127 countries and territories reported treatment outcomes 
for cases started on MDR-TB treatment in 2012. The country 
cohort size ranged from 1 to 16  000 cases. The number of 
cases reported in annual cohorts has steadily increased in 
all six WHO regions over time (with the exception of a small 
decrease in the Region of the Americas between the 2011 and 
the 2012 cohorts). The total reached 70 000 cases globally in 
2012, 33% more than in 2011 (Table 4.3 and Figure 4.9). 
The use of electronic systems to manage MDR-TB patient 
data could help to improve the completeness of reporting on 
treatment outcomes. One of the Global Plan targets is for all 
27 high MDR-TB countries to manage their data on treatment 
of MDR-TB patients electronically by 2015. By 2014, 15 of these 
countries reported that national electronic databases were 
in place for TB patients and another six had systems for MDR-
TB patients only. 
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n FIGURE 4.9 
Treatment outcomes for patients diagnosed with MDR−TB by WHO Region, 2007–2012 cohorts. The total number of cases 
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Overall, the proportion of MDR-TB patients in the 2012 
cohort who successfully completed treatment (i.e. cured or 
treatment completed) was 50%; 16% died, 16% were lost to 
follow-up, treatment failed for 10% and 8% had no outcome 
information (Figure 4.9). The treatment success rate was 
highest in the Eastern Mediterranean Region (65%), and low-
est in the European and South-East Asia regions (49%). In the 
2012 cohort, treatment failure was highest in the European 
Region (13%), and the death rate was highest in the South-
East Asia Region (21%). 
The Global Plan target of achieving a treatment suc-
cess rate of ≥75% by 2015 had already been reached in 40 of 
the 122 countries that reported outcome data for the 2012 
cohort, including three of the 27 high MDR-TB burden coun-
tries (Estonia, Ethiopia, and Myanmar). Between 2007 and 
2012, more than 100 000 people who started MDR-TB treat-
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ment were reported to have had a successful outcome and 
numbers have increased over time (data not shown).
Among 2 685 XDR-TB patients in the 2012 cohorts of 41 
countries for whom outcomes were reported, 682 (26%) com-
pleted treatment successfully; 809 (30%) died; treatment 
failed for 510 (19%); and 684 (25%) were lost to follow-up or 
their treatment outcome was not evaluated. The Russian 
Federation accounted for 51% of the XDR-TB patients for 
whom outcomes were reported in 2012. The high mortality 
of XDR-TB patients in South Africa (47%) is likely to be associ-
ated with a high level of HIV co-infection in TB patients (see 
Chapter 6). 
The introduction of new drugs and novel regimens could 
potentially improve the treatment outcomes of patients with 
MDR- and XDR-TB. By the end of 2014, at least 43 countries 
reported having used bedaquiline to treat patients as part 
of ef forts to expand access to treatment for MDR-TB, either 
for compassionate use or under normal programmatic con-
n FIGURE 4.10 
Countries that had used bedaquiline for the treatment of M/XDR-TB as part of expanded access, compassionate use or 





ditions in the public or private sectors (Figure 4.10). Most 
(75%) of these patients were from two countries: the Russian 
Federation and South Africa. In addition, at least 16 countries 
in Africa and Asia have introduced shorter regimens as part 
of trials or observational studies under operational research 
conditions, and several have started to include repurposed 
drugs in treatment regimens, to try to improve the treatment 
outcomes of MDR-TB and XDR-TB patients.
Since the start of global monitoring, treatment suc-
cess rates among patients with MDR-TB and XDR-TB have 
remained consistently and unacceptably low. Major ef forts 
are required to address this situation, using measures that 
are part of the End TB Strategy. These include adequate 
resources for detection and treatment and building capac-
ity among health care workers to provide high quality care. 
Research and development is also crucial. Without new TB 
drugs and regimens, it will be very dif ficult to improve treat-
ment outcomes in the near future. 
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Key facts and messages
December 2010. By the end of 2014, 69% of countries reported 
that national policy by the end of 2014 indicated the use of 
Xpert MTB/RIF as the initial diagnostic test for people at risk 
of drug-resistant TB, and 60% reported that national policy 
indicated its use as the initial diagnostic test for people living 
with HIV. In 116 of the 145 countries eligible for concessional 
pricing that have purchased the technology, a total of 3 763 
GeneXpert machines had been procured for use in the public 
sector by the end of 2014. In 2014 alone, 4.8 million Xpert MTB/
RIF test cartridges were procured, up from 550 000 in 2011. 
Ensuring the quality of microscopy networks is critical, given 
that smear microscopy remains the most widely used tool for 
TB diagnosis in low- and middle-income countries. Among the 
22 HBCs, only four reported an external quality assessment 
scheme that encompassed all microscopy centres in 2014, and 
five more reported a programme that included at least 90% of 
centres.
Several sources of guidance and training platforms have been 
developed to assist TB reference laboratories to implement 
a quality management system that meets international 
accreditation standards. In 2014, 123 of 173 responding 
countries and territories (71%) indicated that a formal 
quality management system towards achieving laboratory 
accreditation had at least been started at the national reference 
laboratory (NRL).
In 2015, the WHO TB Supranational Reference Laboratory 
Network expanded to include three newly designated 
National Centres of Excellence in the Russian Federation. 
The three laboratories are of particular value for establishing 
and maintaining high-quality laboratory services within the 
country for the programmatic management of drug-resistant 
TB, including through the coordination of technical assistance, 
provision of monitoring and supervision, and organization of 
training for laboratory staf f involved in diagnostic testing for 
drug resistance and monitoring of treatment for patients with 
drug-resistant TB.






The End TB Strategy calls for the early diagnosis of TB and 
universal drug susceptibility testing (DST), highlighting the 
critical role of laboratories in the post-2015 era for rapidly and 
accurately detecting TB and drug resistance.
Laboratory confirmation of TB and drug resistance is essential 
to ensure that individuals with TB are correctly diagnosed and 
have access to the appropriate treat ment as soon as possible. 
Of the 5.2 million incident (new and relapse) pulmonary TB 
patients notified globally in 2014, 3.0 million (58%) were 
bacteriologically confirmed, i.e., were smear- or culture-
positive or positive according to a WHO-recommended rapid 
diagnostic such as Xpert® MTB/RIF. Among new (previously 
untreated) cases of bacteriologically confirmed TB, 12% had 
access to DST; among previously treated cases, 58% had access 
to DST.
A new WHO Policy framework for implementing tuberculosis 
diagnostics was published in April 2015. This provides an 
overview of all current WHO policy recommendations on TB 
diagnostics and the role of each test within ef fective diagnostic 
algorithms across a laboratory network. The document also 
describes the managerial, technical and operational processes 
required for developing and implementing a comprehensive 
national strategy for TB laboratories.
WHO has recently issued policy recommendations on the use of 
the urine lateral flow lipoarabinomannan (LF-LAM) assay (Alere 
DetermineTM TB LAM Ag test). The test is not recommended 
for TB screening or diagnosis of TB in most population groups. 
However, it is recommended to help with the diagnosis of TB in 
two population groups: HIV-positive people who are inpatients 
with signs or symptoms of TB and who have a CD4 cell count 
less than or equal to 100 cells/µL, and HIV-positive people who 
are “seriously ill” (both inpatients and outpatients) with danger 
signs, regardless of CD4 count or if the CD4 count is unknown. 
The use of the rapid molecular test Xpert MTB/RIF continues 
to expand in line with WHO recommendations for its use since 
The microbiological detection of TB and drug susceptibility 
using rapid WHO-recommended diagnostics, together with 
an ef ficient system for transfer of specimens and results, 
allows patients to be correctly diagnosed and started on the 
most ef fective treatment regimen as early as possible. One 
of the core components of the first pillar of the post-2015 End 
TB Strategy (Chapter 1) is the early diagnosis of TB, includ-
ing universal drug susceptibility testing (DST). Operational 
guidance on the implementation of the strategy calls for all 
patients to receive DST at least for rifampicin, with further 
tests for drug susceptibility to first and second-line drugs for 
any TB patients found to have rifampicin resistance. A well-
equipped and staf fed, quality-assured laboratory network 
with an ef ficient referral system is therefore an essential 
requirement for any national TB programme (NTP) in the 
post-2015 era.
For decades, resource-constrained countries have relied on 
sputum smear microscopy as the primary method for detect-
70  n  GLOBAL TUBERCULOSIS REPORT 2015
ing TB. While inexpensive and requiring minimal biosafety 
standards, microscopy is not a sensitive test (particularly for 
people living with HIV and children) and it provides no infor-
mation on the resistance profile of the bacilli. Furthermore, 
microscopy is not able to distinguish between Mycobacterium 
tuberculosis complex and non-tuberculosis mycobacteria. 
Bacteriological culture is considered the reference stand-
ard for detecting TB, but suf fers from the disadvantages 
that results take weeks to obtain and that testing requires a 
well-equipped laboratory, highly trained staf f, and an ef fi-
cient transport system to ensure the viability of specimens. 
Phenotypic DST on cultured specimens is the conventional 
method used to detect resistance to first- and second-line TB 
drugs, and faster commercial liquid culture systems are now 
available. Building adequate culture capacity in many coun-
tries with a high burden of TB has been slow, given the cost 
and infrastructure requirements. 
In recent years, a limited but growing number of rapid 
and more sensitive tests for TB and drug-resistant TB based 
on molecular methods, including Xpert® MTB/RIF (Cepheid, 
USA) and line probe assays (LPAs), have become available to 
replace or complement existing conventional tests. Despite 
the advantages of molecular tests, conventional micros-
copy and culture remain necessary for monitoring patients’ 
response to treatment. Furthermore culture-based DST 
methods are currently the only methods available for accu-
rate testing of susceptibility to second-line drugs.
Of the 5.2 million incident pulmonary TB patients notified 
globally in 2014, only 3.0 million (58%) were bacteriologically 
confirmed, i.e., were smear- or culture-positive or positive 
according to a WHO-recommended rapid diagnostic such 
as Xpert MTB/RIF (Chapter 3). The remaining 42% of patients 
who were not bacteriologically confirmed were diagnosed 
clinically, i.e. based on symptoms, chest X-ray abnormalities 
or suggestive histology. The common symptoms of TB com-
bined with the poor specificity of X-ray screening may result 
in false diagnoses and people without TB being enrolled on 
TB treatment when it is not needed. Furthermore, a low rate 
of laboratory confirmation reflects under-diagnosis of true 
TB cases and contributes in part to the continuing global gap 
between notified and estimated incident TB cases: 6 million 
and 9.6 million in 2014, respectively (Chapter 3). The propor-
tion of new and previously treated cases receiving DST has 
steadily increased but much remains to be done. Globally, 
12% of new bacteriologically-confirmed TB cases and 58% of 
those previously treated for TB were tested for drug resist-
ance in 2014 (Chapter 4).
Laboratory strengthening and new diagnostics are crucial 
to improve the proportion of notified TB cases with a defini-
tive (bacteriologically confirmed) diagnosis of TB, and to 
close detection and treatment gaps for TB and drug-resistant 
TB. This chapter summarizes the status of progress in 2014. 
Section 5.1 highlights key developments in WHO guidance 
on TB diagnostics and laboratory strengthening during 
2014–2015. Section 5.2 presents the status of laboratory 
capacity globally, regionally and nationally in 2014, based on 
data reported to WHO by countries in 2015. Here, the focus 
is on the 36 countries in the combined list of 22 high burden 
countries (HBCs) and 27 high MDR-TB burden countries. 
Section 5.3 describes recent activities to strengthen TB labo-
ratories, including quality management systems, external 
quality assessment and the WHO TB Supranational Refer-
ence Laboratory (SRL) Network.
5.1  Developments in WHO policy guidance 
on TB diagnostics and laboratory 
strengthening, 2014–2015
The WHO Global TB Programme follows a systematic pro-
cess for development of policy recommendations on TB 
diagnostics, involving synthesis of the available evidence 
on performance and cost ef fectiveness through systematic 
reviews, meta-analyses and modelling as appropriate, assess-
ment of the evidence by an external Guideline Development 
Group using the GRADE approach,1 and development of 
policy guidance2 for dissemination to Member States and 
other stakeholders. Policy documents are reviewed periodi-
cally, and revised as necessary when new evidence becomes 
available. 
In June 2015, WHO convened a Guideline Development 
Group to review the evidence on the use of the urine lateral 
flow lipoarabinomannan (LF-LAM) assay (Alere DetermineTM 
TB LAM Ag test, Alere Inc, USA) for detection of TB in people 
living with HIV. A lipoarabinomannan (LAM) antigen is a 
lipopolysaccharide present in mycobacterial cell walls, which 
is released from metabolically active or degenerating bacte-
rial cells and appears to be present only in people with active 
TB disease. Tests based on the detection of LAM in urine have 
the potential to be point-of-care tests for TB. Further advan-
tages over sputum-based testing are that urine is easy to 
collect and store, and lacks the infection control risks associ-
ated with sputum collection.
The urinary LAM assays currently available are unsuit-
able as general diagnostic or screening tests for TB, due to 
suboptimal sensitivity. However, unlike traditional diagnos-
tic methods for TB, they demonstrate improved sensitivity 
among people living with HIV, which further increases as CD4 
counts fall. Following the Guideline Development Group’s 
evaluation of the LF-LAM assay, the resulting 2015 WHO pol-
icy recommendations on its use are summarized in Box 5.1.
In the coming year, evaluations and updated reviews are 
planned for several other technologies. These include LPAs 
for detection of resistance to first- and second-line drugs 
(Hain LifeScience, Germany; and Nipro Corp., Japan); the use 
of sequencing for detection of resistance-conferring muta-
tions; and the Xpert® Ultra assay and GeneXpert® Omni 
(Cepheid, USA). Further potential technologies on the evalu-
1 www.gradeworkinggroup.org
2 WHO handbook for guideline development, 2nd ed. Geneva, World Health 
Organization; 2014. Available at: http://www.who.int/kms/
handbook_2nd_ed.pdf.
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ation horizon include several rapid and sensitive diagnostic 
tests that are expected to be available for use at reference 
laboratory level as well as closer to – or at – the point of 
patient care (Chapter 8).
In April 2015, a new WHO Policy framework for implement-
ing tuberculosis diagnostics was published.1 This document 
provides comprehensive guidance on the managerial, tech-
nical and operational processes required for developing 
and implementing a comprehensive national strategy for 
TB laboratories, which encompass early diagnosis of TB and 
universal access to DST as well as systematic screening of con-
tacts of people with TB and high-risk groups. The positioning 
of WHO-recommended diagnostics at dif ferent levels of a 
laboratory network is described, and templates of diagnos-
tic algorithms are presented. This generic policy framework 
1 WHO Policy framework for implementing tuberculosis diagnostics. 
Geneva, World Health Organization; 2015. Available at: http://www.
who.int/tb/publications/implementing_TB_diagnostics/en/
can be adapted and customized at 
country level to account for the wide 
variation in country resources and 
needs, as well as dif ferences in the 
epidemiology of TB, HIV-associated 
TB and drug-resistant TB.
A comprehensive list of existing 
WHO policy documents, including on 
the use of microscopy, culture, DST 
and non-commercial and molecular 
diagnostic methods, is available at: www.who.int/tb/labora-
tory/policy_statements.
5.2 Status of laboratory capacity globally, 
regionally and nationally 
Smear microscopy continues to be the most widely used 
tool for TB diagnosis in low- and middle-income countries, 
despite its shortcomings. A microscopy network with ade-
quate population coverage and high quality performance 
(see Section 5.3) is therefore critical. The Global Plan to Stop 
TB 2011–2015 includes the target that countries maintain at 
least one smear microscopy centre per 100 000 population.2 
Globally, the target has been met (1.1 centres per 100 000 
population in 2014), but significant disparities remain at 
regional and country levels (Table 5.1). For example, the 
Western Pacific and Eastern Mediterranean regions had 
less than one centre per 100  000 population in 2014. The 
target now requires country-specific adaptation given the 
increased use of Xpert MTB/RIF as an initial diagnostic test, 
especially in settings with high burdens of HIV and MDR-TB. 
In addition, it is important to emphasize that geographic 
variations in the TB epidemic within a country as well as dif-
ferences in access between urban and rural settings require 
that the number and placement of microscopy centres are 
strategically considered within countries.
Fluorescent light-emitting diode (LED) microscopy is 
more sensitive than conventional Ziehl–Neelsen (ZN) light 
microscopy and has further qualitative, operational and 
cost advantages. In 2009, WHO recommended that LED 
microscopy be phased in as an alternative for ZN microscopy. 
Globally, the switch to LED microscopes has been gradual: 
the technology was reported to have been present in only 7% 
of microscopy centres in 2014, up from 2% in 2012. Nonethe-
less, major progress is evident in certain countries. Among 
HBCs, major adopters of LED microscopy include South 
Africa (100% of microscopy sites in 2014), China (38%), Myan-
mar (31%), Bangladesh (22%), Kenya (21%) and Mozambique 
(21%). Adoption of LED microscopy remains particularly low 
in Indonesia (0%), Afghanistan (<1%), Brazil (<1%), Philip-
pines (<1%), the Democratic Republic of the Congo (1%), India 
(2%), and Viet Nam (2%). 
The current target in the Global Plan to Stop TB 2011–2015 
for both culture and DST (to at least rifampicin and isoniazid) 
2 The Global Plan to Stop TB, 2011–2015. Geneva, World Health 
Organization; 2010 (WHO/HTM/STB/2010.2). 
Box 5.1 WHO recommendations on urine  
 lateral flow lipoarabinomannan  
 (LF-LAM) assay (Alere DetermineTM  
 TB LAM Ag test, Alere Inc, USA)
The 2015 WHO recommendations on LF-LAM assay are:
1. LF-LAM should not be used for the diagnosis of TB, except 
as specifically described below for persons with HIV with low CD4 
counts or who are seriously illa (strong recommendation; low 
quality of evidence).
2. LF-LAM may be used to assist in the diagnosis of TB in 
HIV-positive adult inpatients with signs or symptoms of 
TB (pulmonary and/or extrapulmonary) who have a CD4 
cell count less than or equal to 100 cells/µL, or HIV-positive 
patients who are seriously illa regardless of CD4 count or 
with unknown CD4 count (conditional recommendation; 
low quality of evidence).
Remarks
" This recommendation also applies to HIV-positive adult 
outpatients with signs and symptoms of TB (pulmonary 
and/or extrapulmonary) who have a CD4 cell count less 
than or equal to 100 cells/µL, or HIV-positive patients 
who are seriously illa regardless of CD4 count or with 
unknown CD4 count, based on the generalisation of data 
from inpatients.
" This recommendation also applies to children, based 
on the generalisation of data from adults while 
acknowledging very limited data and concern regarding 
the low specificity of the LF-LAM assay in children.
3. LF-LAM should not be used as a screening test for TB (strong 
recommendation; low quality of evidence).
a “seriously ill” is defined based on four danger signs: respiratory 
rate > 30/min, temperature >39 °C, heart rate >120/min and 
unable to walk unaided.
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Afghanistan   720 2.3 < 1 3 0.5 0 0 0 0 1
Armenia   26 0.9 4 1 1.7 1 1.7 1 1.7 2
Azerbaijan   72 0.7 4 7 3.6 3 1.6 2 1 7
Bangladesh   1 104 0.7 22 3 <0.1 3 <0.1 1 <0.1 38
Belarus   154 1.6 2 29 15 8 4.2 8 4.2 15
Brazil   3 382 1.6 < 1 324 7.9 26 0.6 1 <0.1 48
Bulgaria   34 0.5 38 30 21 9 6.2 4 2.8 0
Cambodia   215 1.4 13 4 1.3 3 1 0 0 17
China   2 952 0.2 38 1 825 6.7 399 1.5 157 0.6 654
DR Congo   1 604 2.1 1 4 0.3 3 0.2 1 <0.1 39
Estonia   6 0.5 33 2 7.6 2 7.6 2 7.6 4
Ethiopia   2 972 3.1 9 8 0.4 8 0.4 8 0.4 28
Georgia   11 0.3 9 2 2.5 1 1.2 2 2.5 11
India   13 583 1 2 67 0.3 62 0.2 50 0.2 121
Indonesia   5 689 2.2 0 20 0.4 15 0.3 2 <0.1 41
Kazakhstan   466 2.7 0 85 24 22 6.3 12 3.5 23
Kenya   1 920 4.3 21 3 0.3 3 0.3 5 0.6 70
Kyrgyzstan   131 2.2 8 7 6 2 1.7 2 1.7 8
Latvia   12 0.6 0 5 13 1 2.5 1 2.5 2
Lithuania   13 0.4 15 6 10 6 10 2 3.4 4
Mozambique   336 1.2 21 3 0.6 2 0.4 1 0.2 24
Myanmar   492 0.9 31 3 0.3 2 0.2 2 0.2 38
Nigeria   1 765 1 15 8 0.2 8 0.2 6 0.2 96
Pakistan   1 483 0.8 3 12 0.3 5 0.1 4 0.1 42
Philippines   2 561 2.6 < 1 22 1.1 4 0.2 1 <0.1 84
Republic of Moldova   59 1.4 0 4 4.9 4 4.9 4 4.9 28
Russian Federation   5 347 3.7 6 405 14 299 10 6 0.2 96
South Africa   207 0.4 100 12 1.1 12 1.1 12 1.1 207
Tajikistan   84 1 6 5 3 1 0.6 3 1.8 14
Thailand   908 1.3 3 53 3.9 20 1.5 12 0.9 14
Uganda   1 365 3.6 18 5 0.7 5 0.7 3 0.4 74
Ukraine   676 1.5 0 65 7.2 24 2.7 3 0.3 25
UR Tanzania   945 1.8 14 4 0.4 1 <0.1 3 0.3 59
Uzbekistan   325 1.1 < 1 7 1.2 2 0.3 3 0.5 24
Viet Nam   989 1.1 2 23 1.2 2 0.1 2 0.1 30
Zimbabwe   220 1.4 10 2 0.7 2 0.7 1 0.3 62
High-burden countries – 1.1 8 – 3.1 – 1 – 0.3 –
High MDR-TB burden countries – 1 7 – 3.2 – 1.1 – 0.4 –
AFR – 1.6 14 – 1 – 1.2 – 0.3 –
AMR – 2 2 – 15 – 0.7 – 0.3 –
EMR – 0.7 5 – 2.2 – 0.3 – 0.2 –
EUR – 1.2 5 – 11 – 5.5 – 1.6 –
SEAR – 1.2 3 – 0.4 – 0.3 – 0.2 –
WPR – 0.5 16 – 6 – 1.3 – 0.5 –
Global – 1.1 7 – 4.7 – 1.3 – 0.5 –
–  indicates values that cannot be calculated.
a  The regional and global figures are aggregates of data reported by low- and middle-income countries and territories. Data for the variables shown in 
the table are not requested from high-income countries in the WHO data collection form.
YES     NO 
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Global capacity for drug-susceptibility testing (DST), 2014a






a Data for 2013 were used if data for 2014 were not reported (n=6).
capacity is one laboratory per 5 million population. In 2014, 
12 of the 27 high MDR-TB burden countries did not reach 
the target (Table 5.1), and several countries with large TB 
caseloads continue to completely lack in-country capacity 
for phenotypic DST (Figure 5.1). In 2014, 12 countries reported 
more than 1000 notified TB cases but no capacity to perform 
phenotypic DST: Afghanistan, Burkina Faso, Chad, Congo, 
Equatorial Guinea, Gabon, Guinea-Bissau, Papua New 
Guinea, Sierra Leone, Somalia, South Sudan and Timor Leste. 
Among these, Equatorial Guinea and Sierra Leone also report-
ed lacking any capacity for Xpert MTB/RIF testing, which 
would at least allow for detection of rifampicin resistance. 
Patients with MDR-TB require DST for second-line drugs 
to refine and optimize their treatment regimen. Some 
countries with small caseloads of MDR-TB patients have 
reasonably opted to rely on partner laboratories (includ-
ing WHO Supranational Reference Laboratories) for such 
testing, instead of building in-country capacity. However, 
28 countries with reported RR/MDR-TB cases indicated that 
they had neither in-country capacity nor a linkage with a 
partner laboratory for second-line DST: Albania, Cambodia, 
Central African Republic, Chad, Congo, Djibouti, Eritrea, 
Gabon, Ghana, Guinea, Guinea-Bissau, Guyana, Jordan, Ken-
ya, Kuwait, Malawi, Mali, Mauritania, Mauritius, Morocco, 
Panama, Paraguay, Sao Tome and Principe, Saudi Arabia, 
Syrian Arab Republic, Togo, Turkmenistan and Yemen. Coun-
tries with sizeable TB and MDR-TB caseloads should aim as 
a priority to build sustainable in-country capacity to under-
take DST to at least rifampicin, to allow the timely diagnosis 
of drug-resistant strains.
As a high-throughput molecular tool for use at central 
and regional levels, LPAs have been adopted by many coun-
tries for rapid first-line DST (to rifampicin and isoniazid) on 
smear-positive specimens or cultures. In 2014, 92 countries 
and territories reported at least one facility with capacity to 
perform LPA tests. Of the 27 high MDR-TB burden countries, 
13 reported LPA capacity in more than one laboratory per 
5  million population.
Following initial WHO recommendations issued in 
December 2010, Xpert MTB/RIF has been quickly adopted 
by countries as an ef fective tool for the rapid detection of 
TB and rifampicin resistance at lower levels of the health sys-
tem. By the end of December 2014, a total of 3 763 GeneXpert 
instruments comprising 17 883 modules had been procured 
in the public sector in 116 of the 145 countries eligible for con-
cessional pricing. In 2014, 4.8 million test cartridges were 
procured by eligible countries (Figure 5.2), up from 550 000 
in 2011. Of these, 51% (2.4 million) went to South Africa.
The original WHO policy guidance on Xpert MTB/RIF 
issued in 2010 recommends its use as the initial diagnostic 
test in individuals suspected of having MDR-TB or HIV-asso-
ciated TB (strong recommendations). A policy update in 2013 
expanded its recommended uses, including for the diagno-
sis of TB in children, on selected specimens for the diagnosis 
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of extrapulmonary TB, and for all individuals suspected of 
having pulmonary TB (conditional recommendations). 
High-burden countries have largely adopted the strong rec-
ommendations on its use as the initial diagnostic test for 
individuals suspected of having MDR-TB or HIV-associated 
TB (Table 5.2). While 19 of the 22 high TB burden countries 
have indicated policies on the use of Xpert MTB/RIF for indi-
viduals suspected of having HIV-associated TB, not all of the 
41 TB/HIV priority countries reported having such a policy: by 
the end of 2014, Central African Republic, Chad, China, Cote 
d’Ivoire, Malawi, Myanmar, Namibia, Sierra Leone and Sudan 
indicated that Xpert MTB/RIF was not yet the initial diagnos-
tic test for people suspected of having HIV-associated TB (see 
also Box 6.2 in Chapter 6).
Increasingly, countries are also updating their policies to 
include the use of Xpert MTB/RIF for children and for detec-
tion of extrapulmonary TB (50% and 41% of all reporting 
countries, respectively). A small number of countries with 
suf ficient resources, including South Africa, Swaziland 
and Moldova, are also placing Xpert MTB/RIF as the initial 
diagnostic test for all people suspected of having TB. Some 
countries that cannot af ford the use of Xpert MTB/RIF as 
the initial diagnostic test for all people with suspected TB 
have introduced diagnostic algorithms in which chest X-ray 
is used as an initial screening tool, with those with X-ray 
abnormalities then eligible for testing using Xpert MTB/
RIF. As countries continue to scale-up coverage of Xpert 
MTB/RIF testing, algorithms should be widened to increase 
patient access to the test as a sensitive and rapid tool both for 
detection of rifampicin resistance and for TB case-finding.
The growing number of drug-resistant cases being 
detected by Xpert MTB/RIF and LPAs requires adjustment 
of country culture and phenotypic DST capacities. The intro-
duction of Xpert MTB/RIF and LPAs reduces the need for 
culture as the initial diagnostic test, but at the same time 
the growing detection of drug-resistant TB cases requires 
culture capacity for monitoring of treatment and DST of 
other anti-TB drugs to guide treatment adjustments. It is 
also imperative that the increasing capacity of countries to 
diagnose drug-resistant TB is matched by increased capacity 
to provide appropriate treatment to all diagnosed cases (see 
also Chapter 4).
One of the main reasons for low TB and drug-resistant TB 
case detection rates in many parts of the world (Chapter 3) is 
the existence of a significant private sector, in which care pro-
viders frequently diagnose people with TB and drug-resistant 
TB but fail to notify these to national authorities. The quality 
of diagnostic services in the private sector is highly variable 
or unknown. Furthermore, in some settings, laboratories in 
the public sector that are not under the auspices of the NTP 
also diagnose TB and drug-resistant TB without necessarily 
following recommended guidelines and quality assurance 
procedures. Collaboration between NTPs and all laborato-
ries of fering TB and drug-resistant TB diagnosis is critical to 
ensure that national guidelines are followed, that appropri-
ate diagnostic tests are used, and that patients diagnosed 
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EXTRAPULMONARY TB USING 
SELECTED SPECIMENS
Afghanistan      
Armenia      
Azerbaijan      
Bangladesh      
Belarus      
Brazil      
Bulgaria      
Cambodia      
China      
DR Congo      
Estonia      
Ethiopia      
Georgia      
India      
Indonesia      
Kazakhstan      
Kenya      
Kyrgyzstan      
Latvia      
Lithuania      
Mozambique      
Myanmar      
Nigeria      
Pakistan      
Philippines      
Republic of Moldova      
Russian Federation      
South Africa      
Tajikistan      
Thailand      
Uganda      
Ukraine      
UR Tanzania      
Uzbekistan      
Viet Nam      
Zimbabwe      
High-burden countries 86% 100% 77% 64%
High MDR-TB burden countries 85% 93% 81% 70%
AFR 72% 84% 67% 40%
AMR 52% 48% 35% 30%
EMR 56% 62% 38% 44%
EUR 50% 57% 45% 44%
SEAR 55% 82% 36% 45%
WPR 72% 83% 56% 50%
Global 60% 69% 50% 41%
a  The regional and global figures are aggregates of data reported by low- and middle-income countries and territories. Data for the variables shown in 
the table are not requested from high-income countries in the WHO data collection form. 
YES     NO 
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with TB and drug-resistant TB are notified to the NTP and 
receive proper care. In 2014, 17 of 36 high TB and MDR-TB 
burden countries reported some level of collaboration with 
laboratories in the private sector, and 23 reported collabora-
tion with non-NTP laboratories in the public  sector.
5.3 Strengthening TB laboratories globally, 
regionally and nationally
Strengthening TB laboratories involves not only equipping 
them with modern diagnostics suitable to the various levels 
of the network (Section 5.2), but also ensuring the quality of 
every step in the diagnostic process, from the collection and 
testing of samples, to the recording and reporting of results. 
Implementing a system of quality management should be a 
priority across all TB laboratories in a network. A comprehen-
sive quality management system allows for the necessary 
activities to be carried out at the right time and by the appro-
priately trained people, for the necessary equipment and 
consumables to be in stock, and for all manuals, guidelines, 
forms and standard operating procedures to be in place so 
that processes are carried out correctly. 
Several sources of guidance and training platforms have 
been developed to assist TB reference laboratories to imple-
ment a quality management system that meets international 
accreditation standards. The GLI stepwise process towards TB 
laboratory accreditation is an online interactive guide1 divided 
into four phases, developed by the Royal Tropical Institute 
(KIT), the Union, the United States Centers for Disease 
Control and Prevention, the United States Agency for Inter-
national Development (USAID) and WHO. The framework 
known as the WHO guide for the stepwise laboratory improve-
ment process toward accreditation in the African Region (SLIPTA) 
is based on 12 quality-system essentials, and it is applicable 
to all laboratory settings and disciplines. The United States 
Centers for Disease Control and Prevention has developed 
a task-based mentoring programme known as Strengthen-
ing laboratory management towards accreditation (SLMTA). 
The Foundation for Innovative New Diagnostics (FIND) has 
modified both the SLMTA programme and the SLIPTA frame-
work to include TB-specific guidance, to form TB-SLMTA and 
TB-SLIPTA. In 2014, 123 of 173 responding countries and ter-
ritories (71%) indicated that a formal quality management 
system towards achieving laboratory accreditation had at 
least been started at the national reference laboratory (NRL).
Quality assurance of microscopy remains a critical 
activity of all laboratory networks, and a comprehensive 
external quality assessment (EQA) programme should be 
implemented that includes on-site evaluation, random 
blinded rechecking, and panel testing. Of the 140 countries 
and territories that reported data on the number of smear 
microscopy centres undergoing EQA in 2013, only 34% indi-
cated the existence of a scheme that covered all centres in 
the country, with a further 16% covering at least 90% of cen-
1 http://gliquality.org
tres. Among the 22 HBCs, only four reported a scheme that 
encompassed all centres in 2014 (Bangladesh, India, Uganda 
and Zimbabwe) and five more reported a programme that 
included at least 90% of centres (Cambodia, China, Pakistan, 
South Africa and Viet Nam).
Quality-assured DST is critical to ensure accurate detec-
tion of drug resistance to inform treatment decisions and to 
avoid false diagnoses. Of the high TB and MDR-TB burden 
countries that reported on EQA coverage of DST laboratories 
in 2014 (34 of 36), 24 (71%) reported having a scheme that 
encompassed all DST laboratories. Of the 116 reporting coun-
tries globally, 78 (67%) indicated a scheme that encompassed 
all laboratories. Ensuring quality needs to be a priority for all 
levels of a laboratory network.
As a key partner in strengthening the capacity and qual-
ity of TB laboratories globally, the WHO TB Supranational 
Reference Laboratory (SRL) Network comprises 36 laborato-
ries that provide long-term technical assistance to low- and 
middle-income countries under the framework of collabora-
tive agreements. The network was formed in 1994 to ensure 
the quality of drug resistance surveys, but today SRLs pro-
vide a wide range of technical assistance services, including 
training, on-site supervisory missions, guidance to the 
development of national laboratory strategic plans, and pro-
ficiency testing. 156 countries and territories reported having 
a formal link with a partner SRL in 2014.
The SRL Network also includes ‘National Centres of Excel-
lence’ (SRL-CEs), which are well-performing national and 
regional TB reference laboratories in large, middle-income 
countries. These SRL-CEs have similar terms of reference 
(and national status) to that of an SRL but with an in-country 
focus for its laboratory strengthening activities. To meet its 
objectives, a SRL-CE commits to provide minimum service 
requirements including establishing formal links with at 
least two intermediate level laboratories within the country 
and undertaking at least one annual technical assistance 
visit to each laboratory. A SRL-CE needs to be nominated by 
its NTP to the WHO country of fice, establish a collabora-
tive agreement with an existing SRL, undergo a laboratory 
assessment by WHO, and actively implement a quality man-
agement system towards accreditation.
In 2014, the Ministry of Health of the Russian Federation 
nominated TB laboratories of three Federal Institutes to 
undergo evaluations to assess their suitability for designa-
tion as SRL-CEs: Central Tuberculosis Research Institute, 
Moscow; Novosibirsk Tuberculosis Research Institute, 
Novosibirsk; and Ural Research Institute for Phthisiopul-
monology, Yekaterinburg. Following assessment missions, 
all three of the laboratories were recognized as performing 
well, with high-quality infrastructure and a high calibre of 
suitably-qualified technical staf f. They were all subsequently 
designated as SRL-CEs in April 2015. These laboratories 
have a particular value for establishing and maintaining 
high-quality laboratory services within the country for the 
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programmatic management of drug-resistant TB, including 
through the coordination of technical assistance, provision 
of monitoring and supervision, and organization of trainings 
to laboratory staf f involved in diagnostic testing for drug 
resistance and monitoring of treatment for patients with 
drug-resistant TB. 
The SRL network as of July 2015 is shown in Figure 5.3.
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Addressing the co-epidemics  





Key facts and messages
In 2014, coverage of antiretroviral therapy (ART) for notified TB 
patients who were known to be co-infected with HIV reached 
77% globally. Further ef forts are needed to reach the target of 
100%. This is especially the case given that the number of HIV-
positive TB patients on ART in 2014 represented only 33% of the 
estimated number of people living with HIV who developed TB 
in 2014. 
Coverage of co-trimoxazole preventive therapy (CPT) among 
HIV-positive TB patients remains high, and increased slightly to 
87% globally and 89% in the African Region in 2014. 
The number of people living with HIV who were treated with 
isoniazid preventive therapy (IPT) reached 933 000 in 2014, an 
increase of about 60% compared with 2013. However, provision 
of IPT was reported by just 23% of countries globally, including 
only 13 of the 41 high TB/HIV burden countries. As in previous 
years, a large proportion of the people living with HIV who were 
initiated on IPT were in South Africa (59%), although in most 
countries that reported data in 2013 and 2014, coverage levels 
grew. 
Preventing TB deaths among HIV-positive people requires 
intensified scale-up of TB prevention, diagnosis and treatment 
interventions, including earlier initiation of ART among people 
living with HIV and those with HIV-associated TB. Increased 
ef forts in joint TB and HIV programming could facilitate further 
scale-up and consolidation of collaborative TB/HIV activities. 
In 2014, an estimated 1.2 million (12%) of the 9.6 million people 
who developed TB worldwide were HIV-positive. The African 
Region accounted for 74% of the estimated number of HIV-
positive incident TB cases. 
The number of people dying from HIV-associated TB peaked 
at 570 000 in 2004 and has since fallen to 390 000 in 2014 (a 
reduction of 32%). In 2014, HIV-associated TB deaths accounted 
for 25% of all TB deaths (among HIV-negative and HIV-positive 
people) and one third of the estimated 1.2 million deaths from 
HIV/AIDS. 
In 2004, WHO recommended the implementation of 12 
collaborative TB/HIV activities. Between 2005 and 2014, an 
estimated 5.8 million lives were saved by TB/HIV interventions.
Globally, 51% of notified TB patients had a documented HIV 
test result in 2014, a small increase from 49% in 2013. The figure 
was highest in the African Region, at 79%, and ≥90% in 18 of the 
41 high TB/HIV burden countries.
The prevalence of HIV co-infection among TB patients is 
highest in the African Region. Of the 1.1 million TB patients 
with known HIV status in 44 countries, 39% were HIV-positive 
in 2014, a slight decline compared with 41% in 2013. The 
proportion of TB patients who were known to be HIV-positive 
in the African Region ranged from 6% in Eritrea to 73% in 
Swaziland. 
Globally, people living with HIV are 26 times more likely to 
develop TB disease than those who are HIV-negative.1 Begin-
ning in the 1980s, the HIV epidemic led to a major upsurge 
in TB cases and TB mortality in many countries, especially in 
southern and eastern Africa (Chapter 2). 
In 2014, 1.2 million (12%) of the 9.6 million people who 
developed TB worldwide were HIV-positive (Chapter 2, Table 
2.1); 74% of these HIV-positive TB cases were in the African 
Region. The number of people dying from HIV-associated TB 
peaked at 570 000 in 2004 and has since fallen to 390 000 in 
1 The probability of developing TB among people living with HIV divided 
by the probability of developing TB among HIV-negative people is the 
incidence rate ratio (IRR). The mean estimated global IRR (all ages) in 
2014 was 26 (range 24–28). However, there is considerable variation 
among countries: in 2014, the median IRR was 23 (interquartile range 
14-36). Further details are provided in the online technical appendix.
2014 (a reduction of 32%).2 However, this still represents an 
enormous burden of preventable deaths and ill-health. In 
2014, TB deaths among HIV-positive people accounted for 
25% of all TB deaths (among HIV-negative and HIV-positive 
people) and one third of the estimated 1.2 million deaths 
from HIV/AIDS.3 Current trends indicate that the target set 
by WHO, UNAIDS and the Stop TB Partnership to halve the 
number of HIV-associated TB deaths by 2015 (compared with 
2004) will not be met globally (Chapter 2).4 
WHO recommendations on the interventions needed to
2 Estimates of the total burden of TB disease and of the number of TB 
cases and deaths among HIV-positive people are updated annually by 




4 Of the 41 countries with the highest burden of HIV associated TB, 17 are 
estimated to have met the target by the end of 2014.
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prevent TB in HIV-positive people and to reduce the impact 
of HIV among TB patients were first issued in 2004, and 
are collectively known as collaborative TB/HIV activities.1 
They include: establishing and strengthening coordination 
mechanisms for delivering integrated TB and HIV services; 
HIV testing for all TB patients as well as people with TB signs 
or symptoms; providing antiretroviral therapy (ART) and co-
trimoxazole preventive therapy (CPT) to all HIV-positive TB 
patients; providing HIV prevention services for TB patients; 
intensifying TB case-finding among people living with HIV; 
of fering isoniazid preventive therapy (IPT) to people liv-
ing with HIV who do not have active TB; and preventing the 
transmission of TB infection in health care and congregate 
settings. The latter three activities are referred to as the Three 
‘Is’ for HIV/TB and, together with earlier ART, are the principal 
interventions for preventing TB among people living with 
HIV. Between 2005 and 2014, TB/HIV interventions saved an 
estimated 5.8 million lives.2 
In addition, use of the rapid molecular test, Xpert MTB/RIF 
and early ART among HIV positive TB patients are increas-
ingly considered critical components of collaborative TB/
HIV activities. WHO recommends the use of Xpert MTB/RIF 
as the primary diagnostic test for TB among people living 
with HIV who have TB signs and symptoms, and ART for all 
HIV-positive TB patients within the first eight weeks of start-
ing TB treatment (irrespective of their CD4 cell count). Early 
initiation of ART (within two weeks of starting TB treatment) 
is also important, particularly for TB patients with profound 
immunosuppression (e.g. CD4 cell count less than 50) among 
whom it has been shown to significantly improve survival. 
WHO began monitoring the implementation of collabo-
rative TB/HIV activities in 2004. This chapter presents the 
latest status of progress, using data for each year from 2004 
through 2014. 
6.1 HIV testing and documentation of HIV 
status among TB patients 
WHO recommends that routine HIV testing should be 
of fered to all TB patients, to all those with TB signs and symp-
toms, and to partners of known HIV-positive TB patients.3 In 
the WHO online data collection system, data are reported 
for TB patients only. 
In 2014, 3.2 million notified TB patients had a documented 
HIV test result, equivalent to 51% of notified TB cases (Table 
6.1, Figure 6.1). This represented an increase from 3 million 
and 49% respectively in 2013, and more than 17 times the cov-
1 An update was issued in 2012. See WHO policy on collaborative TB/HIV 
activities: guidelines for national programmes and other stakeholders. 
Geneva, World Health Organization, 2012 (WHO/ HTM/TB/2012.1). 
Available at http://whqlibdoc.who.int/
publications/2012/9789241503006_eng.pdf
2 Estimates of lives saved by TB and HIV interventions are covered in 
more detail in Chapter 2. 
3 WHO policy on collaborative TB/HIV activities: guidelines for national 
programmes and other stakeholders. Geneva: World Health Organization; 
2012 (WHO/ HTM/TB/2012.1). Available at http://whqlibdoc.who.int/
publications/2012/9789241503006_eng.pdf
erage reported in 2004 (Figure 6.1). There were 89 countries 
in which ≥75% of TB patients had a documented HIV test 
result in 2014 (Figure 6.2); this was unchanged from 2013. 
Overall, among the 41 countries identified as priorities for 
the global TB/HIV response (listed in Table 6.1), 60% of noti-
fied TB patients had a documented HIV test result in 2014, up 
from 58% in 2013. There has been a steady increase in these 
41 countries since 2007. However, levels of coverage vary sig-
nificantly, ranging from 5% in Indonesia to 99% in Rwanda 
in 2014.4 Eighteen of the 41 countries reported that ≥90% 
of TB patients knew their HIV status in 2014, of which five 
(Botswana, Kenya, Mozambique, Rwanda and Swaziland) 
have managed to maintain this level since 2011. A further 14 
countries (Burkina Faso, Cambodia, Cameroon, Côte d’Ivoire, 
Lesotho, Malawi, Namibia, Nigeria, South Africa, Togo, Ugan-
da, Tanzania, Zambia and Zimbabwe) have reported that 
≥80% TB patients know their HIV status since 2011. In seven 
high TB/HIV burden countries, the percentage of TB patients 
who know their HIV status has remained persistently low, at 
under 50% since 2011: China, Congo, the Democratic Repub-
lic of the Congo, Indonesia, Mali, Myanmar and Sudan.5 
The percentage of TB patients with known HIV status 
remains highest in the African Region, where it continues 
to increase and reached 79% in 2014, up from 78% in 2013 
(Table 6.1, Figure 6.1). Of the 47 African countries, 30 countries 
reported ≥75% of TB patients had a documented HIV test 
result in 2014, and 23 achieved levels of ≥90% (Figure 6.2). 
4 In India, the national figure fell slightly between 2013 and 2014, from 
63% to 61%. This reflects a large increase in notifications (see Chapter 3, 
Box 3.2) from the private sector (included in the denominator), without 
a corresponding increase in reporting related to HIV testing. When 
analysis is restricted to units that reported data in both 2013 and 2014, 
the percentage of TB patients who knew their HIV status rose from 63% 
to 72%.
5 The reported figure is also relatively low for the Russian Federation. 
However, this is because the denominator available for calculations is 
the total number of new and relapse cases that were notified while the 
numerator available for calculations includes only new TB patients in 
the civilian sector. In practice, testing coverage is estimated to be close 
to 100% in the Russian Federation.
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n TABLE 6.1 
HIV testing for TB patients, treatment for HIV-positive TB patients and prevention of TB among people living with HIV,  
41 high TB/HIV burden countries and WHO regions, 2014. Numbers in thousands except where indicated.
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% OF PEOPLE 
NEWLY 
ENROLLED 
IN HIV CARE 
WHO WERE 
NOTIFIED AS 
A TB CASE 
THE SAME 
YEAR
Angola 23 14–34 28 50 10 – – –
Botswana 4.5 4.1–5.0 5.5 91 60 78 57 –
Brazil 16 14–17 57 70 17 – – –
Burkina Faso 1.2 1.0–1.3 5.6 96 12 86 47 9.8
Burundi 1.9 1.6–2.1 6.7 91 14 68 32 –
Cambodia 1.8 1.6–2.0 36 81 2.7 98 52 0.9 19
Cameroon 20 17–23 23 87 37 70 30 –
Central African Republic 7.6 5.9–9.4 5.2 51 34 – – –
Chad 6.0 4.7–7.4 6.6 54 19 56 12 –
China 13 11–16 344 42 1.5 69 28 2.9
Congo 5.5 4.3–6.9 1.3 13 29 24 1.7 –
Côte d’Ivoire 8.5 7.5–9.6 22 93 24 21 13 3.2
Djibouti 0.54 0.44–0.65 1.9 84 8.5 68 20 –
DR Congo 34 27–42 53 46 14 67 14 4.4
Ethiopiac 19 15–23 89 75 9.7 39 18 10 22
Ghana 11 5.2–19 12 77 24 39 10 –
Haiti 3.7 3.2–4.3 14 88 19 54 38 22 –
India 110 96–120 1 035 61 4.3 90 36 3.1
Indonesia 63 41–90 15 4.6 16 26 1.0 –
Kenya 40 38–42 84 95 36 87 65 –
Lesotho 12 8.5–16 9.1 93 72 74 41 –
Malawi 19 10–31 16 93 54 92 43 135 1.5
Mali 0.71 0.64–0.78 2.6 43 14 100 52 –
Mozambique 85 65–110 56 96 52 81 28 94 –
Myanmar 19 15–24 56 40 11 90 30 3.0 8.5
Namibia 5.6 4.8–6.5 9.1 92 44 84 60 –
Nigeria 100 59–160 84 92 19 75 12 26 –
Russian Federation 5.5 4.5–6.6 67d – – – – 38
Rwanda 1.8 1.5–2.1 5.9 99 25 87 72 –
Sierra Leone 2.3 1.7–3.0 11 87 12 68 39 1.3 8.8
South Africa 270 240–310 295 93 61 79 53 552 10
Sudan 1.2 0.65–2.0 5.5 27 6.0 45 12 18
Swaziland 5.9 4.2–7.9 5.4 97 73 79 53 1.2 –
Thailand 15 7.8–24 51 71 13 69 31 –
Togo 0.83 0.67–1.0 2.5 97 21 76 48 –
Uganda 28 24–32 44 95 45 81 57 –
Ukraine 8.1 7.0–9.3 39 97 20 56 53 16 –
UR Tanzania 62 29–110 58 91 35 83 27 23 12
Viet Nam 7.0 5.7–8.5 74 73 5.2 73 40 –
Zambia 38 25–52 40 93 61 73 46 –
Zimbabwe 25 17–35 29 89 68 86 66 30 15
High TB/HIV burden countries 1 100 1 000–1 200 2 804 60 18 78 34 916 9.0
AFR 870 790–950 1 064 79 39 77 37 876 9.1
AMR 36 34–38 169 74 13 63 20 29 8.4
EMR 12 10–15 68 15 2.4 63 7.9 0.5 20
EUR 20 18–21 200 62 8.2 58 31 21 32
SEAR 210 180–240 1 171 45 5.1 85 24 3.0 3.7
WPR 31 28–35 552 40 2.3 68 27 3.7 3.9
Global 1 200 1 100–1 300 3 224 51 16 77 33 933 8.9
Blank cells indicate data not reported.
–  indicates values that cannot be calculated.
a  Best estimates are followed by the lower and upper bounds of the 95% uncertainty interval.
b  The numerator (i.e. all notified HIV-positive TB cases on ART) includes all notified new, relapse and non-relapse retreatment cases. The denominator 
(i.e. estimated HIV-positive incident TB cases) includes new and relapse cases only.
c  In 2014, ART and IPT data were missing for 3 of Ethiopia’s 11 regions, which in previous years had accounted for about one third of the national totals. In 
the 8 regions that reported data, 65% of HIV-positive TB patients were on ART.
d  Data for the Russian Federation are for new TB patients in the civilian sector only.
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a Data for the Russian Federation are for new TB patients in the civilian sector only.
In the Region of the Americas and the European Region, 
there were small improvements between 2013 and 2014: 
from 72% to 74% and from 59% to 62% respectively.1 Larger 
increases were evident in some countries in the Americas, 
notably Bolivia (70% to 77%), Chile (35% to 50%), Colombia 
(74% to 80%), Guatemala (80% to 86%), Mexico (77% to 
85%), Nicaragua (69% to 77%) and Peru (66% to 74%). 
In the other three WHO regions in which concentrated 
HIV epidemics are the norm, the percentage of TB patients 
with known HIV status has remained low (15%–45%). 
Impressive gains were made in three countries, however: 
Myanmar (from 12% to 40%), Sri Lanka (from 49% to 78%) 
and the Philippines (from 2% to 20%). In Cambodia, 81% of 
TB patients knew their HIV status in 2014, similar to the level 
achieved in 2013. It should also be noted that in China, 91% of 
TB patients knew their HIV status in the counties defined as 
having a high TB/HIV burden, much higher than the national 
average of 42%. 
In some countries with concentrated epidemics, the pro-
grammatic feasibility and value of testing all TB patients for 
HIV has been questioned, especially in settings where both 
access to HIV treatment and funding are limited. At the same 
time, HIV testing for TB patients is a basic standard of care 
and provides a pathway to HIV treatment and prevention 
1 Figures for the European Region are an underestimate, due to 
under-estimation of testing coverage for the Russian Federation. 
services. National programmes should aim to ensure that 
the benefits of HIV testing are available to TB patients, their 
partners, families and the community at large, in the context 
of their specific programmatic settings.2 
6.2 Levels of HIV infection among TB patients 
with HIV test results 
Globally, 16% of TB patients with an HIV test result were HIV-
positive (Table 6.1). The figure was 18% among the 41 high TB/
HIV burden countries that accounted for more than 94% of 
estimated HIV-positive incident TB cases in 2014. Overall, the 
percentage of TB patients testing HIV-positive has been fall-
ing globally since 2008 (Figure 6.3). 
The highest rates of HIV co-infection were reported for 
TB patients in the African Region (Table 6.1), where 39% of 
those with an HIV test result were HIV-positive (compared 
with 41% in 2013). The percentage of TB patients found to be 
HIV-positive in the 28 African countries in the list of 41 high 
TB/HIV burden countries ranged from about 10% in Angola 
and Ethiopia to more than 70% in Lesotho and Swaziland. In 
all other regions, the percentage of TB patients with a docu-
mented HIV test result who were HIV-positive was much 
lower. 
2 WHO policy on collaborative TB/HIV activities: guidelines for national 
programmes and other stakeholders. Geneva: World Health Organization; 
2012 (WHO/ HTM/TB/2012.1). Available at http://whqlibdoc.who.int/
publications/2012/9789241503006_eng.pdf
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Globally, a total of 528 000 HIV-positive TB patients were 
reported by NTPs in 2014. This represented less than 50% 
of the 1.2 million HIV-positive people estimated to have 
developed TB in the same year (Figure 6.4), although there 
was considerable variation among regions. The propor-
tion was highest in the European Region (81%), followed by 
the Region of the Americas (60%) and the African Region 
(50%), and much lower in the Eastern Mediterranean, South-
East Asia and Western Pacific Regions (13%, 29% and 39%, 
respectively). 
6.3 Antiretroviral therapy and co-trimoxazole 
preventive therapy for HIV-positive TB 
patients
6.3.1 Antiretroviral therapy
ART is an intervention that can have an important impact on 
TB morbidity and mortality among HIV-positive TB patients. 
The number of notified HIV-positive TB patients on ART has 
grown from a very low level in 2004 (Figure 6.4) to reach 
392 000 in 2014. Among HIV-positive TB patients notified by 
NTPs in 2014,1 77% were on ART globally (Table 6.1, Figure 
6.3), a further improvement compared with 73% in 2013. 
In the African Region in 2014, 77% of HIV-positive TB 
patients reported by NTPs were started on ART (up from 
72% in 2013). ART coverage increased in 28 of the 41 high 
TB/HIV burden countries between 2013 and 2014 (data not 
shown). Among the top-ten high TB/HIV burden countries, 
the biggest increases between 2013 and 2014 were in the 
Democratic Republic of the Congo (48% to 67%), Mozam-
bique (72% to 81%), the United Republic of Tanzania (73% to 
83%), Nigeria (67% to 75%) and South Africa (72% to 79%). 
Five other countries reported increments of more than 10%: 
Cambodia, Djibouti, Mali, Myanmar and Viet Nam. Six of the 
41 high TB/HIV burden countries have not yet reached levels 
1 In the annual WHO TB data collection form, countries are asked to 
report the number of TB patients notified in the most recent calendar 
year who were living with HIV and who “started or continued on ART”.
of 50%: Sudan, Ethiopia, Ghana, Indonesia, Congo and Côte 
d’Ivoire. In these countries, concerted ef forts are needed to 
improve coverage. 
Early initiation of ART is important to reduce mortality. 
WHO recommends that ART should be initiated as soon as 
possible af ter TB treatment is started, and within the first 
two to eight weeks of treatment. WHO also encourages pro-
grammes to establish mechanisms to monitor the timeliness 
of ART through national data collection systems, and has 
provided guidance about how to do this.2 A recent example 
from India is highlighted in Box 6.1. 
Despite overall progress in ART coverage, there is a sub-
2 World Health Organization. WHO guide to monitoring and evaluation of 
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stantial gap between the number of HIV-positive TB patients 
started on ART, and the estimated total number of HIV-pos-
itive people with TB who are in need of both TB treatment 
and ART. The global number of HIV-positive TB patients 
reported to be started on ART by NTPs in 2014 represented 
only 33% of the estimated 1.2 million HIV-positive people 
who developed TB in the same year (Table 6.1, Figure 6.4). 
The ratio of patients started on ART in 2014 to the estimated 
number of HIV-positive people who developed TB in 2014 
was above 50% in only 14 of the 41 high TB/HIV burden coun-
tries: Botswana, Burkina  Faso, Cambodia, Kenya, Malawi, 
Mali, Namibia, Rwanda, South Africa, Swaziland, Uganda, 
Ukraine, the United Republic of Tanzania and Zambia (Figure 
6.5). While this is an improvement from only eight countries 
in 2013, much remains to be done to improve the detection 
of TB among HIV-positive people, the coverage of HIV test-
ing among TB patients, and enrolment of HIV-positive TB 
patients on ART.
Box 6.1 Monitoring when ART is  
 initiated for HIV-positive TB  
 patients: an example from India
In October–November 2014, data from 70 facilities in India 
where ART is provided were extracted from a system designed 
to capture early warning indicators related to the development 
of drug resistance and the quality of care. This was done by 
the National AIDS Control Organization and WHO India. Of 
the 9468 people living with HIV who had been enrolled in HIV 
care, 1871 (19%) developed TB within two years (Table B6.1.1). 
Data on the timing of initiation on ART were analysed for these 
individuals.
TABLE B6.1.1
Initiation on ART for HIV-positive TB patients in  
62 facilities in India, October–November 2014
STUDY COHORT (ADULTS, N=9468) NUMBER
Patients diagnosed with TB 1871
Patients already on ART at the 
time of TB diagnosis 362
Time between start of TB treatment and ART initiation, for the 
1429 HIV-positive TB patients who were not already on ART 
<2 weeks 200 (14%, 95% CI: 12–16%)
2–8 weeks 933 (65%, 95% CI: 63–68%)
>8 weeks 296 (21%, 95% CI: 19–23%)
Median 23 days
The median time between the start of TB treatment and ART 
was 23 days. About 80% of HIV-positive TB patients were 
started on ART within eight weeks of TB diagnosis, in line with 
WHO recommendations.
These statistics about ART coverage among all estimated 
HIV-positive TB cases can also be compared with the level of 
ART coverage among all people living with HIV. Globally, over 
15 million people were on ART as of 31 March 2015.1 By the end 
of 2014, 40% (uncertainty interval, 37%–45%) of the esti-
mated number of people living with HIV were receiving ART. 
This is more than the estimated level of 33% for HIV-positive 
people who have TB, but also far from universal coverage. 
Major ef forts are urgently required to improve access and 
narrow these gaps. The UNAIDS 90-90-90 fast track treat-
ment targets (by 2020, 90% of people living with HIV know 
their status, 90% of those who know their status are on ART, 
and 90% of those on ART have a suppressed viral load) pro-
vide a platform for doing this.2
6.3.2 Co-trimoxazole preventive therapy
Globally, 427 000 HIV-positive TB patients were enrolled on 
CPT in 2014, representing 87% of all notified HIV-positive TB 
patients, similar to levels achieved in 2013 (Figure 6.3). The 
African and South-East Asia regions maintained their partic-
ularly high levels of enrolment on CPT from 2013, at 89% and 
85% respectively. Of the 34 high TB/HIV burden countries 
(out of a total of 41) that reported data, only four reported 
that less than 50% of HIV-positive TB patients were enrolled 
on CPT in 2014: Côte d’Ivoire (24%), Congo (27%), Indonesia 
(41%) and Ukraine (44%). 
6.4 Intensified TB case-finding and initiation  
of isoniazid preventive therapy among 
people living with HIV 
The high proportion of people with undiagnosed TB found 
in autopsy studies of HIV-positive people3,4,5 shows that 
substantial ef forts are needed to ensure ef fective TB screen-
ing among people living with HIV, so that TB is promptly 
diagnosed and treated and so that those without active TB 
disease are provided with IPT as well as ART. ART reduces the 
individual risk of TB disease among people living with HIV 
by 65%,6 irrespective of CD4 cell count. Its impact is further 
enhanced when IPT is also provided. Recently, IPT for six 
1 How AIDS changed everything – MDG 6. 15 years, 15 lessons of hope from the 
AIDS response. Geneva: UNAIDS; 2015. Available at: http://www.unaids.
org/en/resources/documents/2015/MDG6_15years-
15lessonsfromtheAIDSresponse
2 Understanding Fast-Track. Geneva: UNAIDS; 2015. Available at http://
www.unaids.org/sites/default/files/media_asset/201506_JC2743_
Understanding_FastTrack_en.pdf)
3 Cox JA et.al. An autopsy study describing causes of death and 
comparing clinico-pathological findings among hospitalized patients in 
Kampala, Uganda; Plos One, 2012;7(3):e33685. doi: 10.1371/journal.
pone.0033685. Epub 2012 Mar 14.
4 Wong EB et.al. Causes of death on antiretroviral therapy: a post-
mortem study from South Africa; Plos One 2012;7(10):e47542. doi: 
10.1371/journal.pone.0047542. Epub 2012 Oct 16.
5 Kilale AM et.al. High prevalence of tuberculosis diagnosed during 
autopsy examination at Muhimbili National Hospital in Dar es Salaam, 
Tanzania; Tanzania Journal of Health Research 2013; 15.
6 Suthar AB et al. Antiretroviral therapy for prevention of tuberculosis in 
adults with HIV: a systematic review and meta-analysis. PLoS Med 2012, 
9(7): e1001270. doi:10.1371/journal.pmed.1001270).
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a The numerator (i.e. all notified HIV-positive TB cases on ART) includes all notified new, relapse and non-relapse retreatment cases. The denominator  
(i.e. estimated HIV-positive incident TB cases) includes new and relapse cases only.
months combined with ART for people with CD4 counts of 
>500 cells/mm3 was found to reduce the risk of severe HIV-
related illness by 44% and the risk of death from any cause 
by 35%.1
6.4.1 Intensified case-finding
Systematic screening for TB among people living with HIV 
is recommended by WHO as an essential component of the 
HIV package of care, along with ART, IPT and infection con-
trol. It is the first essential step before both IPT initiation and 
TB diagnosis. In 2014, 78 countries reported about seven mil-
lion people enrolled in HIV care who were screened for TB, up 
from 5.5 million in 64 countries in 2013. 
Being screened for TB does not necessarily guarantee 
completion of the TB diagnostic pathway. As part of ef forts 
to improve the utility of TB screening, WHO encourages 
monitoring of the full cascade of intensified TB case find-
ing, including: 1) identification of TB in those who screened 
positive for TB symptoms; and 2) documentation of what TB 
investigations were done to diagnose or rule out TB disease. 
In December 2010, the rapid molecular test Xpert MTB/RIF 
was endorsed by WHO with a strong recommendation for its 
use as the initial diagnostic test for TB in two groups: people 
1 The TEMPRANO ANRS 12136 Study Group; A Trial of Early Antiretrovirals 
and Isoniazid Preventive Therapy in Africa. The New England Journal of 
Medicine 2015; DOI:10. 1056/NEJMoa1507198.
living with HIV with TB signs and symptoms, and people at 
high risk of having MDR-TB (Chapter 5). This was reiterated in 
the 2013 update to WHO policy recommendations on the use 
of Xpert MTB/RIF,2 and in the 2014 Xpert MTB/RIF implemen-
tation manual in which it is recommended that people living 
with HIV should be prioritized for testing with Xpert MTB/RIF 
when resources are limited.3 
Discussions at a Global Forum of Xpert MTB/RIF imple-
menters held in 2014 indicated that a major motivation 
for the roll-out of Xpert MTB/RIF was of ten the national 
response to multidrug-resistant TB (MDR-TB),4 rather than 
diagnosis of TB among people living with HIV. To maximize 
the detection of TB cases among HIV-positive people, Xpert 
MTB/RIF needs to be widely implemented in settings where 
HIV care is provided, using all available funding sources. 
Early detection of TB in HIV care settings can in turn help to 
2 Policy update: Xpert MTB/RIF assay for the diagnosis of pulmonary and 
extrapulmonary TB in adults and children. Geneva: World Health 
Organization; 2013 (WHO/HTM/TB/2013.16). Available at: http://who.
int/tb/laboratory/xpert_policyupdate/en/ 
3 Xpert MTB/RIF implementation manual: technical and operational ‘how-to’; 
practical considerations. Geneva: World Health Organization; 2014 
(WHO/HTM/TB/2014.1). Available at: http://who.int/tb/publications/
xpert_implem_manual/en/ 
4 Meeting Report of the Xpert MTB/RIF Implementers Global Forum, 1–2 May 
2014. Geneva: World Health Organization; 2014. Available at: http://
www.stoptb.org/wg/gli/assets/documents/Xpert%20
Implementers%20Global%20Forum%20meeting%20report.pdf.
GLOBAL TUBERCULOSIS REPORT 2015  n  85
ensure prompt initiation of ART. Recent analysis suggests 
that there has been progress in adopting the WHO recom-
mendation to use Xpert MTB/RIF as the initial diagnostic test 
for TB among people living with HIV, but that more remains 
to be done (Box 6.2). 
In 2014, 76 countries reported data about the number of 
notified TB cases among those newly enrolled in HIV care to 
UNAIDS (up from 59 countries in 2013). Unfortunately, there 
were data quality problems for eight of these countries. 
Among the remaining 68 countries, 9% (211 000/2 304 000) 
of those newly enrolled in HIV care in 2014 were also notified 
with TB in the same year. Among the 41 high TB/HIV burden 
countries, the proportion ranged from 2–3% in China, Côte 
d’Ivoire, India and Malawi to 38% in the Russian Federa-
tion (Table 6.1). Ensuring good quality data and monitoring 
trends in this indicator are important to track the impact of 
HIV care, especially ART, on the burden of TB in people living 
with HIV. 
6.4.2 Initiation on isoniazid preventive therapy
A total of 49 countries (representing more than 60% of the 
estimated global burden of HIV-associated TB) reported ini-
tiating people living with HIV on IPT. The total number was 
933 000 people in 2014, an increase from just over 600 000 
people in 2013 (Figure 6.6). Thirteen of the 41 high TB/HIV 
burden countries reported provision of IPT in 2014, and 
coverage among people living with HIV who were newly 
enrolled in care was 41%. Coverage ranged from 5% in Swazi-
land to 97% in Haiti. 
As in previous years, South Africa accounted for a high 
proportion (59%) of the global total in 2014: 552 000 HIV-
n FIGURE 6.6
Provision of isoniazid preventive therapy (IPT) to people 

































Box 6.2 The use of Xpert MTB/RIF in diagnosis of TB among people living with HIV
Data on national policies for using Xpert MTB/RIF as the initial 
diagnostic test for TB among people living with HIV were collected 
as part of the 2015 round of global TB data collection. Additional 
data were requested from 15 countries with the highest TB/HIV 
burden, of which nine responded: Ethiopia, India, Indonesia, 
Lesotho, Myanmar, South Africa, Uganda, the United Republic of 
Tanzania and Zimbabwe. 
Of the 41 high TB/HIV burden countries, 33 (80%) had a national 
policy on the use of Xpert MTB/RIF by the end of 2014. The eight 
countries that did not report having such a policy in place were 
Central African Republic, Chad, China, Côte d’Ivoire, Myanmar, 
Namibia, Sierra Leone and Sudan.
Of the nine countries that responded to the more detailed survey, 
all except Myanmar reported a policy that recommended Xpert 
MTB/RIF as the initial diagnostic test for TB among people living 
with HIV. A nationally standardized TB diagnostic algorithm 
for people living with HIV that included Xpert MTB/RIF was also 
reported in these eight countries. Typically, Xpert MTB/RIF testing 
was restricted to secondary and tertiary level health care facilities. 
Exceptions were Ethiopia and South Africa, which reported 
availability at all levels including at primary health care facilities. 
In general, routine documentation and reporting of Xpert MTB/RIF 
test results among people living with HIV was stated to be a major 
challenge, reflecting the fact that national registers and reporting 
systems do not capture such data. 
To improve testing for TB among people living with HIV and ensure 
that progress can be monitored, wider adoption of the WHO 
recommendation to use Xpert/MTB RIF as the initial diagnostic 
test and updating of national monitoring and evaluation systems 
that will allow systematic recording and reporting are required.a 
The use of Xpert MTB/RIF by HIV service providers, including in 
peripheral facilities, also needs to be promoted.
a A guide to monitoring and evaluation for collaborative TB/HIV 
activities. Geneva: World Health Organization; 2015 (WHO/HTM/
TB/2015.02). Available at: http://www.who.int/tb/publications/m_
and_e_document_page/en/
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positive people were started on IPT, out of 1 034 000 (53%) 
people living with HIV who were newly enrolled in care. 
There was evidence of IPT scale-up in the past four years 
in other countries in the African Region. Countries report-
ing higher numbers in 2014 compared with previous years 
included Malawi (135 000), Mozambique (94 000), Zimbabwe 
(30  000) Nigeria (26  000), the United Republic of Tanzania 
(23  000) and Haiti (22  000). Nonetheless, 77% of countries 
did not report provision of IPT as part of HIV care in 2014, 
including 68% (28/41) of the high TB/HIV burden countries. 
As with TB screening, it is clear that countries continue to find 
it challenging to provide IPT and to record and report data 
on its provision or treatment completion. A good example is 
Namibia, where reporting on provision of IPT was not feasi-
ble in 2014 following the withdrawal of donor funding that 
had previously supported the staf f required to record and 
report data. In 2013, more than 15 000 people newly enrolled 
in HIV care were reported to have been provided with IPT in 
Namibia. Global coverage of IPT is thus understated. 
6.5 Improving data quality
Each year, ef forts are made to improve the quality of data 
related to collaborative TB/HIV activities that are reported 
as part of global monitoring ef forts by WHO and UNAIDS. 
Two challenges in particular have been evident: discrepan-
cies between the number of HIV-positive TB patients on ART 
reported by TB and HIV programmes, and inconsistencies in 
the number of people reported to be newly enrolled in HIV 
care for the same country within the same data collection 
form (this number is requested twice in the WHO Universal 
Access Health Sector TB indicators reported through the 
UNAIDS global reporting system for HIV for two separate 
indicators: enrollment on IPT, and TB notifications among 
those newly enrolled in HIV care). Encouragingly, the number 
of countries reporting discrepant data fell in 2014 compared 
with 2013, and in almost all instances these discrepancies 
were resolved following communications with national TB 
and HIV programmes. There were two countries for which 
discrepant data on provision of ART reported by national HIV 
and TB programmes could not be reconciled (Botswana and 
Côte d’Ivoire) and four countries for which discrepancies in 
data about the number of people newly enrolled in HIV care 
could not be resolved (Guinea-Bissau, Mongolia, Saint Vin-
cent and the Grenadines and Uzbekistan). 
In 2015, WHO published A guide to monitoring and evaluation 
for collaborative TB/HIV activities1 and the Consolidated strategic 
information guide for the health sector.2 Both documents have 
harmonized TB/HIV indicators using the same indicator defi-
nitions, to help ensure reporting of the same data through 
global reporting systems for HIV and TB. These guidelines 
also provide a consolidated set of indicators for monitor-
ing progress in the implementation of collaborative TB/HIV 
activities. Countries are being encouraged to adopt, monitor 
and routinely report on these indicators. UNAIDS is currently 
undertaking a review of the Global AIDS Response Progress 
Reporting (GARPR) indicators, in the context of these two 
guidance documents.
1 World Health Organization. A guide to monitoring and evaluation of 
collaborative TB/HIV activities: 2015 revision. Geneva: World Health 
Organization; 2015. Available at: http://www.who.int/tb/publications/
monitoring-evaluation-collaborative-tb-hiv/en/
2 World Health Organization. Consolidated strategic information guidelines 
for HIV in the health sector. Geneva: World Health Organization; 2015. 
Available at: http://who.int/hiv/pub/guidelines/strategic-information-
guidelines/en/








 Key facts and messages
The funding required for a full response to the global TB 
epidemic in low- and middle-income countries is estimated 
at about US$ 8 billion per year in 2015 (excluding research and 
development for new TB diagnostics, drugs and vaccines). 
Of the US$ 8 billion required in 2015, about two thirds 
(US$ 5.3 billion) is for the detection and treatment of drug-
susceptible TB; 20% (US$ 1.6 billion) for treatment of MDR-TB; 
8% (US$ 0.6 billion) for rapid diagnostic tests and associated 
laboratory strengthening, much of which is to improve 
detection of drug-resistant TB; and 6% (US$ 0.5 billion) for 
collaborative TB/HIV activities. Projections made in 2013 
suggested that in 2015, about US$ 6 billion could be mobilized 
from domestic sources and that US$ 2 billion would be needed 
from international donors.
The 123 countries that reported financial data to WHO in 
2015 account for 95% of reported TB cases globally. Based on 
this self-reporting by countries, funding for TB prevention, 
diagnosis and treatment reached US$ 6.6 billion in 2015, up 
from US$ 6.2 billion in 2014 and more than double the level of 
2006 (US$ 3.2 billion). Compared with the estimated global 
resource requirement of US$ 8 billion in 2015 for a full response 
to the TB epidemic in low and middle-income countries, this 
leaves a gap of around US$ 1.4 billion. Countries themselves 
reported smaller gaps, amounting to US$ 0.8 billion in 2015; 
this reflects the fact that national plans for scaling up TB 
prevention, diagnosis and treatment are less ambitious than 
the targets set in the Global Plan to Stop TB, 2011–2015 in many 
countries.
Overall, 87% (US$ 5.8 billion) of the US$ 6.6 billion available in 
2015 is from domestic sources. International donor funding 
has increased since 2006, reaching US$ 0.8 billion in 2015. 
However, the global average for the share of funding provided 
from domestic sources conceals enormous variation among 
individual countries as well as country groups. 
Domestic funding dominates (93–94% of the total funding 
available in 2015) in three (not mutually exclusive) groups: 
Brazil, the Russian Federation, India, China and South Africa 
(BRICS); upper middle-income countries; and regions outside 
Africa and Asia. In addition to BRICS, only one HBC (Thailand) 
has consistently reported levels of domestic funding that 
exceed contributions from international donor funding in 
recent years. 
International donor funding dominates in the group of 17 HBCs 
outside BRICS (72% of the total funding available in 2015) and 
in low-income countries (81% of the total funding available 
in 2015). At the individual country level, international donor 
funding remains absolutely critical in most of the 22 HBCs. In 
four HBCs (Afghanistan, Bangladesh, the Democratic Republic 
of the Congo and Mozambique), ≥90% of available funding in 
2015 is from international donor sources.
The cost per patient treated for drug-susceptible TB in 2014 fell 
into the range of US$ 100−US$ 500 in most countries with a high 
burden of TB. The cost per patient treated for MDR-TB was most 
of ten in the range US$ 5000−10 000, but the average varied 
from US$ 6 826 in low-income countries to US$ 21 265 in upper 
middle-income countries.
Health financing data from national health accounts provide 
insights into the current status of progress towards universal 
health coverage (UHC). Two suggested benchmarks required 
to achieve UHC are that health spending reaches at least 
6% of gross domestic product (GDP) and that out-of-pocket 
expenditures account for less than 15% of total health 
spending. Most countries, including all of the 22 HBCs and all 
low-income countries, have not yet reached these benchmarks. 
Among HBCs, Brazil, Thailand and South Africa are closest to 
doing so.
Progress in TB prevention, diagnosis and treatment requires 
adequate funding sustained over many years. WHO began 
annual monitoring of funding for TB in 2002, with findings 
published in global TB reports and peer-reviewed publica-
tions.1 Particular attention has always been given to the 22 
high-burden countries (HBCs) that account for about 80% 
1 The most recent publication is: Floyd K, Fitzpatrick C, Pantoja A and 
Raviglione M. Domestic and donor financing for tuberculosis care and 
control in low-income and middle-income countries: an analysis of 
trends, 2002–11, and requirements to meet 2015 targets. The Lancet 
Global Health, 2013; 1: e105–15.
of estimated incident cases (Chapter 2) and about 80% of TB 
cases reported by national TB programmes (NTPs) to WHO 
(Chapter 3). 
This chapter covers five main topics. It starts with a sum-
mary of the most up-to-date estimates of financial resources 
required for a full response to the TB epidemic in 2015. This is 
followed by presentation and discussion of trends in funding 
for TB prevention, diagnosis and treatment by category of 
expenditure and source of funding for the period 2006 (when 
the Stop TB Strategy and Global Plan to Stop TB 2006−2015 were 
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both launched)1,2 to 2015, for 123 countries (accounting for 
95% of reported TB cases in 2013) for which data were avail-
able. The third part of the chapter analyses funding gaps 
reported by NTPs to WHO, with breakdowns by category of 
expenditure and country group. The fourth part of the chap-
ter includes the latest estimates of the unit costs of treatment 
for drug-susceptible and multidrug-resistant TB (MDR-TB). 
The new End TB Strategy includes 2025 milestones for a 
75% reduction in TB deaths and a 50% reduction in the TB 
incidence rate, compared with a baseline of 2015 (Chapter  1). 
Achievement of these milestones requires that universal 
health coverage (UHC), defined as access for all to essential 
preventive and treatment health care interventions, with 
financial protection, is in place by 2025.3,4 In this context, the 
fif th and final part of the chapter introduces a new topic to 
the global TB report: an analysis of health financing data and 
what insights these can of fer about the current status of pro-
gress towards UHC. 
Further country-specific data can be found in finance pro-
files that are available online.5 
7.1 Estimates of funding required in 2015 for a 
full response to the global TB epidemic
An updated version of the Global Plan to Stop TB 2006–2015, 
covering the last five years of the plan, was issued in 2010.6 
This set out the actions and estimated funding requirements 
for a full response to the TB epidemic for the five-year period 
2011−2015 in low and middle-income countries, based on the 
Stop TB Strategy, with the overall goal of achieving the 2015 
global targets for reductions in cases of and deaths from TB 
i.e. that incidence should be falling and that prevalence and 
mortality rates should be halved compared with their levels 
in 1990 (Chapter 1, Chapter 2). Key components of the plan 
included increasing the number of patients detected and 
treated according to WHO’s recommended strategy from 5.8 
million in 2011 to 6.9 million by 2015 (equivalent to more than 
80% of the forecast number of incident cases in 2015 at the 
time the projections were done); ensuring testing for drug 
susceptibility for all previously treated patients and all new 
patients with known risk factors for MDR-TB by 2015; enrol-
ment of all reported TB patients with MDR-TB (projected at 
approximately 300  000) in 2015 on second-line treatment; 
HIV testing of all patients with TB; and prompt initiation of 
ART in all HIV-positive TB patients.
1 Raviglione M, Uplekar M. WHO’s new Stop TB strategy. Lancet 2006; 367: 
952–5.
2 The Global Plan to Stop TB, 2006–2015. Geneva, World Health 
Organization; 2006 (WHO/HTM/STB/2006.35).
3 World Health Organisation, World Bank Group. Monitoring progress 
towards universal health coverage at country and global levels. Framework, 
measures and targets. Geneva: World Health Organization; 2014 (WHO/
HIS/HIA/14.1).
4 World Health Organisation. The World Health Report 2010: Health systems 
financing: the path to universal coverage. Geneva, World Health 
Organization; 2010.
5 www.who.int/tb/data
6 The Global Plan to Stop TB, 2011–2015. Geneva, World Health 
Organization; 2010 (WHO/HTM/STB/2010.2).
From January to March 2013, the Global Plan datasets 
were used in combination with new country-specific plan-
ning and budgeting work with nine high TB or high MDR-TB 
burden countries to produce updated estimates of funding 
needs for TB prevention, diagnosis and treatment in low and 
middle-income countries.7 The nine countries were Ethio-
pia, India, Indonesia, Kazakhstan, Kenya, Nigeria, Pakistan, 
South Africa and Ukraine. Analyses were conducted in the 
context of estimates of funding needs and funding gaps 
required for the Global Fund’s replenishment ef forts in 2013.8 
WHO subsequently extended these analyses to cover all low- 
and middle-income countries, including those not eligible to 
apply to the fund.9 Notable countries (in terms of TB burden 
and funding requirements) that are not eligible to apply to 
the Global Fund include Brazil, China and the Russian Fed-
eration. 
During the course of the work done for the first pre-
replenishment meeting held in April 2013, it should be 
highlighted that the Global Fund, WHO, UNAIDS, and other 
partners agreed that funding needs for ART for HIV-positive 
TB patients should be included in estimates of HIV resource 
needs to avoid double counting. For this reason, the esti-
mates of resource requirements for TB/HIV interventions 
included in the updated estimates of resource needs for TB 
are lower than those shown in the Global Plan. 
The total funding required in all low and middle-income 
countries was estimated at about US$ 8 billion in 2015. Of this 
total, about two-thirds (US$ 5.3 billion) was for the detection 
and treatment of drug-susceptible TB; 20% (US$  1.6 bil-
lion) for treatment of MDR-TB; 8% (US$ 0.6 billion) for rapid 
diagnostic tests and associated laboratory strengthening, 
especially for the detection of MDR-TB; and 6% (US$ 0.5 bil-
lion) for collaborative TB/HIV activities (excluding ART). It 
was also estimated that of the total required in 2015, about 
US$ 6 billion could be mobilized from domestic sources and 
around US$  2 billion would be needed from international 
donor sources. The capacities of Brazil, the Russian Federa-
tion, India, China and South Africa (BRICS, which collectively 
account for almost 50% of reported TB cases worldwide) to 
mobilize most of their funding needs from domestic sources, 
in contrast with other country groups including the 17 other 
HBCs and low-income countries (mostly in Africa) where 
large amounts of international funding would be needed, 
were highlighted. 
7 Funding required for research and development for new TB diagnostics, 
drugs and vaccines was not considered. In the Global Plan, it is 
estimated that about US$ 2 billion per year is needed for research and 
development. In 2013, funding for research and development 
amounted to US$ 0.7 billion (see http://www.treatmentactiongroup.
org/tbrd2014).
8 The Global Fund to Fight AIDS, Tuberculosis and Malaria fourth replenishment 
(2014–2016): needs assessment. Geneva, Global Fund to Fight AIDS, 
Tuberculosis and Malaria; 2013.
9 Floyd K, Fitzpatrick C, Pantoja A and Raviglione M. Domestic and donor 
financing for tuberculosis care and control in low-income and 
middle-income countries: an analysis of trends, 2002–11, and 
requirements to meet 2015 targets. The Lancet Global Health, 2013;  
1: e105–15. 
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7.2  TB funding, overall and by category  
of expenditure and source of funding, 
2006–2015
Data reported by NTPs to WHO since 2006 allowed analy-
sis of funding trends 2006–2015 in 123 countries (Table 7.1). 
These countries accounted for 95% of the global number of 
TB cases reported in 2014, and included 120 low and middle-
income countries plus three high TB and/or MDR-TB burden 
countries that have reached high-income status (Estonia, 
Latvia and the Russian Federation). The methods used to 
collect, review and analyse financial data are summarized in 
Box 7.1.
n FIGURE 7.1
Funding for TB prevention, diagnosis and treatment by 




















Funding for drug-susceptible TB and MDR-TB, 2006–2015, by country group (constant 2015 US$ millions)
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n FIGURE 7.3
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Inpatient and outpatient care (best estimate – likely >95% 
is domestic fundinga)
Global Fund (NTP budget)
Other international donors (NTP budget)
a 96% of funding for inpatient and outpatient care is accounted for by 
middle and high-income countries; such countries do not typically 
receive international donor funding for inpatient and outpatient care 
services. Data is an estimate based on country-reported utilization.
In these 123 countries, funding for TB prevention, diag-
nosis and treatment reached US$ 6.6 billion in 2015, up from 
US$  6.2 billion in 2014 and more than double the US$  3.2 
billion that was available in 2006 (Figure 7.1). Of the total of 
US$  6.6 billion, most is for the diagnosis and treatment of 
drug-susceptible TB (US$ 3.9 billion). Funding for MDR-TB has 
grown, especially since 2009, reaching US$ 2.3 billion in 2015 
(Figure 7.1, Figure 7.2). However, it should be highlighted 
that more than half of this funding is accounted for by the 
Russian Federation (Table 7.2), reflecting extensive use of 
hospitalization for patients with MDR-TB. Given the still large 
detection gaps for MDR-TB as well as gaps between the num-
bers of cases detected and started on treatment (Chapter 4), 
much more funding is required for MDR-TB globally and in 
most of the high MDR-TB burden countries. 
A detailed breakdown of the funding estimated to be 
required for drug-susceptible TB, MDR-TB and collaborative 
TB/HIV activities in 2015, based on NTPs assessments of their 
needs, is shown for the 36 high TB and MDR-TB burden coun-
tries in Table 7.2. 
Domestic funding for the TB-specific budgets of NTPs 
accounts for the largest single share of funding, followed by 
funding for inpatient and outpatient care (Figure 7.3). Since 
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n TABLE 7.1
123 low and middle-income countries included in analyses of TB financing, by income group and WHO region, 2015a
LOW-INCOME 
(13% OF NOTIFIED CASES 
GLOBALLY IN 2014)
LOWER-MIDDLE-INCOME 
(57% OF NOTIFIED CASES 
GLOBALLY IN 2014)
UPPER-MIDDLE-INCOME










(33% OF NOTIFIED 
CASES GLOBALLY IN 
2014)
14 HIGH MDR-TB BURDEN 
COUNTRIES (NOT IN THE 
LIST OF 22 HIGH-BURDEN 
COUNTRIES) 
(2% OF NOTIFIED CASES 
GLOBALLY IN 2014)
Africa Benin, Burkina Faso, 
Burundi, Central 
African Republic, 







Rwanda, Sierra Leone, 
South Sudan, Togo, 




Côte d’Ivoire, Ghana, 
Kenya, Lesotho, 
Mauritania, Nigeria, 


























Afghanistan, Somalia Djibouti, Egypt, 
Morocco, Pakistan, 
Sudan, Syria, West 
Bank and Gaza Strip, 
Yemen
Iran (Islamic 



































Myanmar, Sri Lanka, 
Timor-Leste
Maldives, Thailand India Bangladesh, 
Indonesia, 
Myanmar, Thailand
Western Pacific Cambodia Kiribati, Lao 
People’s Democratic 
Republic, Micronesia 
(Federal States of), 












Not included Comoros Albania, Algeria, 
Azerbaijan, Belarus, 
Costa Rica, Cuba, 
Dominica, Grenada, 
Libya, Palau, Saint 
Lucia, Saint Vincent 




a  Analyses focus primarily on low and middle-income countries. Three high-income countries (Estonia, Latvia and the Russian Federation) were included 
because they are in the list of 22 high-burden countries or the list of 27 high MDR-TB burden countries. Additional countries included in trend analyses 
of TB financing compared with those included in previous global reports are shown in bold.
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n TABLE 7.2 
TB budget reported by NTP by intervention area, and estimated cost of inpatient and outpatient care for drug-susceptible 
(DS-TB) and MDR-TB, 36 high TB or MDR-TB burden countries, 2015 (current US$ millions)
TB BUDGET REPORTED BY NTP
RESOURCES REQUIRED  





TOTAL DS-TB MDR-TB TB/HIV DS-TB MDR-TB 
22 HIGH-BURDEN COUNTRIES
Afghanistan 15 13 1.3 0.1 6.7 0.2 22
Bangladesh 48 42 5.6 0.1 1.0 0.1 49
Brazil 77 65 9.4 2.3 47 1.9 126
Cambodia 31 28 1.9 0.6 6.4 0 37
Chinaa 340 313 27 0 – – 340
DR Congo 55 48 3.3 3.1 2.7 0 57
Ethiopia 82 57 19 5.6 8.0 0.3 91
India 261 179 78 4.0 456 70 788
Indonesia 133 119 11 2.7 27.6 5.1 165
Kenya 45 39 0.8 5.2 4.4 0.9 50
Mozambique 29 18 6.4 4.3 3.7 0.3 33
Myanmar 36 23 9.5 4.4 3.0 0.5 40
Nigeria 228 156 54 17 8.5 3.8 240
Pakistan 50 33 17 0 3.0 0.2 53
Philippines 106 84 21 0.9 185 5.9 298
Russian Federationa,b 1 894 637 1 211 47 – – 1 894
South Africa 248 129 61 58 99 363 710
Thailand 32 27 5.2 0.1 7.0 0.1 39
Uganda 24 21 2.1 1.1 0.6 0 25
UR Tanzania 67 53 9.6 4.5 2.4 0.3 70
Viet Nam 66 60 5.9 0.8 33 2.7 102
Zimbabwe 28 22 2.2 3.5 0.5 0 29
22 high-burden countries 3 895 2 166 1 563 165 910 455 5 261
REMAINING HIGH MDR-TB BURDEN COUNTRIES
Armenia 4.2 4.2 0 0 3.7 2.1 10
Azerbaijan 6.3 2.5 3.7 0 19 7.9 33
Belarus 15 1.9 13 <0.1 22 29 66
Bulgaria 15 15 0.2 0 11 0.6 27
Estonia 0.6 0.3 0.3 0 1.3 1.1 3.1
Georgia 17 8.6 8.0 0 5.4 4.6 27
Kazakhstan 195 163 30 1.2 105 81 381
Kyrgyzstan 29 16 13 0 5.1 5.0 39
Latvia 1.6 0.2 1.4 0 11 2.6 15
Lithuania 7.4 11 18
Republic of Moldova 17 13 4.1 0.1 6.8 5.8 30
Tajikistan 25 16 7.7 0.7 5.0 1.9 32
Ukraine 123 59 62 2.2 32 27 182
Uzbekistan 101 88 12 <0.1 35 10 146
27 high MDR-TB burden countries 4 097 2 268 1 681 148 1 101 640 5 838
36 high-TB or high MDR-TB burden countries 4 445 2 555 1 720 170 1 180 644 6 268
Blank cells indicate data not reported.
– indicates values that cannot be calculated.
a  No amount is shown for China and the Russian Federation because the NTP budgets reported by those countries include all budgets for inpatient and 
outpatient care.
b  In the Russian Federation, the staf f and infrastructure reported for TB care and control were allocated to DS-TB (23%) and MDR-TB (77%) by WHO based 
on the proportion of bed-days used by DS-TB and MDR-TB patients.
Box 7.1 Methods used to compile, validate and analyze financial data reported to WHO 
WHO began monitoring government and international donor 
financing for TB in 2002. All data are stored in the WHO global TB 
database. The standard methods used to compile, review, validate 
and analyse these data have been described in detail elsewhere.a,b 
This box provides a summary. 
Each year, WHO requests all low and middle-income countries 
(and the Russian Federation, the only HBC that is a high-income 
country) to report the funding required for TB prevention, 
diagnosis and treatment in their current fiscal year, by category of 
expenditure and source of funding; and expenditures for the most 
recently completed fiscal year, also by category of expenditure and 
source of funding. In the 2015 round of global TB data collection, 
the fiscal years were 2015 and 2014, respectively. Categories of 
expenditure for diagnosis and treatment of drug-susceptible 
TB were synthesized compared to those used 2006–2014, 
to simplify reporting. Six categories were used: laboratory 
infrastructure, equipment and supplies; NTP staf f (central unit 
staf f and subnational TB staf f); drugs to treat drug-susceptible 
TB; programme costs; patient support; and operational research 
including surveys. The main change was that several subcategories 
of programme costs were condensed into one category (this 
means that trends can still be assessed back to 2006). Categories 
of expenditure used for MDR-TB remained the same as those used 
since 2006: second-line drugs, and programmatic management 
of MDR-TB. Budgets and expenditures for collaborative TB/
HIV activities were requested as one consolidated category of 
expenditure, as in previous years. Funding available from four 
major sources was requested, also as in previous years: domestic 
funding excluding loans; external loans, also considered domestic 
funding; the Global Fund; and grant financing from sources other 
than the Global Fund. A simplification compared with previous 
years was that only an overall breakdown of total funding was 
requested, as opposed to a breakdown for each category of 
expenditure. Again, this does not af fect ability to report trends in 
a format consistent with those published in past reports. For high-
income countries (except the Russian Federation which is an HBC), 
only totals for both funding requirements and expenditures were 
requested, without any breakdown by category of expenditure or 
source of funding, as in previous years. 
As usual in 2015, all countries were asked to report on the 
utilization of inpatient and outpatient care required for treatment 
of people with drug-susceptible and MDR-TB, on a per patient 
basis (i.e. the average number of days spent in hospital, and the 
average number of outpatient visits to a health facility). These 
data are used in combination with other information to estimate 
the financial resources used for TB prevention, diagnosis and 
treatment that are not reflected in TB-specific reports of funding 
requirements, available funding and expenditures (further details 
are provided below). 
Core methods used to review and validate data have remained 
consistent since 2002. They include: 
" Routine checks for plausibility and consistency, including 
validation checks that are built into the online reporting 
system. Examples of validation checks are checks for 
implausibly large year-to-year changes (for example in total 
reported funding by source and by category of expenditure), or 
implausibly high or low values of funding for drugs relative to 
the number of TB patients (that dif fer substantially from prices 
quoted by the Global TB Drug Facility). 
" Discussions with country respondents to resolve queries.
" Triangulation with other data sources. One example is the 
detailed budgets prepared by NTPs that are peer-reviewed 
by WHO as part of ef forts to strengthen the budgeting of 
national strategic plans for TB care and control. Comprehensive 
and robust budgets for national strategic plans are now an 
essential requirement for funding applications to the Global 
Fund, as part of this agency’s new funding model introduced 
in 2013. Two tools promoted by WHO (the WHO TB planning 
and budgeting tool and the OneHealth tool)c,d for estimating 
funding requirements allow mapping of detailed budgets 
to the line items used in the WHO TB data collection form, 
and comparisons with data reported online. Triangulation is 
also undertaken with data available from the Global Fund,e 
USAID,f and the Organization for Economic Cooperation 
and Development’s Creditor Reporting System. In 2015, for 
example, reported data were compared with data submitted 
to the Global Fund as part of the funding gap analyses required 
for funding proposals and follow-up and adjustments made as 
appropriate.
In 2014 and 2015, additional elements of review and validation 
included facilitation of communications between focal points 
for National Health Accounts and NTP managers, with the aim of 
using expenditure data generated from implementation of the 
System of Health Accounts 2011 (that allows expenditures to be 
reported by disease) for reporting of TB expenditures wherever 
available.
In reviewing and validating data, particular attention has always 
been given to the 22 HBCs. A summary of data validation methods 
used for HBCs is provided in Table B7.1.
TB funding reported by NTPs usually does not include the financial 
costs associated with the inpatient and outpatient care required 
during TB treatment (among HBCs, the notable exceptions are 
China and the Russian Federation, since treatment is provided 
in TB-specific clinics or hospitals for which earmarked budgets 
and funding exist). Since many detailed costing studies in a wide 
range of countries show that these costs account for a large share 
of the cost of treating someone with TB,g analyses of TB financing 
undertaken by WHO have always included estimates of the 
funding used for both inpatient and outpatient care. 
As in past reports, WHO estimates the funding used for inpatient 
and outpatient care of TB patients by multiplying the number of 
outpatient visits and days of inpatient care per patient (reported by 
NTPs each year) by the cost per bed-day and clinic visits available 
from the WHO-CHOICE databaseh and then by the reported 
number of TB patients notified or projected to be notified. This 
is done separately for drug-susceptible TB and MDR-TB. For a 
further three countries (Belarus, Burkina Faso and the Democratic 
Republic of the Congo), data from a recent National Health 
Account (NHA) were used.i It is hoped that in the near future, NHA 
data will be routinely available for many more countries, including 
a breakdown by source of funding (domestic vs international) that 
is currently not available for any country. 
a Floyd K, Pantoja A, Dye C. Financing tuberculosis monitoring system. 
Bulletin of the World Health Organization; 2007; 85:334–40.
b Floyd K, Fitzpatrick C., Pantoja A and Raviglione M. Domestic and donor 
funding for tuberculosis care and control in low-income and middle-
income countries: an analysis of trends 2002–11, and requirements to 
meet 2015 targets. The Lancet Global Health; 1: e105–15.
c Planning and budgeting for TB control activities. Geneva, World Health 
Organization; 2015. http://www.who.int/tb/dots/planning_budgeting_
tool/en/ 
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TABLE B7.1 
Methods used to review and validate financing data reported by NTPs, high TB and MDR-TB burden countries 
COUNTRY
ROUTINE REAL-TIME CHECKS FOR 
PLAUSIBILITY AND INTERNAL 
CONSISTENCY (TRENDS OVER TIME), 
REVIEW AND FOLLOW-UP CHECKS 
BY WHO FINANCE DATA REVIEWERS, 
UPDATES/ CORRECTIONS ENCOURAGED 
REVIEW BY  
IN-COUNTRY  
WHO TB MEDICAL 
OFFICER
NATIONAL TB STRATEGIC 
PLANNING AND BUDGETING 
AND ASSOCIATED ASSESSMENT 
OF SOURCES OF FUNDING USING 
WHO RECOMMENDED  
COSTING TOOLS b





22 HIGH TB BURDEN COUNTRIES
Afghanistan yes yes yes (2013) no
Bangladesh yes yes yes (2014) yes
Brazil yes yes no yes
Cambodia yes yes yes (2009) yes
China yes yes no yes
DR Congo yes yes yes (2014) no
Ethiopia yes sometimes yes (2014) yes
India yes yes yes (2013) yes
Indonesia yes yes yes (2013) yes
Kenya yes yes yes (2013) yes
Mozambique yes mostly yes (2013) no
Myanmar yes yes yes (2011) no
Nigeria yes yes yes (2013) yes
Pakistan yes yes yes (2013) yes
Philippines yes yes yes (2011) yes
Russian Federation yes yes no yes
South Africa yes yes yes (2013) yes
UR Tanzania yes yes no yes
Thailand yes yes yes (2015) yes
Uganda yes yes yes (2013) yes
Viet Nam yes yes no yes
Zimbabwe yes yes yes (2013) yes
REMAINING HIGH MDR-TB BURDEN COUNTRIES
Armenia yes Wolfheze working group on financing yes (2010) no
Azerbaijan yes no no no
Belarus yes Wolfheze working group on financing no no
Bulgaria yes no no no
Georgia yes no no no
Kazakhstan yes no yes (2013) no
Kyrgyzstan yes yes yes (2013) no
Latvia yes no no yes
Lithuaniaa no no no no
Republic of Moldova yes no no no
Tajikistan yes no no yes
Ukraine yes yes yes (2013) yes
Uzbekistan yes no yes (2011) no
Source: GTB compilation based on data review process and Lawrence Y. et al, 2015.
a Data for Lithuania has never been reported to WHO.
b The tools recommended by WHO are the OneHealth tool and the WHO TB Planning and Budgeting tool.   
d Planning and budgeting for TB control activities as part of sector wide national 
strategic health plans and policies. Geneva, Inter-Agency working group; 
2015. Available at: http://www.who.int/choice/onehealthtool/en/
e For example, data available at http://web-api.theglobalfund.org/odata/ 
were accessed in May 2015.
f FY 2013 Congressional Budget Justification for Foreign Operations. 
Released March and April 2012, USAID http://www.state.gov/f/releases/
iab/fy2013cbj/pdf/
g Laurence YV, Grif fiths UK, Vassall A. Costs to Health Services and 
the Patient of Treating Tuberculosis: A Systematic Literature Review. 
PharmacoEconomics. 2015:1–17.
h Choosing interventions that are cost ef fective (WHO-CHOICE). Geneva, 
World Health Organization; 2008. Available at: http://www.who.int/
choice/cost-ef fectiveness/inputs/health_service/en/
i National Health Accounts http://www.who.int/health-accounts/en/
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almost all (96%) of the funding estimated to be used for 
inpatient and outpatient care is accounted for by middle- or 
high-income countries, it can be assumed that virtually all of 
this funding is from domestic sources (international donor 
funding for inpatient and outpatient care is only likely to 
occur in low-income countries, via general budget support 
to the health sector). Overall, 87% of the estimated funding 
of US$  6.6 billion in 2015 is from domestic sources. Interna-
tional donor funding for the TB-specific budgets of NTPs has 
increased since 2006, reaching US$ 0.8 billion in 2015. 
It is important to highlight that the funding reported by 
NTPs does not capture all international donor funding for 
TB; donor funding is also provided to entities other than 
NTPs, including international and national governmental 
and nongovernmental organizations. A more comprehen-
sive analysis of international donor funding, based on donor 
reports to the Organization for Economic Cooperation and 
Development (OECD), is provided in Box 7.2.1 
It is also important to emphasize that the global average 
for the share of funding provided from domestic sources con-
ceals enormous variation among individual countries, as well 
as country groups that can be defined based on TB burden, 
geography, political/economic profile and income level (Fig-
ure 7.4, Table 7.3). 
Domestic funding dominates (93–94% of the total fund-
ing available in 2015) in three (not mutually exclusive) groups: 
BRICS, upper middle-income countries and regions outside 
Africa and Asia. In addition to BRICS, only one HBC (Thai-
land) has consistently reported levels of domestic funding 
that exceed contributions from international donor funding 
in recent years. 
In lower middle-income countries, domestic fund-
ing has risen from US$  0.2 billion in 2006 to over US$  0.5 
billion in 2015, but international donor funding has also 
assumed greater and greater importance, reaching parity 
with domestic funding in 2015. Most of the increase in lower 
middle-income countries has been driven by grants from the 
Global Fund.
International donor funding dominates in the group of 
17 HBCs outside BRICS (73% of the total funding available in 
2015) and in low-income countries (80% of the total funding 
available in 2015). At the individual country level, it remains 
absolutely critical to funding for TB prevention, diagno-
sis and treatment in most of the 22 HBCs, and in four HBCs 
(Afghanistan, Bangladesh, the Democratic Republic of the 
Congo and Mozambique), ≥90% of available funding in 2015 
is from international donor sources. 
1 Out-of-pocket expenditures are also not included in NTP reports. These 
are analysed in more detail in section 7.5. 
7.3  Funding gaps reported by national  
TB programmes, 2006–2015
Despite growth in funding from domestic and international 
donor sources, many NTPs continue to be unable to mobi-
lize all the funding required for full implementation of their 
national strategic plans (Figure 7.5). Funding gaps (i.e. the 
dif ference between assessments by NTPs of funding needs 
for TB prevention, diagnosis and treatment and the actual 
amount of funds mobilized) have persisted and in 2015 
amounted to a total of US$  0.8 billion. This is considerably 
less than the gap of US$  1.4 billion that exists between the 
US$ 8 billion estimated to be needed for a full response to the 
TB epidemic in 2015 (section 7.1) and the US$ 6.6 billion avail-
able in 2015 (section 7.2). The dif ference can be explained 
by the fact that national strategic plans for TB remain less 
ambitious than the targets set in the Global Plan to Stop TB, 
2011–2015 (section 7.1) in many countries. 
Lower middle-income countries account for the larg-
est reported funding gaps (about US$ 0.5 billion in 2015), of 
which US$ 0.4 billion was in five countries (Nigeria, Indone-
sia, Ukraine, Viet Nam and the Philippines, in descending 
order). There may be additional capacity to mobilize more 
domestic funding in these countries. Funding gaps were rela-
tively small in upper middle-income countries in 2015 (Figure 
7.5), and have fallen in recent years – mostly explained by 
large reductions in the funding gaps reported by the Russian 
Federation and Kazakhstan. These two countries reported 
no funding gaps in 2014 or 2015. Funding gaps reported by 
low-income countries fell between 2014 and 2015, reflect-
ing a shif t of some countries from the low to middle-income 
country group between 2014 and 2015. 
Geographically, the African Region has by far the largest 
funding gap: US$ 0.4 billion in 2015, equivalent to half of the 
global total. The largest gap was reported by Nigeria (US$ 154 
million, see Table 7.3). 
Of the US$  0.8 billion funding gap reported by NTPs in 
2015, US$ 0.64 billion is for drug-susceptible TB and US$ 0.14 
billion is for MDR-TB. Relative to total funding needs, the 
funding gap is larger for drug-susceptible TB. Domestic fund-
ing accounts for a larger share of the funding for MDR-TB 
compared with drug-susceptible TB, which is not surprising 
given that most of the high MDR-TB burden countries are 
middle or high-income countries and 14 of 27 are in the Euro-
pean Region. 
7.4  Unit costs of treatment for drug-
susceptible and MDR-TB, 2014
The cost per patient treated for drug-susceptible and MDR-
TB could be estimated for 117 countries and 90 countries, 
respectively. The analysis of the cost per TB patient with 
drug-susceptible TB was limited to countries that had noti-
fied at least 100 TB cases in 2014. Estimates of the unit cost of 
MDR-TB treatment were restricted to countries that report-
ed at least 10 patients on second-line treatment for MDR-TB. 
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TB budget reported by NTP, available funding from domestic and international donor sources, funding gap and share of 























Afghanistan 15 0.9 10 8.1% 92% 4.0
Bangladesh 48 0.1 33 0.4% 100% 14
Brazil 77 55 0.6 99% 1.1% 21
Cambodia 31 3.6 14 20% 80% 13
China 340 306 6 98% 2% 28
DR Congo 55 3.0 27 10% 90% 24
Ethiopia 82 9.1 35 21% 79% 38
India 261 121 140 46% 54% 0
Indonesia 133 18 27 39% 61% 88
Kenya 45 12 13 48% 52% 20
Mozambique 29 1.6 19 7.9% 92% 8.1
Myanmar 36 3.9 25 14% 86% 8
Nigeria 228 30 44 41% 59% 154
Pakistan 50 8.4 30 22% 78% 12
Philippines 106 25 42 37% 63% 40
Russian Federation 1 894 1 893 1.0 100% 0% 0
South Africa 248 208 19 91% 8.6% 21
Thailand 32 17 3.6 82% 18% 12
Uganda 24 2.4 17 12% 88% 5.2
UR Tanzania 67 8.5 12 41% 59% 47
Viet Nam 66 6.7 12 37% 63% 48
Zimbabwe 28 2.0 17 11% 89% 10
22 high-burden countries 3 895 2 735 546 83% 17% 614
REMAINING HIGH MDR-TB BURDEN COUNTRIES
Armenia 4.2 3.0 1.2 71% 29% 0
Azerbaijan 6.3 1.2 5.1 19% 81% 0
Belarus 15 7.1 3.6 66% 34% 4.7
Bulgaria 15 13 1.8 88% 12% 0
Estonia 0.6 0.6 0 100% <1% 0
Georgia 17 5.5 7.9 41% 59% 3.2
Kazakhstan 195 195 0 100% 0% 0
Kyrgyzstan 29 11 18 37% 63% 0
Latvia 1.6 1.6 0 100% 0% 0
Lithuania – –
Republic of Moldova 17 10 7.1 59% 41% 0
Tajikistan 25 6.9 13 35% 65% 5.1
Ukraine 123 50 23 68% 32% 50
Uzbekistan 101 86 14 86% 14% 0
27 high MDR-TB burden countries 4 097 3 023 536 85% 15% 538
36 high-TB or high MDR-TB burden countries 4 445 3 126 641 83% 17% 678
Blank cells indicate data not reported.
– indicates values that cannot be calculated.
a The funding gap reflects the anticipated gap for the year at the time a country reported data in the 2015 round of global TB data collection.
Box 7.2 International donor funding for TB prevention, diagnosis and treatment,  
 based on donor reports to the Organization for Economic Cooperation  
 and Development
International donor funding provided for TB prevention, diagnosis 
and treatment is channelled to NTPs and other recipients. The 
financial data reported to WHO by NTPs therefore understates the 
total amount of international donor funding being provided each 
year. 
The creditor reporting system (CRS) of the Organization for 
Economic Cooperation and Development (OECD) is the most 
comprehensive source of information about international donor 
funding. Reports are provided by 31 multilateral organizations, 
the 26 countries that are members of the OECD’s Development 
Assistance Committee and a further two non-committee members 
(Kuwait and the United Arab Emirates). The OECD compiles data 
on commitments and disbursements from both governments 
and multilateral organizations. Disbursement data include both 
direct transfers to countries as well as the provision of goods and 
services, such as in-kind transfers or technical assistance. 
Data on gross disbursements for TB (as opposed to commitments 
that may not always be translated into actual funding) were 
analysed for 2004−2013. All funding coded as for TB (code 12263: 
tuberculosis control) was included. It should be highlighted that 
funding for TB that flows between OECD countries is not recorded 
in the OECD database. It is also important to note that in the OECD 
database, government contributions to multilateral organizations 
are not attributed to the government of origin but only to the 
multilateral organization (for example, funding received by 
countries from Global Fund grants are attributed to the Global 
Fund, as opposed to the original donor to the Global Fund). 
Figure B7.2.1 shows that international donor funding for TB 
increased from US$ 148 million in 2004 to US$ 1022 million in 
2013. Most of the funding that was provided 2004−2013 came 
from the Global Fund (72%), followed by the government of the 
United States of America (14%). Remaining funding for TB came 
from other countries (8%) and other multilateral organizations 
(6%), among which the largest donors were the governments 
of Canada (4%) and the United Kingdom (3%). The Global Fund 
has consistently been the largest provider of international donor 
funding for TB, including US$ 788 million in 2013.a Funding 
increased steadily from 2004 to 2013 with the exception of a drop 
from 2010 to 2011. Disbursements from the government of the 
United States of America steadily increased from 2007 to 2011 
FIGURE B7.2.2 
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FIGURE B7.2.1 
International donor funding for TB prevention, diagnosis 
















a The increase between 2012 and 2013 was mostly accounted for by India, 
which had a Global Fund disbursement of US$ 11 million in 2012 and  
US$ 165 million in 2013.
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FIGURE B7.2.3 
International donor funding for TB prevention, diagnosis and treatment to non-OECD countries, 2011–2013  
(constant 2013 US$, million). Donors are listed on the lef t and recipients of donor funding are listed on the right. The Global 
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and have since levelled of f. However, it should also be noted 
that contributions from the government of the United States of 
America captured in the OECD database are lower than of ficial 
allocations. In 2013, the allocation for TB was US$ 232 million and 
in addition more than US$ 130 million was allocated for TB/HIV via 
the President’s Emergency Plan for AIDS Relief (PEPFAR). 
The Global Fund disbursed TB funding (in at least one year 
between 2004 and 2013) in 105 of the 109 countries that received 
any TB donor assistance. The top recipients of funding, with total 
amounts of over US$ 100 million each during the years 2004−2013, 
were (in descending order of the total funding received): China, 
India, Indonesia, the Philippines, Bangladesh, Nigeria and 
Pakistan. Collectively, these countries accounted for over 58% of 
the TB cases notified in 2014. Figure B7.2.2 shows that Africa, Asia, 
and Europe all experienced major increases in disbursements 
between 2012 and 2013 while amounts disbursed to the Americas 
remained relatively flat. The main drivers of these changes 
between 2012 and 2013 were increased financing from the Global 
Fund for Zambia (US$ 86 million in 2013), India (US$ 165 million in 
2013), and Ukraine (US$ 17 million in 2013).
Figure B7.2.3 shows the flow of international donor funding 
for TB during the period 2011–2013. In this figure, amounts of 
funding flowing to the Global Fund from countries and other 
donors were estimated on the assumption that 18% of a donor’s 
total contribution to the Global Fund was for TB, in line with the 
overall share of Global Fund financing that is used for TB. The 
Global Fund publishes the amounts received from each donor on 
its website. The four largest country donors (the United States 
of America, France, Germany and the UK) are shown separately, 
as is the largest non-country donor (the Bill and Melinda Gates 
Foundation). The importance of the United States of America in the 
global funding of TB is particularly evident in this presentation of 
data, since it accounted for about one third of contributions to the 
Global Fund in addition to funding provided via bilateral channels.
 
a For comparison, the total funding reported by countries to WHO 
amounted to 85% of this total, US$ 669 million. 
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n FIGURE 7.4
Funding for TB prevention, diagnosis and treatment from domestic sources and international donors, 2006–2015,  
9 country groups  (constant 2015 US$ billions)
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a. BRICS b. 17 HBCs excluding BRICS c. Rest of worlda
d.  Low-income countries e. Lower-middle-income countries f. Upper-middle-income countriesb
g.  Africa h. Asiac i. Other regionsd
2006 2009 2012 20152006 2009 2012 2015 2006 2009 2012 2015
a  Rest of the world includes 101 countries that are not in the list of 22 high TB burden or 27 high MDR-TB burden countries.
b  The upper-middle-income category includes three high-income countries that are in the list of TB and/or high MDR-TB burden countries: Estonia, Latvia 
and the Russian Federation.
c  Asia includes the WHO regions of South-East Asia and the Western Pacific. 
d  “Other regions” consists of three WHO regions: the Eastern Mediterranean Region, the European Region, and the Region of the Americas.
e  This includes the Global Fund.
Of the 36 countries that are in the list of high TB burden or 
high MDR-TB countries, 35 could be included in the analysis 
(the exception was Lithuania). Analytical methods are sum-
marized in Box 7.3.
Unit cost estimates for 2014 are shown for drug-suscepti-
ble and MDR-TB in Figure 7.6 and Figure 7.7. 
7.4.1 Drug-susceptible TB
The cost per patient treated for drug-susceptible TB was 
generally in the range US$ 100−US$ 1 000. In general, approx-
imately 80% of this cost was accounted for by reported 
NTP expenditures, with the remainder being inpatient and 
outpatient care. The cost per patient treated was typically 
higher, but still quite varied, in countries of the former Soviet 
Union, ranging from US$ 1 123−US$ 18 836. In these countries, 
lengthy hospitalizations play a more significant role in the 
total cost of care, with admissions lasting up to an average 
of 75 days and accounting for approximately 40–60% of 
the total cost per patient. However, there are some strik-
ing examples of reductions in reliance on hospitalization. 
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n FIGURE 7.5
Funding gaps for TB prevention, diagnosis and treatment reported by countries, by income group and WHO region, 
2006–2015 (constant 2015 US$ millions)a
a The upper-middle-income category includes three high-income countries that are in the list of TB and/or high MDR-TB burden countries: Estonia, Latvia 
and the Russian Federation.
Box 7.3 Methods used to estimate the cost per patient treated for drug-susceptible  
 and MDR-TB
Two main data sources were used. The first was the validated 
expenditure data reported by NTPs that are stored in the WHO 
global TB database. The second was country-specific estimates 
of the unit costs of bed-days and outpatient visits available from 
WHO’s CHOosing Interventions that are Cost-Ef fective (WHO-
CHOICE) model and associated database (managed by the Health 
Governance and Financing department). In a few instances when 
no expenditure data could be reported, information about the 
total funding available was used as a proxy for expenditures. For 
a few countries, WHO-CHOICE estimates were replaced with 
estimates of unit costs obtained directly from recent studies or 
discussions with experts.
Costs were calculated separately for drug-susceptible and MDR-
TB. In each case, the numerator was the total estimated cost of 
treatment, which has two main parts: 1) the national expenditures 
reported by the NTP; and 2) the costs associated with the 
utilization of health services by patients with TB and MDR-TB. 
As explained in Box 7.1, national NTP expenditures are reported 
annually to WHO using the online WHO global TB data 
collection system, and then reviewed and validated. Categories 
of expenditure considered as costs for MDR-TB were second-
line drugs, and all other inputs/activities implemented for the 
programmatic management of MDR-TB. All other categories (with 
the exception of collaborative TB/HIV activities) were assumed to 
be for drug-susceptible TB. 
For almost all countries, the total costs associated with utilization 
of inpatient and outpatient care were calculated using information 
about the typical number of days of inpatient care and outpatient 
visits required on a per patient basis during treatment (reported 
separately for drug-susceptible and MDR-TB by NTPs) combined 
with WHO-CHOICE unit cost estimates, multiplied by the 
number of patients treated in a given year (based on notification 
data – see Chapter 3 for drug-susceptible TB and Chapter 4 for 
MDR-TB). Multiplying quantities of visits and bed-days by their 
price estimates yields the total estimated cost of inpatient and 
outpatient services. For three countries (Belarus, Burkina Faso 
and the Democratic Republic of the Congo), TB inpatient and 
outpatient expenditures available from National Health Accounts 
were used in lieu of the estimated cost from this ingredients-based 
approach.
Unit costs were then calculated as the sum of 2014 NTP 
expenditures and total costs for utilization of inpatient and 
outpatient care, divided by the reported number of patients 
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n FIGURE 7.6 
Estimated cost per patient treated for drug-susceptible TB in 117 countries, 2014a
n FIGURE 7.7 
Estimated cost per patient treated for MDR-TB in 90 countries, 2014a
a Limited to countries with at least 20 patients on second-line treatment in 2014.
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Although not yet be reflected in analyses for 2014, the Rus-
sian Federation reported hospitalization of about 65% of TB 
patients with drug-susceptible TB in 2015, compared with 
93% in 2014. 
Low-income countries spent on average US$  516 per TB 
patient, while upper-middle-income or high-income coun-
tries invested an average of US$ 5  558. In the 22 HBCs, the 
estimated cost per patient treated for drug-susceptible TB 
in 2014 ranged from US$  74 in Pakistan to US$12  988 in the 
Russian Federation. In all of the 22 HBCs, the cost per patient 
treated for drug-susceptible TB was less than gross domestic 
product (GDP) per capita. Six countries – China, India, South 
Africa, Indonesia, Bangladesh and Pakistan, which together 
account for 58% of the global TB burden – have costs per 
patient treated that are relatively low compared with their 
GDP per capita. While the level of GDP per capita clearly 
influences the cost of TB treatment, this shows that the size 
of the total patient caseload is also an important factor (for 
example, when numbers of patients treated are very large, 
economies of scale can be realised). 
7.4.2 MDR-TB
For MDR-TB, the cost per patient treated ranged from an 
average of US$ 6 826 in low-income countries to an average of 
US$ 21 265 in upper middle-income countries in 2014. As for 
drug-susceptible TB, the cost per patient treated for MDR-TB 
was typically higher in countries of the former Soviet Union, 
ranging from US$ 2  935 in Uzbekistan to US$ 64  250 in Lat-
via (where all patients with MDR-TB are hospitalized for an 
average of 120 days, at an estimated cost of US$ 262 per day). 
This mainly reflects greater reliance on inpatient care, with 
admissions lasting up to an average of 240 days per patient 
and accounting for about 60% of the total cost of treatment. 
7.5 Progress towards UHC: insights from 
health financing data
UHC is defined as access for all to essential preventive and 
treatment health care interventions, with financial protec-
tion.1 In financing terms, the absolute level of funding for 
health care must be high enough to ensure that it is possible 
to provide essential health services to the whole population; 
additionally, the costs of using those services, once avail-
able, must not be prohibitive (using them should not result 
in financial hardship). Mandatory pre-payment financing 
mechanisms (such as taxation or social insurance schemes) 
need to form the core of domestic health financing.2
There are three health financing indicators for which 
benchmarks required to achieve UHC have been suggested 
and for which recent estimates are available for all countries 
1 World Health Organisation, World Bank Group. Monitoring progress 
towards universal health coverage at country and global levels. Framework, 
measures and targets. Geneva: World Health Organization; 2014 (WHO/
HIS/HIA/14.1).
2 World Health Organization. The World Health Report 2010. Health systems 
financing: the path to universal coverage. Geneva: World Health 
Organization; 2010.
to which the indicator applies. Analysis of data (from the 
WHO Global Health Expenditure database) for these three 
indicators can therefore provide useful insights into a coun-
try’s progress towards, or achievement of, UHC. The three 
indicators are:
"" Total government spending on health as a proportion of 
GDP: the suggested benchmark is 5–6%;3,4,5 
"" Government and donor-funded health expenditure per 
capita in low-income countries: the suggested benchmark 
is US$ 86 (in 2012 prices);2
"" The share of out-of-pocket expenditures (OOP) in total 
health expenditures: the suggested benchmark is less 
than 15%.1,6,7
OOP expenditures are defined as direct payments made to 
health care providers by individuals at the time of service 
use, excluding prepayment for health services (for example 
in the form of taxes or specific insurance premiums or con-
tributions) and, where possible, net of any reimbursements 
to the individual who made the payment.8 The level of OOP 
expenditures provides a proxy measure of the degree to 
which people lack financial protection.
7.5.1 Government spending on health as a proportion 
of GDP
The latest data on government health expenditures (GHE) 
are for 2013.9 GHE was less than 6% of GDP in most countries 
in 2013 (149/190, 78%), including all of the 36 countries in the 
current lists of high TB burden and/or MDR-TB burden coun-
tries (Figure 7.8). Among HBCs, those at the lowest end of the 
range were Bangladesh, Indonesia, India, Nigeria, Myanmar, 
Pakistan and the Philippines (all <1.5%); those closest to the 
6% threshold were Brazil, South Africa and Thailand (all at 
around 4.5%). Among WHO regions, the South-East Asia 
Region had the lowest levels of health spending as a propor-
tion of GDP. 
There were 41 countries where government spending on 
health exceeded 6% of GDP. Of these, only six were low or 
lower-middle income countries: Rwanda, Swaziland, Leso-
tho, Samoa, Kiribati and Micronesia. 
3 World Health Organization. The World Health Report 2010. Health systems 
financing: the path to universal coverage. Geneva: World Health 
Organization; 2010.
4 McIntyre et al. Fiscal Space for Domestic Funding of Health and Other Social 
Services. London: Chatham House; 2014.
5 World Health Organization and Pan American Health Organization. 
Resolution CD53.R14 Strategy for universal access to health and universal 
health coverage. 53rd Directing Council, 66th Session of the Regional 
Committee of WHO for the Americas. Washington: World Health 
Organization and Pan American Health Organization, 2014.
6 Xu et al, Protecting Households from Catastrophic Health Spending, 
Health Af fairs 2007; 26(4): 972–983.
7 Xu et al., Household Catastrophic Health Expenditure: A Multicountry 
Analysis, The Lancet 2003;362: 111–117.
8 World Health Organization and World Bank. First Global Monitoring 
Report on Tracking Universal Health Coverage, 2015. http://www.who.int/
healthinfo/universal_health_coverage/report/2015/en/.
9 WHO National Health Accounts database, accessed July 2015 via http://
apps.who.int/nha/database
cvv
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n FIGURE 7.8 
Government spending on health, as a percentage of gross domestic product (GDP), 2013a
n FIGURE 7.9 
Government spending on health per capita in low-income countries (shown in blue), 2013. Middle and high-income 









a Data for Bahrain and Brazil are for 2012.
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n FIGURE 7.11
Total health expenditures by source of financing in 
selected high TB burden and high-income countries, 2013
Private expenditures, other














































































n FIGURE 7.10 








7.5.2 Government spending on health per capita, 
low-income countries
In 2013, government spending on health per capita was far 
below the suggested benchmark of US$  86 per capita in all 
low-income countries (Figure 7.9). Most countries spent less 
than US$ 20 per capita. The countries that were closest to the 
benchmark were Rwanda (US$ 41 per capita) and Kyrgyzstan 
(US$ 51 per capita). 
7.5.3 Share of out-of-pocket expenditures in total 
health expenditures
In 2013, OOP expenditures were less than 15% of total health 
spending in 43 of 190 countries for which data were avail-
able, including three HBCs: Mozambique, Thailand and 
South Africa (Figure 7.10). At the other end of the scale, there 
were 49 countries where OOP expenditures accounted for at 
least 45% of total health expenditures, including ten HBCs: 
Bangladesh, India, Indonesia, Cambodia, Nigeria, Myanmar, 
Pakistan, Philippines, Viet Nam and the Russian Federa-
tion. The global average in 2013 was 32%, a small reduction 
compared with 36% in 2000.1 The breakdown of total health 
expenditures by source of funding, including OOP expendi-
tures, is shown for selected high TB burden and high-income 
countries in Figure 7.11.
1 World Health Organization and World Bank. First Global Monitoring 
Report on Tracking Universal Health Coverage, 2015. http://www.who.
int/healthinfo/universal_health_coverage/report/2015/en/.
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7.5.4 Beyond financial risk protection
One of the three main targets in the End TB Strategy (2016–
2035) is that no TB patients or their households should face 
catastrophic costs as a result of TB disease (Chapter 1). This 
target was specifically included because it is a key marker 
of financial risk protection and progress towards UHC and 
social protection for TB-af fected households.1 Catastrophic 
cost is a broader concept than catastrophic health expendi-
ture, since it includes not only direct expenditures on health 
services but also (1) non-medical payments (such as trans-
portation or lodging charges) that are directly related to 
accessing TB diagnosis and treatment and (2) indirect costs 
such as income losses (for example, related to time lost from 
work or loss of employment). 
The proportion of patients and their households that 
experience catastrophic costs can be measured using peri-
odic surveys. To support such surveys, WHO established a 
Task Force in 2015. The main focus of the Task Force’s work in 
2015 has been to develop a generic protocol and accompany-
ing questionnaires,2 building on methods used in previous 
studies of patient costs. 
1 Uplekar M, Weil D, Lonnroth K, Jaramillo E, Lienhardt C, Dias HM, et al. 
WHO’s new End TB Strategy. The Lancet. 2015;385:1799-801. See in 
particular Panel 2 in the supplementary appendix. 
2 Protocol for survey to determine direct and indirect costs due to TB and to 
estimate proportion of TB-af fected households experiencing catastrophic costs 
– Field testing version, 2015. Available from the Global TB Programme in 
WHO upon request.
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 Key facts and messages
first, bedaquiline, was approved by the US Food and Drug 
Administration (FDA) in December 2012 and the second, 
delamanid, was approved by the European Medicines Agency 
in November 2013. WHO issued interim guidance on the use 
of these two drugs in the treatment of MDR-TB in June 2013 
and October 2014, respectively. Additionally, there are eight 
new or repurposed anti-TB drugs in advanced phases of clinical 
development. For the first time in six years, a new anti-TB 
drug candidate has entered a Phase I clinical trial: TBA-354, 
a nitroimidazole that is part of the same class of drugs as 
delamanid and pretomanid. 
Results from three Phase III trials investigating four-month 
regimens for the treatment of drug-susceptible TB that 
include fluoroquinolones were released in 2014. These shorter 
regimens failed to show non-inferiority to the six-month 
standard of care regimen currently recommended by WHO. 
Several new regimens, including new and/or re-purposed 
drugs, are now being tested in a series of Phase II/III trials for 
the treatment of drug-susceptible and/or drug-resistant TB.
Two recent observational studies of the ef fectiveness of shorter 
treatment regimens for patients with MDR-TB in Niger and 
Cameroon have shown that a 12-month treatment regimen was 
ef fective and well-tolerated in patients not previously exposed 
to second-line drugs. 
There are 15 vaccine candidates in clinical trials. Results of 
Phase II ef ficacy data to determine whether BCG and/or H4:IC31 
can prevent infection, and M72 can prevent disease, as well as 
phase III data of whether M.vaccae can prevent disease, will 
shortly be available. Major shif ts in TB vaccine research and 
development include the introduction of more stringent gating 
criteria/mechanisms for candidate entry into and progress 
in clinical trials; vaccine discovery that explores induction 
of immunity beyond conventional T cells; and support of 
experimental medicine studies for knowledge generation and 
to better connect data from animal models and human studies.
Intensified research and development is one of the three 
pillars of the WHO post-2015 global TB strategy, and will play a 
crucial role in accelerating the reductions in TB incidence and 
mortality required to reach global TB targets by 2035. Ef forts to 
develop new TB diagnostics, drugs, and vaccines intensified in 
the past decade, but considerable progress and investment is 
still needed. 
The diagnostic technology landscape continues to look 
promising although very few technologies are at adequately 
advanced stages for WHO evaluation. Technologies under 
development include rapid tests to detect TB, drug resistance, 
or TB and drug resistance combined. Those based on molecular 
technologies such as nucleic acid amplification tests are the 
most advanced. 
A new diagnostic platform called the GeneXpert Omni® is in 
development. This is intended for point-of-care testing for TB 
and rifampicin-resistant TB using existing Xpert MTB/RIF® 
cartridges. This new platform will be assessed by WHO for 
equivalence to the current GeneXpert platform in 2016. A next-
generation cartridge called Xpert Ultra® is also in development, 
and is expected to replace the Xpert MTB/RIF cartridge. The 
Xpert Ultra assay will be assessed in 2016 in two stages, first as 
a replacement for the current Xpert MTB/RIF assay and second 
as a replacement for conventional diagnostic culture. 
In 2015, three diagnostic tests were reviewed by WHO: 
Determine TB LAM (lipoarabinomannan), referred to as 
LF-LAM; and two new generic versions of line probe assays 
(LPAs) for first-line drugs. LF-LAM is not recommended for 
the diagnosis of TB (pulmonary and extrapulmonary), with 
the exception of people living with HIV who have low CD4 
counts or who are seriously ill. WHO will update current policy 
recommendations for the use of LPAs in early 2016. 
Two new drugs have recently been recommended for 
the treatment of MDR-TB under specific conditions. The 
The goal of the End TB strategy endorsed by the World 
Health Assembly (WHA) in May 2014 is to end the global TB 
epidemic (Chapter 1). Despite major progress in TB preven-
tion, diagnosis and treatment since the mid-1990s (Chapters 
2−7), reaching this goal will require major technological 
breakthroughs from the research and development pipeline 
by 2025; these would make possible a major acceleration in 
the rate at which TB incidence declines compared with his-
toric levels. Critical components include: the availability of 
af fordable short, ef fective and well-tolerated treatments 
for all forms of TB (latent TB infection, drug-susceptible and 
drug-resistant TB disease); a point-of-care diagnostic test 
with capacity to identify resistance to the most important 
anti-TB drugs; and an ef fective post-exposure vaccine.
This is the fif th successive year in which a chapter on 
research and development is included in the Global tubercu-
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losis report. The status of progress in the development of new 
TB diagnostics, drugs and vaccines as of August 2015 is sum-
marized, based on recent publications and communications 
with and contributions from the secretariats of the relevant 
Working Groups of the Stop TB Partnership.
8.1 New diagnostics for TB
The End TB strategy targets set for 2035 are to reduce the 
absolute number of TB deaths by 95% and to reduce the 
TB incidence rate by 90%, compared with a baseline of 
2015 (Chapter 1). To achieve these targets, national TB pro-
grammes (NTPs) first need to implement strategies that 
fully optimize the use of existing diagnostic technologies. 
Research and development is required so that new rapid 
tests that can be used at the point of care, and that accelerate 
access to testing for drug susceptibility for all bacteriologi-
cally-confirmed TB cases, become available. 
8.1.1 An overview of the diagnostics pipeline
Although very few technologies are at an advanced stage of 
evaluation, the diagnostic technology landscape continues 
to look promising. An overview of the diagnostic pipeline 
for rapid molecular tests in August 2015 is shown in Fig-
ure 8.1. The list of technologies is not necessarily complete 
or exhaustive, but does reflect technologies that have been 
documented in recent reports published by UNITAID1 and 
1 UNITAID. 2014. Tuberculosis Diagnostic Technology and Market 
Landscape 3rd edition. Geneva: World Health Organization. Available 
at: http://www.unitaid.eu/images/marketdynamics/publications/
UNITAID_TB_Diagnostics_Landscape_3rd-edition.pdf 
Treatment Action Group (TAG).2 Tools using molecular tech-
nologies such as nucleic acid amplification tests (NAATs) 
are the most advanced. Technologies under development 
include tests to detect TB, drug resistance, or TB and drug 
resistance combined. These include microarray-based multi-
plexing diagnostic platforms for the simultaneous detection 
of a large number of resistance-conferring mutations. Unfor-
tunately, most tests under development are intended for use 
at the reference or intermediate laboratory level only, requir-
ing dedicated infrastructure and experienced staf f. 
There are at least three technologies that are commer-
cially available (Epistem Genedrive, Epistem, UK; Molbio 
Truelab, Molbio, India and EASYNAT, Ustar, China) that are 
intended for use at the microscopy level. However, to date no 
multicentre evaluation and/or demonstration studies in dif-
ferent epidemiological setting have been conducted. These 
are necessary to generate the performance data required 
by WHO to assess and produce recommendations on these 
technologies (Figure 8.2). Evaluation studies are expensive, 
and therefore additional funding is urgently needed, both 
to expedite the progress of promising new technologies 
through the pipeline and to conduct the necessary evalua-
tion studies. Priority should be given to tests that are suitable 
for use at the lower levels of the health system. The Foun-
dation for Innovative New Diagnostics (FIND) remains the 
lead organization conducting field evaluations of dif ferent 
2 Harrington M. “The tuberculosis diagnostics pipeline” in 2015 Pipeline 
Report: HIV, Hepatitis C Virus (HCV) and Tuberculosis Drugs, Diagnostics, 
Vaccines, Preventive Technologies, Research Toward a Cure, and Immune-
Based and Gene Therapies in Development. New York, Treatment Action 
Group, 2015. Available at: http://www.pipelinereport.org/sites/g/files/
g575521/f/201507/2015%20Pipeline%20Report%20Full.pdf
n FIGURE 8.1
An overview of progress in the development of molecular TB diagnostics, August 2015a
FOR USE IN REFERENCE -LEVEL 
LABORATORIES
n m2000 RealTime MTB assay, Abbott, USA 
n TruArray MDR-TB, Akkoni, USA
n BioFilmChip MDR-TB, AutoGenomics, USA
n MTBC-OCTA, AutoGenomics, USA
n BD ProbeTec ET Direct TB assay, BD, USA
n TB drug resistance array, Capital Bio, 
China
n AMTD test, Hologic Genprobe, USA
n Cobas TaqMan MTB test, Roche, 
Switzerland
n Anyplex™, Seegene, Korea
n Magicplex™ MTB, Seegene, Korea
n TRC Rapid®M.TB, Tosoh Bioscience, Japan
n MeltPro®, Zeesan Biotech, China
FOR USE IN INTERMEDIATE-LEVEL 
LABORATORIES 
n FluoroType MTB / FluoroType MTB RNA, 
Hain Lifesciences, Germany
n iCubate System, iCubate, USA 
n AdvanSure, LG Life sciences, Republic of 
Korea
n LPA NTM/MTB DR, Nipro, Japan
n vereMTB, Veredus Laboratories, 
Singapore
n SPEED-OLIGO®, Vircell, Spain
n MolecuTech REBA, YD Diagnostics, Korea
n LATE-PCR, Brandeis University, USA
n GeneXpert XDR cartridge, Cepheid, USA
n Xpert Ultra, Cepheid, USA
n Enigma ML, Enigma Diagnostics, UK
FOR USE IN PERIPHERAL-LEVEL 
LABORATORIES 
n Alere Q, Alere, USA 
n TB-LAMP, Eiken, Japan
n B-SMART, LabCorp, USA
n Genedrive MTB/RIF ID, Epistem, UK
n HYDRA, Insilixa Inc, USA
n TBDx System, KGI, USA
n Truelab/Truenat MTB, Molbio/bigtec 
Diagnostics, India
n Savanna, NWGHF, USA
n EasyNAT TB Diagnostic kit, Ustar 
Biotechnologies, China
n EOSCAPE-TB, Wave 80 Biosciences, USA
n GenePOC test, GenePOC, Canada
n Xpert Omni, Cepheid, USA
a This is not an exhaustive list of technologies in development. Those listed are the ones documented in publications by UNITAID and TAG: 
 UNITAID. 2014. Tuberculosis Diagnostic Technology and Market Landscape 3rd edition. Geneva: World Health Organization. Available at: http://www.
unitaid.eu/images/marketdynamics/publications/UNITAID_TB_Diagnostics_Landscape_3rd-edition.pdf 
 Harrington M. “The tuberculosis diagnostics pipeline” in 2015 Pipeline Report: HIV, Hepatitis C Virus (HCV) and Tuberculosis Drugs, Diagnostics, Vaccines, 
Preventive Technologies, Research Toward a Cure, and Immune-Based and Gene Therapies in Development. New York, Treatment Action Group, 2015. Available at: 
http://www.pipelinereport.org/sites/g/files/g575521/f/201507/2015%20Pipeline%20Report%20Full.pdf
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technologies, but the engagement of other stakeholders and 
adequate funding are urgently needed. 
A new diagnostic platform called the GeneXpert Omni® 
is in development. This is intended for point-of-care testing 
for TB and rifampicin-resistant TB using existing Xpert MTB/
RIF® cartridges. The device is expected to be smaller, lighter, 
and less expensive than other currently available platforms 
for point-of-care nucleic acid detection. The platform will 
come with a built-in four-hour battery; an auxiliary battery 
that provides an additional 12 hours of run time is also avail-
able. In 2016, this new platform will be assessed by WHO for 
non-inferiority to the current GeneXpert platform.
Major gaps still remain in the diagnostic pipeline, and 
slow progress in the evaluation of technologies in the late 
stages of development is the major barrier to these tools 
reaching the market. There are insuf ficient tests under 
development for the diagnosis of TB in children, assessment 
of susceptibility to drugs that may be part of new treatment 
regimens, prediction of progression from latent TB infection 
(LTBI) to active TB disease and alternatives to TB culture for 
treatment monitoring. The development and implementa-
tion of such tests as well as increasing access to technologies 
already endorsed by WHO will be essential to meet targets 
outlined in the End TB Strategy.
8.1.2 TB diagnostic tests reviewed by WHO in 2015
In 2015, three diagnostic tests were reviewed by WHO: 
Determine TB LAM (lipoarabinomannan), referred to as 
LF-LAM, developed by Alere, USA; and two new generic ver-
sions of line probe assays (LPAs), one developed by the Nipro 
Corporation, Japan and the other by Hain Lifesciences. 
LF-LAM (Alere, USA)
LF-LAM is a lateral flow test that has been evaluated in sev-
eral studies for the detection of active TB in people living 
with HIV who are severely immunocompromised. Evidence 
from a systematic review of the performance characteristics 
of the assay was considered by a Guideline Development 
Group convened by WHO in 2015. This group recommended 
that LF-LAM should not be used for the diagnosis of TB (pul-
monary and extrapulmonary), with the exception of people 
living with HIV who have low CD4 counts or who are seriously 
ill. More details on these recommendations are provided in 
Chapter 5.
New generic versions of LPAs (Nipro Corporation, MTBDRplus 
version 2)
For new versions of technologies that WHO has already rec-
ommended, WHO requires a head-to-head comparison with 
the existing technology. If non-inferiority (that is, their equiv-
alence) in performance can be demonstrated, then WHO will 
recommend the new version. 
In 2008, WHO endorsed the use of LPAs for the rapid 
detection of rifampicin resistance, beginning what might 
be considered to be the molecular revolution in detection of 
drug-resistant TB. The evidence and subsequent recommen-
dations for the utility of LPAs included an assessment of the 
performance of the GenoType® MTBDRplus assay, Hain Life-
science (Hain Version 1 assay). This assay incorporates rpoB 
probes for rifampicin resistance detection as well as katG 
probes and inhA probes for the determination of isoniazid 
resistance. Hain Lifesciences have subsequently developed 
an updated version of their MTBDRplus line probe assay 
(Hain Version 2 assay).
n FIGURE 8.2
The phases of TB diagnostics development and assessment for WHO recommendation using the GRADE (Grading of 
Recommendations Assessment, Development and Evaluation) process
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Nipro Corporation, Japan has developed an LPA that is 
similar to that of Hain Lifesciences, which was registered in 
Japan in 2012 (Nipro assay). This assay allows for the detec-
tion of rifampicin and isoniazid conferring mutations, the 
identification of M. tuberculosis complex and the identifi-
cation of some common nontuberculous mycobacteria 
including M. avium, M. intracellulare and M. kansasii. 
In 2014 and 2015, FIND coordinated a multi-center, 
blinded cross-sectional study of the diagnostic accuracy of 
these two tests, to compare their performance against that 
of the Hain Version 1 assay. A composite reference standard 
including phenotypic drug susceptibility testing (DST) and 
DNA sequencing was used. The study was divided into two 
distinct phases. Phase 1 was designed to evaluate the perfor-
mance of the newer assays on a wide range of clinical isolates 
and Phase 2 to evaluate their performance on sputum speci-
mens from patients with pulmonary TB.
The study demonstrated non-inferiority of the newer 
LPA assay versions (Hain Version 2 and Nipro) in comparison 
with the Hain Version 1 assay; these assays showed compa-
rable performance for the detection of M. tuberculosis and 
rifampicin resistance conferring mutations in acid-fast bacilli 
smear-positive samples and isolates of M. tuberculosis. WHO 
will update current policy recommendations for the use of 
LPAs and review new evidence about the clinical utility of the 
Hain Lifescience GenoType MTBDRsl assay and will assess 
the role of sequencing in detecting resistance to second-line 
drugs in 2016. 
8.1.3 Technologies scheduled for field evaluation 
studies in 2016
There are two technologies scheduled for field evaluation in 
2016. 
Xpert Ultra, Cepheid
A new version of the Xpert MTB/RIF assay, called Xpert 
Ultra®, is in development. The aim is to improve the sensitiv-
ity and specificity of the current assay in detection of TB and 
rifampicin resistance, respectively. In 2016, FIND will initiate 
a two-step evaluation process. The first step is a rapid non-
inferiority study that will compare the new Xpert Ultra assay 
with the current Xpert MTB/RIF assay. If non-inferiority is 
demonstrated, the Xpert Ultra assay will be recommended 
as a replacement for the current Xpert MTB/RIF assay. The 
second step will be multi-country evaluation studies. It is 
anticipated that these studies will demonstrate that the 
Xpert Ultra assay has superior performance (for example, 
about 95% sensitivity in detecting smear-negative, culture-
positive TB from a single sputum specimen). The Xpert Ultra 
assay will be developed for use on the Omni platform 
(described above).
Alere Q, Alere
The Alere™ q TB diagnostic system is being developed with 
funding support from the Bill & Melinda Gates Foundation. 
It is a rapid and sensitive test for detection of TB, followed by 
an immediate reflex test for a full analysis of drug resistance 
for people found to have TB. A sputum sample is collected in 
a cup that is then screwed onto the test cartridge, which con-
tains all reagents. The inoculated cartridge is subsequently 
placed into a battery-powered stand-alone device that 
allows for sample processing, DNA amplification, detection 
and result interpretation and reporting in approximately 20 
minutes. This technology is a major step towards achieving 
universal DST for all TB cases. Multi-centre evaluation stud-
ies are planned for 2016–2017.
8.1.4 Tests that predict progression from latent to 
active TB
Most people with LTBI have no signs and symptoms of TB dis-
ease. People with LTBI are not infectious, but they are at risk 
for developing active disease and becoming infectious. On 
average, 5–15% of those infected will develop active TB dur-
ing their lifetime, typically within the first 2–5 years af ter the 
initial infection. Current tests for LTBI (i.e. interferon gamma 
release assays, IGRAs; and the tuberculin skin test, TST) are 
immunity-based and have very limited ability to identify 
which individuals are likely to progress to active TB. They also 
have limited sensitivity in people with HIV infection, and 
are not able to dif ferentiate between recent and remote 
infection or to distinguish if a person has been re-infected if 
re-exposed. 
In May 2015, WHO hosted a meeting on behalf of FIND 
and the New Diagnostics Working Group of the Stop TB Part-
nership to review a set of minimal and optimal performance 
characteristics and develop a target product profile (TPP) for 
a biomarker-based test to predict the risk of progression to 
active TB from LTBI and rule out active TB. The meeting was 
attended by representatives from the diagnostic develop-
ment industry, universities, clinicians and technical partners. 
Following the meeting, the process to define the TPP for 
a test for progression of LTBI has continued alongside the 
development of standardized study protocols that could be 
used to evaluate the performance of such tests.
8.2 New drugs and drug regimens to treat TB
Much progress has been made during the last ten years 
in the treatment of TB. The body of knowledge about the 
use of various drugs in combination regimens, as well their 
potential interaction with ARVs and the optimum timing of 
ART in the treatment of HIV-positive TB patients, has grown 
substantially. However, TB treatment remains centred on the 
standard 6 month regimen of isoniazid, rifampicin, pyrazi-
namide and ethambutol. Ensuring adherence to treatment 
remains a challenge, and drug-resistant TB remains a major 
threat to global TB prevention, diagnosis and treatment 
(Chapter 4). This section provides an overview of the latest 
status of the development of new TB drugs and new TB treat-
ment regimens.
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n FIGURE 8.3
The development pipeline for new TB drugs, August 2015a
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Chemical classes:  fluoroquinolone, rifamycin, oxazolidinone, nitroimidazole, diarylquinoline, benzothiazinone
a Details for projects listed can be found at http://www.newtbdrugs.org/pipeline.php and ongoing projects without a lead compound series identified 
can be viewed at http://www.newtbdrugs.org/pipeline-discovery.php
b OBR = Optimized Background Regimen




8.2.1 The pipeline of new and re-purposed  
anti-TB drugs 
The status of the pipeline for new and repurposed anti-TB 
drugs in August 2015 is shown in Figure 8.3. There are eight 
drugs in Phase I, Phase II or Phase III trials for the treatment 
of drug-susceptible, multidrug-resistant TB (MDR-TB) or 
LTBI. Two of these compounds (AZD5847 and Sutezolid) do 
not appear to have progressed in the last two years. Howev-
er, for the first time in six years, a new anti-TB drug candidate 
has entered a Phase I clinical trial: TBA-354, a nitroimidazole 
that is part of the same class of drugs as delamanid and 
pretomanid (formerly PA-824).1 In addition, more diversified 
fundamental research is being conducted to better under-
stand the diversity of the metabolic stages of M.  tuberculosis 
and associated host responses, and to identify novel targets 
against which therapeutic chemicals can be directed. This is 
important to ensure that drugs are ef fective throughout the 
various stages of TB – from acute disease through treatment 
of chronic bacterial carriage to cure.
Rifapentine for drug-susceptible TB
Investigation of the potential ef fectiveness of rifapen-
tine in the treatment of drug-susceptible TB, is continuing 
based on the results of the TB Trial Consortium (TBTC) Study 
29 that showed comparable ef ficacy of daily rifapentine 
1 ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of 
Medicine (U.S.). 2000. Identifier NCT02288481, A phase 1 study to 
evaluate the safety, tolerability, and pharmacokinetics of TBA-354 in 
healthy adult subjects; 2014 November 7. https://clinicaltrials.gov/ct2/
show/NCT02288481 
(10 mg/kg) and rifampicin (10 mg/kg) when provided 
along side standard doses of isoniazid, ethambutol and 
pyrazinamide. The outcome of interest is culture conversion 
at two months in smear-positive pulmonary TB patients.2 A 
further study (Study 29X), aimed at investigating the ef fect of 
various dosages of rifapentine (10, 15 or 20 mg/kg, given seven 
days a week with food supplements), showed that the substi-
tution of high-dose daily rifapentine for rifampicin improved 
the antimicrobial activity of combination chemotherapy dur-
ing the intensive phase of treatment, and that this activity 
was driven by rifapentine exposure.3 The observed safety and 
tolerability combined with the high levels of antimicrobial 
activity observed in the groups that received higher doses of 
rifapentine provide support for the evaluation of high-dose 
daily rifapentine-containing regimens of less than six months 
duration in Phase III clinical trials. 
Rifampicin
Assessment of whether higher doses of rifampicin could 
reduce treatment duration for drug-susceptible TB has 
continued. Results from the PanACEA MAMS-TB-01 trial 
presented at the Conference on Retroviruses and Opportun-
istic Infections (CROI) in March 2015 showed that daily dosing 
with 35 mg/kg of rifampin (in addition to standard doses of 
isoniazid, ethambutol, and pyrazinamide) reduced the time 
2 Dorman S et al. Substitution of Rifapentine for Rifampin During 
Intensive Phase Treatment of Pulmonary Tuberculosis: Study 29 of the 
Tuberculosis Trials Consortium. J Infect Dis. 2012, 206 (7): 1030–1040.
3 Dorman S et al. Daily Rifapentine for Treatment of Pulmonary 
Tuberculosis: A Randomized, Dose-Ranging Trial. Am J Respir Crit Care 
Med 2015, 191; 333–343.
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to stable culture conversion when measured over 12 weeks 
on liquid media, but not on solid media, compared to the 
standard six month regimen.1 In the same trial, a second 
arm in which 20 mg/kg of rifampin + moxifloxacin was pro-
vided showed a non-significant improvement in the time 
to culture conversion on liquid media over 12 weeks, but no 
improvement when measured using solid media. Both arms 
appeared safe and well tolerated, but a slightly higher per-
centage of patients (14% versus 10%) experienced grade 3 
adverse events compared with the control arm. There were 
potentially higher rates of hepatic adverse events that result-
ed in a change of treatment in the 35 mg/kg rifampin arm. 
Final analysis of results is underway. Further research about 
the safety and ef ficacy of higher dosages of rifampicin, with 
or without moxifloxacin, and its capacity to shorten treat-
ment, is needed. 
Fluoroquinolones
The results from three Phase III trials of four-month combi-
nation regimens for the treatment of drug-susceptible TB, all 
of which included a fluoroquinolone, were published in late 
2014. These were: (i) the OFLOTUB trial, in which gatifloxa-
cin was substituted for ethambutol;2 (ii) the ReMOX trial, in 
which moxifloxacin was substituted for either ethambutol or 
isoniazid;3 and (iii) the Rifaquin trial, in which moxifloxacin 
was substituted for isoniazid in the intensive phase of treat-
ment and rifapentine was used in the continuation phase of 
treatment.4 
Disappointingly, all of these trials showed that the short-
ened regimen cannot be recommended for the treatment of 
uncomplicated smear-positive pulmonary TB. Moreover, the 
inclusion of a third-generation fluoroquinolone as a substi-
tute for either ethambutol or isoniazid was associated with 
a higher risk of relapse compared with the standard regimen 
of six months. 
Bedaquiline
In December 2012, bedaquiline was approved by the US Food 
and Drug Administration (FDA) for treatment of MDR-TB as 
part of combination therapy for adults with pulmonary TB 
when other alternatives are not available. The drug is being 
introduced in several countries for the treatment of severe 
forms of MDR-TB (Chapter 4), following interim guidance 
issued by WHO in 2013.5
1 Boeree M, Hoelscher M. High-dose rifampin, SQ109 and moxifloxacin 
for treating TB: the PanACEA MAMS-TB trial. Paper presented at: 22nd 
Conference on Retroviruses and Opportunistic Infections; 2015 
February 23–26; Seattle, WA.
2 Merle CS et al. A Four-Month Gatifloxacin-Containing Regimen for 
Treating Tuberculosis. N Engl J Med 2014;371:1588–98.
3 Gillespie SH et al. Four-Month Moxifloxacin-Based Regimens for 
Drug-Sensitive Tuberculosis. N Engl J Med 2014;371:1577–87.
4 Jindani A et al. High-Dose Rifapentine with Moxifloxacin for Pulmonary 
Tuberculosis. N Engl J Med 2014;371:1599–608.
5 The use of bedaquiline in the treatment of multidrug-resistant tuberculosis: 
Interim policy guidance. Geneva: World Health Organization; 2013 (WHO/
HTM/TB/2013.6). Available at: http://apps.who.int/iris/
bitstream/10665/84879/1/9789241505482_eng.pdf
The safety and ef ficacy of bedaquiline in combination 
with short MDR-TB regimens of six and nine months dura-
tion is currently being investigated as part of the Phase III 
STREAM trial. These shorter regimens are being compared 
with the current standard of care for MDR-TB recommended 
by WHO. 
Delamanid
In November 2013, a conditional marketing authorization 
for delamanid was granted by the Committee for Medicinal 
Products for Human Use (CHMP) of the European Medicines 
Agency (EMA). Delamanid was authorized for use as part 
of a combination regimen for pulmonary MDR-TB in adult 
patients “when an ef fective treatment regimen cannot oth-
erwise be composed for reasons of resistance or tolerability”. 
Interim guidance on the use of delamanid was issued by 
WHO in October 2014.6
Delamanid is currently being tested in a Phase III clinical 
trial, as an addition to an optimized background regimen 
(OBR) for the treatment of MDR-TB. The trial is comparing 
six months of treatment with delamanid plus the OBR with a 
placebo plus OBR. It is anticipated that the trial will be com-
pleted in 2016. 
Two other trials are evaluating the use of delamanid in the 
treatment of children with MDR-TB. The first trial is a 10-day 
open label pharmacokinetic (PK) study of delamanid plus an 
OBR. Patients who successfully complete this trial may then 
be enrolled in a second, open-label study (Trial 242-12-233) to 
assess the safety, tolerability, PK, and ef ficacy of delamanid 
plus an OBR over a six-month treatment period. These trials 
are scheduled for completion in 2017. 
Pretomanid 
Pretomanid is a nitroimidazole developed by the Global Alli-
ance for TB drug development. It is being tested as part of 
three potential combination regimens for the treatment of 
both drug-susceptible and drug-resistant TB (further details 
are provided in section 8.2.2). 
SQ109
Preliminary results from the PanACEA MAMS-TB-01 trial 
presented at CROI in March 2015 showed that there was no 
benefit of including SQ109 instead of ethambutol in stand-
ard therapy for drug-susceptible TB, in terms of time to 
culture conversion measured over 12 weeks.1 
8.2.2 Trials of new regimens for the treatment of 
drug-susceptible and/or drug-resistant TB
Besides individual compounds, new combinations of drugs 
are being tested in several Phase II or Phase III trials. 
The NC-002 Phase IIb trial, conducted by the Global Alli-
6 The use of delamanid in the treatment of multidrug-resistant tuberculosis: 
Interim policy guidance. Geneva: World Health Organization; 2014(WHO/
HTM/TB/2014.23). Available at: http://apps.who.int/iris/
bitstream/10665/137334/1/WHO_HTM_TB_2014.23_eng.pdf
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ance for TB Drug Development (referred to in this text as “TB 
Alliance”) in South Africa and the United Republic of Tanza-
nia, investigated the ef ficacy, safety and tolerability of the 
combination of moxifloxacin + pretomanid + pyrazinamide 
(MPaZ) af ter eight weeks of treatment in 207 adult patients 
with newly diagnosed drug-susceptible or smear-positive 
pulmonary MDR-TB.1 Two doses of pretomanid were tested 
(100 mg and 200 mg); the 26 MDR-TB patients received 
only the higher dose. The primary endpoint was the rate of 
change in colony forming units (CFUs) from sputum on solid 
culture over eight weeks. Results of this trial showed that the 
MPaZ regimen had active bactericidal activity against both 
drug-susceptible and MDR-TB over two months and that this 
bactericidal activity was significantly greater than that of 
isoniazid, rifampicin, pyrazinamide and ethambutol (HRZE) 
therapy in patients with drug-susceptible TB when the 
MPa(200mg)Z regimen was used. The frequency of adverse 
events was similar to standard treatment in all groups. The 
combination of moxifloxacin, pretomanid, and pyrazina-
mide thus appeared to be safe, well-tolerated, and showed 
superior bactericidal activity for treatment of drug-suscepti-
ble TB during the first eight weeks of treatment.
On the basis of the results from the Phase IIb trial, a Phase 
III trial was launched in February 2015. Known as the STAND 
trial, it will be implemented in 16 countries and is a partially 
randomized clinical trial. Treatments are assigned to five 
parallel groups: Pa(100mg)-M-Z for 4 months for 350 patients 
with drug-susceptible TB; Pa(200mg)-M-Z for four months 
for 350 patients with drug-susceptible TB; Pa(200mg)-M-Z 
for six months for 350 patients with drug-susceptible TB; 
HRZE for six months for 350 patients with drug-susceptible 
TB; and Pa(200mg)-M-Z for six months for 350 patients with 
drug-resistant TB. 
The NC-003 trial tested the 14 day early bactericidal 
activity (EBA) of various combinations of clofazimine, 
bedaquiline, pretomanid and pyrazinamide in patients with 
drug-susceptible TB.2 Following the results from this trial, 
a Phase IIb trial, NC-005, has been launched. This is testing 
all-oral combination regimens that include bedaquiline 
(two dif ferent doses), pretomanid, and pyrazinamide for 
patients with drug-susceptible TB, and these drugs in com-
bination with moxifloxacin for patients with MDR-TB. The 
trial is measuring the decline in CFUs over eight weeks, and 
the time to positivity based on results from pooled sputum 
sampling every 16 hours. This study started in October 2014, 
and results are expected in mid-2016.
The NiX-TB study, implemented by the TB Alliance in 
South Africa, started in April 2015. It is investigating the safe-
1 Dawson R et al. Ef ficiency and safety of the combination of 
moxifloxacin, pretomanid (PA-824), and pyrazinamide during the first 8 
weeks of antituberculosis treatment: a phase 2b, open-label, partly 
randomised trial in patients with drug-susceptible or drug-resistant 
pulmonary tuberculosis. Lancet 2015
2 Everitt D et al. 14 Day EBA study of clofazimine alone and in 
combination. 44th Union World Conference on Lung Health, 
Late-breaker session, Paris, 2013
ty and ef ficacy of a six month combination of bedaquiline, 
pretomanid and linezolid (all compounds that are new or 
to which there is little pre-existing resistance due to limited 
use) for TB patients with XDR-TB. The primary endpoint is the 
incidence of bacteriologic failure or relapse or clinical failure, 
with follow-up for 24 months af ter the end of treatment. 
Alongside the Nix-TB study, the TB Alliance is undertak-
ing a study of the response to dif ferent doses of linezolid in 
patients with drug-susceptible TB over two weeks. This study 
will inform dosing adjustments that may need to be made 
for linezolid in the NiX-TB trial or other regimens that include 
linezolid. 
There are two clinical trials scheduled to start around the 
end of 2015. The first is called the endTB trial. It is a Phase 
III trial funded by UNITAID and implemented by Partners 
in Health and Médecins Sans Frontières. It will evaluate 
five new all-oral short regimens for the treatment of MDR-
TB. These regimens contain one new anti-TB drug (either 
bedaquiline or delamanid), moxifloxacin or levofloxacin, 
and pyrazinamide plus linezolid or clofazimine or both, in 
various combinations. They will be compared with the cur-
rent WHO standard of care. Potential sites include Georgia, 
Kazakhstan, Kyrgyzstan, Lesotho and Peru. The second is the 
TB-PRACTECAL trial. This is a randomized, controlled, open-
label, Phase II/III adaptive trial that will evaluate the safety 
and ef ficacy of six-month regimens that contain bedaqui-
line, pretomanid and linezolid with or without moxifloxacin 
or clofazimine for the treatment of adults with MDR-TB or 
XDR-TB. The trial is funded by Médecins Sans Frontières and 
will be conducted in Uzbekistan and Swaziland.
In addition to trials, two recent observational studies 
investigating the ef fectiveness of shorter treatment regi-
mens for patients with MDR-TB in Niger3 and Cameroon4 
have shown that a 12-month treatment regimen was ef fec-
tive and well-tolerated in patients not previously exposed to 
second-line drugs. 
8.2.3 Treatment of latent TB infection (LTBI)
Since the publication of WHO guidelines on the treatment 
of LTBI in 2015,5 new evidence about the benefits of isonia-
zid preventive therapy (IPT) when provided in addition to 
antiretroviral therapy (ART) to HIV-positive people with very 
high CD4 counts has become available from the TEMPRANO 
ANRS 12136 trial.6 This trial included 2056 patients in Côte 
3 Piubello A, Harouna SH, Souleymane MB et al. High Cure Rate with 
Standardised Short-Course Multidrug-Resistant Tuberculosis 
Treatment in Niger: No Relapses. Int J Tuberc Lung Dis 2015;18:1188–94.
4 Kuaban C, Noeske J, Rieder HL et al. High Ef fectiveness of a 12-Month 
Regimen for MDR-TB Patients in Cameroon. The International Journal 
of Tuberculosis and Lung Disease. Int J Tuberc Lung Dis 2015;19: 517–24.
5 World Health Organization. Guidelines on the management of latent 
tuberculosis infection. Geneva: World Health Organization; 2015. 
Available at: http://www.who.int/tb/publications/ltbi_document_page/
en/
6 The TEMPRANO ANRS 12136 Study Group. A Trial of Early Antiretrovirals 
and Isoniazid Preventive Therapy in Africa. N Engl J Med 2015; 
373:808–822.
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d’Ivoire and found that IPT and ART provided together had a 
higher ef ficacy in preventing TB disease than ART alone. The 
study also found lower rates of severe illness when ART was 
started immediately alongside 6 months of IPT, compared 
with deferred ART and no IPT. This was true overall and 
among patients with CD4 counts of ≥500 cells/mm3. Study 
authors also highlighted that isoniazid can be prescribed 
safely when given early in the course of HIV disease. 
8.3  New vaccines to prevent TB
The slow decline in TB incidence globally (Chapter 2) and the 
persistent threat of MDR-TB both highlight the critical need 
for new ef fective TB vaccines. It is estimated that at least 
US$ 8 billion is required each year for TB diagnosis and treat-
ment using currently available interventions (Chapter 7). 
A recent modelling study showed that developing at least 
one new TB vaccine over the next 10–15 years would cost 
about US$ 0.8–1 billion, approximately 1% of diagnosis and 
treatment costs, and that an adolescent and adult vaccine 
with 60% ef ficacy delivered to 20% of the population-at-
risk could avert as many as 30–50 million new cases of TB by 
2050.1 Recent modelling also indicates that targeting ado-
lescents will prevent morbidity and mortality in infants and 
young children, and is a more ef fective strategy to protect 
1 Aeras, TB Vaccine Research and Development: A Business Case for Investment. 
Rockville: Aeras; 2014. Available at: http://bit.ly/1EodJBj
them from TB than direct vaccination of infants with a similar 
vaccine.2
The potential for an adult/adolescent vaccine to have a 
meaningful impact on the global TB epidemic, compared 
with the limited impact of an infant vaccine, has shif ted the 
focus of TB vaccine development. The new paradigm empha-
sises the development of a diverse pipeline of new TB vaccine 
candidates that target the prevention of active TB in these 
older age groups. 
Scientific advances have also enabled the pursuit of more 
sophisticated approaches to vaccine design. The global 
pipeline of TB vaccine candidates in clinical trials is more 
robust than at any previous period in history, now includ-
ing recombinant BCGs, attenuated M. tuberculosis strains, 
recombinant viral-vectored platforms, protein/adjuvant 
combinations, and mycobacterial extracts.
The status of the pipeline for new vaccines in August 2015 
is shown in Figure 8.4. These vaccines aim either to prevent 
infection (pre-exposure) or to prevent primary progression 
to disease or reactivation of latent TB (post-exposure). Fur-
ther details are provided below.
2 White, R. Indirect ef fects in infants on the force of TB disease from vaccinating 
adolescents and adults. London: TB Modelling Group, TB Centre, Centre 
for the Mathematical Modelling of Infectious Diseases; 2015.
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The development pipeline for new TB vaccines, August 2015
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8.3.1 Phase II and Phase III clinical trials
There are currently eight vaccines in Phase II or Phase III tri-
als. 
M72/AS01E (made by GlaxoSmithKline (GSK)) is a recom-
binant fusion protein of the M. tuberculosis antigens 32A and 
39A with the  AS01E  adjuvant. A large  randomized place-
bo-controlled  Phase IIb trial  (NCT01755598, conducted by 
GSK and Aeras) is enrolling pulmonary TB-negative, IGRA-
positive, HIV-negative adults in Kenya, South Africa and 
Zambia. The aim is to enroll 3506 adults; by July 2015, 2096 
participants had been enrolled. The primary endpoint will 
be the protective ef ficacy of two doses of M72/AS01E against 
pulmonary TB disease. Secondary endpoints include safety 
and immunogenicity. 
Three vaccines are protein subunits with adjuvants, initially 
developed by the Statens Serum Institute (SSI) in Copenha-
gen, Denmark. These are:
"" H1:IC31® is an adjuvanted subunit vaccine combining the 
M. tuberculosis antigens Ag85B and ESAT-6 with Valneva’s 
IC31 adjuvant. The H1:IC31® vaccine was the first TB vaccine 
to commence clinical development by SSI, and Aeras sub-
sequently joined this ef fort. The H1:IC31® vaccine has been 
evaluated in three Phase I trials, which showed the vac-
cine to be safe and immunogenic in HIV-negative adults 
who were either M. tuberculosis naïve, BCG vaccinated or 
latently infected, in low- and high TB burden settings. A 
Phase II double-blind and placebo controlled trial in HIV-
positive individuals with or without LTBI confirmed that 
the vaccine was safe and immunogenic.1 Recently, a large 
Phase II trial investigating the influence of dose, sched-
ule and LTBI status on the immunogenicity of H1:IC31® in 
240 adolescents in South Africa was finalized; H1:IC31® 
was the first TB vaccine to be tested in a large trial in this 
important target population. A paper in which results will 
be published is in preparation. In parallel, the H1:IC31® 
subunit vaccine construct has been improved with the 
addition of a third antigen, Rv2660c, becoming H56:IC31®. 
Clinical data on H1:IC31® will support the further develop-
ment of H56:IC31®. No further clinical trials with H1:IC31® 
are planned.
"" H4:IC31 is being developed as a booster vaccine to BCG 
with Sanofi Pasteur. The vaccine candidate contains a 
fusion protein of Ag85B and TB10.4 formulated with IC31 
adjuvant. H4:IC31 is currently being evaluated in Phase 
II studies in African infants with Sanofi and SSI (and also 
with the International Maternal Pediatric Adolescent AIDS 
Clinical Trials Group (IMPAACT) network and the HIV Vac-
cine Trials Network (HVTN) in conjunction with NIAID). 
In addition, the H4:IC31 candidate is being assessed in a 
1 Reither K, Katsoulis L, Beattie T et al. Safety and Immunogenicity of H1/
IC31®, an Adjuvanted TB Subunit Vaccine, in HIV-Infected Adults with 
CD4+ Lymphocyte Counts Greater than 350 cells/mm3: A Phase II, 
Multi-Centre, Double-Blind, Randomized, Placebo-Controlled Trial. 
PLoS ONE. 2014;9(12):e114602.
Phase II proof-of-concept study for its ability to prevent de 
novo infection with M. tuberculosis among IGRA-negative, 
HIV-uninfected South African adolescents at high risk of 
acquiring M. tuberculosis infection. An intensive immuno-
genicity study of H4:IC31 in South African adolescents is 
underway. 
"" H56:IC31. This is an adjuvanted subunit vaccine that 
combines three M. tuberculosis antigens (Ag85B, ESAT-6, 
and Rv2660c) with Valneva’s IC31 adjuvant. It is being 
developed by SSI and Aeras. A Phase I study to evaluate 
the safety and immunogenicity profile of H56:IC31 in HIV-
negative adults with and without LTBI and no history or 
evidence of TB disease has been completed. Two Phase I 
studies are currently ongoing to determine the safety and 
immunogenicity profile of H56:IC31 in HIV-negative, BCG-
vaccinated adults with and without LTBI and in patients 
who have recently been treated for pulmonary TB disease, 
respectively. A study to determine the ef ficacy of H56:IC31 
in preventing TB infection in LTBI negative adolescents is 
planned for 2016. 
VPM 1002, originally developed at the Max Planck Institute 
of Infection Biology with further development by Vakzine 
Projekt Management, the Tuberculosis Vaccine Initiative 
(TBVI), and Serum Institute of India, is a live recombinant 
vaccine. It has been derived from the Prague strain of BCG 
into which the listerolysin gene from Listeria monocytogenes 
has been cloned, and the urease gene deleted, to potentially 
improve immunogenicity. A Phase IIa trial of this vaccine 
has been completed in South Africa. The Phase II trial (in 
planning) will assess the safety and immunogenicity of the 
vaccine in HIV exposed and unexposed newborns. 
RUTI®  is a non-live and polyantigenic vaccine based on 
fragmented and detoxified M. tuberculosis bacteria. The 
product is a liposome suspension of the Drug Substance with 
a charge excipient. RUTI® is being developed by Archivel 
Farma as an immunotherapeutic vaccine. A Phase II trial in 
South Africa was completed recently and other clinical trials 
are in the planning stages. 
MTBVAC is being developed by the University of Zaragosa, 
Institut Pasteur, BIOFABRI and TBVI. It is a live M. tuberculosis 
strain attenuated via deletions of the phoP and fadD26 genes. 
It is the first live attenuated M. tuberculosis vaccine to enter 
a Phase I trial, which was recently completed. The next trial 
will be a Phase I/II trial among adults in South Africa. The vac-
cine is being developed both as a BCG replacement vaccine 
and as a potential boost vaccine in adolescents and adults. 
M. Vaccae™ is a specified lysate developed by the pharma-
ceutical company Anhui Zhifei Longcom Biologic Pharmacy 
Co., Ltd. and licensed by the China Food and Drug Adminis-
tration as an immunotherapeutic agent to help shorten TB 
treatment for patients with drug-susceptible TB.  It is in a 
Phase III trial to assess its ef ficacy and safety in preventing 
TB disease in people with LTBI. The trial is being conducted 
in collaboration with the Guangxi Center for Disease Con-
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trol and Prevention in China. It is the largest TB vaccine trial 
undertaken in the last decade, including 10 000 people aged 
15–65 with a PPD>15mm. The trial is scheduled to be com-
pleted by April 2016. 
Of note, MVA85A, the attenuated vaccinia virus-vec-
tored vaccine candidate expressing Ag85A of M. tuberculosis 
designed at Oxford University as a booster vaccine for BCG 
vaccinated infants, has now completed a Phase II safety and 
immunogenicity study.1 The study was conducted in 650 
BCG-vaccinated, HIV-positive participants in Senegal and 
South Africa. As in the infant study2, the vaccine was well 
tolerated and immunogenic, but no ef ficacy against M. tuber-
culosis infection or disease was demonstrated (although the 
study was not powered to detect an ef fect against disease). 
Current and future clinical approaches focus on evaluating 
MVA85A delivered by aerosol, alone or in a prime-boost com-
bination with a second virally vectored vaccine, ChAdOx1.85A 
(see below).
8.3.2 Phase I clinical trials
There are seven vaccines in Phase I clinical trials. 
ID93 + GLA-SE, developed by the Infectious Disease 
Research Institute (IDRI) in collaboration with Aeras, com-
prises  three M. tuberculosis immunodominant antigens 
(Rv2608, Rv3619 and Rv3620), one M. tuberculosis latency-
associated antigen (Rv1813), and the adjuvant GLA-SE. A 
Phase I trial in 60 adults in the United States to assess safety 
and immunogenicity was recently completed.  The vaccine 
was found to have an acceptable safety profile, and T cell 
responses were seen at all of the dose levels that were stud-
ied. A further Phase I trial in South Africa is being conducted 
to describe the safety and immunogenicity profile of ID93 + 
GLA-SE in BCG-vaccinated, QuantiFERON TB-Gold negative 
and positive healthy adults. A Phase IIa trial in South Africa, 
with the support of the Wellcome Trust, is evaluating safety 
and immunogenicity in patients that have recently complet-
ing treatment for pulmonary TB disease.  A  Phase IIb  trial 
to assess whether the vaccine can prevent recurrence of TB 
disease in patients who have recently and successfully com-
pleted TB treatment is being planned by IDRI  and South 
African collaborators in the same population.
Ad5 Ag85A is an adenovirus serotype 5 vector expressing 
Ag85A. It has been developed by McMaster University with 
support from CanSino, a Chinese biotechnology company. 
Ad5Ag85A was evaluated in 24 healthy human volunteers 
(both BCG-naïve and previously BCG-immunized) for safety 
and immunogenicity following a single intra-muscular 
injection in a Phase I clinical study completed at McMaster 
1 Ndiaye BP, Thienemann F, Ota M, et al. Safety, immunogenicity, and 
ef ficacy of the candidate tuberculosis vaccine MVA85A in healthy 
adults infected with HIV-1: a randomised, placebo-controlled, phase 2 
trial. Lancet Respir Med 2015;3:190–200.
2 Tameris MD, Hatherill M, Landry BS, et al. Safety and ef ficacy of 
MVA85A, a new tuberculosis vaccine, in infants previously vaccinated 
with BCG: a randomised placebo-controlled phase 2b trial. Lancet 
2013;381:1021–28
University, Canada. Immunization of Ad5Ag85A was safe and 
well-tolerated in both trial volunteer groups, with only reac-
tions at the injection site. Pre-existing Ad5 antibodies did 
not appear to af fect the immune response. Ad5Ag85A was 
immunogenic in both groups and stimulated polyfunctional 
T cell responses, but it more potently boosted both CD4+ and 
CD8+ T cell immunity in previously BCG-vaccinated volun-
teers compared with BCG-naïve individuals.
DAR 901 is a heat-inactivated M. obuense. It has been 
developed by investigators at Dartmouth University, USA, 
and manufactured by Aeras. Enrolment in a Phase I safety 
and immunogenicity study in 60 BCG-vaccinated, HIV-infect-
ed and -uninfected individuals was recently completed in the 
USA. The study remains blinded while subjects continue to 
be followed. No serious adverse events have been reported 
and plans are underway to complete in-depth immunologic 
evaluations by the end of 2015, using data for the first people 
enrolled in the trial. 
TB/FLU-04L is a recombinant influenza vectored vaccine 
candidate developed by the Research Institute for Biological 
Safety Problems and the Research Institute on Influenza in 
the Russian Federation, with support and assistance from 
international experts. The influenza virus strain A/Puerto 
Rico/8/34 (H1N1) was used as a parent strain for construc-
tion of an attenuated replication-deficient vector expressing 
M. tuberculosis antigens Ag85A and ESAT-6. It was designed 
as a mucosal “boost” vaccine for infants, adolescents and 
adults. A Phase I trial in BCG-vaccinated QuantiFERON TB-
Gold negative healthy adult volunteers using intranasal 
administration was recently completed, and a Phase IIa trial 
is planned.
ChAdOx1.85A is a simian adenovirus expressing anti-
gen 85A that was developed at the University of Oxford. 
ChAdOX1.85A is being evaluated in a Phase I trial in BCG-
vaccinated adults, both alone and as part of a prime-boost 
strategy with MVA85A. In this first-in-humans study, 
ChAdOx1.85A is being administered intramuscularly. Future 
plans include evaluation of the aerosol route of delivery of 
ChAdOx1.85A.
Crucell Ad35/AERAS-402 and MVA85A are now being 
tested in combination, to try and induce both CD4+ and CD8+ 
T cells. One or two doses of Crucell Ad35 followed by a dose 
of MVA85A is being compared with 3 doses of Crucell Ad35 in 
a Phase I/II trial in adults in the United Kingdom. The trial is 
being implemented by Oxford University, Aeras and Crucell.
MVA85A (Aerosol) is an aerosolized MVA85A candidate 
developed by Oxford that recently underwent a Phase I 
double-blind trial to compare the safety and immunogenic-
ity of aerosol-administered and intradermally administered 
MVA85A in 24 BCG-vaccinated adults in the United Kingdom. 
The study concluded that aerosol vaccination with MVA85A 
appeared to be a safe and feasible vaccination that produced 
stronger CD4+ T-cell response than intradermal MVA85A. 
Further studies assessing the aerosol route are necessary. 
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8.3.3 Early stage, translational research
As documented above, there is a reasonably robust pipeline 
of vaccine candidates, including those based on whole cell 
approaches, antibody-inducing vaccines and nucleic acid-
based (DNA and RNA) vaccines. This may help to diversify 
the clinical portfolio and fill the scientific gaps that currently 
exist. 
To supplement existing ef forts, there is also a re-pri-
oritized focus on early stage, translational research. This 
will test hypotheses about immunological mechanisms, 
delivery methods, and candidate biomarkers, and help to 
broaden preclinical scientific approaches, antigen selection 
strategies, and evaluation strategies, with the overall goal 
of ensuring that a more diverse pipeline of new TB vaccine 
candidates can move forward into clinical trials.1 Discussions 
about relevant clinical endpoints, beyond immunological 
measures that indicate prevention of disease or infection, 
and how these endpoints may be assessed through biomark-
ers early in clinical trials or pre-clinically to select the most 
promising candidate vaccines/adjuvants, are also underway.
8.4 The End TB Strategy: the critical role of 
research and development 
The End TB Strategy includes “Intensified Research and Inno-
vation” as one of three fundamental pillars (Chapter 1). This 
has two essential and complementary components: 
(1) Discovery, development and rapid uptake of new tools, 
interventions and strategies; and 
(2) Research to optimize implementation and impact.
The overall aim of the pillar is that intensified research will 
result in revolutionary new technologies, strategies and 
models of service delivery that will transform the way in 
which TB is diagnosed, treated and prevented. As high
1 Brennan MJ and Thole J, Eds. Tuberculosis vaccines: A strategic 
blueprint for the next decade. Tuberculosis. 2012; 92: Supplement 1; 
S6–S13.
lighted at the beginning of this chapter, such changes are 
necessary by 2025, so that the rate at which TB incidence 
falls can be accelerated beyond the best-ever historic perfor-
mance and targets that correspond to ending the global TB 
epidemic by 2035 can be achieved.
A massive increase in funding for research is required. 
This includes funding to create or expand research-enabling 
environments for the next generation of scientists in low and 
middle-income countries with the largest burden of TB, so 
that they can play a lead role in research based on domes-
tic investments, alongside established global expertise. 
Increased domestic investments in research in countries 
with a high burden of TB will be facilitated by advocacy from 
key players including national public health authorities, 
researchers, care providers, and civil society. It is also impor-
tant that high-income countries and their institutions, 
international agencies and philanthropic organizations 
increase their investments in TB research and training, in 
close collaboration with high-burden countries.
Once new technologies and innovative approaches are 
developed, they need to be translated into policies and prac-
tices, and then adapted to particular country contexts as 
appropriate. This will require expanded ef forts to dissemi-
nate research results, particularly to policy makers. 
To foster and intensify high-quality research at national 
and international levels, WHO has developed a Global Action 
Framework for Research towards TB Elimination that covers the 
period 2016–2025. This plan shows how to operationalize 
Pillar 3 of the End TB Strategy, including through the devel-
opment of country-specific TB research strategic plans, 
capacity strengthening, and development/reinforcement 
of networks at country level, and through regular meetings 
and the development of international networks for research, 
capacity building and advocacy at global and regional levels. 

Access to  







118  n  GLOBAL TUBERCULOSIS REPORT 2015
GLOBAL TUBERCULOSIS REPORT 2015  n  119
A.1 Database contents
The 2015 global TB report is based on data collected annually from countries and territories, including 194 Member States. 
These data are stored in the global TB database. 
In 2015, data were collected on the following topics: TB case notifications and treatment outcomes, including breakdowns 
by TB case type, age, sex and HIV status; laboratory diagnostic services; monitoring and evaluation, including surveillance 
and surveys specifically related to drug-resistant TB; management of drug-resistant TB; collaborative TB/HIV activities; TB 
infection control; engagement of all public and private care providers in TB control; community engagement; the budgets of 
national TB control programmes (NTPs) in 2015; utilization of general health services (hospitalization and outpatient visits) 
during treatment in 2015; and NTP expenditures in 2014. A shortened version of the online questionnaire was used for high-
income countries (that is, countries with a gross national income per capita of ≥ US$ 12 736 in 2014, as defined by the World 
Bank)1 and/or low-incidence countries (defined as countries with an incidence rate of <20 cases per 100 000 population or <10 
cases in total). 
Countries reported data using a dedicated website (https://extranet.who.int/tme), which was opened for reporting in mid-
March. Countries in the European Union submitted notification and treatment outcomes data to the TESSy system managed 
by the European Centre for Disease Prevention and Control (ECDC). Data from TESSy were uploaded into the global TB data-
base. 
Additional data about the provision of isoniazid preventive therapy (IPT) to people living with HIV and antiretroviral therapy 
(ART) for HIV-positive TB patients were collected by the Joint United Nations Programme on HIV/AIDS (UNAIDS) and the HIV 
department in WHO. These data were jointly validated by UNAIDS and the WHO’s Global TB Programme and HIV department, 
and uploaded into the global TB database.
Following review and follow-up with countries, the data used for the main part of this report were those data available 
on 6 August 2015. The number of countries and territories that had reported data by 6 August 2015 is shown in Table A1.1.
n TABLE A1.1
Reporting of data in the 2015 round of global TB data collection
WHO REGION OR SET OF COUNTRIES
COUNTRIES AND TERRITORIES WHO MEMBER STATES
NUMBER NUMBER THAT REPORTED  DATA NUMBER NUMBER THAT REPORTED DATA
African Region 47 47 47 47
Eastern Mediterranean Region 22 21 21 20
European Regiona 54 46 53 46
Region of the Americas 46 45 35 34
South-East Asia Region 11 11 11 11
Western Pacific Region 36 35 27 27
High-burden countries 22 22 22 22
World 216 205 194 185
a Countries that did not report by the deadline were mostly low-incidence countries in Western Europe. 
1  http://data.worldbank.org/about/country-classifications
A.2 Accessing TB data using the WHO Global TB Programme website 
You can find most of the data held in the global TB database by going to www.who.int/tb/data. This web page gives you access 
to country profiles, comma-separated value (CSV) data files and data visualisations. 
A2.1 Country profiles
Profiles can be viewed and downloaded for all 216 countries and territories that report TB data to WHO each year, and not just 
the 22 high burden countries shown in the printed version of the global TB report. The profiles can be generated on-demand 
directly from the global TB database and therefore may include updates received af ter publication of the global TB report.
TB financial profiles can be viewed and downloaded for over 100 countries and territories that report detailed TB financial 
data to WHO.
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A2.2 CSV data files
These files are the primary resource for anyone interested in conducting their own analyses of the records in the global TB 
database. Data reported by countries, such as time series for case notifications and treatment outcomes and WHO’s estimates 
of TB disease burden, can be downloaded as comma-separated value (CSV) files covering all years for which data are available. 
These CSV files can be imported into many spreadsheet, statistical analysis and database packages.
A data dictionary that defines each of the variables available in the CSV files is also available and can be downloaded.
The CSV files are generated on-demand directly from the global TB database, and therefore may include updates received 
af ter publication of the global TB report.
A2.3 Data visualisations
There are several interactive web pages that can be used to view maps, graphs and underlying data on TB case notifications, 
drug-resistant TB cases and treatment outcomes, laboratory capacity and WHO estimates of TB incidence, prevalence and 
mortality (Figure A1.1).
A.3 Accessing TB data using the WHO Global Health Observatory
The WHO Global Health Observatory (GHO) at www.who.int/gho/ is WHO’s portal, providing access to data and analyses for 
monitoring the global health situation. It includes a data repository.
Key data from WHO’s global TB database can be viewed, filtered, aggregated and downloaded from within the GHO Data 
Repository at http://apps.who.int/gho/data/node.main.1315  
The GHO data table headers include links to variable and indicator definitions. The data can be downloaded in many for-
mats, including as CSV and Excel files (Figure A1.2).
There is also an Application Programme Interface (API) for analysts and programmers to use GHO data directly in their sof t-
ware applications. See http://apps.who.int/gho/data/node.resources 
n FIGURE A1.1
Interactive page to view MDR-TB indicators by region or country and year
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n FIGURE A1.2
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Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in 
consultation with countries.
a Ranges represent uncertainty intervals.
b Includes cases with unknown previous TB treatment history.
c Includes patients diagnosed before 2014 and patients who were not laboratory-confirmed  
 as having RR-/MDR-TB.
Afghanistan  Population 2014 32 million
Estimates of TB burdena 2014
 NUMBER (thousands) RATE (per 100 000 population)
Mortality (excludes HIV+TB) 14 (10–18) 44 (32–57)
Mortality (HIV+TB only) 0.087 (0.072–0.1) 0.28 (0.23–0.33)
Prevalence  (includes HIV+TB) 110 (56–180) 340 (178–555)
Incidence  (includes HIV+TB) 60 (53–67) 189 (167–212)
Incidence (HIV+TB only) 0.32 (0.25–0.4) 1 (0.8–1.3)
Case detection, all forms (%) 53 (47–60)  
Estimates of MDR-TB burdena 2014
 NEW RETREATMENT
% of TB cases with MDR-TB 3.2 (2.3–4.1) 17 (11–23)
MDR-TB cases among notified  
pulmonary TB cases 750 (540–960) 360 (240–490)
TB case notifications 2014
 NEWb RELAPSE
Pulmonary, bacteriologically confirmed 14 737 1 209
Pulmonary, clinically diagnosed 8 573  
Extrapulmonary 7 227  
Total new and relapse 31 746  
Previously treated, excluding relapses 966  
Total cases notified 32 712  
Among 30 537 new cases:
4 454 (15%) cases aged under 15 years; male:female ratio: 0.7
Reported cases of RR-/MDR-TB 2014 
 NEW RETREATMENT TOTALb
Cases tested for RR-/MDR-TB 2 (<1%) 184 (8%) 186
Laboratory-confirmed RR-/MDR-TB cases   88
Patients started on MDR-TB treatmentc   88
TB/HIV 2014
 NUMBER (%)
TB patients with known HIV status 10 443 (32)
HIV-positive TB patients 4 (<1)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT)  
HIV-positive TB patients on antiretroviral therapy (ART)  
HIV-positive people screened for TB 142 
HIV-positive people provided with IPT 7 
Treatment success rate and cohort size
 (%) COHORT
New and relapse cases registered in 2013 (88) 30 507
Previously treated cases, excluding relapse, registered in 2013 (74) 1 115
HIV-positive TB cases, all types, registered in 2013  
RR-/MDR-TB cases started on second-line treatment in 2012 (71) 38
XDR-TB cases started on second-line treatment in 2012  0
Laboratories 2014 
Smear (per 100 000 population) 2.3
Culture (per 5 million population) 0.5
Drug susceptibility testing (per 5 million population) 0
Sites performing Xpert MTB/RIF 1
Is second-line drug susceptibility testing available? Yes, outside country
Financing TB control 2015 
National TB programme budget (US$ millions) 15
% Funded domestically 6%
% Funded internationally 67%
% Unfunded 27%
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Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in 
consultation with countries.
a Ranges represent uncertainty intervals. A joint reassessment of estimates of TB disease  
 burden will be undertaken following completion of the national TB prevalence survey.
b Includes cases with unknown previous TB treatment history.
c Includes patients diagnosed before 2014 and patients who were not laboratory-confirmed  
 as having RR-/MDR-TB.
Bangladesh  Population 2014 159 million
Estimates of TB burdena 2014
 NUMBER (thousands) RATE (per 100 000 population)
Mortality (excludes HIV+TB) 81 (59–110) 51 (37–68)
Mortality (HIV+TB only) 0.18 (0.14–0.22) 0.11 (0.09–0.14)
Prevalence  (includes HIV+TB) 640 (340–1 000) 404 (211–659)
Incidence  (includes HIV+TB) 360 (320–410) 227 (200–256)
Incidence (HIV+TB only) 0.57 (0.45–0.71) 0.36 (0.28–0.45)
Case detection, all forms (%) 53 (47–60)  
Estimates of MDR-TB burdena 2014
 NEW RETREATMENT
% of TB cases with MDR-TB 1.4 (0.7–2.5) 29 (24–34)
MDR-TB cases among  
notified pulmonary TB cases 2 100 (1 000–3 700) 2 700 (2 200–3 200)
TB case notifications 2014
 NEWb RELAPSE
Pulmonary, bacteriologically confirmed 106 767 2 989
Pulmonary, clinically diagnosed 42 832  863
Extrapulmonary 37 406 309
    
Total new and relapse 191 166  
Previously treated, excluding relapses 5 631  
Total cases notified 196 797  
Among 187 005 new cases:
6 262 (3%) cases aged under 15 years; male:female ratio: 1.5 
Reported cases of RR-/MDR-TB 2014 
 NEW RETREATMENT TOTALb
Cases tested for RR-/MDR-TB 12 573 (12%) 4 959 (51%) 43 360
Laboratory-confirmed RR-/MDR-TB cases   994
Patients started on MDR-TB treatmentc   945
TB/HIV 2014
 NUMBER (%)
TB patients with known HIV status 1 110 (<1)
HIV-positive TB patients 45 (4)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT) 45 (100)
HIV-positive TB patients on antiretroviral therapy (ART) 45 (100)
HIV-positive people screened for TB 726 
HIV-positive people provided with IPT 0 
Treatment success rate and cohort size
 (%) COHORT
New and relapse cases registered in 2013 (93) 184 077
Previously treated cases, excluding relapse, registered in 2013 (86) 6 327
HIV-positive TB cases, all types, registered in 2013 (75) 68
RR-/MDR-TB cases started on second-line treatment in 2012 (72) 505
XDR-TB cases started on second-line treatment in 2012 (25) 4
Laboratories 2014 
Smear (per 100 000 population) 0.7
Culture (per 5 million population) <0.1
Drug susceptibility testing (per 5 million population) <0.1
Sites performing Xpert MTB/RIF 38
Is second-line drug susceptibility testing available? Yes, in and outside country
Financing TB control 2015  
National TB programme budget (US$ millions) 48
% Funded domestically <1%
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Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in 
consultation with countries.
a Ranges represent uncertainty intervals.
b Includes cases with unknown previous TB treatment history.
c Includes patients diagnosed before 2014 and patients who were not laboratory-confirmed  
 as having RR-/MDR-TB.
Brazil  Population 2014 206 million
Estimates of TB burdena 2014
 NUMBER (thousands) RATE (per 100 000 population)
Mortality (excludes HIV+TB) 5.3 (4.9–5.7) 2.6 (2.4–2.7)
Mortality (HIV+TB only) 2.4 (1.8–3.2) 1.2 (0.87–1.6)
Prevalence  (includes HIV+TB) 110 (51–180) 52 (25–89)
Incidence  (includes HIV+TB) 90 (86–95) 44 (42–46)
Incidence (HIV+TB only) 16 (14–17) 7.6 (6.9–8.4)
Case detection, all forms (%) 82 (78–86)    
Estimates of MDR-TB burdena 2014
 NEW RETREATMENT
% of TB cases with MDR-TB 1.4 (1–1.8) 7.5 (5.7–9.9)
MDR-TB cases among notified  
pulmonary TB cases 820 (590–1 100) 950 (720–1 300)
TB case notifications 2014
 NEWb RELAPSE
Pulmonary, bacteriologically confirmed 41 120  3 602
Pulmonary, clinically diagnosed 17 801  1 488
Extrapulmonary 9 479  480
       
Total new and relapse 73 970    
Previously treated, excluding relapses 7 542    
Total cases notified 81 512    
Among 73 970 new and relapse cases:
2 368 (3%) cases aged under 15 years; male:female ratio: 2.1  
Reported cases of RR-/MDR-TB 2014 
 NEW RETREATMENT TOTALb
Cases tested for RR-/MDR-TB     15 344
Laboratory-confirmed RR-/MDR-TB cases     702
Patients started on MDR-TB treatmentc     702
TB/HIV 2014
 NUMBER (%)
TB patients with known HIV status 56 981 (70)
HIV-positive TB patients 9 578 (17)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT)    
HIV-positive TB patients on antiretroviral therapy (ART)    
HIV-positive people screened for TB 37 540  
HIV-positive people provided with IPT    
Treatment success rate and cohort size
 (%) COHORT
New and relapse cases registered in 2013 (72) 76 543
Previously treated cases, excluding relapse, registered in 2013 (38) 6 945
HIV-positive TB cases, all types, registered in 2013 (46) 9 460
RR-/MDR-TB cases started on second-line treatment in 2012 (51) 825
XDR-TB cases started on second-line treatment in 2012 (25) 24
Laboratories 2014  
Smear (per 100 000 population) 1.6
Culture (per 5 million population) 7.9
Drug susceptibility testing (per 5 million population) 0.6
Sites performing Xpert MTB/RIF 48
Is second-line drug susceptibility testing available? Yes, in country
Financing TB control 2015  
National TB programme budget (US$ millions) 77
% Funded domestically 72%
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Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in 
consultation with countries.
a Ranges represent uncertainty intervals.
b Includes cases with unknown previous TB treatment history.
c Includes patients diagnosed before 2014 and patients who were not laboratory-confirmed  
 as having RR-/MDR-TB.
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Cambodia  Population 2014 15 million
Estimates of TB burdena 2014
 NUMBER (thousands) RATE (per 100 000 population)
Mortality (excludes HIV+TB) 8.9 (6.3–12) 58 (41–78)
Mortality (HIV+TB only) 0.82 (0.63–1) 5.3 (4.1–6.7)
Prevalence  (includes HIV+TB) 100 (87–120) 668 (565–780)
Incidence  (includes HIV+TB) 60 (54–66) 390 (353–428)
Incidence (HIV+TB only) 1.8 (1.6–2) 12 (10–13)
Case detection, all forms (%) 72 (66–80)  
Estimates of MDR-TB burdena 2014
 NEW RETREATMENT
% of TB cases with MDR-TB 1.4 (0.7–2.5) 11 (4–22)
MDR-TB cases among notified  
pulmonary TB cases 330 (160–590) 200 (73–400)
TB case notifications 2014
 NEWb RELAPSE
Pulmonary, bacteriologically confirmed 12 168  445
Pulmonary, clinically diagnosed 11 286  709
Extrapulmonary 18 310  141
       
Total new and relapse 43 059    
Previously treated, excluding relapses 679    
Total cases notified 43 738    
Among 43 059 new and relapse cases:
12 050 (28%) cases aged under 15 years; male:female ratio: 1.2  
Reported cases of RR-/MDR-TB 2014 
 NEW RETREATMENT TOTALb
Cases tested for RR-/MDR-TB 646 (5%) 1 329 (67%) 1 975
Laboratory-confirmed RR-/MDR-TB cases     110
Patients started on MDR-TB treatmentc     110
TB/HIV 2014
 NUMBER (%)
TB patients with known HIV status 35 635 (81)
HIV-positive TB patients 953 (3)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT) 938 (98)
HIV-positive TB patients on antiretroviral therapy (ART) 938 (98)
HIV-positive people screened for TB 3 504  
HIV-positive people provided with IPT 901  
Treatment success rate and cohort size
 (%) COHORT
New and relapse cases registered in 2013 (93) 35 536
Previously treated cases, excluding relapse, registered in 2013 (90) 1 701
HIV-positive TB cases, all types, registered in 2013    
RR-/MDR-TB cases started on second-line treatment in 2012 (79) 110
XDR-TB cases started on second-line treatment in 2012    
Laboratories 2014  
Smear (per 100 000 population) 1.4
Culture (per 5 million population) 1.3
Drug susceptibility testing (per 5 million population) 1.0
Sites performing Xpert MTB/RIF 17
Is second-line drug susceptibility testing available? No
Financing TB control 2015  
National TB programme budget (US$ millions) 31
% Funded domestically 12%
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Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in 
consultation with countries.
a Ranges represent uncertainty intervals.
b Includes cases with unknown previous TB treatment history.
c Includes patients diagnosed before 2014 and patients who were not laboratory-confirmed  
 as having RR-/MDR-TB.
China  Population 2014 1 369 million
Estimates of TB burdena 2014
 NUMBER (thousands) RATE (per 100 000 population)
Mortality (excludes HIV+TB) 38 (37–40) 2.8 (2.7–2.9)
Mortality (HIV+TB only) 0.7 (0.53–0.9) 0.05 (0.04–0.07)
Prevalence  (includes HIV+TB) 1 200 (1 100–1 400) 89 (78–102)
Incidence  (includes HIV+TB) 930 (860–1 000) 68 (63–73)
Incidence (HIV+TB only) 13 (11–16) 0.98 (0.79–1.2)   
Case detection, all forms (%) 88 (82–95)    
Estimates of MDR-TB burdena 2014
 NEW RETREATMENT
% of TB cases with MDR-TB 5.7 (4.5–7) 26 (22–30)
MDR-TB cases among notified  
pulmonary TB cases 43 000 (34 000–53 000) 8 200 (6 900–9 500)
TB case notifications 2014
 NEWb RELAPSE
Pulmonary, bacteriologically confirmed 235 704  25 125
Pulmonary, clinically diagnosed 526 106    
Extrapulmonary 32 348    
       
Total new and relapse 819 283    
Previously treated, excluding relapses 6 872    
Total cases notified 826 155    
Among 819 283 new and relapse cases:
4 164 (<1%) cases aged under 15 years; male:female ratio: 2.3  
Reported cases of RR-/MDR-TB 2014 
 NEW RETREATMENT TOTALb
Cases tested for RR-/MDR-TB 45 664 (19%) 17 210 (54%) 62 874
Laboratory-confirmed RR-/MDR-TB cases     5 807
Patients started on MDR-TB treatmentc     2 846
TB/HIV 2014
 NUMBER (%)
TB patients with known HIV status 343 515 (42)
HIV-positive TB patients 5 309 (2)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT)    
HIV-positive TB patients on antiretroviral therapy (ART) 3 675 (69)
HIV-positive people screened for TB 423 254  
HIV-positive people provided with IPT    
Treatment success rate and cohort size
 (%) COHORT
New and relapse cases registered in 2013 (95) 841 999
Previously treated cases, excluding relapse, registered in 2013 (90) 7 847
HIV-positive TB cases, all types, registered in 2013 (82) 4 649
RR-/MDR-TB cases started on second-line treatment in 2012 (42) 1 906
XDR-TB cases started on second-line treatment in 2012 (13) 115
Laboratories 2014  
Smear (per 100 000 population) 0.2
Culture (per 5 million population) 6.7
Drug susceptibility testing (per 5 million population) 1.5
Sites performing Xpert MTB/RIF 654
Is second-line drug susceptibility testing available? Yes, in country
Financing TB control 2015  
National TB programme budget (US$ millions) 340
% Funded domestically 90%
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Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in 
consultation with countries.
a Ranges represent uncertainty intervals.
b Includes cases with unknown previous TB treatment history.
c Includes patients diagnosed before 2014 and patients who were not laboratory-confirmed  
 as having RR-/MDR-TB.
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Democratic Republic of the Congo  Population 2014 75 million
Estimates of TB burdena 2014
 NUMBER (thousands) RATE (per 100 000 population)
Mortality (excludes HIV+TB) 52 (38–68) 69 (50–90)
Mortality (HIV+TB only) 6.3 (5–7.7) 8.4 (6.7–10)
Prevalence  (includes HIV+TB) 400 (210–640) 532 (282–859)
Incidence  (includes HIV+TB) 240 (220–270) 325 (295–356)
Incidence (HIV+TB only) 34 (27–42) 45 (36–56)
Case detection, all forms (%) 48 (43–52)    
Estimates of MDR-TB burdena 2014
 NEW RETREATMENT
% of TB cases with MDR-TB 2.2 (0.3–4.1) 11 (6.2–16)
MDR-TB cases among notified  
pulmonary TB cases 2 000 (270–3 700) 790 (450–1 100)
TB case notifications 2014
 NEWb RELAPSE
Pulmonary, bacteriologically confirmed 75 631 4 298
Pulmonary, clinically diagnosed 13 494  1 892
Extrapulmonary 19 566 914
       
Total new and relapse 115 795    
Previously treated, excluding relapses 1 099    
Total cases notified 116 894    
Among 75 631 new cases:
3 438 (5%) cases aged under 15 years; male:female ratio: 1.3 
Reported cases of RR-/MDR-TB 2014 
 NEW RETREATMENT TOTALb
Cases tested for RR-/MDR-TB 545 (<1%) 6 135 (75%) 6 817
Laboratory-confirmed RR-/MDR-TB cases     442
Patients started on MDR-TB treatmentc     436
TB/HIV 2014
 NUMBER (%)
TB patients with known HIV status 53 285 (46)
HIV-positive TB patients 7 206 (14)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT) 5 671 (79)
HIV-positive TB patients on antiretroviral therapy (ART) 4 799 (67)
HIV-positive people screened for TB 33 743  
HIV-positive people provided with IPT    
Treatment success rate and cohort size
 (%) COHORT
New cases registered in 2013 (87) 112 439
Previously treated cases registered in 2013 (66) 1 164
HIV-positive TB cases, all types, registered in 2013    
RR-/MDR-TB cases started on second-line treatment in 2012 (64) 134
XDR-TB cases started on second-line treatment in 2012    
Laboratories 2014  
Smear (per 100 000 population) 2.1
Culture (per 5 million population) 0.3
Drug susceptibility testing (per 5 million population) 0.2
Sites performing Xpert MTB/RIF 39
Is second-line drug susceptibility testing available? Yes, in and outside country
Financing TB control 2015  
National TB programme budget (US$ millions) 55
% Funded domestically 5%
% Funded internationally 50%
% Unfunded 44%
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Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in 
consultation with countries.
a Ranges represent uncertainty intervals.
b Includes cases with unknown previous TB treatment history.
c Includes patients diagnosed before 2014 and patients who were not laboratory-confirmed  
 as having RR-/MDR-TB.
d ART and IPT data were missing for 3 of Ethiopia’s  11 regions, which in previous years had  
 accounted for about one third of the national totals. In the 8 regions that reported data,  
 65% of HIV-positive TB patients were on ART.
Ethiopia  Population 2014 97 million
Estimates of TB burdena 2014
 NUMBER (thousands) RATE (per 100 000 population)
Mortality (excludes HIV+TB) 32 (22–43) 33 (23–44)
Mortality (HIV+TB only) 5.5 (4.4–6.8) 5.7 (4.6–7)
Prevalence  (includes HIV+TB) 190 (160–240) 200 (161–243)
Incidence  (includes HIV+TB) 200 (160–240) 207 (168–250)
Incidence (HIV+TB only) 19 (15–23) 19 (15–24)
Case detection, all forms (%) 60 (49–73)    
Estimates of MDR-TB burdena 2014
 NEW RETREATMENT
% of TB cases with MDR-TB 1.6 (0.86–2.8) 12 (5.6–21)
MDR-TB cases among notified  
pulmonary TB cases 1 300 (700–2 300)  
TB case notifications 2014
 NEWb RELAPSE
Pulmonary, bacteriologically confirmed 40 087    
Pulmonary, clinically diagnosed 41 575    
Extrapulmonary 37 930    
       
Total new and relapse 119 592    
Previously treated, excluding relapses      
Total cases notified 119 592    
Among 119 592 new cases:
15 917 (13%) cases aged under 15 years; male:female ratio: 1.2  
Reported cases of RR-/MDR-TB 2014 
 NEW RETREATMENT TOTALb
Cases tested for RR-/MDR-TB 2 405 (6%) 7 682 10 151
Laboratory-confirmed RR-/MDR-TB cases     503
Patients started on MDR-TB treatmentc     557
TB/HIV 2014
 NUMBER (%)
TB patients with known HIV status 89 320 (75)
HIV-positive TB patients 8 670 (10)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT)d    
HIV-positive TB patients on antiretroviral therapy (ART)d 3 396 (39)
HIV-positive people screened for TB 341 534  
HIV-positive people provided with IPT 10 385  
Treatment success rate and cohort size
 (%) COHORT
New cases registered in 2013 (89) 43 86
Previously treated cases registered in 2013    
HIV-positive TB cases, all types, registered in 2013    
RR-/MDR-TB cases started on second-line treatment in 2012 (83) 271
XDR-TB cases started on second-line treatment in 2012    
Laboratories 2014  
Smear (per 100 000 population) 3.1
Culture (per 5 million population) 0.4
Drug susceptibility testing (per 5 million population) 0.4
Sites performing Xpert MTB/RIF 28
Is second-line drug susceptibility testing available? Yes, in country
Financing TB control 2015  
National TB programme budget (US$ millions) 82
% Funded domestically 11%
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Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in 
consultation with countries.
a Ranges represent uncertainty intervals.
b Includes cases with unknown previous TB treatment history.
c Includes patients diagnosed before 2014 and patients who were not laboratory-confirmed  
 as having RR-/MDR-TB.
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India  Population 2014 1 295 million
Estimates of TB burdena 2014
 NUMBER (thousands) RATE (per 100 000 population)
Mortality (excludes HIV+TB) 220 (150–350) 17 (12–27)
Mortality (HIV+TB only) 31 (25–38) 2.4 (2–2.9)
Prevalence  (includes HIV+TB) 2 500 (1 700–3 500) 195 (131–271)
Incidence  (includes HIV+TB) 2 200 (2 000–2 300) 167 (156–179)
Incidence (HIV+TB only) 110 (96–120) 8.3 (7.4–9.3)
Case detection, all forms (%) 74 (70–80)    
Estimates of MDR-TB burdena 2014
 NEW RETREATMENT
% of TB cases with MDR-TB 2.2 (1.9–2.6) 15 (11–19)
MDR-TB cases among notified  
pulmonary TB cases 24 000 (21 000–29 000) 47 000 (35 000–59 000)
TB case notifications 2014
 NEWb RELAPSE
Pulmonary, bacteriologically confirmed 754 268  124 679
Pulmonary, clinically diagnosed 343 032  112 066
Extrapulmonary 275 502    
       
Total new and relapse 1 609 547    
Previously treated, excluding relapses 74 368    
Total cases notified 1 683 915    
Among 1 609 547 new and relapse cases:
95 709 (6%) cases aged under 15 years; male:female ratio: 1.9  
Reported cases of RR-/MDR-TB 2014 
 NEW RETREATMENT TOTALb
Cases tested for RR-/MDR-TB 12 795 (2%) 214 209 (69%) 255 897
Laboratory-confirmed RR-/MDR-TB cases     25 748
Patients started on MDR-TB treatmentc     24 073
TB/HIV 2014
 NUMBER (%)
TB patients with known HIV status 1 034 712 (61)
HIV-positive TB patients 44 171 (4)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT) 41 066 (93)
HIV-positive TB patients on antiretroviral therapy (ART) 39 800 (90)
HIV-positive people screened for TB 1 114 394  
HIV-positive people provided with IPT    
Treatment success rate and cohort size
 (%) COHORT
New and relapse cases registered in 2013 (88) 1 243 905
Previously treated cases, excluding relapse, registered in 2013 (66) 171 712
HIV-positive TB cases, all types, registered in 2013 (76) 44 027
RR-/MDR-TB cases started on second-line treatment in 2012 (46) 9 874
XDR-TB cases started on second-line treatment in 2012 (33) 91
Laboratories 2014  
Smear (per 100 000 population) 1.0
Culture (per 5 million population) 0.3
Drug susceptibility testing (per 5 million population) 0.2
Sites performing Xpert MTB/RIF 121
Is second-line drug susceptibility testing available? Yes, in country
Financing TB control 2015  
National TB programme budget (US$ millions) 261
% Funded domestically 46%
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Data for all years can be downloaded from www.who.int/tb/data  GLOBAL TUBERCULOSIS REPORT 2015  n  133
Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in 
consultation with countries.
a Ranges represent uncertainty intervals.
b The prevalence rate of bacteriologically confirmed TB was 531 (421–655) per 100 000  
 population; the prevalence rate of clinically diagnosed TB (i.e. smear-negative and culture- 
 negative TB, including all extra-pulmonary cases) was 116 (91–143) per 100 000 population;  
 the prevalence rate of extra-pulmonary TB (a subset of those in the clinically diagnosed  
 category) was 58 (43–75) per 100 000 population.
c Includes cases with unknown previous TB treatment history.
d Includes patients diagnosed before 2014 and patients who were not laboratory-confirmed  
 as having RR-/MDR-TB.
Indonesia  Population 2014 254 million
Estimates of TB burdena 2014
 NUMBER (thousands) RATE (per 100 000 population)
Mortality (excludes HIV+TB) 100 (66–150) 41 (26–59)
Mortality (HIV+TB only) 22 (13–32) 8.5 (5.2–13)
Prevalence  (includes HIV+TB)b 1 600 (1 300–2 000) 647 (513–797)
Incidence  (includes HIV+TB) 1 000 (700–1 400) 399 (274–546)
Incidence (HIV+TB only) 63 (41–90) 25 (16–36)
Case detection, all forms (%) 32 (23–46)    
Estimates of MDR-TB burdena 2014
 NEW RETREATMENT
% of TB cases with MDR-TB 1.9 (1.4–2.5) 12 (8.1–17)
MDR-TB cases among notified  
pulmonary TB cases 5 600 (4 200–7 400) 1 100 (770–1 600)
TB case notifications 2014
 NEWc RELAPSE
Pulmonary, bacteriologically confirmed 193 321  6 449
Pulmonary, clinically diagnosed 101 991  1 391
Extrapulmonary 19 653  1
       
Total new and relapse 322 806    
Previously treated, excluding relapses 1 733    
Total cases notified 324 539    
Among 322 806 new and relapse cases:
23 170 (7%) cases aged under 15 years; male:female ratio: 1.4  
Reported cases of RR-/MDR-TB 2014 
 NEW RETREATMENT TOTALb
Cases tested for RR-/MDR-TB 1 058 (<1%) 8 445 (88%) 9 503
Laboratory-confirmed RR-/MDR-TB cases     1 812
Patients started on MDR-TB treatmentd     1 284
TB/HIV 2014
 NUMBER (%)
TB patients with known HIV status 15 074 (5)
HIV-positive TB patients 2 355 (16)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT) 963 (41)
HIV-positive TB patients on antiretroviral therapy (ART) 624 (26)
HIV-positive people screened for TB    
HIV-positive people provided with IPT    
Treatment success rate and cohort size
 (%) COHORT
New and relapse cases registered in 2013 (88) 325 582
Previously treated cases, excluding relapse, registered in 2013 (64) 1 521
HIV-positive TB cases, all types, registered in 2013 (49) 2 438
RR-/MDR-TB cases started on second-line treatment in 2012 (54) 432
XDR-TB cases started on second-line treatment in 2012 (64) 11
Laboratories 2014  
Smear (per 100 000 population) 2.2
Culture (per 5 million population) 0.4
Drug susceptibility testing (per 5 million population) 0.3
Sites performing Xpert MTB/RIF 41
Is second-line drug susceptibility testing available? Yes, in country
Financing TB control 2015  
National TB programme budget (US$ millions) 133
% Funded domestically 13%








































































2011 2012 2013 2014 2015















New                    Retreatment                    New and relapse
Retreatment excluding relapse                    HIV-positive

























































Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in 
consultation with countries.
a Ranges represent uncertainty intervals.
b Includes cases with unknown previous TB treatment history.
c Includes patients diagnosed before 2014 and patients who were not laboratory-confirmed  
 as having RR-/MDR-TB.
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Kenya  Population 2014 45 million
Estimates of TB burdena 2014
 NUMBER (thousands) RATE (per 100 000 population)
Mortality (excludes HIV+TB) 9.4 (6.7–12) 21 (15–28)
Mortality (HIV+TB only) 8.1 (6.4–10) 18 (14–22)
Prevalence  (includes HIV+TB) 120 (64–190) 266 (142–427)
Incidence  (includes HIV+TB) 110 (110–110) 246 (240–252)
Incidence (HIV+TB only) 40 (38–42) 89 (84–93)
Case detection, all forms (%) 80 (78–82)    
Estimates of MDR-TB burdena 2014
 NEW RETREATMENT
% of TB cases with MDR-TB 2.2 (0.3–4.1) 14 (12–15)
MDR-TB cases among notified  
pulmonary TB cases 1 400 (200–2 700) 1 100 (930–1 200)
TB case notifications 2014
 NEWb RELAPSE
Pulmonary, bacteriologically confirmed 34 997  3 569
Pulmonary, clinically diagnosed 30 872  2 947
Extrapulmonary 14 640  1 000
       
Total new and relapse 88 025    
Previously treated, excluding relapses 1 269    
Total cases notified 89 294    
Among 89 294 new and relapse cases:
8 448 (9%) cases aged under 15 years; male:female ratio: 1.5  
Reported cases of RR-/MDR-TB 2014 
 NEW RETREATMENT TOTALb
Cases tested for RR-/MDR-TB 17 619 (50%) 7 436 (85%) 23 865
Laboratory-confirmed RR-/MDR-TB cases     644
Patients started on MDR-TB treatmentc     544
TB/HIV 2014
 NUMBER (%)
TB patients with known HIV status 84 423 (95)
HIV-positive TB patients 30 002 (36)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT) 29 735 (99)
HIV-positive TB patients on antiretroviral therapy (ART) 26 142 (87)
HIV-positive people screened for TB 426 102  
HIV-positive people provided with IPT    
Treatment success rate and cohort size
 (%) COHORT
New cases registered in 2013 (86) 81 255
Previously treated cases registered in 2013 (78) 8 445
HIV-positive TB cases, all types, registered in 2013 (79) 31 755
RR-/MDR-TB cases started on second-line treatment in 2012 (83) 197
XDR-TB cases started on second-line treatment in 2012   0
Laboratories 2014  
Smear (per 100 000 population) 4.3
Culture (per 5 million population) 0.3
Drug susceptibility testing (per 5 million population) 0.3
Sites performing Xpert MTB/RIF 70
Is second-line drug susceptibility testing available? No
Financing TB control 2015  
National TB programme budget (US$ millions) 45
% Funded domestically 26%
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Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in 
consultation with countries.
a Ranges represent uncertainty intervals.
b Includes cases with unknown previous TB treatment history.
c Includes patients diagnosed before 2014 and patients who were not laboratory-confirmed  
 as having RR-/MDR-TB.
d Treatment outcomes were available for new pulmonary bacteriologically confirmed cases  
 only.
Mozambique  Population 2014 27 million
Estimates of TB burdena 2014
 NUMBER (thousands) RATE (per 100 000 population)
Mortality (excludes HIV+TB) 18 (12–26) 67 (44–96)
Mortality (HIV+TB only) 37 (29–45) 134 (106–165)
Prevalence  (includes HIV+TB) 150 (80–240) 554 (295–893)
Incidence  (includes HIV+TB) 150 (120–180) 551 (435–680)
Incidence (HIV+TB only) 85 (65–110) 311 (237–395)
Case detection, all forms (%) 39 (31–49)    
Estimates of MDR-TB burdena 2014
 NEW RETREATMENT
% of TB cases with MDR-TB 3.5 (2.2–4.8) 11 (0–25)
MDR-TB cases among notified  
pulmonary TB cases 1 700 (1 100–2 300) 460 (0–1 000)
TB case notifications 2014
 NEWc RELAPSE
Pulmonary, bacteriologically confirmed 24 430  1 542
Pulmonary, clinically diagnosed 23 455  2 070
Extrapulmonary 6 276    
       
Total new and relapse 57 773    
Previously treated, excluding relapses 497    
Total cases notified 58 270    
Reported cases of RR-/MDR-TB 2014 
 NEW RETREATMENT TOTALb
Cases tested for RR-/MDR-TB 886 (4%) 906 (22%) 3 716
Laboratory-confirmed RR-/MDR-TB cases     544
Patients started on MDR-TB treatmentc     482
TB/HIV 2014
 NUMBER (%)
TB patients with known HIV status 55 943 (96)
HIV-positive TB patients 29 337 (52)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT) 27 504 (94)
HIV-positive TB patients on antiretroviral therapy (ART) 23 801 (81)
HIV-positive people screened for TB 563 377  
HIV-positive people provided with IPT 94 252  
Treatment success rate and cohort size
 (%) COHORT
New cases registered in 2013d (88) 23 072
Previously treated cases registered in 2013    
HIV-positive TB cases, all types, registered in 2013    
RR-/MDR-TB cases started on second-line treatment in 2012 (28) 214
XDR-TB cases started on second-line treatment in 2012 (0)  4
Laboratories 2014  
Smear (per 100 000 population) 1.2
Culture (per 5 million population) 0.6
Drug susceptibility testing (per 5 million population) 0.4
Sites performing Xpert MTB/RIF 24
Is second-line drug susceptibility testing available? Yes, in country
Financing TB control 2015  
National TB programme budget (US$ millions) 29
% Funded domestically 6%
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Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in 
consultation with countries.
a Ranges represent uncertainty intervals.
b Includes cases with unknown previous TB treatment history.
c Includes patients diagnosed before 2014 and patients who were not laboratory-confirmed  
 as having RR-/MDR-TB.
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Myanmar  Population 2014 53 million
Estimates of TB burdena 2014
 NUMBER (thousands) RATE (per 100 000 population)
Mortality (excludes HIV+TB) 28 (20–37) 53 (38–70)
Mortality (HIV+TB only) 4.1 (3.3–5.1) 7.7 (6.1–9.5)
Prevalence  (includes HIV+TB) 240 (190–310) 457 (352–575)
Incidence  (includes HIV+TB) 200 (180–220) 369 (334–406)
Incidence (HIV+TB only) 19 (15–24) 36 (28–44)
Case detection, all forms (%) 70 (64–78)    
Estimates of MDR-TB burdena 2014
 NEW RETREATMENT
% of TB cases with MDR-TB 5 (3.1–6.8) 27 (15–39)
MDR-TB cases among notified  
pulmonary TB cases 5 600 (3 500–7 700) 3 400 (1 900–4 900)
TB case notifications 2014
 NEWb RELAPSE
Pulmonary, bacteriologically confirmed 42 608 5 276
Pulmonary, clinically diagnosed 70 305  3 650
Extrapulmonary 16 108  405
       
Total new and relapse 138 352    
Previously treated, excluding relapses 3 605    
Total cases notified 141 957    
Among 138 352 new and relapse cases:
36 301 (26%) cases aged under 15 years; male:female ratio: 1.6  
Reported cases of RR-/MDR-TB 2014 
 NEW RETREATMENT TOTALb
Cases tested for RR-/MDR-TB 10 295 (24%) 15 166 (117%) 26 240
Laboratory-confirmed RR-/MDR-TB cases     3 495
Patients started on MDR-TB treatmentc     1 537
TB/HIV 2014
 NUMBER (%)
TB patients with known HIV status 56 133 (40)
HIV-positive TB patients 6 412 (11)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT) 4 666 (73)
HIV-positive TB patients on antiretroviral therapy (ART) 5 749 (90)
HIV-positive people screened for TB 54 178  
HIV-positive people provided with IPT 2 997  
Treatment success rate and cohort size
 (%) COHORT
New cases registered in 2013 (87) 135 614
Previously treated cases registered in 2013 (71) 7 147
HIV-positive TB cases, all types, registered in 2013    
RR-/MDR-TB cases started on second-line treatment in 2012 (79) 443
XDR-TB cases started on second-line treatment in 2012    
Laboratories 2014  
Smear (per 100 000 population) 0.9
Culture (per 5 million population) 0.3
Drug susceptibility testing (per 5 million population) 0.2
Sites performing Xpert MTB/RIF 38
Is second-line drug susceptibility testing available? Yes, outside country
Financing TB control 2015  
National TB programme budget (US$ millions) 36
% Funded domestically 11%
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Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in 
consultation with countries.
a Ranges represent uncertainty intervals.
b Includes cases with unknown previous TB treatment history.
c Includes patients diagnosed before 2014 and patients who were not laboratory-confirmed  
 as having RR-/MDR-TB.
Nigeria  Population 2014 177 million
Estimates of TB burdena 2014
 NUMBER (thousands) RATE (per 100 000 population)
Mortality (excludes HIV+TB) 170 (91–280) 97 (51–156)
Mortality (HIV+TB only) 78 (53–110) 44 (30–61)
Prevalence  (includes HIV+TB) 590 (450–740) 330 (253–417)
Incidence  (includes HIV+TB) 570 (340–870) 322 (189–488)
Incidence (HIV+TB only) 100 (59–160) 59 (33–92)
Case detection, all forms (%) 15 (10–26)    
Estimates of MDR-TB burdena 2014
 NEW RETREATMENT
% of TB cases with MDR-TB 2.9 (2.1–4) 14 (10–19)
MDR-TB cases among notified  
pulmonary TB cases 2 300 (1 700–3 200) 1 000 (750–1 400)
TB case notifications 2014
 NEWc RELAPSE
Pulmonary, bacteriologically confirmed 49 825 2 415
Pulmonary, clinically diagnosed 29 460    
Extrapulmonary 4 764  0
       
Total new and relapse 86 464    
Previously treated, excluding relapses 4 890    
Total cases notified 91 354    
Among 91 354 new and relapse cases:
5 463 (6%) cases aged under 15 years; male:female ratio: 1.5  
Reported cases of RR-/MDR-TB 2014 
 NEW RETREATMENT TOTALb
Cases tested for RR-/MDR-TB     24 225
Laboratory-confirmed RR-/MDR-TB cases     798
Patients started on MDR-TB treatmentc     423
TB/HIV 2014
 NUMBER (%)
TB patients with known HIV status 84 161 (92)
HIV-positive TB patients 16 066 (19)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT) 14 569 (91)
HIV-positive TB patients on antiretroviral therapy (ART) 11 997 (75)
HIV-positive people screened for TB 335 357  
HIV-positive people provided with IPT 26 383  
Treatment success rate and cohort size
 (%) COHORT
New cases registered in 2013 (86) 91 997
Previously treated cases registered in 2013 (83) 8 404
HIV-positive TB cases, all types, registered in 2013 (80) 7 481
RR-/MDR-TB cases started on second-line treatment in 2012 (62) 154
XDR-TB cases started on second-line treatment in 2012   0
Laboratories 2014  
Smear (per 100 000 population) 1.0
Culture (per 5 million population) 0.2
Drug susceptibility testing (per 5 million population) 0.2
Sites performing Xpert MTB/RIF 96
Is second-line drug susceptibility testing available? Yes, in country
Financing TB control 2015  
National TB programme budget (US$ millions) 228
% Funded domestically 13%
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Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in 
consultation with countries.
a Ranges represent uncertainty intervals.
b Includes cases with unknown previous TB treatment history.
c Includes patients diagnosed before 2014 and patients who were not laboratory-confirmed  
 as having RR-/MDR-TB.
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Pakistan  Population 2014 185 million
Estimates of TB burdena 2014
 NUMBER (thousands) RATE (per 100 000 population)
Mortality (excludes HIV+TB) 48 (11–110) 26 (6–61)
Mortality (HIV+TB only) 1.3 (0.76–1.9) 0.68 (0.41–1)
Prevalence  (includes HIV+TB) 630 (530–740) 341 (285–402)
Incidence  (includes HIV+TB) 500 (370–650) 270 (201–350)
Incidence (HIV+TB only) 6.4 (4.4–8.7) 3.4 (2.4–4.7)
Case detection, all forms (%) 62 (48–83)  
Estimates of MDR-TB burdena 2014
 NEW RETREATMENT
% of TB cases with MDR-TB 3.7 (2.5–5) 18 (13–23)
MDR-TB cases among notified  
pulmonary TB cases 9 000 (6 100–12 000) 2 900 (2 100–3 700)
TB case notifications 2014
 NEWb RELAPSE
Pulmonary, bacteriologically confirmed 122 537  7 420
Pulmonary, clinically diagnosed 120 350 426
Extrapulmonary 57 463  221
       
Total new and relapse 308 417    
Previously treated, excluding relapses 8 160    
Total cases notified 316 577    
Among 308 417 new and relapse cases:
27 245 (9%) cases aged under 15 years; male:female ratio: 1.0  
Reported cases of RR-/MDR-TB 2014 
 NEW RETREATMENT TOTALb
Cases tested for RR-/MDR-TB 361 (<1%) 11 685 (72%) 20 143
Laboratory-confirmed RR-/MDR-TB cases     3 243
Patients started on MDR-TB treatmentc     2 662
TB/HIV 2014
 NUMBER (%)
TB patients with known HIV status 10 715 (3)
HIV-positive TB patients 90 (<1)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT) 90 (100)
HIV-positive TB patients on antiretroviral therapy (ART) 90 (100)
HIV-positive people screened for TB    
HIV-positive people provided with IPT    
Treatment success rate and cohort size
 (%) COHORT
New and relapse cases registered in 2013 (93) 289 376
Previously treated cases, excluding relapse, registered in 2013 (80) 7 217
HIV-positive TB cases, all types, registered in 2013 (81) 37
RR-/MDR-TB cases started on second-line treatment in 2012 (71) 858
XDR-TB cases started on second-line treatment in 2012 (32) 41
Laboratories 2014  
Smear (per 100 000 population) 0.8
Culture (per 5 million population) 0.3
Drug susceptibility testing (per 5 million population) 0.1
Sites performing Xpert MTB/RIF 42
Is second-line drug susceptibility testing available? Yes, in country
Financing TB control 2015  
National TB programme budget (US$ millions) 50
% Funded domestically 17%
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Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in 
consultation with countries.
a Ranges represent uncertainty intervals.
b Includes cases with unknown previous TB treatment history.
c Includes patients diagnosed before 2014 and patients who were not laboratory-confirmed  
 as having RR-/MDR-TB.
Philippines  Population 2014 99 million
Estimates of TB burdena 2014
 NUMBER (thousands) RATE (per 100 000 population)
Mortality (excludes HIV+TB) 10 (9–11) 10 (9.1–11)
Mortality (HIV+TB only) 0.08 (0.055–0.11) 0.08 (0.06–0.11)
Prevalence  (includes HIV+TB) 410 (360–470) 417 (367–471)
Incidence  (includes HIV+TB) 290 (250–320) 288 (254–324)
Incidence (HIV+TB only) 2.5 (2–3.2) 2.6 (2–3.2)
Case detection, all forms (%) 85 (76–97)    
Estimates of MDR-TB burdena 2014
 NEW RETREATMENT
% of TB cases with MDR-TB 2 (1.4–2.7) 21 (16–29)
MDR-TB cases among notified  
pulmonary TB cases 4 600 (3 300–6 300) 6 500 (4 700–8 700)
TB case notifications 2014
 NEWc RELAPSE
Pulmonary, bacteriologically confirmed 92 991  6 277
Pulmonary, clinically diagnosed 139 950    
Extrapulmonary 4 161    
       
Total new and relapse 243 379    
Previously treated, excluding relapses 24 057    
Total cases notified 267 436    
Among 97 578 new and relapse cases:
12 191 (12%) cases aged under 15 years; male:female ratio: 1.8  
Reported cases of RR-/MDR-TB 2014 
 NEW RETREATMENT TOTALb
Cases tested for RR-/MDR-TB 4 415 (5%) 20 196 (67%) 27 287
Laboratory-confirmed RR-/MDR-TB cases     3 000
Patients started on MDR-TB treatmentc     2 680
TB/HIV 2014
 NUMBER (%)
TB patients with known HIV status 53 354 (20)
HIV-positive TB patients 108 (<1)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT) 20 (19)
HIV-positive TB patients on antiretroviral therapy (ART) 53 (49)
HIV-positive people screened for TB 5 995  
HIV-positive people provided with IPT    
Treatment success rate and cohort size
 (%) COHORT
New and relapse cases registered in 2013 (90) 216 250
Previously treated cases, excluding relapse, registered in 2013 (86) 2 924
HIV-positive TB cases, all types, registered in 2013    
RR-/MDR-TB cases started on second-line treatment in 2012 (43) 1 798
XDR-TB cases started on second-line treatment in 2012 (10) 10
Laboratories 2014  
Smear (per 100 000 population) 2.6
Culture (per 5 million population) 1.1
Drug susceptibility testing (per 5 million population) 0.2
Sites performing Xpert MTB/RIF 84
Is second-line drug susceptibility testing available? Yes, in country
Financing TB control 2015  
National TB programme budget (US$ millions) 106
% Funded domestically 23%
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Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in 
consultation with countries.
a UN Population Division estimates are lower than the population registered by the Federal  
 State Statistics Service of the Russian Federation.
b Ranges represent uncertainty intervals.
c Includes cases with unknown previous TB treatment history.
d Includes patients diagnosed before 2014 and patients who were not laboratory-confirmed  
 as having RR-/MDR-TB.
e  The reported number of TB patients with known HIV status is for new TB patients in the  
 civilian sector only. It was not possible to calculate the percentage of all TB patients with  
 known HIV status.
Russian Federation  Population 2014a 143 million
Estimates of TB burdenb 2014
 NUMBER (thousands) RATE (per 100 000 population)
Mortality (excludes HIV+TB) 16 (15–16) 11 (11–11)
Mortality (HIV+TB only) 1.1 (0.83–1.3) 0.73 (0.58–0.91)
Prevalence  (includes HIV+TB) 160 (70–270) 109 (49–192)
Incidence  (includes HIV+TB) 120 (110–130) 84 (76–93)
Incidence (HIV+TB only) 5.5 (4.5–6.6) 3.8 (3.1–4.6)
Case detection, all forms (%) 85 (77–94)    
Estimates of MDR-TB burdenb 2014
 NEW RETREATMENT
% of TB cases with MDR-TB 19 (14–25) 49 (40–59)
MDR-TB cases among notified  
pulmonary TB cases 15 000 (11 000–19 000) 24 000 (19 000–29 000)
TB case notifications 2014
 NEWc RELAPSE
Pulmonary, bacteriologically confirmed 37 296  7 982
Pulmonary, clinically diagnosed 40 894  6 753
Extrapulmonary 8 763  652
       
Total new and relapse 102 340    
Previously treated, excluding relapses 33 828    
Total cases notified 136 168    
Among 102 340 new and relapse cases:
3 195 (3%) cases aged under 15 years; male:female ratio: 2.3  
Reported cases of RR-/MDR-TB 2014 
 NEW RETREATMENT TOTALb
Cases tested for RR-/MDR-TB 31 250 (84%) 13 925 (28%) 45 175
Laboratory-confirmed RR-/MDR-TB cases     15 585
Patients started on MDR-TB treatmentd     21 904
TB/HIV 2014
 NUMBER (%)
TB patients with known HIV statuse 67 425  
HIV-positive TB patients 5 251  
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT)    
HIV-positive TB patients on antiretroviral therapy (ART)    
HIV-positive people screened for TB    
HIV-positive people provided with IPT    
Treatment success rate and cohort size
 (%) COHORT
New and relapse cases registered in 2013 (68) 83 301
Previously treated cases, excluding relapse, registered in 2013 (39) 6 934
HIV-positive TB cases, all types, registered in 2013    
RR-/MDR-TB cases started on second-line treatment in 2012 (40) 16 021
XDR-TB cases started on second-line treatment in 2012 (26) 1 318
Laboratories 2014  
Smear (per 100 000 population) 3.7
Culture (per 5 million population) 14.1
Drug susceptibility testing (per 5 million population) 10.4
Sites performing Xpert MTB/RIF 96
Is second-line drug susceptibility testing available? Yes, in country
Financing TB control 2015  
National TB programme budget (US$ millions) 1 894
% Funded domestically 100%
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Data for all years can be downloaded from www.who.int/tb/data  GLOBAL TUBERCULOSIS REPORT 2015  n  141
Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in 
consultation with countries.
a Ranges represent uncertainty intervals.
b Includes cases with unknown previous TB treatment history.
c Includes patients diagnosed before 2014 and patients who were not laboratory-confirmed  
 as having RR-/MDR-TB.
South Africa  Population 2014 54 million
Estimates of TB burdena 2014
 NUMBER (thousands) RATE (per 100 000 population)
Mortality (excludes HIV+TB) 24 (22–26) 44 (41–48)
Mortality (HIV+TB only) 72 (58–89) 134 (107–164)
Prevalence  (includes HIV+TB) 380 (210–590) 696 (390–1 088)
Incidence  (includes HIV+TB) 450 (400–510) 834 (737–936)
Incidence (HIV+TB only) 270 (240–310) 509 (439–584)
Case detection, all forms (%) 68 (61–77)    
Estimates of MDR-TB burdena 2014
 NEW RETREATMENT
% of TB cases with MDR-TB 1.8 (1.4–2.3) 6.7 (5.4–8.2)
MDR-TB cases among notified  
pulmonary TB cases 4 700 (3 700–5 900) 1 500 (1 200–1 800)
TB case notifications 2014
 NEWc RELAPSE
Pulmonary, bacteriologically confirmed 155 473  7 430
Pulmonary, clinically diagnosed 106 482  2 693
Extrapulmonary 33 522 566
       
Total new and relapse 306 166    
Previously treated, excluding relapses 12 027    
Total cases notified 318 193    
Among 306 166 new and relapse cases:
31 977 (10%) cases aged under 15 years; male:female ratio: 1.3  
Reported cases of RR-/MDR-TB 2014 
 NEW RETREATMENT TOTALb
Cases tested for RR-/MDR-TB     218 231
Laboratory-confirmed RR-/MDR-TB cases     18 734
Patients started on MDR-TB treatmentc     11 538
TB/HIV 2014
 NUMBER (%)
TB patients with known HIV status 295 136 (93)
HIV-positive TB patients 179 756 (61)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT) 155 017 (86)
HIV-positive TB patients on antiretroviral therapy (ART) 141 755 (79)
HIV-positive people screened for TB 1 148 477  
HIV-positive people provided with IPT 551 787  
Treatment success rate and cohort size
 (%) COHORT
New and relapse cases registered in 2013 (78) 321 087
Previously treated cases, excluding relapse, registered in 2013 (69) 18 292
HIV-positive TB cases, all types, registered in 2013 (76) 191 189
RR-/MDR-TB cases started on second-line treatment in 2012 (49) 8 084
XDR-TB cases started on second-line treatment in 2012 (20) 607
Laboratories 2014  
Smear (per 100 000 population) 0.4
Culture (per 5 million population) 1.1
Drug susceptibility testing (per 5 million population) 1.1
Sites performing Xpert MTB/RIF 207
Is second-line drug susceptibility testing available? Yes, in country
Financing TB control 2015  
National TB programme budget (US$ millions) 248
% Funded domestically 84%
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Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in 
consultation with countries.
a Ranges represent uncertainty intervals.
b Includes cases with unknown previous TB treatment history.
c Includes patients diagnosed before 2014 and patients who were not laboratory-confirmed  
 as having RR-/MDR-TB.
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Thailand  Population 2014 68 million
Estimates of TB burdena 2014
 NUMBER (thousands) RATE (per 100 000 population)
Mortality (excludes HIV+TB) 7.4 (3.9–12) 11 (5.7–18)
Mortality (HIV+TB only) 4.5 (2.3–7.4) 6.6 (3.4–11)
Prevalence  (includes HIV+TB) 160 (110–220) 236 (161–326)
Incidence  (includes HIV+TB) 120 (61–190) 171 (90–276)
Incidence (HIV+TB only) 15 (7.8–24) 22 (12–36)
Case detection, all forms (%) 59 (36–110)    
Estimates of MDR-TB burdena 2014
 NEW RETREATMENT
% of TB cases with MDR-TB 2 (1.4–2.8) 19 (14–25)
MDR-TB cases among notified  
pulmonary TB cases 1 100 (780–1 600) 1 100 (800–1 500)
TB case notifications 2014
 NEWb RELAPSE
Pulmonary, bacteriologically confirmed 34 394  1 969
Pulmonary, clinically diagnosed 21 115  0
Extrapulmonary 10 244  0
       
Total new and relapse 67 722    
Previously treated, excluding relapses 3 896    
Total cases notified 71 618    
Among 34 394 new cases:
119 (<1%) cases aged under 15 years; male:female ratio: 2.5  
Reported cases of RR-/MDR-TB 2014 
 NEW RETREATMENT TOTALb
Cases tested for RR-/MDR-TB 4 370 (13%) 2 209 (38%) 9 580
Laboratory-confirmed RR-/MDR-TB cases     506
Patients started on MDR-TB treatmentc      
TB/HIV 2014
 NUMBER (%)
TB patients with known HIV status 50 670 (71)
HIV-positive TB patients 6 831 (13)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT) 4 359 (64)
HIV-positive TB patients on antiretroviral therapy (ART) 4 691 (69)
HIV-positive people screened for TB    
HIV-positive people provided with IPT    
Treatment success rate and cohort size
 (%) COHORT
New and relapse cases registered in 2013 (81) 65 867
Previously treated cases, excluding relapse, registered in 2013 (66) 1 812
HIV-positive TB cases, all types, registered in 2013 (67) 7 665
RR-/MDR-TB cases started on second-line treatment in 2012    
XDR-TB cases started on second-line treatment in 2012    
Laboratories 2014  
Smear (per 100 000 population) 1.3
Culture (per 5 million population) 3.9
Drug susceptibility testing (per 5 million population) 1.5
Sites performing Xpert MTB/RIF 14
Is second-line drug susceptibility testing available? Yes, in country
Financing TB control 2015  
National TB programme budget (US$ millions) 32
% Funded domestically 52%
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Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in 
consultation with countries.
a Ranges represent uncertainty intervals.
b Includes cases with unknown previous TB treatment history.
c Includes patients diagnosed before 2014 and patients who were not laboratory-confirmed  
 as having RR-/MDR-TB.
Uganda  Population 2014 38 million
Estimates of TB burdena 2014
 NUMBER (thousands) RATE (per 100 000 population)
Mortality (excludes HIV+TB) 4.5 (3.2–6.1) 12 (8.4–16)
Mortality (HIV+TB only) 6.4 (5–8.1) 17 (13–21)
Prevalence  (includes HIV+TB) 60 (33–95) 159 (87–253)
Incidence  (includes HIV+TB) 61 (53–69) 161 (141–183)
Incidence (HIV+TB only) 28 (24–32) 73 (63–84)
Case detection, all forms (%) 72 (64–83)    
Estimates of MDR-TB burdena 2014
 NEW RETREATMENT
% of TB cases with MDR-TB 1.4 (0.6–2.2) 12 (6.8–19)
MDR-TB cases among notified  
pulmonary TB cases 530 (230–830) 480 (270–770)
TB case notifications 2014
 NEWc RELAPSE
Pulmonary, bacteriologically confirmed 26 079  1 499
Pulmonary, clinically diagnosed 11 854  468
Extrapulmonary 4 180  107
       
Total new and relapse 44 187    
Previously treated, excluding relapses 1 984    
Total cases notified 46 171    
Among 44 187 new and relapse cases:
3 316 (8%) cases aged under 15 years; male:female ratio: 1.8  
Reported cases of RR-/MDR-TB 2014 
 NEW RETREATMENT TOTALb
Cases tested for RR-/MDR-TB 1 958 (8%) 737 (18%) 3 569
Laboratory-confirmed RR-/MDR-TB cases     255
Patients started on MDR-TB treatmentc     213
TB/HIV 2014
 NUMBER (%)
TB patients with known HIV status 43 883 (95)
HIV-positive TB patients 19 612 (45)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT) 19 211 (98)
HIV-positive TB patients on antiretroviral therapy (ART) 15 877 (81)
HIV-positive people screened for TB 729 268  
HIV-positive people provided with IPT    
Treatment success rate and cohort size
 (%) COHORT
New and relapse cases registered in 2013 (75) 44 605
Previously treated cases, excluding relapse, registered in 2013 (67) 2 572
HIV-positive TB cases, all types, registered in 2013 (73) 16 762
RR-/MDR-TB cases started on second-line treatment in 2012 (80) 41
XDR-TB cases started on second-line treatment in 2012   0
Laboratories 2014  
Smear (per 100 000 population) 3.6
Culture (per 5 million population) 0.7
Drug susceptibility testing (per 5 million population) 0.7
Sites performing Xpert MTB/RIF 74
Is second-line drug susceptibility testing available? Yes, in country
Financing TB control 2015  
National TB programme budget (US$ millions) 24
% Funded domestically 10%
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Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in 
consultation with countries.
a Ranges represent uncertainty intervals.
b Includes cases with unknown previous TB treatment history.
c Includes patients diagnosed before 2014 and patients who were not laboratory-confirmed  
 as having RR-/MDR-TB.
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United Republic of Tanzania  Population 2014 52 million
Estimates of TB burdena 2014
 NUMBER (thousands) RATE (per 100 000 population)
Mortality (excludes HIV+TB) 30 (13–54) 58 (26–104)
Mortality (HIV+TB only) 28 (15–43) 53 (30–84)
Prevalence  (includes HIV+TB) 270 (110–510) 528 (215–979)
Incidence  (includes HIV+TB) 170 (80–290) 327 (155–561)
Incidence (HIV+TB only) 62 (29–110) 120 (56–208)
Case detection, all forms (%) 36 (21–77)    
Estimates of MDR-TB burdena 2014
 NEW RETREATMENT
% of TB cases with MDR-TB 1.1 (0.5–2) 3.1 (0.9–7.9)
MDR-TB cases among notified  
pulmonary TB cases 520 (230–940) 80 (23–200)
TB case notifications 2014
 NEWb RELAPSE
Pulmonary, bacteriologically confirmed 23 583 1 008
Pulmonary, clinically diagnosed 23 380    
Extrapulmonary 13 600    
       
Total new and relapse 61 571    
Previously treated, excluding relapses 1 580    
Total cases notified 63 151    
Among 61 571 new and relapse cases:
6 463 (10%) cases aged under 15 years; male:female ratio: 1.5  
Reported cases of RR-/MDR-TB 2014 
 NEW RETREATMENT TOTALb
Cases tested for RR-/MDR-TB 9 506 (40%) 882 (34%) 35 923
Laboratory-confirmed RR-/MDR-TB cases     516
Patients started on MDR-TB treatmentc     143
TB/HIV 2014
 NUMBER (%)
TB patients with known HIV status 57 612 (91)
HIV-positive TB patients 20 055 (35)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT) 19 388 (97)
HIV-positive TB patients on antiretroviral therapy (ART) 16 564 (83)
HIV-positive people screened for TB 525 713  
HIV-positive people provided with IPT 23 124  
Treatment success rate and cohort size
 (%) COHORT
New and relapse cases registered in 2013 (91) 64 053
Previously treated cases, excluding relapse, registered in 2013 (79) 1 679
HIV-positive TB cases, all types, registered in 2013 (72) 20 320
RR-/MDR-TB cases started on second-line treatment in 2012 (73) 45
XDR-TB cases started on second-line treatment in 2012   0
Laboratories 2014  
Smear (per 100 000 population) 1.8
Culture (per 5 million population) 0.4
Drug susceptibility testing (per 5 million population) <0.1
Sites performing Xpert MTB/RIF 59
Is second-line drug susceptibility testing available? Yes, in country
Financing TB control 2015  
National TB programme budget (US$ millions) 67
% Funded domestically  
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Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in 
consultation with countries.
a Ranges represent uncertainty intervals.
b Includes cases with unknown previous TB treatment history.
c Includes patients diagnosed before 2014 and patients who were not laboratory-confirmed  
 as having RR-/MDR-TB.
Viet Nam  Population 2014 92 million
Estimates of TB burdena 2014
 NUMBER (thousands) RATE (per 100 000 population)
Mortality (excludes HIV+TB) 17 (11–23) 18 (12–25)
Mortality (HIV+TB only) 1.9 (1.3–2.5) 2 (1.4–2.7)
Prevalence  (includes HIV+TB) 180 (76–330) 198 (83–362)
Incidence  (includes HIV+TB) 130 (110–150) 140 (116–167)
Incidence (HIV+TB only) 7 (5.7–8.5) 7.6 (6.1–9.2)
Case detection, all forms (%) 77 (65–94)    
Estimates of MDR-TB burdena 2014
 NEW RETREATMENT
% of TB cases with MDR-TB 4 (2.5–5.4) 23 (17–30)
MDR-TB cases among notified  
pulmonary TB cases 3 000 (1 900–4 100) 2 100 (1 500–2 600)
TB case notifications 2014
 NEWc RELAPSE
Pulmonary, bacteriologically confirmed 49 938  7 114
Pulmonary, clinically diagnosed 25 179    
Extrapulmonary 18 118    
       
Total new and relapse 100 349    
Previously treated, excluding relapses 1 738    
Total cases notified 102 087    
Among 49 929 new cases:
144 (<1%) cases aged under 15 years; male:female ratio: 3.0  
Reported cases of RR-/MDR-TB 2014 
 NEW RETREATMENT TOTALb
Cases tested for RR-/MDR-TB 2 756 (6%) 8 511 (96%) 13 829
Laboratory-confirmed RR-/MDR-TB cases     2 198
Patients started on MDR-TB treatmentc     1 532
TB/HIV 2014
 NUMBER (%)
TB patients with known HIV status 74 092 (73)
HIV-positive TB patients 3 875 (5)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT) 2 936 (76)
HIV-positive TB patients on antiretroviral therapy (ART) 2 827 (73)
HIV-positive people screened for TB 90 592  
HIV-positive people provided with IPT    
Treatment success rate and cohort size
 (%) COHORT
New and relapse cases registered in 2013 (89) 102 196
Previously treated cases, excluding relapse, registered in 2013    
HIV-positive TB cases, all types, registered in 2013 (71) 4 453
RR-/MDR-TB cases started on second-line treatment in 2012 (71) 713
XDR-TB cases started on second-line treatment in 2012   0
Laboratories 2014  
Smear (per 100 000 population) 1.1
Culture (per 5 million population) 1.2
Drug susceptibility testing (per 5 million population) 0.1
Sites performing Xpert MTB/RIF 30
Is second-line drug susceptibility testing available? Yes, in and outside country
Financing TB control 2015  
National TB programme budget (US$ millions) 66
% Funded domestically 10%
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Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in 
consultation with countries.
a Ranges represent uncertainty intervals.
b Includes cases with unknown previous TB treatment history.
c Includes patients diagnosed before 2014 and patients who were not laboratory-confirmed  
 as having RR-/MDR-TB.
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Zimbabwe  Population 2014 15 million
Estimates of TB burdena 2014
 NUMBER (thousands) RATE (per 100 000 population)
Mortality (excludes HIV+TB) 2.3 (1.4–3.4) 15 (9.5–22)
Mortality (HIV+TB only) 5.2 (3.2–7.8) 34 (21–51)
Prevalence  (includes HIV+TB) 44 (24–71) 292 (158–465)
Incidence  (includes HIV+TB) 42 (29–58) 278 (193–379)
Incidence (HIV+TB only) 25 (17–35) 167 (114–229)
Case detection, all forms (%) 70 (51–100)    
Estimates of MDR-TB burdena 2014
 NEW RETREATMENT
% of TB cases with MDR-TB 2.2 (0.3–4.1) 11 (6.2–16)
MDR-TB cases among notified  
pulmonary TB cases 540 (73–1 000) 410 (230–590)
TB case notifications 2014
 NEWb RELAPSE
Pulmonary, bacteriologically confirmed 11 224  1 369
Pulmonary, clinically diagnosed 13 151    
Extrapulmonary 3 909    
       
Total new and relapse 29 653    
Previously treated, excluding relapses 2 363    
Total cases notified 32 016    
Among 29 653 new and relapse cases:
2 290 (8%) cases aged under 15 years; male:female ratio: 1.3  
Reported cases of RR-/MDR-TB 2014 
 NEW RETREATMENT TOTALb
Cases tested for RR-/MDR-TB 341 (3%) 237 (6%) 7 585
Laboratory-confirmed RR-/MDR-TB cases     412
Patients started on MDR-TB treatmentc     381
TB/HIV 2014
 NUMBER (%)
TB patients with known HIV status 28 508 (89)
HIV-positive TB patients 19 290 (68)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT) 18 200 (94)
HIV-positive TB patients on antiretroviral therapy (ART) 16 522 (86)
HIV-positive people screened for TB 133 997  
HIV-positive people provided with IPT 30 420  
Treatment success rate and cohort size
 (%) COHORT
New cases registered in 2013 (80) 35 278
Previously treated cases registered in 2013    
HIV-positive TB cases, all types, registered in 2013    
RR-/MDR-TB cases started on second-line treatment in 2012 (75) 234
XDR-TB cases started on second-line treatment in 2012    
Laboratories 2014  
Smear (per 100 000 population) 1.4
Culture (per 5 million population) 0.7
Drug susceptibility testing (per 5 million population) 0.7
Sites performing Xpert MTB/RIF 62
Is second-line drug susceptibility testing available? Yes, in and outside country
Financing TB control 2015  
National TB programme budget (US$ millions) 28
% Funded domestically 7%
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Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in 
consultation with countries.
a Ranges represent uncertainty intervals.
b Includes cases with unknown previous TB treatment history.
c Includes patients diagnosed before 2014 and patients who were not laboratory-confirmed  
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WHO African Region  Population 2014 963 million
New, or new and relapse
Retreatment, or retreatment excluding relapse





































































































WHO MEMBER STATES  47 
Estimates of TB burdena 2014
 NUMBER (thousands) RATE (per 100 000 population)
Mortality (excludes HIV+TB) 450 (350–560) 46 (36–58)
Mortality (HIV+TB only) 310 (270–350) 32 (28–36)
Prevalence  (includes HIV+TB) 3 200 (2 800–3 600) 330 (288–375)
Incidence  (includes HIV+TB) 2 700 (2 400–3 000) 281 (250–313)
Incidence (HIV+TB only) 870 (790–950) 90 (82–99) 
Case detection, all forms (%) 48 (43–54)  
Estimates of MDR-TB burdena 2014
 NEW RETREATMENT
% of TB cases with MDR-TB 2.1 (0.5–3.7) 11 (6.7–16)
MDR-TB cases among notified  
pulmonary TB cases 22 000 (5 200–38 000) 11 000 (6 200–15 000)
TB case notifications 2014
 NEWb RELAPSE
Pulmonary, bacteriologically confirmed 635 560 39 782
Pulmonary, clinically diagnosed 399 155 11 217 
Extrapulmonary 212 057 3 081 
   
Total new and relapse 1 300 852  
Previously treated, excluding relapses 41 548  
Total cases notified 1 342 400  
Among 1 054 331 reported new and relapsec cases disaggregated by age, 90 523 
(8.6%) cases were aged < 15 years   
Among 1 056 629 reported new and relapsec cases disaggregated by sex, 
male:female ratio = 1.4   
Reported cases of RR-/MDR-TB 2014 
 NEW RETREATMENT TOTALb
Cases tested for RR-/MDR-TB 40 940 (6.4%) 31 952 (33%) 367 223
Laboratory-confirmed RR-/MDR-TB cases   25 531 
Patients started on MDR-TB treatmentd   17 352 
TB/HIV 2014
 NUMBER (%)e
TB patients with known HIV status 1 064 385 79
HIV-positive TB patients 415 657 39
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT) 360 015 89
HIV-positive TB patients on antiretroviral therapy (ART) 317 773 77
HIV-positive people screened for TB 5 166 166
HIV-positive people provided with IPT 875 886
Treatment success rate and cohort size
 (%) COHORT
New and relapsec cases registered in 2013 79 1 165 070
Previously treated cases, excluding relapse, registered in 2013 70 70 144
HIV-positive TB cases, all types, registered in 2013 70 326 597
RR-/MDR-TB cases started on second-line treatment in 2012 53 10 246
XDR-TB cases started on second-line treatment in 2012 20 618
Laboratories 2014 NUMBER OF MEMBER STATESf
Smear (per 100 000 population) ≥ 1  28 out of 44 
Culture (per 5 million population) ≥ 1  15 out of 44 
Drug susceptibility testing (per 5 million population) ≥ 1 10 out of 44 
Financing TB control (low- and middle-income countries)f,g 2015 
National TB programme budget (US$ millions) 1 080 
% Funded domestically 34 
% Funded internationally 29 
% Unfunded 37 
Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in 
consultation with countries.
a Ranges represent uncertainty intervals.
b Includes cases with unknown previous TB treatment history.
c Some countries reported on new cases only.
d Includes patients diagnosed before 2014 and patients who were not laboratory-confirmed  
 as having RR-/MDR-TB.
e Calculations exclude countries with missing numerators or denominators.
f Data are not collected from all Member States.
g Financing indicators exclude funding for general healthcare services provided outside NTPs.
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WHO/PAHO Region of the Americas  Population 2014 982 million
New, or new and relapse
Retreatment, or retreatment excluding relapse










































































Notified (new and relapse) Incidence
Incidence (HIV+TB only)
Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in 
consultation with countries.
a Ranges represent uncertainty intervals.
b Includes cases with unknown previous TB treatment history.
c Some countries reported on new cases only.
d Includes patients diagnosed before 2014 and patients who were not laboratory-confirmed  
 as having RR-/MDR-TB.
e Calculations exclude countries with missing numerators or denominators.
f Data are not collected from all Member States.
g Financing indicators exclude funding for general healthcare services provided outside NTPs.
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Estimates of TB burdena 2014
 NUMBER (thousands) RATE (per 100 000 population)
Mortality (excludes HIV+TB) 17 (16–18) 1.7 (1.6–1.8)
Mortality (HIV+TB only) 6  (5–7) 0.61 (0.53–0.69)
Prevalence  (includes HIV+TB) 350 (270–440) 36 (28–45)
Incidence  (includes HIV+TB) 280 (270–290) 28 (27–29)
Incidence (HIV+TB only) 36 (34–38) 3.7 (3.5–3.9)
Case detection, all forms (%) 77 (75–81)
Estimates of MDR-TB burdena 2014
 NEW RETREATMENT
% of TB cases with MDR-TB 2.4 (1.3–3.5) 11 (6.5–16)
MDR-TB cases among notified  
pulmonary TB cases 4 000 (2 200–5 900) 3 000 (1 700–4 200)
TB case notifications 2014
 NEWb RELAPSE
Pulmonary, bacteriologically confirmed 127 864 10 193 
Pulmonary, clinically diagnosed 40 746 2 918
Extrapulmonary 32 501 1 021
Total new and relapse 215 243  
Previously treated, excluding relapses 13 233  
Total cases notified 228 476
Among 208 839 reported new and relapsec cases disaggregated by age, 10 489 
(5.0%) cases were aged < 15 years   
Among 210 774 reported new and relapsec cases disaggregated by sex, male:female 
ratio = 1.7
Reported cases of RR-/MDR-TB 2014 
 NEW RETREATMENT TOTALb
Cases tested for RR-/MDR-TB 30 531 (24%) 8 724 (32%) 60 468 
Laboratory-confirmed RR-/MDR-TB cases   3 745 
Patients started on MDR-TB treatmentd   3 568 
TB/HIV 2014
 NUMBER (%)e
TB patients with known HIV status 169 141 74
HIV-positive TB patients 21 913 13
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT) 5 719 52
HIV-positive TB patients on antiretroviral therapy (ART) 7 209 63
HIV-positive people screened for TB 56 856 
HIV-positive people provided with IPT 28 556 
Treatment success rate and cohort size
 (%) COHORT
New and relapsec cases registered in 2013 75 200 726
Previously treated cases, excluding relapse, registered in 2013 48 14 753
HIV-positive TB cases, all types, registered in 2013 53 19 816
RR-/MDR-TB cases started on second-line treatment in 2012 57 2 866
XDR-TB cases started on second-line treatment in 2012 30 67
Laboratories 2014 NUMBER OF MEMBER STATESf
Smear (per 100 000 population) ≥ 1  19 out of 23 
Culture (per 5 million population) ≥ 1  20 out of 23 
Drug susceptibility testing (per 5 million population) ≥ 1 6 out of 23 
Financing TB control (low- and middle-income countries)f,g 2015 
National TB programme budget (US$ millions) 285 
% Funded domestically 71 
% Funded internationally 7.3
% Unfunded 22
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WHO Eastern Mediterranean Region  Population 2014 636 million
New, or new and relapse
Retreatment, or retreatment excluding relapse

































































































Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in 
consultation with countries.
a Ranges represent uncertainty intervals.
b Includes cases with unknown previous TB treatment history.
c Some countries reported on new cases only.
d Includes patients diagnosed before 2014 and patients who were not laboratory-confirmed  
 as having RR-/MDR-TB.
e Calculations exclude countries with missing numerators or denominators.
f Data are not collected from all Member States.
g Financing indicators exclude funding for general healthcare services provided outside NTPs.
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Estimates of TB burdena 2014
 NUMBER (thousands) RATE (per 100 000 population)
Mortality (excludes HIV+TB) 88 (43–150) 14 (6.8–23)
Mortality (HIV+TB only) 3 (3–4) 0.51 (0.41–0.62)
Prevalence  (includes HIV+TB) 1 000 (880–1 200) 160 (139–183)
Incidence  (includes HIV+TB) 740 (610–890) 117 (96–140)
Incidence (HIV+TB only) 12 (10–15) 1.9 (1.6–2.3)
Case detection, all forms (%) 61 (51–75)  
Estimates of MDR-TB burdena 2014
 NEW RETREATMENT
% of TB cases with MDR-TB 3.2 (2.3–4.1) 18 (12–25)
MDR-TB cases among notified  
pulmonary TB cases 11 000 (7 700–14 000) 4 700 (3 000–6 400)
TB case notifications 2014
 NEWb RELAPSE
Pulmonary, bacteriologically confirmed 183 630 12 368
Pulmonary, clinically diagnosed 151 696 866
Extrapulmonary 103 959 87
   
Total new and relapse 453 393
Previously treated, excluding relapses 12 284
Total cases notified 465 677  
Among 441 071 reported new and relapsec cases disaggregated by age, 42 028 
(9.5%) cases were aged < 15 years
Among 449 016 reported new and relapsec cases disaggregated by sex, male:female 
ratio = 1.0   
Reported cases of RR-/MDR-TB 2014 
 NEW RETREATMENT TOTALb
Cases tested for RR-/MDR-TB 8 404 (4.6%) 13 703 (52%) 30 519 
Laboratory-confirmed RR-/MDR-TB cases   4 348 
Patients started on MDR-TB treatmentd   3 423 
TB/HIV 2014
 NUMBER (%)e
TB patients with known HIV status 67 624 15
HIV-positive TB patients 1 629 2.4
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT) 686 67
HIV-positive TB patients on antiretroviral therapy (ART) 943 63
HIV-positive people screened for TB 14 775 
HIV-positive people provided with IPT 478 
Treatment success rate and cohort size
 (%) COHORT
New and relapsec cases registered in 2013 91 431 622
Previously treated cases, excluding relapse, registered in 2013 76 11 281
HIV-positive TB cases, all types, registered in 2013 60 681
RR-/MDR-TB cases started on second-line treatment in 2012 65 1 271
XDR-TB cases started on second-line treatment in 2012 33 43
Laboratories 2014 NUMBER OF MEMBER STATESf
Smear (per 100 000 population) ≥ 1  3 out of 15
Culture (per 5 million population) ≥ 1  9 out of 15
Drug susceptibility testing (per 5 million population) ≥ 1 4 out of 15
Financing TB control (low- and middle-income countries)f,g 2015 
National TB programme budget (US$ millions) 183 
% Funded domestically 46
% Funded internationally 43 
% Unfunded 11
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WHO European Region  Population 2014 907 million
New, or new and relapse
Retreatment, or retreatment excluding relapse


































































































Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in 
consultation with countries.
a Ranges represent uncertainty intervals.
b Includes cases with unknown previous TB treatment history.
c Some countries reported on new cases only.
d Includes patients diagnosed before 2014 and patients who were not laboratory-confirmed  
 as having RR-/MDR-TB.
e Calculations exclude countries with missing numerators or denominators.
f Data are not collected from all Member States.
g Financing indicators exclude funding for general healthcare services provided outside NTPs.
WHO MEMBER STATES 53 | OTHER COUNTRIES AND TERRITORIES  1
Estimates of TB burdena 2014
 NUMBER (thousands) RATE (per 100 000 population)
Mortality (excludes HIV+TB) 33 (33–34) 3.7 (3.6–3.8)
Mortality (HIV+TB only) 3 (3–4) 0.35 (0.3–0.4)
Prevalence  (includes HIV+TB) 440 (330–560) 48 (36–61)
Incidence  (includes HIV+TB) 340 (320–350) 37 (35–39)
Incidence (HIV+TB only) 20 (18–21) 2.2 (2–2.4)
Case detection, all forms (%) 79 (75–83)
Estimates of MDR-TB burdena 2014
 NEW RETREATMENT
% of TB cases with MDR-TB 15 (10–19) 48 (43–53)
MDR-TB cases among notified  
pulmonary TB cases 28 000 (20 000–37 000) 44 000 (39 000–48 000)
TB case notifications 2014
 NEWb RELAPSE
Pulmonary, bacteriologically confirmed 112 416 23 935
Pulmonary, clinically diagnosed 76 759 11 483
Extrapulmonary 39 175 2 290
   
Total new and relapse 266 058  
Previously treated, excluding relapses 55 363  
Total cases notified 321 421  
Among 260 844 reported new and relapsec cases disaggregated by age, 9 898 
(3.8%) cases were aged < 15 years
Among 261 563 reported new and relapsec cases disaggregated by sex, male:female 
ratio = 2.0
Reported cases of RR-/MDR-TB 2014 
 NEW RETREATMENT TOTALb
Cases tested for RR-/MDR-TB 108 569 (97%) 48 234 (52%) 161 202 
Laboratory-confirmed RR-/MDR-TB cases   42 293 
Patients started on MDR-TB treatmentd   49 074 
TB/HIV 2014
 NUMBER (%)e
TB patients with known HIV status 199 810 62
HIV-positive TB patients 16 630 8.2
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT) 5 452 53
HIV-positive TB patients on antiretroviral therapy (ART) 6 279 58
HIV-positive people screened for TB 37 266 
HIV-positive people provided with IPT 21 014 
Treatment success rate and cohort size
 (%) COHORT
New and relapsec cases registered in 2013 75 240 741
Previously treated cases, excluding relapse, registered in 2013 58 30 125
HIV-positive TB cases, all types, registered in 2013 47 9 504
RR-/MDR-TB cases started on second-line treatment in 2012 49 37 638
XDR-TB cases started on second-line treatment in 2012 26 1 563
Laboratories 2014 NUMBER OF MEMBER STATESf
Smear (per 100 000 population) ≥ 1  10 out of 53 
Culture (per 5 million population) ≥ 1  44 out of 53 
Drug susceptibility testing (per 5 million population) ≥ 1 39 out of 53 
Financing TB control (low- and middle-income countries)f,g 2015 
National TB programme budget (US$ millions) 2 513
% Funded domestically 93 
% Funded internationally 4.1 
% Unfunded 2.5
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WHO South-East Asia Region  Population 2014 1 906 million
New, or new and relapse
Retreatment, or retreatment excluding relapse








































































Notified (new and relapse) Incidence
Incidence (HIV+TB only)
Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in 
consultation with countries.
a Ranges represent uncertainty intervals.
b Includes cases with unknown previous TB treatment history.
c Some countries reported on new cases only.
d Includes patients diagnosed before 2014 and patients who were not laboratory-confirmed  
 as having RR-/MDR-TB.
e Calculations exclude countries with missing numerators or denominators.
f Data are not collected from all Member States.
g Financing indicators exclude funding for general healthcare services provided outside NTPs.
WHO MEMBER STATES 11
Estimates of TB burdena 2014
 NUMBER (thousands) RATE (per 100 000 population)
Mortality (excludes HIV+TB) 460 (350–570) 24 (19–30)
Mortality (HIV+TB only) 62 (51–74) 3.3 (2.7–3.9)
Prevalence  (includes HIV+TB) 5 400 (4 400–6 500) 286 (233–343)
Incidence  (includes HIV+TB) 4 000 (3 700–4 400) 211 (192–232)
Incidence (HIV+TB only) 210 (180–240) 11 (9.4–12)
Case detection, all forms (%) 62 (56–68)  
Estimates of MDR-TB burdena 2014
 NEW RETREATMENT
% of TB cases with MDR-TB 2.2 (1.9–2.6) 16 (14–17)
MDR-TB cases among notified  
pulmonary TB cases 40 000 (35 000–47 000) 59 000 (52 000–65 000)
TB case notifications 2014
 NEWb RELAPSE
Pulmonary, bacteriologically confirmed 1 188 654 152 498
Pulmonary, clinically diagnosed 632 418 117 970
Extrapulmonary 389 819 715
Total new and relapse 2 482 074
Previously treated, excluding relapses 98 531
Total cases notified 2 580 605
Among 2 416 375 reported new and relapsec cases disaggregated by age, 168 310 
(7.0%) cases were aged < 15 years
Among 2 435 769 reported new and relapsec cases disaggregated by sex, 
male:female ratio = 1.8
Reported cases of RR-/MDR-TB 2014 
 NEW RETREATMENT TOTALb
Cases tested for RR-/MDR-TB 45 056 (3.8%) 247 336 (67%) 350 871
Laboratory-confirmed RR-/MDR-TB cases   33 264 
Patients started on MDR-TB treatmentd   28 536 
TB/HIV 2014
 NUMBER (%)e
TB patients with known HIV status 1 171 258 45
HIV-positive TB patients 60 235 5.1
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT) 51 141 85
HIV-positive TB patients on antiretroviral therapy (ART) 51 231 85
HIV-positive people screened for TB 1 183 007 
HIV-positive people provided with IPT 3 049 
Treatment success rate and cohort size
 (%) COHORT
New and relapsec cases registered in 2013 88 2 100 508
Previously treated cases, excluding relapse, registered in 2013 67 196 439
HIV-positive TB cases, all types, registered in 2013 74 54 235
RR-/MDR-TB cases started on second-line treatment in 2012 49 11 566
XDR-TB cases started on second-line treatment in 2012 37 108
Laboratories 2014 NUMBER OF MEMBER STATESf
Smear (per 100 000 population) ≥ 1  9 out of 11
Culture (per 5 million population) ≥ 1  3 out of 11
Drug susceptibility testing (per 5 million population) ≥ 1 2 out of 11
Financing TB control (low- and middle-income countries)f,g 2015 
National TB programme budget (US$ millions) 559
% Funded domestically 33
% Funded internationally 45
% Unfunded 22
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Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in 
consultation with countries.
a Ranges represent uncertainty intervals.
b Includes cases with unknown previous TB treatment history.
c Some countries reported on new cases only.
d Includes patients diagnosed before 2014 and patients who were not laboratory-confirmed  
 as having RR-/MDR-TB.
e Calculations exclude countries with missing numerators or denominators.
f Data are not collected from all Member States.
g Financing indicators exclude funding for general healthcare services provided outside NTPs.
WHO Western Pacific Region  Population 2014 1 845 million
New, or new and relapse
Retreatment, or retreatment excluding relapse



































































































WHO MEMBER STATES 27 | OTHER COUNTRIES AND TERRITORIES 9
Estimates of TB burdena 2014
 NUMBER (thousands) RATE (per 100 000 population)
Mortality (excludes HIV+TB) 88 (81–95) 4.8 (4.4–5.1)
Mortality (HIV+TB only) 5 (4–6) 0.27 (0.23–0.31)
Prevalence  (includes HIV+TB) 2 100 (1 900–2 400) 116 (104–128)
Incidence  (includes HIV+TB) 1 600 (1 500–1 600) 85 (80–89)
Incidence (HIV+TB only) 31 (28–35) 1.7 (1.5–1.9)
Case detection, all forms (%) 85 (81–90)  
Estimates of MDR-TB burdena 2014
 NEW RETREATMENT
% of TB cases with MDR-TB 4.4 (2.5–6.3) 22 (18–25)
MDR-TB cases among notified  
pulmonary TB cases 52 000 (30 000–75 000) 19 000 (16 000–22 000)
TB case notifications 2014
 NEWb RELAPSE
Pulmonary, bacteriologically confirmed 449 845 44 354
Pulmonary, clinically diagnosed 734 179 3 037
Extrapulmonary 103 085 1 316
   
Total new and relapse 1 335 816
Previously treated, excluding relapses 39 756
Total cases notified 1 375 572
Among 1 100 525 reported new and relapsec cases disaggregated by age, 37 273 
(3.4%) cases were aged < 15 years
Among 1 112 985 reported new and relapsec cases disaggregated by sex, 
male:female ratio = 2.1
Reported cases of RR-/MDR-TB 2014 
 NEW RETREATMENT TOTALb
Cases tested for RR-/MDR-TB 92 801 (21%) 54 560 (62%) 164 449
Laboratory-confirmed RR-/MDR-TB cases   13 437 
Patients started on MDR-TB treatmentd   8 850 
TB/HIV 2014
 NUMBER (%)e
TB patients with known HIV status 552 040 40
HIV-positive TB patients 12 657 2.3
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT) 4 271 59
HIV-positive TB patients on antiretroviral therapy (ART) 8 453 68
HIV-positive people screened for TB 528 464 
HIV-positive people provided with IPT 3 680 
Treatment success rate and cohort size
 (%) COHORT
New and relapsec cases registered in 2013 92 1 298 402
Previously treated cases, excluding relapse, registered in 2013 81 18 523
HIV-positive TB cases, all types, registered in 2013 73 10 756
RR-/MDR-TB cases started on second-line treatment in 2012 51 6 176
XDR-TB cases started on second-line treatment in 2012 29 286
Laboratories 2014 NUMBER OF MEMBER STATESf
Smear (per 100 000 population) ≥ 1  13 out of 16
Culture (per 5 million population) ≥ 1  10 out of 16
Drug susceptibility testing (per 5 million population) ≥ 1 5 out of 16
Financing TB control (low- and middle-income countries)f,g 2015
National TB programme budget (US$ millions) 603
% Funded domestically 63
% Funded internationally 16
% Unfunded 22
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Estimates of mortality, prevalence and incidence 
Estimated values are shown as best estimates followed by 
lower and upper bounds. The lower and upper bounds are 
defined as the 2.5th and 97.5th centiles of outcome distribu-
tions produced in simulations. For details about the methods 
used to produce these estimates see the technical appendix 
at http://www.who.int/tb/publications/global_report/.
Estimated numbers are shown rounded to two significant 
figures. Estimated rates are shown rounded to three signifi-
cant figures unless the value is under 100, in which case rates 
are shown rounded to two significant figures.
Data source
Data shown in this file were taken from the WHO global TB 
database on 7 October 2015. Data shown in the main part of 
the report were taken from the database on 6 August 2015. 
As a result, data in this annex may dif fer slightly from those 
in the main part of the report.
Downloadable data
This annex is provided as a reference for looking up figures as 
and when needed. It is not suitable for conducting analyses 
or producing graphs and tables. Instead, download data for 
all countries and all years as comma-separated value (CSV) 
files from the WHO global TB database at www.who.int/tb/
data/. See Annex 1 for more details. 
Country notes
Bangladesh
A joint reassessment of estimates of TB disease burden will 
be undertaken following completion of the national TB prev-
alence survey which was launched in March 2015.
Caribbean Islands
Data collection from Caribbean Islands that are not Member 
States of WHO was resumed in 2011 af ter a break of a few 
years. This includes Aruba, Curaçao, Puerto Rico and Sint 
Maarten, which are Associate Members of the Pan American 
Health Organization, plus the territories of Anguilla, Bermu-
da, Bonaire, Saint Eustatius and Saba, British Virgin Islands, 
Cayman Islands, Montserrat and Turks and Caicos Islands. 
Data are not currently independently collected from the US 
Virgin Islands.
Denmark
Data for Denmark exclude Greenland.
European Union/ European Economic Area countries
Notification and treatment outcome data for European 
Union and European Economic Area countries are provision-
al.
France
Data from France include data from 5 overseas departments 
(French Guiana, Guadeloupe, Martinique, Mayotte and 
Ré union) and exclude French territories of the Pacific.
Russian Federation
UN Population Division estimates are lower than the popula-
tion registered by the Federal State Statistics Service of the 
Russian Federation. The reported number of TB patients 
with known HIV status (Table A4.8) is for new TB patients 
in the civilian sector only. It was not possible to calculate the 
percentage of all TB patients with known HIV status.
United States of America
In addition to the 51 reporting areas, the USA includes ter-
ritories that report separately to WHO. The data for these 
territories are not included in the data reported by the USA. 
Definitions of case types and outcomes do not exactly match 
those used by WHO.
Contents
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Afghanistan 32 60 (53–67) 189 (167–212) 0.32 (0.25–0.40) 1 (0.80–1.3) 31 746 100 53 (47–60)
Albania 3 0.54 (0.460–0.630) 19 (16–22) <0.01 (<0.01–<0.01) 0.12 (<0.1–0.15) 408 14 75 (65–88)
Algeria 39 31 (25–37) 78 (64–94) 0.2 (0.15–0.26) 0.52 (0.39–0.67) 22 517 58 74 (62–90)
American Samoa < 1 <0.01 (<0.01–<0.01) 7 (5.6–8.6) 0 (0–<0.01) <0.1 (<0.1–<0.1)
Andorra < 1 <0.01 (<0.01–<0.01) 9.2 (8.1–10) 6 8.2 89 (79–100)
Angola 24 90 (58–130) 370 (240–529) 23 (14–34) 95 (58–141) 53 552 221 60 (42–92)
Anguilla < 1 <0.01 (<0.01–<0.01) 23 (19–27) 1 6.9 31 (26–37)
Antigua and Barbuda < 1 <0.01 (<0.01–<0.01) 7.6 (6.6–8.6) <0.01 (<0.01–<0.01) 2.5 (1.8–3.3) 3 3.3 44 (39–50)
Argentina 43 10 (9.1–12) 24 (21–27) 0.74 (0.58–0.92) 1.7 (1.3–2.1) 9 195 21 89 (78–100)
Armenia 3 1.4 (1.2–1.5) 45 (40–50) 0.08 (0.071–0.090) 2.7 (2.4–3.0) 1 329 44 98 (88–110)
Aruba < 1 0.011 (<0.01–0.013) 11 (9.6–12) 2 1.9 18 (16–20)
Australia 24 1.5 (1.3–1.7) 6.4 (5.6–7.2) 0.026 (0.023–0.030) 0.11 (0.10–0.13) 1 330 5.6 88 (78–100)
Austria 9 0.66 (0.580–0.750) 7.8 (6.8–8.8) 0.022 (0.017–0.028) 0.26 (0.20–0.33) 564 6.6 85 (75–97)
Azerbaijan 10 7.4 (6.5–8.3) 77 (68–86) 0.13 (0.11–0.15) 1.4 (1.2–1.6) 5 788 60 78 (70–89)
Bahamas < 1 0.045 (0.040–0.051) 12 (10–13) 0.014 (0.012–0.016) 3.7 (3.2–4.2) 50 13 110 (98–130)
Bahrain 1 0.2 (0.170–0.220) 14 (13–16) <0.01 (<0.01–0.011) 0.68 (0.57–0.80)
Bangladesh 159 360 (320–410) 227 (200–256) 0.57 (0.45–0.71) 0.36 (0.28–0.45) 191 166 120 53 (47–60)
Barbados < 1 <0.01 (<0.01–<0.01) 0.91 (0.80–1.0) <0.01 (<0.01–<0.01) 0.91 (0.80–1.0) 5 1.8 190 (170–220)
Belarus 10 5.5 (4.7–6.4) 58 (50–67) 0.31 (0.26–0.37) 3.3 (2.8–3.8) 3 858 41 70 (60–81)
Belgium 11 1 (0.880–1.1) 9 (7.8–10) 0.072 (0.061–0.085) 0.65 (0.54–0.76) 886 7.9 88 (78–100)
Belize < 1 0.13 (0.120–0.140) 37 (34–41) 0.024 (0.020–0.029) 6.9 (5.7–8.2) 72 20 55 (50–60)
Benin 11 6.5 (5.3–7.9) 61 (50–74) 1 (0.82–1.3) 9.7 (7.7–12) 3 886 37 60 (49–73)
Bermuda < 1 0 0 0 0
Bhutan < 1 1.3 (1.1–1.4) 164 (148–181) 0.091 (0.072–0.11) 12 (9.4–15) 1 066 139 85 (77–94)
Bolivia (Plurinational State of) 11 13 (11–14) 120 (106–135) 0.51 (0.40–0.63) 4.8 (3.8–6.0) 8 079 76 64 (57–72)
Bonaire, Saint Eustatius and Saba < 1 0 0 0 0
Bosnia and Herzegovina 4 1.6 (1.2–2.1) 42 (31–55) <0.01 (<0.01–<0.01) <0.1 (<0.1–0.10) 1 196 31 75 (57–100)
Botswana 2 8.5 (8.0–9.1) 385 (361–410) 4.5 (4.1–5.0) 204 (183–227) 6 019 271 70 (66–75)
Brazil 206 90 (86–95) 44 (42–46) 16 (14–17) 7.6 (6.9–8.4) 73 970 36 82 (78–86)
British Virgin Islands < 1 <0.01 (<0.01–<0.01) 1.7 (1.5–1.9) 0 0 0
Brunei Darussalam < 1 0.26 (0.230–0.290) 62 (54–70) <0.01 (<0.01–<0.01) <0.1 (<0.1–<0.1) 198 47 77 (68–88)
Bulgaria 7 1.9 (1.8–2.1) 27 (24–29) <0.01 (<0.01–<0.01) <0.1 (<0.1–<0.1) 1 825 25 95 (87–100)
Burkina Faso 18 9.4 (8.5–10) 54 (48–59) 1.2 (1.0–1.3) 6.6 (5.7–7.4) 5 546 32 59 (53–65)
Burundi 11 14 (13–15) 126 (116–136) 1.9 (1.6–2.1) 17 (15–20) 7 226 67 53 (49–58)
Cabo Verde < 1 0.71 (0.630–0.800) 138 (122–156) 0.066 (0.055–0.078) 13 (11–15) 274 53 39 (34–44)
Cambodia 15 60 (54–66) 390 (353–428) 1.8 (1.6–2.0) 12 (10–13) 43 059 281 72 (66–80)
Cameroon 23 50 (44–56) 220 (195–247) 20 (17–23) 88 (75–103) 26 038 114 52 (46–59)
Canada 36 1.9 (1.6–2.1) 5.2 (4.6–5.9) 0.1 (0.079–0.13) 0.29 (0.22–0.36)
Cayman Islands < 1 <0.01 (<0.01–<0.01) 7 (6.1–7.9) <0.01 (<0.01–<0.01) 0.28 (<0.1–0.62) 0 0 0
Central African Republic 5 18 (16–20) 375 (333–420) 7.6 (5.9–9.4) 157 (124–195) 10 186 212 57 (50–64)
Chad 14 22 (19–24) 159 (141–179) 6 (4.7–7.4) 44 (35–55) 11 973 88 55 (49–62)
Chile 18 2.8 (2.4–3.2) 16 (14–18) 0.13 (0.10–0.16) 0.73 (0.57–0.91) 2 383 13 85 (75–97)
China 1 369 930 (860–1 000) 68 (63–73) 13 (11–16) 0.98 (0.79–1.2) 819 283 60 88 (82–95)
China, Hong Kong SAR 7 5.4 (4.7–6.1) 74 (65–84) 0.032 (0.028–0.037) 0.45 (0.38–0.52) 4 759 66 89 (79–100)
China, Macao SAR < 1 0.48 (0.420–0.540) 82 (72–93) <0.01 (<0.01–<0.01) 1.3 (1.2–1.5) 394 68 83 (73–94)
Colombia 48 16 (14–17) 33 (29–37) 3.4 (2.9–3.9) 7.1 (6.1–8.2) 11 875 25 76 (68–86)
Comoros < 1 0.27 (0.220–0.320) 35 (28–41) <0.01 (<0.01–0.010) 1.1 (0.88–1.3) 148 19 56 (47–68)
Congo 5 17 (15–19) 381 (335–430) 5.5 (4.3–6.9) 122 (96–152) 10 017 222 58 (52–66)
Cook Islands < 1 <0.01 (<0.01–<0.01) 12 (11–14) 2 9.7 79 (70–90)
Costa Rica 5 0.53 (0.470–0.600) 11 (9.8–13) 0.054 (0.047–0.061) 1.1 (0.99–1.3) 463 9.7 87 (77–99)
Croatia 4 0.53 (0.460–0.590) 12 (11–14) <0.01 (<0.01–<0.01) <0.1 (<0.1–0.12) 496 12 94 (83–110)
Cuba 11 1.1 (0.920–1.2) 9.4 (8.1–11) 0.11 (0.093–0.13) 0.97 (0.82–1.1) 729 6.4 68 (60–79)
Curaçao < 1 <0.01 (<0.01–<0.01) 3.7 (3.2–4.2) <0.01 (<0.01–<0.01) 3.7 (2.9–4.6) 5 3.2 87 (77–99)
Cyprus 1 0.061 (0.054–0.069) 5.3 (4.6–6.0) <0.01 (<0.01–<0.01) <0.1 (<0.1–<0.1) 39 3.4 64 (56–73)
Czech Republic 11 0.49 (0.430–0.550) 4.6 (4.1–5.2) <0.01 (<0.01–<0.01) <0.1 (<0.1–<0.1) 474 4.5 97 (86–110)
Côte d'Ivoire 22 36 (33–40) 165 (150–179) 8.5 (7.5–9.6) 39 (34–43) 23 275 105 64 (59–70)
Democratic People's Republic of Korea 25 110 (100–120) 442 (412–473) 0.31 (0.25–0.38) 1.2 (0.99–1.5) 103 045 412 93 (87–100)
Democratic Republic of the Congo 75 240 (220–270) 325 (295–356) 34 (27–42) 45 (36–56) 115 795 155 48 (43–52)
Denmark 6 0.4 (0.350–0.450) 7.1 (6.2–8.0) 0.012 (<0.01–0.015) 0.22 (0.17–0.27) 293 5.2 73 (65–84)
Djibouti < 1 5.4 (4.8–6.1) 619 (547–696) 0.54 (0.44–0.65) 62 (51–74) 2 220 253 41 (36–46)
Dominica < 1 <0.01 (<0.01–<0.01) 0.71 (0.62–0.80) 1 1.4 190 (170–220)
Dominican Republic 10 6.2 (5.5–7.0) 60 (53–68) 1.7 (1.4–1.9) 16 (14–19) 4 405 42 71 (63–80)
Ecuador 16 8.6 (6.3–11) 54 (39–71) 1.1 (0.82–1.5) 7.2 (5.2–9.6) 5 157 32 60 (46–82)






 Rates are per 100 000 population
b
 New cases, relapse cases and cases for which the treatment history is unknown.
TABLE A4.1
TB incidence estimates, notification and case detection rates, all forms of TB case, 2014
a Rates are per 100 000 population.
b New c s s, relapse cases and cases for which the treatment history is unknown.
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TB incidence estimates, notification and case detection rates, all forms of TB case, 2014











El Salvador 6 2.5 (2.3–2.7) 41 (38–45) 0.24 (0.22–0.26) 3.9 (3.6–4.3) 2 206 36 87 (80–95)
Equatorial Guinea < 1 1.3 (1.2–1.5) 162 (142–184) 0.67 (0.52–0.84) 82 (64–102) 1 166 142 88 (77–100)
Eritrea 5 4 (2.9–5.2) 78 (57–103) 0.25 (0.18–0.34) 4.9 (3.5–6.6) 2 391 47 60 (46–82)
Estonia 1 0.27 (0.240–0.300) 20 (18–23) 0.024 (0.021–0.027) 1.8 (1.6–2.1) 236 18 88 (78–100)
Ethiopia 97 200 (160–240) 207 (168–250) 19 (15–23) 19 (15–24) 119 592 123 60 (49–73)
Fiji < 1 0.59 (0.480–0.720) 67 (55–81) 0.027 (0.022–0.034) 3.1 (2.5–3.8) 378 43 64 (53–78)
Finland 5 0.31 (0.270–0.350) 5.6 (4.9–6.4) <0.01 (<0.01–<0.01) 0.1 (<0.1–0.13) 252 4.6 82 (72–93)
France 64 5.6 (5.3–6.0) 8.7 (8.2–9.3) 0.34 (0.28–0.42) 0.53 (0.43–0.65) 4 535 7.1 81 (76–86)
French Polynesia < 1 0.061 (0.054–0.069) 22 (19–25) 56 20 91 (81–100)
Gabon 2 7.5 (6.6–8.4) 444 (393–497) 0.53 (0.46–0.61) 32 (27–36) 5 608 332 75 (67–84)
Gambia 2 3.4 (2.8–4.0) 174 (145–206) 0.78 (0.64–0.93) 40 (33–48) 2 552 132 76 (64–91)
Georgia 4 4.3 (4.0–4.6) 106 (99–114) 0.16 (0.13–0.19) 3.9 (3.2–4.8) 3 200 79 75 (70–80)
Germany 81 5 (4.3–5.6) 6.2 (5.4–7.0) 0.12 (0.095–0.15) 0.15 (0.12–0.19) 4 328 5.4 87 (77–100)
Ghana 27 44 (21–75) 165 (80–281) 11 (5.2–19) 42 (20–72) 14 668 55 33 (19–69)
Greece 11 0.53 (0.460–0.600) 4.8 (4.2–5.4) 0.016 (0.012–0.019) 0.14 (0.11–0.18) 484 4.4 92 (81–100)
Greenland < 1 0.11 (0.097–0.130) 197 (173–223)
Grenada < 1 <0.01 (<0.01–<0.01) 1.3 (1.0–1.5) <0.01 (<0.01–<0.01) 0.11 (<0.1–0.14) 0 0 0
Guam < 1 0.067 (0.059–0.076) 40 (35–45) <0.01 (<0.01–<0.01) <0.1 (<0.1–<0.1) 56 33 83 (74–95)
Guatemala 16 9.2 (8.1–10) 57 (51–64) 0.84 (0.70–1.0) 5.3 (4.3–6.3) 3 163 20 34 (31–39)
Guinea 12 22 (19–24) 177 (156–199) 4.7 (3.9–5.5) 38 (32–45) 11 734 96 54 (48–61)
Guinea-Bissau 2 6.6 (4.7–8.9) 369 (261–495) 2.9 (2.0–4.0) 162 (110–224) 2 282 127 34 (26–49)
Guyana < 1 0.79 (0.700–0.890) 103 (91–116) 0.17 (0.14–0.20) 22 (19–26) 545 71 69 (62–78)
Haiti 11 21 (19–24) 200 (177–225) 3.7 (3.2–4.3) 35 (31–41) 15 806 150 75 (66–85)
Honduras 8 3.4 (3.0–3.9) 43 (38–48) 0.34 (0.30–0.39) 4.3 (3.8–4.9) 2 820 35 82 (73–93)
Hungary 10 1.2 (1.0–1.3) 12 (11–14) 0.011 (<0.01–0.014) 0.11 (<0.1–0.14) 799 8.1 67 (59–77)
Iceland < 1 0.011 (<0.01–0.012) 3.3 (2.9–3.8) <0.01 (<0.01–<0.01) 0 (0–0) 8 2.4 74 (65–84)
India 1 295 2 200 (2 000–2 300) 167 (156–179) 110 (96–120) 8.3 (7.4–9.3) 1 609 547 124 74 (70–80)
Indonesia 254 1 000 (700–1 400) 399 (274–546) 63 (41–90) 25 (16–36) 322 806 127 32 (23–46)
Iran (Islamic Republic of) 78 17 (14–20) 22 (18–26) 0.4 (0.30–0.52) 0.51 (0.38–0.66) 10 191 13 60 (50–74)
Iraq 35 15 (13–17) 43 (38–49) <0.01 (<0.01–<0.01) <0.1 (<0.1–<0.1) 8 268 23 54 (48–62)
Ireland 5 0.35 (0.300–0.390) 7.4 (6.5–8.4) 0.015 (0.011–0.018) 0.31 (0.24–0.39) 297 6.4 85 (75–97)
Israel 8 0.46 (0.400–0.520) 5.8 (5.1–6.6) 0.032 (0.028–0.037) 0.41 (0.36–0.46) 368 4.6 80 (71–91)
Italy 60 3.6 (3.1–4.1) 6 (5.2–6.8) 0.24 (0.19–0.30) 0.4 (0.31–0.50)
Jamaica 3 0.13 (0.110–0.160) 4.7 (3.8–5.7) 0.029 (0.023–0.036) 1.1 (0.84–1.3) 86 3.1 66 (55–81)
Japan 127 23 (20–26) 18 (16–21) 0.099 (0.083–0.12) <0.1 (<0.1–<0.1) 19 615 15 84 (75–96)
Jordan 7 0.41 (0.360–0.460) 5.5 (4.9–6.2) <0.01 (<0.01–<0.01) <0.1 (0–<0.1) 385 5.2 94 (84–110)
Kazakhstan 17 17 (11–25) 99 (64–141) 0.59 (0.38–0.84) 3.4 (2.2–4.8) 15 244 88 89 (62–140)
Kenya 45 110 (110–110) 246 (240–252) 40 (38–42) 89 (84–93) 88 025 196 80 (78–82)
Kiribati < 1 0.55 (0.450–0.660) 497 (406–597) <0.01 (<0.01–<0.01) 1.7 (1.3–2.1) 414 375 75 (63–92)
Kuwait 4 0.8 (0.700–0.910) 21 (19–24) <0.01 (<0.01–<0.01) 0.14 (0.11–0.17) 734 20 92 (81–100)
Kyrgyzstan 6 8.3 (7.3–9.3) 142 (126–160) 0.18 (0.16–0.20) 3.1 (2.7–3.5) 6 390 109 77 (68–87)
Lao People's Democratic Republic 7 13 (9.5–16) 189 (141–244) 0.5 (0.34–0.68) 7.4 (5.1–10) 4 264 64 34 (26–45)
Latvia 2 0.98 (0.910–1.0) 49 (46–53) 0.21 (0.19–0.24) 11 (9.4–12) 738 37 76 (71–81)
Lebanon 6 0.92 (0.800–1.1) 16 (14–19) 0.11 (0.096–0.13) 2 (1.7–2.2) 673 12 73 (64–84)
Lesotho 2 18 (13–24) 852 (612–1 130) 12 (8.5–16) 578 (405–781) 8 840 419 49 (37–69)
Liberia 4 14 (12–15) 308 (273–346) 2.1 (1.7–2.7) 49 (38–61) 2 702 61 20 (18–23)
Libya 6 2.5 (2.1–3.0) 40 (33–48) 0.1 (0.080–0.12) 1.6 (1.3–2.0) 1 153 18 46 (39–56)
Lithuania 3 1.8 (1.7–2.0) 62 (57–68) 0.057 (0.050–0.064) 2 (1.7–2.2) 1 481 51 82 (75–89)
Luxembourg < 1 0.037 (0.032–0.041) 6.6 (5.8–7.5) <0.01 (<0.01–<0.01) 0.49 (0.38–0.61) 24 4.3 65 (58–75)
Madagascar 24 55 (49–62) 235 (207–264) 2.2 (1.7–2.8) 9.5 (7.4–12) 28 466 121 51 (46–58)
Malawi 17 38 (20–61) 227 (122–365) 19 (10–31) 115 (60–186) 16 267 97 43 (27–80)
Malaysia 30 31 (25–37) 103 (83–124) 2.2 (1.8–2.6) 7.3 (5.9–8.8) 24 054 80 78 (65–96)
Maldives < 1 0.15 (0.130–0.170) 41 (36–47) <0.01 (<0.01–<0.01) <0.1 (<0.1–0.11) 131 37 89 (78–100)
Mali 17 9.8 (9.5–10) 58 (56–59) 0.71 (0.64–0.78) 4.1 (3.8–4.5) 5 809 34 59 (57–61)
Malta < 1 0.052 (0.045–0.058) 12 (11–14) <0.01 (<0.01–<0.01) 0.52 (0.37–0.69) 45 11 87 (77–100)
Marshall Islands < 1 0.18 (0.140–0.210) 335 (274–402) <0.01 (<0.01–<0.01) 0.68 (0.50–0.88) 142 268 80 (67–98)
Mauritania 4 4.4 (3.2–5.9) 111 (79–148) 0.41 (0.27–0.57) 10 (6.8–14) 2 420 61 55 (41–77)
Mauritius 1 0.28 (0.240–0.310) 22 (19–24) 0.042 (0.036–0.048) 3.3 (2.8–3.8) 126 9.9 46 (41–52)
Mexico 125 26 (23–29) 21 (19–23) 2.1 (1.9–2.4) 1.7 (1.5–1.9) 21 196 17 81 (72–91)
Micronesia (Federated States of) < 1 0.2 (0.090–0.360) 195 (87–347) 188 181 92 (52–210)
Monaco < 1 <0.01 (<0.01–<0.01) 2.2 (1.9–2.5)
Mongolia 3 5 (4.3–5.6) 170 (149–193) 0.011 (<0.01–0.012) 0.37 (0.31–0.42) 4 483 154 90 (80–100)
Montenegro < 1 0.13 (0.110–0.150) 21 (18–24) <0.01 (<0.01–<0.01) <0.1 (<0.1–<0.1) 113 18 87 (77–99)
Montserrat < 1 0 0 0 0
a
 Rates are per 100 000 population
b
 New cases, relapse cases and cases for which the treatment history is unknown.
TABLE A4.1
TB incidence estimates, notification and case detection rates, all forms of TB case, 2014
a Rates are per 100 000 population.
b New c s s, relapse cases and cases for which the treatment history is unknown.
160  n  GLOBAL TUBERCULOSIS REPORT 2015 Data for all years can be downloaded from www.who.int/tb/data
Table A4.1
TB incidence estimates, notification and case detection rates, all forms of TB case, 2014











Morocco 34 36 (33–39) 106 (97–115) 0.77 (0.61–0.94) 2.3 (1.8–2.8) 29 843 88 83 (77–91)
Mozambique 27 150 (120–180) 551 (435–680) 85 (65–110) 311 (237–395) 57 773 212 39 (31–49)
Myanmar 53 200 (180–220) 369 (334–406) 19 (15–24) 36 (28–44) 138 352 259 70 (64–78)
Namibia 2 13 (12–15) 561 (492–635) 5.6 (4.8–6.5) 232 (198–269) 8 972 373 67 (59–76)
Nauru < 1 <0.01 (<0.01–<0.01) 73 (64–83) 8 79 110 (95–120)
Nepal 28 44 (39–50) 158 (139–178) 1.5 (1.2–1.9) 5.4 (4.2–6.7) 35 277 125 79 (71–90)
Netherlands 17 0.97 (0.850–1.1) 5.8 (5.1–6.5) 0.052 (0.043–0.061) 0.31 (0.26–0.36) 814 4.8 84 (74–95)
New Caledonia < 1 0.038 (0.034–0.043) 15 (13–17) 29 11 76 (67–86)
New Zealand 4 0.33 (0.290–0.380) 7.4 (6.5–8.4) <0.01 (<0.01–<0.01) <0.1 (<0.1–<0.1) 297 6.6 89 (79–100)
Nicaragua 6 3.5 (3.2–3.8) 58 (53–63) 0.14 (0.11–0.17) 2.3 (1.8–2.8) 2 632 44 76 (70–82)
Niger 19 19 (17–21) 98 (87–110) 1.5 (1.3–1.8) 7.9 (6.6–9.3) 10 851 57 58 (51–65)
Nigeria 177 570 (340–870) 322 (189–488) 100 (59–160) 59 (33–92) 86 464 49 15 (10–26)
Niue < 1 0 0 0 0
Northern Mariana Islands < 1 0.033 (0.029–0.038) 61 (53–69) <0.01 (<0.01–<0.01) 0.21 (0.16–0.26) 26 48 78 (69–89)
Norway 5 0.42 (0.370–0.470) 8.1 (7.1–9.2) 0.012 (<0.01–0.014) 0.23 (0.18–0.28) 303 5.9 73 (64–83)
Oman 4 0.41 (0.360–0.460) 9.6 (8.4–11) <0.01 (<0.01–<0.01) 0.11 (<0.1–0.12) 358 8.5 88 (78–100)
Pakistan 185 500 (370–650) 270 (201–350) 6.4 (4.4–8.7) 3.4 (2.4–4.7) 308 417 167 62 (48–83)
Palau < 1 <0.01 (<0.01–<0.01) 42 (36–47) <0.01 (<0.01–<0.01) <0.1 (<0.1–<0.1) 14 66 160 (140–180)
Panama 4 1.8 (1.5–2.2) 46 (38–56) 0.18 (0.14–0.21) 4.6 (3.7–5.5) 1 457 38 81 (68–100)
Papua New Guinea 7 31 (23–41) 417 (304–547) 3.5 (2.4–4.8) 47 (32–64) 26 170 351 84 (64–120)
Paraguay 7 2.8 (2.7–3.0) 43 (41–45) 0.29 (0.27–0.32) 4.5 (4.1–4.9) 2 246 34 80 (76–84)
Peru 31 37 (30–45) 120 (98–145) 2.5 (2.0–3.1) 8.1 (6.5–9.9) 30 008 97 81 (67–99)
Philippines 99 290 (250–320) 288 (254–324) 2.5 (2.0–3.2) 2.6 (2.0–3.2) 243 379 245 85 (76–97)
Poland 39 8 (7.0–9.0) 21 (18–23) 0.1 (0.081–0.13) 0.27 (0.21–0.34) 6 539 17 82 (73–94)
Portugal 10 2.6 (2.3–2.9) 25 (22–28) 0.37 (0.31–0.43) 3.5 (3.0–4.1) 2 169 21 84 (74–96)
Puerto Rico 4 0.051 (0.045–0.058) 1.4 (1.2–1.6) <0.01 (<0.01–<0.01) 0.2 (0.17–0.23) 44 1.2 86 (76–99)
Qatar 2 0.63 (0.550–0.720) 29 (26–33) <0.01 (<0.01–<0.01) <0.1 (<0.1–<0.1) 465 21 74 (65–84)
Republic of Korea 50 43 (41–46) 86 (81–91) 0.19 (0.15–0.23) 0.37 (0.30–0.45) 40 190 80 93 (88–99)
Republic of Moldova 4 6.2 (5.5–7.0) 153 (135–172) 0.5 (0.43–0.58) 12 (11–14) 4 058 100 65 (58–74)
Romania 20 16 (14–18) 81 (71–91) 0.51 (0.44–0.59) 2.6 (2.2–3.0) 14 861 76 94 (83–110)
Russian Federation 143 120 (110–130) 84 (76–93) 5.5 (4.5–6.6) 3.8 (3.1–4.6) 102 340 71 85 (77–94)
Rwanda 11 7.1 (6.1–8.2) 63 (54–72) 1.8 (1.5–2.1) 16 (14–18) 5 761 51 81 (71–94)
Saint Kitts and Nevis < 1 <0.01 (<0.01–<0.01) 7.2 (6.3–8.1) 0 (0–0) <0.1 (<0.1–<0.1) 7 13 180 (160–200)
Saint Lucia < 1 0.017 (0.015–0.019) 9.1 (8.0–10) <0.01 (<0.01–<0.01) 1.4 (1.2–1.6) 6 3.3 36 (32–41)
Saint Vincent and the Grenadines < 1 0.026 (0.022–0.031) 24 (20–29) <0.01 (<0.01–0.011) 8.4 (6.7–10) 5 4.6 19 (16–23)
Samoa < 1 0.037 (0.030–0.045) 19 (16–23) 23 12 62 (51–77)
San Marino < 1 <0.01 (<0.01–<0.01) 1.6 (1.4–1.8)
Sao Tome and Principe < 1 0.18 (0.160–0.200) 97 (85–109) 0.038 (0.033–0.042) 20 (18–23) 158 85 87 (78–99)
Saudi Arabia 31 3.9 (3.4–4.4) 12 (11–14) 0.13 (0.11–0.16) 0.43 (0.36–0.50) 3 248 11 84 (75–96)
Senegal 15 20 (18–23) 138 (122–154) 1.5 (1.3–1.8) 10 (8.9–12) 13 332 91 66 (59–75)
Serbia 9 2.1 (1.8–2.4) 24 (21–27) 0.017 (0.013–0.021) 0.19 (0.15–0.24) 1 818 20 87 (77–99)
Seychelles < 1 0.025 (0.022–0.028) 26 (23–29) <0.01 (<0.01–<0.01) 0.76 (0.59–0.95) 13 14 52 (46–60)
Sierra Leone 6 20 (15–25) 310 (235–394) 2.3 (1.7–3.0) 37 (28–47) 12 477 198 64 (50–84)
Singapore 6 2.7 (2.4–3.1) 49 (43–56) 0.075 (0.065–0.086) 1.4 (1.2–1.6) 2 171 39 80 (71–92)
Sint Maarten (Dutch part) < 1 0 0 0 0
Slovakia 5 0.36 (0.320–0.410) 6.7 (5.9–7.6) <0.01 (<0.01–<0.01) <0.1 (<0.1–<0.1) 320 5.9 88 (78–100)
Slovenia 2 0.16 (0.140–0.180) 7.7 (6.7–8.7) <0.01 (<0.01–<0.01) <0.1 (<0.1–<0.1) 142 6.9 89 (79–100)
Solomon Islands < 1 0.49 (0.410–0.590) 86 (71–102) 345 60 70 (59–85)
Somalia 11 29 (25–32) 274 (242–308) 2.2 (1.7–2.7) 21 (16–26) 12 903 123 45 (40–51)
South Africa 54 450 (400–510) 834 (737–936) 270 (240–310) 509 (439–584) 306 166 567 68 (61–77)
South Sudan 12 17 (14–21) 146 (121–173) 2.9 (2.3–3.6) 25 (20–30) 8 335 70 48 (40–58)
Spain 46 5.5 (4.8–6.2) 12 (10–13) 0.31 (0.27–0.37) 0.68 (0.58–0.79) 4 818 10 88 (77–100)
Sri Lanka 21 13 (12–15) 65 (57–73) 0.053 (0.041–0.066) 0.26 (0.20–0.32) 9 305 45 69 (62–79)
Sudan 39 37 (20–58) 94 (52–148) 1.2 (0.65–2.0) 3.2 (1.7–5.1) 19 266 49 52 (33–95)
Suriname < 1 0.2 (0.170–0.250) 38 (31–46) 0.064 (0.052–0.077) 12 (9.6–14) 149 28 73 (61–89)
Swaziland 1 9.3 (6.8–12) 733 (533–963) 5.9 (4.2–7.9) 464 (330–619) 5 583 440 60 (46–83)
Sweden 10 0.72 (0.630–0.820) 7.5 (6.5–8.4) 0.024 (0.018–0.030) 0.24 (0.19–0.30) 635 6.5 88 (77–100)
Switzerland 8 0.52 (0.450–0.590) 6.3 (5.5–7.1) 0.037 (0.029–0.047) 0.46 (0.36–0.57) 423 5.2 82 (72–93)
Syrian Arab Republic 19 3.1 (2.6–3.7) 17 (14–20) <0.01 (<0.01–<0.01) <0.1 (<0.1–<0.1) 3 481 19 110 (94–130)
Tajikistan 8 7.6 (6.7–8.5) 91 (80–103) 0.23 (0.20–0.27) 2.8 (2.4–3.2) 5 807 70 77 (68–87)
Thailand 68 120 (61–190) 171 (90–276) 15 (7.8–24) 22 (12–36) 67 722 100 59 (36–110)
The Former Yugoslav Republic of 
Macedonia 2 0.32 (0.280–0.360) 15 (13–17) <0.01 (<0.01–<0.01) <0.1 (<0.1–<0.1) 284 14 90 (79–100)
Timor-Leste 1 5.8 (4.8–6.9) 498 (411–594) 0.057 (0.042–0.073) 4.9 (3.7–6.3) 3 657 316 63 (53–77)
a
 Rates are per 100 000 population
b
 New cases, relapse cases and cases for which the treatment history is unknown.
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Togo 7 4.1 (3.4–5.0) 58 (47–70) 0.83 (0.67–1.0) 12 (9.4–14) 2 525 35 61 (51–75)
Tokelau < 1 0 0 0 0
Tonga < 1 0.015 (0.012–0.018) 14 (11–17) <0.01 (<0.01–<0.01) <0.1 (<0.1–<0.1) 13 12 88 (73–110)
Trinidad and Tobago 1 0.29 (0.260–0.330) 22 (19–24) 0.071 (0.062–0.081) 5.3 (4.6–6.0) 251 19 86 (76–98)
Tunisia 11 3.7 (3.4–4.0) 33 (31–36) 0.023 (0.018–0.028) 0.2 (0.16–0.25) 3 134 28 84 (77–92)
Turkey 78 14 (12–16) 18 (16–21) 0.045 (0.035–0.057) <0.1 (<0.1–<0.1) 13 108 17 93 (82–110)
Turkmenistan 5 3.4 (2.7–4.1) 64 (52–78) 2 570 48 76 (62–94)
Turks and Caicos Islands < 1 <0.01 (<0.01–<0.01) 10 (8.8–11) <0.01 (<0.01–<0.01) 5 (4.0–6.1) 1 3 30 (26–34)
Tuvalu < 1 0.019 (0.015–0.023) 190 (154–228) 15 152 80 (66–98)
US Virgin Islands < 1 <0.01 (<0.01–<0.01) 7.7 (6.8–8.7)
Uganda 38 61 (53–69) 161 (141–183) 28 (24–32) 73 (63–84) 44 187 117 72 (64–83)
Ukraine 45 43 (38–48) 94 (83–106) 8.1 (7.0–9.3) 18 (16–21) 31 701 70 75 (66–84)
United Arab Emirates 9 0.14 (0.100–0.190) 1.6 (1.1–2.1) <0.01 (<0.01–<0.01) <0.1 (<0.1–<0.1) 60 0.66 42 (32–58)
United Kingdom of Great Britain and 
Northern Ireland 64 7.8 (7.3–8.4) 12 (11–13) 0.39 (0.31–0.47) 0.6 (0.49–0.74) 6 622 10 84 (79–90)
United Republic of Tanzania 52 170 (80–290) 327 (155–561) 62 (29–110) 120 (56–208) 61 571 119 36 (21–77)
United States of America 319 9.9 (8.7–11) 3.1 (2.7–3.5) 0.6 (0.52–0.68) 0.19 (0.16–0.21) 8 949 2.8 90 (80–100)
Uruguay 3 1 (0.910–1.2) 30 (27–34) 0.16 (0.14–0.18) 4.7 (4.0–5.3) 862 25 83 (73–95)
Uzbekistan 29 24 (18–31) 82 (61–107) 0.83 (0.61–1.1) 2.8 (2.1–3.6) 18 345 62 76 (58–100)
Vanuatu < 1 0.16 (0.130–0.190) 63 (52–74) 112 43 69 (58–84)
Venezuela (Bolivarian Republic of) 31 7.3 (6.4–8.3) 24 (21–27) 0.7 (0.60–0.81) 2.3 (2.0–2.6) 6 392 21 87 (77–99)
Viet Nam 92 130 (110–150) 140 (116–167) 7 (5.7–8.5) 7.6 (6.1–9.2) 100 349 109 77 (65–94)
Wallis and Futuna Islands < 1 <0.01 (<0.01–<0.01) 3.7 (3.2–4.2) 0 0 0
West Bank and Gaza Strip 5 0.26 (0.230–0.300) 5.8 (5.1–6.6) <0.01 (<0.01–<0.01) <0.1 (0–<0.1) 43 0.95 16 (14–19)
Yemen 26 13 (11–14) 48 (42–54) 0.08 (0.062–0.10) 0.31 (0.24–0.38) 9 628 37 77 (68–88)
Zambia 16 64 (44–88) 406 (279–557) 38 (25–52) 239 (162–331) 37 931 241 59 (43–86)
Zimbabwe 15 42 (29–58) 278 (193–379) 25 (17–35) 167 (114–229) 29 653 194 70 (51–100)
WHO regions
African Region 963 2 700 (2 400–3 000) 281 (250–313) 870 (790–950) 90 (82–99) 1 300 852 135 48 (43–54)
Region of the Americas 982 280 (270–290) 28 (27–29) 36 (34–38) 3.7 (3.5–3.9) 215 226 22 77 (75–81)
Eastern Mediterranean Region 636 740 (610–890) 117 (96–140) 12 (10–15) 1.9 (1.6–2.3) 453 393 71 61 (51–75)
European Region 907 340 (320–350) 37 (35–39) 20 (18–21) 2.2 (2.0–2.4) 273 381 30 81 (78–86)
South-East Asia Region 1 906 4 000 (3 700–4 400) 211 (192–232) 210 (180–240) 11 (9.4–12) 2 482 074 130 62 (56–68)
Western Pacific Region 1 845 1 600 (1 500–1 600) 85 (80–89) 31 (28–35) 1.7 (1.5–1.9) 1 335 816 72 85 (81–90)
Global 7 239 9 600 (9 100–10 000) 133 (126–141) 1 200 (1 100–1 300) 16 (15–17) 6 060 742 84 63 (60–66)
a
 Rates are per 100 000 population
b
 New cases, relapse cases and cases for which the treatment history is unknown.
TABLE A4.1
TB incidence estimates, notification and case detection rates, all forms of TB case, 2014
a Rates are per 100 000 population.
b New cases, relapse cases and cases for which the treatment history is unknown.
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Table A4.2
Estimates of TB mortality, 2014. Deaths from TB among HIV-positive people are officially classified as deaths caused by HIV/AIDS in 










Afghanistan 32 14 (10–18) 44 (32–57) 0.087 (0.072–0.10) 0.28 (0.23–0.33) 14 (10–18) 44 (32–58)
Albania 3 0.017 (0.012–0.023) 0.58 (0.40–0.79) <0.01 (<0.01–<0.01) <0.1 (<0.1–<0.1) 0.019 (0.014–0.025) 0.65 (0.47–0.85)
Algeria 39 4.4 (3.1–6.1) 11 (7.9–16) 0.046 (0.019–0.085) 0.12 (<0.1–0.22) 4.5 (3.1–6.1) 12 (8.0–16)
American Samoa < 1 <0.01 (<0.01–<0.01) 0.52 (0.31–0.80) 0 0 <0.01 (<0.01–<0.01) 0.52 (0.31–0.80)
Andorra < 1 <0.01 (<0.01–<0.01) 0.76 (0.47–1.1) 0 0 <0.01 (<0.01–<0.01) 0.76 (0.47–1.1)
Angola 24 13 (7.5–19) 52 (31–79) 3.5 (1.5–6.2) 14 (6.2–26) 16 (10–23) 67 (43–95)
Anguilla < 1 0 0 0 0 0 0
Antigua and Barbuda < 1 <0.01 (<0.01–<0.01) 3.8 (3.4–4.4) 0 0 <0.01 (<0.01–<0.01) 3.8 (3.4–4.4)
Argentina 43 0.61 (0.580–0.630) 1.4 (1.4–1.5) 0.058 (0.023–0.11) 0.13 (<0.1–0.25) 0.67 (0.620–0.720) 1.5 (1.4–1.7)
Armenia 3 0.14 (0.120–0.160) 4.7 (3.9–5.5) 0.012 (<0.01–0.016) 0.4 (0.29–0.53) 0.15 (0.130–0.180) 5.1 (4.3–5.9)
Aruba < 1 <0.01 (<0.01–<0.01) 0.9 (0.56–1.3) 0 0 <0.01 (<0.01–<0.01) 0.9 (0.56–1.3)
Australia 24 0.042 (0.042–0.042) 0.18 (0.18–0.18) <0.01 (<0.01–<0.01) <0.1 (<0.1–<0.1) 0.047 (0.045–0.049) 0.2 (0.19–0.21)
Austria 9 0.055 (0.054–0.056) 0.65 (0.64–0.66) <0.01 (<0.01–<0.01) <0.1 (0–<0.1) 0.056 (0.055–0.057) 0.66 (0.64–0.67)
Azerbaijan 10 0.041 (0.037–0.045) 0.42 (0.38–0.47) 0.028 (0.021–0.036) 0.29 (0.21–0.38) 0.069 (0.060–0.078) 0.72 (0.63–0.81)
Bahamas < 1 <0.01 (<0.01–<0.01) 0.63 (0.60–0.65) <0.01 (<0.01–<0.01) 0.78 (0.52–1.1) <0.01 (<0.01–<0.01) 1.4 (1.1–1.7)
Bahrain 1 <0.01 (<0.01–<0.01) 0.42 (0.36–0.47) 0 0 <0.01 (<0.01–<0.01) 0.42 (0.36–0.47)
Bangladesh 159 81 (59–110) 51 (37–68) 0.18 (0.14–0.22) 0.11 (<0.1–0.14) 82 (59–110) 51 (37–68)
Barbados < 1 <0.01 (<0.01–<0.01) 0 (0–0) 0 0 <0.01 (<0.01–<0.01) 0 (0–0)
Belarus 10 0.73 (0.680–0.790) 7.7 (7.1–8.3) 0.08 (0.064–0.098) 0.84 (0.67–1.0) 0.81 (0.750–0.870) 8.5 (7.9–9.2)
Belgium 11 0.031 (0.030–0.032) 0.28 (0.27–0.29) 0.01 (<0.01–0.014) <0.1 (<0.1–0.13) 0.041 (0.037–0.046) 0.37 (0.33–0.41)
Belize < 1 <0.01 (<0.01–<0.01) 1.8 (1.8–1.8) <0.01 (<0.01–<0.01) 2 (1.4–2.6) 0.013 (0.011–0.015) 3.8 (3.2–4.4)
Benin 11 1 (0.720–1.4) 9.8 (6.8–13) 0.31 (0.24–0.40) 3 (2.2–3.8) 1.4 (1.0–1.7) 13 (9.6–16)
Bermuda < 1 0 0 0 0 0 0
Bhutan < 1 0.072 (0.039–0.120) 9.5 (5.1–15) <0.01 (<0.01–<0.01) 0.13 (<0.1–0.29) 0.073 (0.040–0.120) 9.6 (5.2–15)
Bolivia (Plurinational State of) 11 0.33 (0.210–0.480) 3.1 (2.0–4.5) 0.13 (0.11–0.16) 1.2 (1.0–1.5) 0.46 (0.330–0.610) 4.4 (3.1–5.8)
Bonaire, Saint Eustatius and Saba < 1 0 0 0 0 0 0
Bosnia and Herzegovina 4 0.15 (0.130–0.160) 3.8 (3.5–4.2) 0 0 0.15 (0.130–0.160) 3.8 (3.5–4.2)
Botswana 2 0.62 (0.440–0.820) 28 (20–37) 1 (0.80–1.3) 47 (36–59) 1.7 (1.4–2.0) 75 (61–90)
Brazil 206 5.3 (4.9–5.7) 2.6 (2.4–2.7) 2.4 (1.8–3.2) 1.2 (0.87–1.6) 7.7 (7.0–8.5) 3.8 (3.4–4.1)
British Virgin Islands < 1 <0.01 (<0.01–<0.01) 5 (5.0–5.1) 0 0 <0.01 (<0.01–<0.01) 5 (5.0–5.1)
Brunei Darussalam < 1 0.015 (0.014–0.016) 3.6 (3.3–3.9) 0 0 0.015 (0.014–0.016) 3.6 (3.3–3.9)
Bulgaria 7 0.15 (0.150–0.160) 2.1 (2.1–2.2) 0 0 0.15 (0.150–0.160) 2.1 (2.1–2.2)
Burkina Faso 18 1.6 (1.2–2.1) 9.1 (6.6–12) 0.47 (0.39–0.56) 2.7 (2.2–3.2) 2.1 (1.6–2.6) 12 (9.2–15)
Burundi 11 2.5 (1.8–3.3) 23 (17–30) 0.69 (0.57–0.82) 6.4 (5.3–7.5) 3.2 (2.5–4.0) 30 (23–37)
Cabo Verde < 1 0.16 (0.110–0.210) 31 (22–41) 0.026 (0.022–0.031) 5.1 (4.2–6.0) 0.18 (0.140–0.240) 36 (27–46)
Cambodia 15 8.9 (6.3–12) 58 (41–78) 0.82 (0.63–1.0) 5.3 (4.1–6.7) 9.7 (7.1–13) 64 (46–83)
Cameroon 23 7.1 (5.1–9.4) 31 (22–41) 7.6 (6.3–9.2) 34 (28–40) 15 (12–17) 65 (54–77)
Canada 36 0.082 (0.081–0.082) 0.23 (0.23–0.23) 0.016 (<0.01–0.025) <0.1 (<0.1–<0.1) 0.098 (0.090–0.110) 0.27 (0.25–0.30)
Cayman Islands < 1 0 0 0 0 0 0
Central African Republic 5 2.3 (1.6–3.1) 48 (34–65) 3.1 (2.2–4.1) 64 (46–86) 5.4 (4.3–6.7) 113 (89–140)
Chad 14 3.1 (2.2–4.1) 23 (16–30) 2.1 (1.4–3.0) 15 (10–22) 5.2 (4.1–6.5) 38 (30–48)
Chile 18 0.29 (0.280–0.290) 1.6 (1.6–1.6) <0.01 (<0.01–<0.01) <0.1 (<0.1–<0.1) 0.29 (0.290–0.300) 1.6 (1.6–1.7)
China 1 369 38 (37–40) 2.8 (2.7–2.9) 0.7 (0.53–0.90) <0.1 (<0.1–<0.1) 39 (37–40) 2.8 (2.7–2.9)
China, Hong Kong SAR 7 0.18 (0.180–0.180) 2.5 (2.4–2.5) 0 0 0.18 (0.180–0.180) 2.5 (2.4–2.5)
China, Macao SAR < 1 0.023 (0.022–0.024) 4 (3.9–4.1) 0 0 0.023 (0.022–0.024) 4 (3.9–4.1)
Colombia 48 0.73 (0.710–0.750) 1.5 (1.5–1.6) 0.4 (0.30–0.51) 0.84 (0.64–1.1) 1.1 (1.0–1.2) 2.4 (2.1–2.6)
Comoros < 1 0.058 (0.041–0.078) 7.5 (5.3–10) 0 0 0.058 (0.041–0.078) 7.5 (5.3–10)
Congo 5 2.1 (1.5–2.8) 46 (32–61) 2.5 (2.1–3.0) 55 (46–66) 4.6 (3.8–5.4) 101 (84–119)
Cook Islands < 1 <0.01 (<0.01–<0.01) 1.8 (1.3–2.4) 0 0 <0.01 (<0.01–<0.01) 1.8 (1.3–2.4)
Costa Rica 5 0.039 (0.037–0.041) 0.83 (0.78–0.87) <0.01 (<0.01–<0.01) 0.15 (0.11–0.19) 0.046 (0.043–0.049) 0.97 (0.91–1.0)
Croatia 4 0.046 (0.045–0.046) 1.1 (1.1–1.1) 0 0 0.046 (0.045–0.046) 1.1 (1.1–1.1)
Cuba 11 0.029 (0.029–0.029) 0.25 (0.25–0.26) <0.01 (<0.01–<0.01) <0.1 (<0.1–<0.1) 0.036 (0.034–0.038) 0.32 (0.30–0.33)
Curaçao < 1 0 (0–<0.01) 0 (0–<0.1) 0 0 0 (0–0) 0 (0–0)
Cyprus 1 <0.01 (<0.01–<0.01) 0.42 (0.37–0.46) 0 0 <0.01 (<0.01–<0.01) 0.42 (0.37–0.46)
Czech Republic 11 0.06 (0.059–0.060) 0.56 (0.56–0.57) 0 0 0.06 (0.059–0.060) 0.56 (0.56–0.57)
Côte d'Ivoire 22 4.8 (3.5–6.3) 22 (16–29) 2.4 (1.9–2.9) 11 (8.7–13) 7.2 (5.8–8.8) 32 (26–40)
Democratic People's Republic of 
Korea 25 5 (2.0–9.3) 20 (7.9–37) 0.021 (0.015–0.028) <0.1 (<0.1–0.11) 5 (2.0–9.3) 20 (8.0–37)
Democratic Republic of the Congo 75 52 (38–68) 69 (50–90) 6.3 (5.0–7.7) 8.4 (6.7–10) 58 (44–74) 77 (58–99)
Denmark 6 0.024 (0.023–0.025) 0.42 (0.40–0.45) <0.01 (<0.01–<0.01) <0.1 (<0.1–<0.1) 0.025 (0.024–0.026) 0.44 (0.42–0.46)
Djibouti < 1 1.1 (0.760–1.4) 120 (87–159) 0.14 (0.12–0.17) 16 (13–19) 1.2 (0.900–1.5) 137 (103–175)
Dominica < 1 <0.01 (<0.01–<0.01) 2.7 (2.6–2.7) 0 0 <0.01 (<0.01–<0.01) 2.7 (2.6–2.7)






(HIV-negative and HIV-positive people)b
a Rates are per 100 000 population
b
 All calculations are made before numbers are rounded.
TABLE A4.2
Estimates of TB mortality, 2014. Deaths from TB among HIV-positive people are of ficially classified as deaths caused by  
HIV/AIDS in the International classification of diseases.
a R es   100 000 pop l i .
b All calculations are ade before nu bers are rounded.
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Table A4.2
Estimates of TB mortality, 2014. Deaths from TB among HIV-positive people are officially classified as deaths caused by HIV/AIDS in 















(HIV-negative and HIV-positive people)b
Ecuador 16 0.47 (0.390–0.560) 2.9 (2.4–3.5) 0.31 (0.23–0.40) 1.9 (1.5–2.5) 0.78 (0.660–0.900) 4.9 (4.2–5.7)
Egypt 90 0.22 (0.200–0.250) 0.25 (0.22–0.27) 0.043 (0.035–0.051) <0.1 (<0.1–<0.1) 0.27 (0.240–0.290) 0.3 (0.27–0.32)
El Salvador 6 0.12 (0.089–0.150) 1.9 (1.5–2.5) 0.031 (0.022–0.041) 0.51 (0.36–0.68) 0.15 (0.120–0.180) 2.4 (1.9–3.0)
Equatorial Guinea < 1 0.054 (0.033–0.081) 6.6 (4.0–9.9) 0.049 (0.033–0.069) 6 (4.0–8.4) 0.1 (0.076–0.140) 13 (9.2–17)
Eritrea 5 0.71 (0.460–1.0) 14 (9.0–20) 0.1 (0.058–0.15) 2 (1.1–3.0) 0.81 (0.550–1.1) 16 (11–22)
Estonia 1 0.027 (0.027–0.027) 2.1 (2.0–2.1) <0.01 (<0.01–<0.01) 0.3 (0.20–0.43) 0.031 (0.030–0.033) 2.4 (2.3–2.5)
Ethiopia 97 32 (22–43) 33 (23–44) 5.5 (4.4–6.8) 5.7 (4.6–7.0) 37 (27–48) 38 (28–50)
Fiji < 1 0.041 (0.041–0.042) 4.7 (4.6–4.8) <0.01 (<0.01–<0.01) 0.56 (0.45–0.69) 0.046 (0.045–0.048) 5.2 (5.1–5.4)
Finland 5 0.011 (0.011–0.011) 0.19 (0.19–0.19) 0 0 0.011 (0.011–0.011) 0.19 (0.19–0.19)
France 64 0.37 (0.360–0.390) 0.58 (0.56–0.61) 0.062 (0.034–0.099) 0.1 (<0.1–0.15) 0.43 (0.400–0.470) 0.68 (0.62–0.74)
French Polynesia < 1 <0.01 (<0.01–<0.01) 1.8 (1.1–2.6) 0 0 <0.01 (<0.01–<0.01) 1.8 (1.1–2.6)
Gabon 2 0.94 (0.660–1.3) 55 (39–75) 0.3 (0.24–0.37) 18 (14–22) 1.2 (0.950–1.6) 73 (56–93)
Gambia 2 0.35 (0.240–0.470) 18 (12–25) 0.14 (0.10–0.18) 7.2 (5.4–9.3) 0.49 (0.370–0.620) 25 (19–32)
Georgia 4 0.27 (0.200–0.340) 6.6 (5.1–8.3) 0.017 (0.010–0.025) 0.42 (0.26–0.63) 0.28 (0.220–0.350) 7 (5.5–8.7)
Germany 81 0.33 (0.320–0.330) 0.4 (0.40–0.41) 0.011 (<0.01–0.015) <0.1 (<0.1–<0.1) 0.34 (0.330–0.340) 0.42 (0.41–0.43)
Ghana 27 9.7 (4.4–17) 36 (16–64) 4.2 (2.3–6.5) 16 (8.8–24) 14 (7.9–21) 52 (30–80)
Greece 11 0.11 (0.110–0.120) 1 (0.96–1.1) <0.01 (<0.01–<0.01) <0.1 (<0.1–<0.1) 0.12 (0.110–0.120) 1 (0.98–1.1)
Greenland < 1 <0.01 (<0.01–0.013) 16 (10–24) 0 0 <0.01 (<0.01–0.013) 16 (10–24)
Grenada < 1 <0.01 (<0.01–<0.01) 0.44 (0.43–0.44) 0 0 <0.01 (<0.01–<0.01) 0.44 (0.43–0.44)
Guam < 1 <0.01 (<0.01–<0.01) 3.3 (2.1–4.8) 0 0 <0.01 (<0.01–<0.01) 3.3 (2.1–4.8)
Guatemala 16 0.26 (0.240–0.280) 1.6 (1.5–1.7) 0.54 (0.46–0.63) 3.4 (2.9–3.9) 0.8 (0.720–0.890) 5 (4.5–5.5)
Guinea 12 3.6 (2.6–4.8) 29 (21–39) 1.5 (1.2–1.8) 12 (10–15) 5.1 (4.0–6.3) 42 (33–51)
Guinea-Bissau 2 1.1 (0.700–1.7) 63 (39–93) 1.5 (1.1–1.9) 81 (60–104) 2.6 (2.0–3.3) 144 (111–181)
Guyana < 1 0.16 (0.140–0.170) 21 (18–23) 0.042 (0.033–0.052) 5.5 (4.3–6.8) 0.2 (0.180–0.220) 26 (24–29)
Haiti 11 2.1 (1.5–2.9) 20 (14–27) 0.77 (0.61–0.95) 7.3 (5.8–9.0) 2.9 (2.2–3.7) 27 (21–35)
Honduras 8 0.075 (0.075–0.076) 0.95 (0.94–0.95) 0.046 (0.034–0.060) 0.58 (0.43–0.75) 0.12 (0.110–0.130) 1.5 (1.4–1.7)
Hungary 10 0.069 (0.069–0.069) 0.7 (0.70–0.70) <0.01 (<0.01–<0.01) <0.1 (0–<0.1) 0.07 (0.069–0.071) 0.71 (0.70–0.72)
Iceland < 1 <0.01 (<0.01–<0.01) 0.28 (0.28–0.28) 0 0 <0.01 (<0.01–<0.01) 0.28 (0.28–0.28)
India 1 295 220 (150–350) 17 (12–27) 31 (25–38) 2.4 (2.0–2.9) 250 (170–360) 20 (13–28)
Indonesia 254 100 (66–150) 41 (26–59) 22 (13–32) 8.5 (5.2–13) 130 (86–170) 49 (34–67)
Iran (Islamic Republic of) 78 2.7 (1.9–3.7) 3.5 (2.4–4.7) 0.11 (0.070–0.15) 0.14 (<0.1–0.19) 2.8 (2.0–3.8) 3.6 (2.5–4.9)
Iraq 35 0.79 (0.016–3.0) 2.2 (<0.1–8.6) 0 0 0.79 (0.016–3.0) 2.2 (<0.1–8.6)
Ireland 5 0.02 (0.020–0.020) 0.43 (0.43–0.43) 0 0 0.02 (0.020–0.021) 0.43 (0.42–0.45)
Israel 8 0.014 (0.013–0.014) 0.17 (0.17–0.18) <0.01 (<0.01–<0.01) <0.1 (<0.1–<0.1) 0.016 (0.015–0.017) 0.2 (0.19–0.21)
Italy 60 0.26 (0.260–0.260) 0.44 (0.43–0.44) 0.031 (0.019–0.046) <0.1 (<0.1–<0.1) 0.29 (0.280–0.310) 0.49 (0.46–0.51)
Jamaica 3 <0.01 (<0.01–0.010) 0.31 (0.26–0.38) <0.01 (<0.01–0.011) 0.32 (0.25–0.41) 0.018 (0.015–0.021) 0.64 (0.54–0.74)
Japan 127 2.2 (2.1–2.3) 1.8 (1.7–1.8) 0.01 (<0.01–0.017) <0.1 (0–<0.1) 2.2 (2.2–2.3) 1.8 (1.7–1.8)
Jordan 7 0.025 (0.024–0.025) 0.33 (0.33–0.34) 0 0 0.025 (0.024–0.025) 0.33 (0.33–0.34)
Kazakhstan 17 1.5 (1.2–1.8) 8.6 (7.0–10) 0.037 (<0.01–0.11) 0.21 (<0.1–0.64) 1.5 (1.2–1.9) 8.8 (7.1–11)
Kenya 45 9.4 (6.7–12) 21 (15–28) 8.1 (6.4–10) 18 (14–22) 17 (14–21) 39 (32–47)
Kiribati < 1 0.054 (0.044–0.065) 49 (40–59) 0 0 0.054 (0.044–0.065) 49 (40–59)
Kuwait 4 <0.01 (<0.01–<0.01) 0.16 (0.16–0.17) 0 0 <0.01 (<0.01–<0.01) 0.16 (0.16–0.17)
Kyrgyzstan 6 0.65 (0.630–0.670) 11 (11–12) 0.055 (0.042–0.070) 0.94 (0.71–1.2) 0.71 (0.690–0.730) 12 (12–13)
Lao People's Democratic Republic 7 3.7 (2.4–5.2) 55 (36–78) 0.28 (0.21–0.35) 4.1 (3.2–5.2) 3.9 (2.6–5.5) 59 (40–82)
Latvia 2 0.054 (0.053–0.055) 2.7 (2.7–2.8) 0.019 (0.014–0.024) 0.96 (0.72–1.2) 0.073 (0.068–0.078) 3.7 (3.4–3.9)
Lebanon 6 0.089 (0.061–0.120) 1.6 (1.1–2.2) 0 0 0.089 (0.061–0.120) 1.6 (1.1–2.2)
Lesotho 2 1.4 (0.810–2.1) 64 (38–97) 4.9 (3.4–6.6) 231 (160–315) 6.2 (4.6–8.1) 296 (218–384)
Liberia 4 3 (2.2–4.0) 68 (49–90) 0.33 (0.28–0.39) 7.5 (6.3–8.8) 3.3 (2.5–4.3) 76 (57–98)
Libya 6 0.61 (0.430–0.820) 9.7 (6.8–13) 0 0 0.61 (0.430–0.820) 9.7 (6.8–13)
Lithuania 3 0.22 (0.220–0.220) 7.7 (7.6–7.7) 0.02 (0.015–0.025) 0.69 (0.53–0.86) 0.24 (0.240–0.250) 8.3 (8.2–8.5)
Luxembourg < 1 <0.01 (<0.01–<0.01) 0.16 (0.15–0.16) 0 0 <0.01 (<0.01–<0.01) 0.16 (0.15–0.16)
Madagascar 24 12 (8.7–16) 51 (37–68) 0.48 (0.39–0.58) 2 (1.7–2.4) 13 (9.2–16) 53 (39–70)
Malawi 17 2.8 (1.6–4.4) 17 (9.7–26) 7 (4.1–11) 42 (25–64) 9.8 (6.6–14) 59 (40–82)
Malaysia 30 2.4 (1.3–3.7) 8 (4.5–12) 0.62 (0.38–0.93) 2.1 (1.3–3.1) 3 (1.9–4.3) 10 (6.4–15)
Maldives < 1 <0.01 (<0.01–0.010) 2.3 (1.9–2.8) 0 0 <0.01 (<0.01–0.010) 2.3 (1.9–2.8)
Mali 17 1.8 (1.3–2.4) 11 (7.9–14) 0.4 (0.30–0.52) 2.4 (1.8–3.0) 2.2 (1.7–2.8) 13 (10–16)
Malta < 1 <0.01 (<0.01–<0.01) 0.26 (0.26–0.26) 0 0 <0.01 (<0.01–<0.01) 0.26 (0.26–0.26)
Marshall Islands < 1 0.02 (0.014–0.028) 38 (26–53) 0 0 0.02 (0.014–0.028) 38 (26–53)
Mauritania 4 0.89 (0.570–1.3) 22 (14–32) 0.026 (0.020–0.033) 0.65 (0.50–0.83) 0.91 (0.590–1.3) 23 (15–33)
Mauritius 1 0.016 (0.016–0.017) 1.3 (1.3–1.3) 0.01 (<0.01–0.014) 0.79 (0.54–1.1) 0.026 (0.023–0.030) 2.1 (1.8–2.4)
Mexico 125 2.1 (2.1–2.1) 1.7 (1.7–1.7) 0.31 (0.24–0.38) 0.24 (0.19–0.30) 2.4 (2.3–2.5) 1.9 (1.9–2.0)
Micronesia (Federated States of) < 1 0.017 (<0.01–0.028) 16 (7.6–27) 0 0 0.017 (<0.01–0.028) 16 (7.6–27)
a Rates are per 100 000 population
b
 All calculations are made before numbers are rounded.
TABLE A4.2
Estimates of TB mortality, 2014. Deaths from TB among HIV-positive people are of ficially classified as deaths caused by  
HIV/AIDS in the International classification of diseases.
a R es   100 000 pop l i .
b All calculations are ade before nu bers are rounded.
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Table A4.2
Estimates of TB mortality, 2014. Deaths from TB among HIV-positive people are officially classified as deaths caused by HIV/AIDS in 















(HIV-negative and HIV-positive people)b
Monaco < 1 <0.01 (<0.01–<0.01) 0.18 (0.11–0.26) 0 0 <0.01 (<0.01–<0.01) 0.18 (0.11–0.26)
Mongolia 3 0.064 (0.059–0.070) 2.2 (2.0–2.4) <0.01 (<0.01–<0.01) <0.1 (<0.1–<0.1) 0.066 (0.061–0.072) 2.3 (2.1–2.5)
Montenegro < 1 <0.01 (<0.01–<0.01) 0.58 (0.56–0.60) 0 0 <0.01 (<0.01–<0.01) 0.58 (0.56–0.60)
Montserrat < 1 <0.01 (<0.01–<0.01) 21 (20–21) 0 0 <0.01 (<0.01–<0.01) 21 (20–21)
Morocco 34 2.7 (0.022–11) 7.9 (<0.1–33) 0.12 (0.066–0.18) 0.34 (0.19–0.54) 2.8 (0.033–11) 8.2 (0.10–33)
Mozambique 27 18 (12–26) 67 (44–96) 37 (29–45) 134 (106–165) 55 (25–97) 201 (90–355)
Myanmar 53 28 (20–37) 53 (38–70) 4.1 (3.3–5.1) 7.7 (6.1–9.5) 32 (24–41) 60 (45–77)
Namibia 2 1.5 (1.1–2.0) 63 (45–83) 1.5 (1.2–1.9) 64 (51–79) 3 (2.5–3.6) 127 (104–152)
Nauru < 1 <0.01 (<0.01–<0.01) 6 (3.8–8.8) 0 0 <0.01 (<0.01–<0.01) 6 (3.8–8.8)
Nepal 28 4.9 (3.4–6.7) 17 (12–24) 0.38 (0.28–0.50) 1.4 (1.0–1.8) 5.3 (3.7–7.1) 19 (13–25)
Netherlands 17 0.022 (0.021–0.022) 0.13 (0.13–0.13) <0.01 (<0.01–<0.01) <0.1 (<0.1–<0.1) 0.027 (0.024–0.029) 0.16 (0.14–0.17)
New Caledonia < 1 <0.01 (<0.01–<0.01) 1.2 (0.76–1.8) 0 0 <0.01 (<0.01–<0.01) 1.2 (0.76–1.8)
New Zealand 4 <0.01 (<0.01–<0.01) 0.13 (0.13–0.13) 0 0 <0.01 (<0.01–<0.01) 0.13 (0.12–0.15)
Nicaragua 6 0.21 (0.160–0.260) 3.4 (2.7–4.3) 0.022 (0.017–0.028) 0.37 (0.28–0.47) 0.23 (0.180–0.280) 3.8 (3.0–4.7)
Niger 19 3.4 (2.4–4.5) 18 (13–23) 0.47 (0.39–0.56) 2.5 (2.0–2.9) 3.8 (2.9–4.9) 20 (15–26)
Nigeria 177 170 (91–280) 97 (51–156) 78 (53–110) 44 (30–61) 250 (160–360) 141 (91–201)
Niue < 1 0 0 0 0 0 0
Northern Mariana Islands < 1 <0.01 (<0.01–<0.01) 5 (3.1–7.3) 0 0 <0.01 (<0.01–<0.01) 5 (3.1–7.3)
Norway 5 <0.01 (<0.01–<0.01) 0.15 (0.14–0.15) 0 0 <0.01 (<0.01–<0.01) 0.15 (0.14–0.16)
Oman 4 0.024 (0.015–0.035) 0.56 (0.36–0.82) <0.01 (<0.01–<0.01) <0.1 (<0.1–<0.1) 0.025 (0.016–0.036) 0.59 (0.38–0.84)
Pakistan 185 48 (11–110) 26 (6.0–61) 1.3 (0.76–1.9) 0.68 (0.41–1.0) 50 (12–110) 27 (6.5–61)
Palau < 1 <0.01 (<0.01–<0.01) 1.2 (0.25–3.0) 0 0 <0.01 (<0.01–<0.01) 1.2 (0.25–3.0)
Panama 4 0.21 (0.200–0.230) 5.5 (5.1–5.9) 0.046 (0.034–0.060) 1.2 (0.87–1.6) 0.26 (0.240–0.280) 6.7 (6.2–7.2)
Papua New Guinea 7 3 (1.9–4.3) 40 (25–58) 0.54 (0.33–0.80) 7.2 (4.4–11) 3.5 (2.4–4.9) 47 (32–65)
Paraguay 7 0.19 (0.160–0.230) 2.9 (2.4–3.5) 0.053 (0.042–0.065) 0.81 (0.64–1.0) 0.25 (0.210–0.280) 3.7 (3.2–4.3)
Peru 31 2.2 (1.8–2.7) 7.2 (5.7–8.8) 0.25 (0.18–0.34) 0.81 (0.57–1.1) 2.5 (2.0–3.0) 8 (6.5–9.6)
Philippines 99 10 (9.0–11) 10 (9.1–11) 0.08 (0.055–0.11) <0.1 (<0.1–0.11) 10 (9.1–11) 10 (9.2–12)
Poland 39 0.53 (0.510–0.550) 1.4 (1.3–1.4) 0.016 (0.010–0.023) <0.1 (<0.1–<0.1) 0.54 (0.530–0.560) 1.4 (1.4–1.5)
Portugal 10 0.12 (0.120–0.130) 1.2 (1.1–1.3) 0.038 (0.023–0.057) 0.37 (0.22–0.54) 0.16 (0.150–0.180) 1.6 (1.4–1.7)
Puerto Rico 4 <0.01 (<0.01–<0.01) 0.19 (0.19–0.19) 0 0 <0.01 (<0.01–<0.01) 0.19 (0.19–0.19)
Qatar 2 <0.01 (<0.01–<0.01) 0.15 (<0.1–0.23) 0 0 <0.01 (<0.01–<0.01) 0.15 (<0.1–0.23)
Republic of Korea 50 1.9 (1.8–2.1) 3.8 (3.6–4.1) <0.01 (<0.01–0.013) <0.1 (<0.1–<0.1) 1.9 (1.8–2.1) 3.8 (3.6–4.1)
Republic of Moldova 4 0.32 (0.300–0.340) 7.8 (7.4–8.3) 0.11 (0.089–0.14) 2.7 (2.2–3.3) 0.43 (0.400–0.460) 11 (9.9–11)
Romania 20 1.1 (1.1–1.1) 5.5 (5.5–5.5) 0.054 (0.035–0.077) 0.27 (0.18–0.39) 1.1 (1.1–1.2) 5.8 (5.7–5.9)
Russian Federation 143 16 (15–16) 11 (11–11) 1.1 (0.83–1.3) 0.73 (0.58–0.91) 17 (16–18) 12 (11–12)
Rwanda 11 0.73 (0.510–0.990) 6.4 (4.5–8.7) 0.31 (0.21–0.42) 2.7 (1.8–3.7) 1 (0.790–1.3) 9.1 (7.0–12)
Saint Kitts and Nevis < 1 <0.01 (<0.01–<0.01) 2.7 (2.3–3.1) 0 0 <0.01 (<0.01–<0.01) 2.7 (2.3–3.1)
Saint Lucia < 1 <0.01 (<0.01–<0.01) 2.4 (2.3–2.5) 0 0 <0.01 (<0.01–<0.01) 2.4 (2.3–2.5)
Saint Vincent and the Grenadines < 1 <0.01 (<0.01–<0.01) 1 (1.0–1.1) 0 0 <0.01 (<0.01–<0.01) 1 (1.0–1.1)
Samoa < 1 <0.01 (<0.01–<0.01) 3.4 (2.4–4.6) 0 0 <0.01 (<0.01–<0.01) 3.4 (2.4–4.6)
San Marino < 1 0 0 0 0 0 0
Sao Tome and Principe < 1 0.014 (<0.01–0.019) 7.3 (4.8–10) <0.01 (<0.01–0.010) 2.7 (0.86–5.5) 0.019 (0.012–0.026) 10 (6.7–14)
Saudi Arabia 31 0.65 (0.210–1.4) 2.1 (0.67–4.4) 0 0 0.65 (0.210–1.4) 2.1 (0.67–4.4)
Senegal 15 3.1 (2.2–4.1) 21 (15–28) 0.43 (0.34–0.52) 2.9 (2.3–3.6) 3.5 (2.7–4.6) 24 (18–31)
Serbia 9 0.12 (0.110–0.130) 1.4 (1.3–1.5) 0 0 0.12 (0.110–0.130) 1.4 (1.3–1.5)
Seychelles < 1 0 0 0 0 0 0
Sierra Leone 6 2.8 (1.9–3.9) 45 (30–62) 0.7 (0.47–0.98) 11 (7.4–16) 3.5 (2.5–4.7) 56 (40–74)
Singapore 6 0.057 (0.048–0.068) 1 (0.87–1.2) 0.013 (<0.01–0.018) 0.24 (0.17–0.32) 0.07 (0.060–0.082) 1.3 (1.1–1.5)
Sint Maarten (Dutch part) < 1 0 0 0 0 0 0
Slovakia 5 0.025 (0.024–0.025) 0.45 (0.45–0.46) 0 0 0.025 (0.024–0.025) 0.45 (0.45–0.46)
Slovenia 2 0.016 (0.016–0.016) 0.76 (0.75–0.76) 0 0 0.016 (0.016–0.016) 0.76 (0.75–0.76)
Solomon Islands < 1 0.076 (0.053–0.100) 13 (9.3–18) 0 0 0.076 (0.053–0.100) 13 (9.3–18)
Somalia 11 7 (5.1–9.3) 67 (48–88) 0.44 (0.34–0.56) 4.2 (3.2–5.3) 7.5 (5.5–9.7) 71 (52–92)
South Africa 54 24 (22–26) 44 (41–48) 72 (58–89) 134 (107–164) 96 (81–110) 178 (151–209)
South Sudan 12 3.4 (2.4–4.7) 29 (20–39) 0 0 3.4 (2.4–4.7) 29 (20–39)
Spain 46 0.23 (0.230–0.240) 0.5 (0.50–0.51) 0.061 (0.036–0.093) 0.13 (<0.1–0.20) 0.29 (0.270–0.320) 0.64 (0.57–0.70)
Sri Lanka 21 1.3 (1.0–1.6) 6.1 (4.8–7.6) 0.014 (0.010–0.018) <0.1 (<0.1–<0.1) 1.3 (1.0–1.6) 6.2 (4.9–7.7)
Sudan 39 8.3 (4.3–14) 21 (11–34) 1 (0.67–1.4) 2.5 (1.7–3.6) 9.3 (5.2–15) 24 (13–37)
Suriname < 1 0.011 (0.011–0.012) 2.1 (2.0–2.2) 0.011 (<0.01–0.014) 2 (1.5–2.7) 0.022 (0.019–0.026) 4.1 (3.6–4.7)
Swaziland 1 0.65 (0.400–0.950) 51 (32–75) 1.7 (1.2–2.4) 135 (91–187) 2.4 (1.7–3.1) 186 (137–243)
Sweden 10 0.025 (0.025–0.026) 0.26 (0.26–0.27) <0.01 (<0.01–<0.01) <0.1 (<0.1–<0.1) 0.027 (0.027–0.028) 0.28 (0.27–0.29)
Switzerland 8 0.01 (0.010–0.010) 0.12 (0.12–0.13) <0.01 (<0.01–<0.01) <0.1 (<0.1–<0.1) 0.012 (0.011–0.013) 0.15 (0.13–0.16)
a Rates are per 100 000 population
b
 All calculations are made before numbers are rounded.
TABLE A4.2
Estimates of TB mortality, 2014. Deaths from TB among HIV-positive people are of ficially classified as deaths caused by  
HIV/AIDS in the International classification of diseases.
a R es   100 000 pop l i .
b All calculations are ade before nu bers are rounded.
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Table A4.2
Estimates of TB mortality, 2014. Deaths from TB among HIV-positive people are officially classified as deaths caused by HIV/AIDS in 















(HIV-negative and HIV-positive people)b
Syrian Arab Republic 19 0.012 (0.010–0.013) <0.1 (<0.1–<0.1) 0 0 0.012 (0.010–0.013) <0.1 (<0.1–<0.1)
Tajikistan 8 0.27 (0.200–0.360) 3.3 (2.4–4.4) 0.055 (0.039–0.074) 0.66 (0.47–0.89) 0.33 (0.250–0.420) 3.9 (3.0–5.0)
Thailand 68 7.4 (3.9–12) 11 (5.7–18) 4.5 (2.3–7.4) 6.6 (3.4–11) 12 (7.5–17) 18 (11–26)
The Former Yugoslav Republic of 
Macedonia 2 0.049 (0.048–0.050) 2.3 (2.3–2.4) 0 0 0.049 (0.048–0.050) 2.3 (2.3–2.4)
Timor-Leste 1 1.1 (0.760–1.5) 94 (66–126) 0 0 1.1 (0.760–1.5) 94 (66–126)
Togo 7 0.63 (0.440–0.850) 8.8 (6.1–12) 0.3 (0.23–0.38) 4.2 (3.3–5.3) 0.93 (0.720–1.2) 13 (10–16)
Tokelau < 1 0 0 0 0 0 0
Tonga < 1 <0.01 (<0.01–<0.01) 2.1 (1.4–2.9) 0 0 <0.01 (<0.01–<0.01) 2.1 (1.4–2.9)
Trinidad and Tobago 1 0.027 (0.024–0.029) 2 (1.8–2.2) 0.012 (<0.01–0.015) 0.89 (0.69–1.1) 0.039 (0.035–0.042) 2.8 (2.6–3.1)
Tunisia 11 0.23 (0.047–0.540) 2 (0.42–4.9) <0.01 (<0.01–0.010) <0.1 (<0.1–<0.1) 0.23 (0.052–0.550) 2.1 (0.47–4.9)
Turkey 78 0.47 (0.400–0.550) 0.61 (0.52–0.70) <0.01 (<0.01–0.012) <0.1 (<0.1–<0.1) 0.48 (0.410–0.550) 0.62 (0.53–0.72)
Turkmenistan 5 0.18 (0.150–0.210) 3.4 (2.9–4.0) 0 0 0.18 (0.150–0.210) 3.4 (2.9–4.0)
Turks and Caicos Islands < 1 <0.01 (<0.01–<0.01) 0.75 (0.72–0.77) 0 0 <0.01 (<0.01–<0.01) 0.75 (0.72–0.77)
Tuvalu < 1 <0.01 (<0.01–<0.01) 14 (8.3–21) 0 0 <0.01 (<0.01–<0.01) 14 (8.3–21)
US Virgin Islands < 1 <0.01 (<0.01–<0.01) 0.98 (0.96–0.99) 0 0 <0.01 (<0.01–<0.01) 0.98 (0.96–0.99)
Uganda 38 4.5 (3.2–6.1) 12 (8.4–16) 6.4 (5.0–8.1) 17 (13–21) 11 (8.9–13) 29 (24–35)
Ukraine 45 5.7 (5.6–5.8) 13 (13–13) 1.2 (0.82–1.6) 2.7 (1.8–3.7) 6.9 (6.5–7.4) 15 (14–16)
United Arab Emirates 9 0.029 (0.024–0.035) 0.32 (0.26–0.38) 0 0 0.029 (0.024–0.035) 0.32 (0.26–0.38)
United Kingdom of Great Britain 
and Northern Ireland 64 0.3 (0.290–0.300) 0.46 (0.45–0.46) 0.013 (<0.01–0.024) <0.1 (<0.1–<0.1) 0.31 (0.300–0.320) 0.48 (0.46–0.49)
United Republic of Tanzania 52 30 (13–54) 58 (26–104) 28 (15–43) 53 (30–84) 58 (36–85) 112 (69–164)
United States of America 319 0.46 (0.450–0.470) 0.14 (0.14–0.15) 0.11 (0.054–0.19) <0.1 (<0.1–<0.1) 0.57 (0.510–0.650) 0.18 (0.16–0.20)
Uruguay 3 0.057 (0.054–0.060) 1.7 (1.6–1.7) 0.024 (0.017–0.032) 0.7 (0.51–0.92) 0.081 (0.073–0.089) 2.4 (2.1–2.6)
Uzbekistan 29 2.7 (2.3–3.1) 9.1 (8.0–10) 0.16 (0.12–0.20) 0.54 (0.42–0.69) 2.9 (2.5–3.2) 9.7 (8.5–11)
Vanuatu < 1 0.02 (0.014–0.028) 7.9 (5.4–11) 0 0 0.02 (0.014–0.028) 7.9 (5.4–11)
Venezuela (Bolivarian Republic of) 31 0.54 (0.540–0.550) 1.8 (1.8–1.8) 0.12 (0.083–0.17) 0.4 (0.27–0.55) 0.67 (0.620–0.710) 2.2 (2.0–2.3)
Viet Nam 92 17 (11–23) 18 (12–25) 1.9 (1.3–2.5) 2 (1.4–2.7) 19 (13–25) 20 (14–27)
Wallis and Futuna Islands < 1 <0.01 (<0.01–<0.01) 0.3 (0.19–0.44) 0 0 <0.01 (<0.01–<0.01) 0.3 (0.19–0.44)
West Bank and Gaza Strip 5 <0.01 (<0.01–<0.01) 0.17 (0.17–0.18) <0.01 (<0.01–<0.01) <0.1 (<0.1–<0.1) <0.01 (<0.01–<0.01) 0.2 (0.19–0.21)
Yemen 26 1.1 (0.740–1.6) 4.4 (2.8–6.2) 0.025 (0.019–0.031) 0.1 (<0.1–0.12) 1.2 (0.760–1.7) 4.4 (2.9–6.3)
Zambia 16 5.1 (3.1–7.5) 32 (20–48) 11 (7.4–16) 72 (47–102) 16 (12–22) 104 (76–137)
Zimbabwe 15 2.3 (1.4–3.4) 15 (9.5–22) 5.2 (3.2–7.8) 34 (21–51) 7.6 (5.2–10) 50 (34–68)
WHO regions
African Region 963 450 (350–560) 46 (36–58) 310 (270–350) 32 (28–36) 750 (650–870) 78 (67–90)
Region of the Americas 982 17 (16–18) 1.7 (1.6–1.8) 6 (5.2–6.8) 0.61 (0.53–0.69) 23 (22–24) 2.3 (2.2–2.5)
Eastern Mediterranean Region 636 88 (43–150) 14 (6.8–23) 3.2 (2.6–4.0) 0.51 (0.41–0.62) 91 (46–150) 14 (7.2–24)
European Region 907 33 (33–34) 3.7 (3.6–3.8) 3.2 (2.7–3.7) 0.35 (0.30–0.40) 37 (36–38) 4 (3.9–4.1)
South-East Asia Region 1 906 460 (350–570) 24 (19–30) 62 (51–74) 3.3 (2.7–3.9) 520 (410–630) 27 (22–33)
Western Pacific Region 1 845 88 (81–95) 4.8 (4.4–5.1) 4.9 (4.2–5.7) 0.27 (0.23–0.31) 93 (86–100) 5 (4.6–5.4)
Global 7 239 1 100 (970–1 300) 16 (13–18) 390 (350–430) 5.3 (4.8–5.9) 1 500 (1 400–1 700) 21 (19–23)
a Rates are per 100 000 population
b
 All calculations are made before numbers are rounded.
TABLE A4.2
Estimates of TB mortality, 2014. Deaths from TB among HIV-positive people are of ficially classified as deaths caused by  
HIV/AIDS in the International classification of diseases.
a R es   100 000 pop l i .
b All calculations are ade before nu bers are rounded.
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TABLE A4.3
TB case notifications, 2014able A4.3





Afghanistan 31 746 14 737 8 573 7 227 1 209 966
Albania 408 159 83 145 16 2 3 0
Algeria 22 517 7 206 1 239 13 708 364 0 0 198
American Samoa
Andorra 6 3 0 2 1 0 0
Angola 53 552 22 046 25 262 3 562 2 682 0 0 1 654
Anguilla 1 1 0 0 0 0 0 0
Antigua and Barbuda 3 2 1 0 0 0 0 0
Argentina 9 195 5 249 2 218 1 255 319 107 47 843
Armenia 1 329 356 434 249 49 147 94 13
Aruba 2 2 0 0
Australia 1 330 721 78 474 42 1 14 13
Austria 564 388 58 104 9 3 2 18
Azerbaijan 5 788 1 877 1 678 829 905 359 140 1 751
Bahamas 50 25 20 1 2 2 0 0
Bahrain
Bangladesh 191 166 106 767 42 832 37 406 2 989 863 309 5 631
Barbados 5 3 1 1 0 0 0 0
Belarus 3 858 2 045 872 310 615 6 10 416
Belgium 886 531 97 258 73
Belize 72 33 29 8 2 0 15
Benin 3 886 3 079 313 359 135 0 0 91
Bermuda 0 0 0 0 0 0 0 0
Bhutan 1 066 454 91 466 55 0 0 16
Bolivia (Plurinational State of) 8 079 5 476 449 1 642 428 32 52 122
Bonaire, Saint Eustatius and Saba 0 0 0 0 0 0 0 0
Bosnia and Herzegovina 1 196 613 328 147 59 43 6 0
Botswana 6 019 2 218 1 819 1 008 439 403 132
Brazil 73 970 41 120 17 801 9 479 3 602 1 488 480 7 542
British Virgin Islands 0 0 0 0 0 0 0 0
Brunei Darussalam 198 150 6 35 5 0 2 0
Bulgaria 1 825 800 369 481 95 50 30 47
Burkina Faso 5 546 3 722 815 683 217 109 0 246
Burundi 7 226 4 265 653 2 102 206 0 0 83
Cabo Verde 274 172 41 52 9 0 0 18
Cambodia 43 059 12 168 11 286 18 310 445 709 141 679
Cameroon 26 038 15 410 5 472 4 060 1 096 479
Canada
Cayman Islands 0 0 0 0 0 0 0 0
Central African Republic 10 186 5 106 3 012 1 685 383 0 0 0
Chad 11 973 5 724 4 257 1 499 493 0 0 332
Chile 2 383 1 481 237 467 158 15 25 57
China 819 283 235 704 526 106 32 348 25 125 6 872
China, Hong Kong SAR 4 759 2 435 952 917 297 94 64 25
China, Macao SAR 394 250 55 60 21 4 4 0
Colombia 11 875 7 073 1 949 2 289 415 117 32 560
Comoros 148 83 29 32 4 0 0 2
Congo 10 017 3 876 3 479 2 466 196 177
Cook Islands 2 1 1 0 0 0 0 0
Costa Rica 463 380 7 63 10 0 3 6
Croatia 496 346 74 41 30 3 2 1
Cuba 729 467 130 80 41 7 4 13
Curaçao 5 4 1 0 0 0 0 0
Cyprus 39 31 3 4 0 1 0 2
Czech Republic 474 326 81 67 0 0 0 40
Côte d'Ivoire 23 275 14 233 2 901 5 243 898 475
Democratic People's Republic of Korea 103 045 34 622 41 423 18 587 8 413 0 0 7 245
Democratic Republic of the Congo 115 795 75 631 13 494 19 566 4 298 1 892 914 1 099
Denmark 293 200 26 67 27
Djibouti 2 220 1 069 986 165 7
















 Includes cases for which the treatment history is unknown.a Includes cases f r hich the treatment history is u known.
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Dominica 1 0 1 0 0 0 0 0
Dominican Republic 4 405 2 630 926 483 300 64 2 200
Ecuador 5 157 3 649 341 913 254 0 0 195
Egypt 7 177 3 697 886 2 285 309 0 0 290
El Salvador 2 206 1 564 215 291 134 0 2 14
Equatorial Guinea 1 166 700 280 142 41 3 0 47
Eritrea 2 391 771 714 774 86 34 12 34
Estonia 236 163 29 13 22 7 2 10
Ethiopia 119 592 40 087 41 575 37 930
Fiji 378 105 131 109 4 24 5 7
Finland 252 156 30 60 4 1 1 7
France 4 535 2 515 790 1 230 0 0 0 310
French Polynesia 56 37 8 11 0 0 0 3
Gabon 5 608 2 184 2 754 448 222 0 0 691
Gambia 2 552 1 475 787 209 81 0 0 31
Georgia 3 200 1 797 349 661 306 44 43 650
Germany 4 328 2 621 550 1 015 90 24 28 160
Ghana 14 668 7 682 5 364 1 181 441 608
Greece 484 354 51 79 0 0 0 35
Greenland
Grenada 0 0 0 0 0 0 0 0
Guam 56 31 21 3 1 0 0 0
Guatemala 3 163 2 103 550 352 132 15 11 61
Guinea 11 734 6 449 2 334 2 478 473 0 0 0
Guinea-Bissau 2 282 1 544 602 93 43 0 0 6
Guyana 545 284 153 58 19 31 0 103
Haiti 15 806 9 747 3 521 1 541 641 281 75 157
Honduras 2 820 1 810 380 406 180 22 22 0
Hungary 799 313 414 26 11 34 1 52
Iceland 8 3 2 2 1 0 0 0
India 1 609 547 754 268 343 032 275 502 124 679 112 066 74 368
Indonesia 322 806 193 321 101 991 19 653 6 449 1 391 1 1 733
Iran (Islamic Republic of) 10 191 5 601 1 251 2 869 339 69 62 204
Iraq 8 268 2 563 2 030 3 069 297 193 116 73
Ireland 297 149 35 113 19
Israel 368 201 62 99 4 2 0 0
Italy
Jamaica 86 34 44 6 2 0 0 0
Japan 19 615 12 120 2 061 4 255 797 171 211
Jordan 385 117 101 161 6 0 0 20
Kazakhstan 15 244 8 026 1 883 1 571 2 414 1 050 300 474
Kenya 88 025 34 997 30 872 14 640 3 569 2 947 1 000 1 269
Kiribati 414 151 198 55 10 0 0 18
Kuwait 734 319 177 237 1 0 0 0
Kyrgyzstan 6 390 1 849 2 407 1 624 510 1 033
Lao People's Democratic Republic 4 264 2 973 685 408 198 0 0 86
Latvia 738 487 97 53 91 9 1 23
Lebanon 673 306 120 238 9 0 0 10
Lesotho 8 840 2 619 4 312 1 363 519 27 0 1 016
Liberia 2 702 1 703 0 957 42 0 0 24
Libya 1 153 526 232 384 11 0 0 32
Lithuania 1 481 949 255 109 160 0 8 126
Luxembourg 24 12 4 8 0 0 0 0
Madagascar 28 466 18 825 2 093 5 658 1 562 328 470
Malawi 16 267 5 564 5 589 4 567 547 0 0 1 456
Malaysia 24 054 14 099 5 743 3 055 749 300 108 657
Maldives 131 90 0 41 0 0 0
Mali 5 809 3 804 632 1 208 165 0 167
Malta 45 20 13 12 0 0 0 1
Marshall Islands 142 53 46 37 4 1 1 11
a
 Includes cases for which the treatment history is unknown.
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TB case notifications, 2014
a Includes cases f r hich the treatment history is u known.
168  n  GLOBAL TUBERCULOSIS REPORT 2015 Data for all years can be downloaded from www.who.int/tb/data
Table A4.3




















Mauritania 2 420 1 364 350 588 118 18
Mauritius 126 114 0 10 2 0 0 1
Mexico 21 196 13 177 3 060 3 892 779 192 96 685
Micronesia (Federated States of) 188 36 126 26 0 0 0 1
Monaco
Mongolia 4 483 1 791 676 1 705 241 24 46 288
Montenegro 113 63 27 13 7 2 1 0
Montserrat 0 0 0 0 0 0 0 0
Morocco 29 843 12 302 2 436 13 397 1 189 97 422 881
Mozambique 57 773 24 430 23 455 6 276 1 542 2 070 497
Myanmar 138 352 42 608 70 305 16 108 5 276 3 650 405 3 605
Namibia 8 972 4 335 2 035 1 469 1 133 910
Nauru 8 5 2 1 0 0 0 0
Nepal 35 277 15 947 8 445 8 583 2 302 1 748
Netherlands 814 354 87 363 5 1 4 9
New Caledonia 29 12 3 12 2 0 0
New Zealand 297 160 19 111 4 0 3 5
Nicaragua 2 632 1 447 717 338 130 0 0 207
Niger 10 851 7 073 1 698 1 710 370 251
Nigeria 86 464 49 825 29 460 4 764 2 415 0 4 890
Niue 0 0 0 0 0 0 0 0
Northern Mariana Islands 26 19 6 0 1 0 0 0
Norway 303 241 31 31 22
Oman 358 234 0 116 7 0 1 0
Pakistan 308 417 122 537 120 350 57 463 7 420 426 221 8 160
Palau 14 7 4 3 0 0 0 0
Panama 1 457 713 353 284 50 38 19 71
Papua New Guinea 26 170 3 840 10 716 11 406 208 0 2 397
Paraguay 2 246 1 370 459 208 163 42 4 169
Peru 30 008 17 823 4 204 5 348 2 128 366 139 1 453
Philippines 243 379 92 991 139 950 4 161 6 277 24 057
Poland 6 539 4 216 1 476 374 337 125 11 159
Portugal 2 169 1 257 219 595 71 11 16 57
Puerto Rico 44 39 0 5 0 0 0 0
Qatar 465 150 5 310 0 0 0 0
Republic of Korea 40 190 18 784 9 350 6 987 2 705 1 665 699 2 898
Republic of Moldova 4 058 1 774 1 157 343 477 276 31 578
Romania 14 861 7 874 2 421 2 209 1 899 356 102 1 045
Russian Federation 102 340 37 296 40 894 8 763 7 982 6 753 652 33 828
Rwanda 5 761 4 003 554 857 347 0 0 263
Saint Kitts and Nevis 7 1 6 0 0 0 0 0
Saint Lucia 6 5 1 0 0 0 0 0
Saint Vincent and the Grenadines 5 4 1 0 0 0 0 1
Samoa 23 9 10 3 1 0 0 0
San Marino
Sao Tome and Principe 158 70 50 20 9 9 0
Saudi Arabia 3 248 1 942 412 789 93 4 8 88
Senegal 13 332 9 278 1 514 1 653 653 234 0 315
Serbia 1 818 902 432 351 81 44 8 14
Serbia (without Kosovo) 984 666 113 124 59 14 14
Kosovo 834 236 319 227 22 30 0
Seychelles 13 7 1 5 0 0 0 0
Sierra Leone 12 477 7 453 4 239 509 276 0 244
Singapore 2 171 1 056 649 313 93 42 18 0
Sint Maarten (Dutch part) 0 0 0 0 0 0 0 0
Slovakia 320 155 77 57 21 5 5 16
Slovenia 142 89 9 39 5 0 0 2
Solomon Islands 345 145 79 111 8 2 0 1
Somalia 12 903 6 248 3 378 2 813 372 70 22 227
South Africa 306 166 155 473 106 482 33 522 7 430 2 693 566 12 027
a
 Includes cases for which the treatment history is unknown.
TABLE A4.3
TB case notifications, 2014
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South Sudan 8 335 3 565 2 887 1 624 259 521
Spain 4 818 2 843 673 1 302 0 0 0 230
Sri Lanka 9 305 4 345 1 962 2 710 288 0 0 168
Sudan 19 266 6 106 7 934 4 571 655 1 126
Suriname 149 100 16 26 4 2 1 9
Swaziland 5 583 2 540 1 606 765 322 350 33
Sweden 635 313 44 270 4 0 4 35
Switzerland 423 272 30 121 50
Syrian Arab Republic 3 481 1 161 441 1 796 55 6 22 95
Tajikistan 5 807 2 432 1 162 1 423 540 139 111 453
Thailand 67 722 34 394 21 115 10 244 1 969 0 0 3 896
The Former Yugoslav Republic of 
Macedonia 284 167 31 64 19 0 3 1
Timor-Leste 3 657 1 838 1 222 519 78 121
Togo 2 525 1 899 177 339 110 0 0 52
Tokelau 0 0 0 0 0 0 0 0
Tonga 13 8 5 0 0 0 0 0
Trinidad and Tobago 251 128 88 25 5 5 0 42
Tunisia 3 134 1 052 214 1 834 34 39
Turkey 13 108 5 799 1 897 4 557 568 119 168 270
Turkmenistan 2 570 1 944 415 173 38 317
Turks and Caicos Islands 1 0 0 0 1 0 0 2
Tuvalu 15 8 6 0 1 0
US Virgin Islands
Uganda 44 187 26 079 11 854 4 180 1 499 468 107 1 984
Ukraine 31 701 14 242 9 296 2 596 4 566 800 201 8 601
United Arab Emirates 60 37 3 16 3 1 0 1
United Kingdom of Great Britain and 
Northern Ireland 6 622 2 672 872 3 078 455
United Republic of Tanzania 61 571 23 583 23 380 13 600 1 008 1 580
United States of America 8 949 5 838 1 234 1 877 0 0 0 458
Uruguay 862 536 180 83 50 12 1 26
Uzbekistan 18 345 4 404 6 261 4 514 1 809 1 092 265 4 459
Vanuatu 112 38 22 51 1 0 0 0
Venezuela (Bolivarian Republic of) 6 392 3 526 1 458 1 079 243 80 6 223
Viet Nam 100 349 49 938 25 179 18 118 7 114 1 738
Wallis and Futuna Islands 0 0 0 0 0 0 0 0
West Bank and Gaza Strip 43 14 18 8 3 0 0 0
Yemen 9 628 2 912 3 135 3 390 191 0 0 65
Zambia 37 931 12 070 15 568 8 584 1 709 4 785
Zimbabwe 29 653 11 224 13 151 3 909 1 369 2 363
WHO regions
African Region 1 300 852 635 560 399 155 212 057 39 782 11 217 3 081 41 407
Region of the Americas 215 226 127 844 40 751 32 500 10 192 2 918 1 021 13 234
Eastern Mediterranean Region 453 393 183 630 151 696 103 959 12 368 866 874 12 284
European Region 273 381 116 599 78 170 40 857 23 956 11 508 2 291 55 889
South-East Asia Region 2 482 074 1 188 654 632 418 389 819 152 498 117 970 715 98 531
Western Pacific Region 1 335 816 449 845 734 179 103 085 44 354 3 037 1 316 39 756
Global 6 060 742 2 702 132 2 036 369 882 277 283 150 147 516 9 298 261 101
a
 Includes cases for which the treatment history is unknown.
TABLE A4.3
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Table A4.4
Notified new and relapse TB cases by age and sex, 2014
0–14 > 15 Unknown 0–4 5–14 15–24 25–34 35–44 45–54 55–64 > 65
Afghanistan* Female 2 283 11 890 3 921 34 33
Male 2 171 6 966 3 306 41 24
Albania Female 8 130 0 3.5 2.8 10 8.2 7.3 12 12 15
Male 13 257 0 4.3 4.7 19 22 17 20 28 28
Algeria* Female 46 2 649 23 18 13 13 19 33




Male 6 35 18 49
Angola Female 514 8 649 0 1.3 14 111 163 162 141 107 97
Male 395 12 488 0 1.6 10 136 253 262 241 186 160
Anguilla Female 0 1 0 0 0 0 91 0 0 0 0
Male 0 0 0 0 0 0 0 0 0 0 0
Antigua and Barbuda Female 0 3 0 0 0 13 0 15 0 0 27
Male 0 0 0 0 0 0 0 0 0 0 0
Argentina Female 410 3 454 24 7.7 7.6 27 26 20 16 19 13
Male 435 4 824 48 8.1 7.7 33 35 28 29 31 28
Armenia Female 11 306 0 0.99 6.1 24 22 22 28 30 12
Male 21 991 0 9.1 5.9 51 76 94 108 136 83
Aruba Female 2 35
Male
Australia Female 25 598 0 1.5 1 5.6 12 7 4.5 3.3 4.2
Male 28 679 0 1.5 1.1 6.2 9.5 6.2 4.7 6.8 9
Austria Female 8 190 0 1.5 1.3 6.1 8.2 4.2 3.6 5.2 4.2
Male 6 359 0 0.49 1.2 13 11 9.4 8.7 7.2 12
Azerbaijan* Female 60 1 103 0 2.4 8.7 39 31 21 25 29 20
Male 119 3 107 0 6.1 14 102 78 84 85 79 61
Bahamas Female 1 23 0 7.1 0 9.2 13 18 19 15 17
Male 1 25 0 0 3.8 18 13 26 24 6 7.8
Bahrain Female
Male
Bangladesh* Female 3 369 70 547 0 4.8 19 103 113 119 156 225 145
Male 2 893 110 196 0 7.2 14 91 137 155 249 491 526
Barbados* Female 1 1 0 0 5.5 0 0 0 0 5.4 0
Male 0 3 0 0 0 0 11 0 0 6.2 0
Belarus Female 8 1 038 0 0.71 1.3 20 34 32 19 14 23
Male 16 2 796 0 2 2.1 22 71 104 110 90 52
Belgium Female 32 287 0 5.7 2.3 8.5 11 7.6 3.7 3.4 3.8
Male 29 538 0 4.2 2.4 11 18 15 7.9 9.5 11
Belize Female 2 23 0 0 5.2 2.7 27 23 26 23 46
Male 3 44 0 0 7.7 14 36 29 70 44 120
Benin* Female 39 1 064 25 50 40 31 25 26
Male 21 1 955 27 75 95 96 78 85
Bermuda Female 0 0 0 0 0 0 0 0 0 0 0
Male 0 0 0 0 0 0 0 0 0 0 0
Bhutan Female 24 507 0 18 26 298 225 127 90 115 170
Male 32 503 0 23 33 214 135 118 151 177 247
Bolivia (Plurinational State of)* Female 189 2 760 0 6.9 13 87 76 52 52 86 119
Male 205 4 413 0 8.1 13 127 103 86 123 164 219
Bonaire, Saint Eustatius and Saba Female 0 0 0 0 0 0 0 0 0 0 0
Male 0 0 0 0 0 0 0 0 0 0 0
Bosnia and Herzegovina Female 2 490 0 0 1.2 26 10 21 15 23 73
Male 13 691 0 3.3 5.6 27 20 31 44 52 87
Botswana Female 203 2 324 0 80 44 190 344 419 352 278 314
Male 216 3 274 0 110 31 158 370 628 697 627 964
Brazil Female 1 095 23 113 0 5.6 4.2 27 31 29 28 28 28
Male 1 273 48 489 0 7.6 4.1 45 66 66 72 76 67
British Virgin Islands Female 0 0 0 0 0 0 0 0 0 0 0
Male 0 0 0 0 0 0 0 0 0 0 0
Brunei Darussalam Female 1 77 0 0 3.2 20 46 60 32 53 186
Male 0 120 0 0 0 30 63 61 67 95 339
Bulgaria Female 64 519 0 9 15 14 13 18 20 13 17
Male 81 1 161 0 19 14 20 36 42 51 44 37
Burkina Faso* Female 33 1 072 0 0.52 1 11 24 25 33 37 37
Male 22 2 595 0 0.13 0.8 17 63 86 91 94 129
Notified cases by age group 
(rate per 100 000 population)
Notified cases by age
(Number)
* New cases only
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Notified new and relapse TB cases by age and sex, 2014
0–14 > 15 Unknown 0–4 5–14 15–24 25–34 35–44 45–54 55–64 > 65
Notified cases by age group 
(rate per 100 000 population)
Notified cases by age
(Number)
Burundi* Female 247 2 249 0 11 9.5 49 70 107 108 79 90
Male 281 4 243 0 13 10 58 146 221 253 205 209
Cabo Verde* Female 5 57 0 3.8 8.1 26 33 43 23 35 28
Male 6 197 0 11 5.9 67 70 240 191 60 100
Cambodia Female 5 289 14 663 136 269 96 152 256 366 584 854





Cayman Islands Female 0 0 0 0 0 0 0 0 0 0 0
Male 0 0 0 0 0 0 0 0 0 0 0
Central African Republic* Female 107 2 042 0 107 179 193 142 99 43
Male 99 2 637 0 93 225 299 275 166 85
Chad Female 431 3 853 0 14 13 55 122 150 176 169 112
Male 550 7 139 0 20 14 77 219 320 375 306 309
Chile Female 23 822 5 1 1.4 5.9 9.3 11 11 16 18
Male 30 1 492 11 2 1.4 9.4 18 17 22 27 51
China Female 2 010 248 755 0 0.25 2.7 47 40 33 36 52 73
Male 2 154 566 364 0 0.47 2.4 76 65 69 93 140 204
China, Hong Kong SAR Female 8 1 732 0 2.4 1.6 36 44 40 40 49 95
Male 12 3 007 0 1.1 3.8 36 45 52 64 115 293
China, Macao SAR Female 2 131 0 0 9.8 41 70 33 39 43 77
Male 2 259 0 0 9.1 70 70 67 111 195 185
Colombia Female 298 4 223 0 8.3 3.7 17 23 20 18 27 45
Male 292 7 062 0 7.4 3.7 25 36 30 41 57 100
Comoros Female 55 20 29 26 26 18 26
Male 88 27 51 33 49 32 51
Congo* Female 68 1 465 0 2.7 9.9 112 131 126 100 90 62
Male 35 2 308 0 1.3 5.1 118 241 248 182 143 81
Cook Islands Female 0 0 0 0 0 0 0 0 0 0 0
Male 0 2 0 0 0 0 0 0 0 129 164
Costa Rica Female 15 142 0 4.1 2.3 4.2 5.9 9.6 7.2 8.5 14
Male 11 295 0 2.8 1.6 6.7 13 14 20 28 29
Croatia Female 0 187 0 0 0 5.1 8.6 6.6 5.7 9.9 17
Male 3 306 0 0.92 0.92 7.3 9.7 13 24 21 30
Cuba Female 8 163 0 0.69 0.96 3.2 3.8 3 3.3 3.8 3.7
Male 7 551 0 0.98 0.6 5.8 11 15 13 14 9.3
Curaçao Female 0 1 0 0 0 0 0 0 0 0 7.6
Male 0 4 0 0 0 0 0 12 0 11 21
Cyprus Female 0 18 0 0 0 3.6 5.4 7.5 4.2 0 1.3
Male 0 21 0 0 0 4.4 8.5 3.4 2.7 0 4.6
Czech Republic Female 2 146 0 0.38 0.2 1.5 2.5 2.2 2.2 2.7 6.1
Male 3 323 0 0.71 0.19 2.1 5 5.9 11 9.9 10
Côte d'Ivoire* Female 217 5 120 0.95 6.8 59 110 101 74 80 86
Male 169 8 727 0.78 5.2 72 196 185 141 119 110
Democratic People's Republic of Korea* Female 2 521 33 374 0 44 121 238 405 456 395 330 115
Male 3 110 55 627 0 49 144 367 632 739 671 667 377
Democratic Republic of the Congo* Female 1 856 30 748 126 1.3 17 90 171 201 210 207 118
Male 1 582 41 153 166 1.4 14 97 215 301 330 323 236
Denmark Female 4 116 0 2.1 0.31 3.9 9 8.3 4.7 3.2 2.1
Male 5 168 0 1.3 0.88 4.2 12 6.4 11 7.3 3.6
Djibouti* Female 27 348 6 26 119 136 126 110 77 93
Male 24 670 1.9 24 180 304 247 211 208 161
Dominica Female 0 0 0 0 0 0 0 0 0 0 0
Male 0 1 0 0 0 0 0 0 23 0 0
Dominican Republic Female 17 839 479 0.77 1.3 22 26 26 20 19 19
Male 30 1 677 1 363 0.74 2.5 36 60 58 45 42 33
Ecuador Female 111 1 816 0 4.5 5.1 29 33 28 28 34 50
Male 113 3 117 0 3.5 5.4 44 60 48 60 64 81
Egypt* Female 189 2 644 0 0.6 1.8 4.4 8.7 14 11 12 5.7
Male 240 3 795 0 0.88 2 6.7 10 16 20 20 12
El Salvador* Female 101 677 0 11 13 13 21 25 38 42 55
Male 72 1 220 0 6.3 9.3 42 81 59 47 59 95
Equatorial Guinea Female 27 416 0 8 22 153 219 253 133 125 70
Male 31 550 0 9.5 25 125 258 358 219 213 74
* New cases only
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0–14 > 15 Unknown 0–4 5–14 15–24 25–34 35–44 45–54 55–64 > 65
Notified cases by age group 
(rate per 100 000 population)
Notified cases by age
(Number)
Eritrea Female 138 958 13 13 36 57 74 103 109 133
Male 168 1 127 17 14 52 51 91 116 129 313
Estonia Female 0 72 0 0 0 4.3 16 17 8.9 11 12
Male 1 163 0 0 1.4 8.1 20 41 52 52 18
Ethiopia* Female 7 438 46 876 0 21 46
Male 8 479 56 799 0 35 45
Fiji Female 19 123 0 12 17 39 46 38 28 28 63
Male 26 210 0 24 17 24 61 57 106 95 114
Finland Female 5 109 0 2 0.69 2.5 6.8 1.9 2.7 2.9 8.2
Male 3 135 0 0.64 0.66 3.9 4.8 4.5 2.1 4.9 14
France Female 135 1 597 0 3.5 1.8 6.6 9.5 6.5 4.3 3.4 5.6
Male 135 2 645 0 3.3 1.7 9.1 15 12 8.8 8.5 10
French Polynesia Female 1 25 0 9.6 0 21 14 10 28 57 29
Male 1 29 0 9.1 0 8 23 29 10 23 109
Gabon Female 211 2 190 0 55 75 281 435 552 517 552 385
Male 252 2 955 0 57 93 365 572 630 799 743 518
Gambia Female
Male
Georgia Female 61 1 000 0 11 24 86 93 52 42 28 36
Male 68 2 071 0 13 22 94 159 151 160 142 85
Germany Female 67 1 522 1 1.8 1.1 4.6 5.9 4.5 3 3 4.7
Male 79 2 653 0 1.9 1.3 12 9.3 7.7 5.6 5.9 7.7
Ghana Female 341 4 826 6.4 6.9 26 54 71 80 80 122
Male 372 9 129 7.2 6.8 34 84 169 207 203 262
Greece Female 4 142 0 1.1 0.19 2.2 4.2 2.2 2.1 0.72 4.8
Male 5 328 3 1.1 0.37 5 9.3 7.1 5.5 7.3 8.2
Greenland Female
Male
Grenada Female 0 0 0 0 0 0 0 0 0 0 0
Male 0 0 0 0 0 0 0 0 0 0 0
Guam Female 4 25 0 0 28 15 35 28 19 78 104
Male 3 24 0 14 13 6.8 17 55 53 38 93
Guatemala Female 141 1 215 0 15 21 22 35 40 29
Male 143 1 664 0 20 31 38 50 60 65
Guinea* Female 198 3 180 34 106 107 152 131 131
Male 212 7 671 86 243 316 321 302 356
Guinea-Bissau Female 44 823 1 16 9.7 110 181 225 161 126 92
Male 64 1 348 2 18 17 126 331 348 340 289 230
Guyana Female 5 146 0 0 6.2 25 78 62 56 81 65
Male 6 388 0 0 7.4 53 174 213 184 166 158
Haiti Female 860 6 632 62 41 187 229 197 152 153 103
Male 835 7 479 70 32 176 270 259 213 191 195
Honduras Female 58 1 017 0 5.2 4.3 22 35 37 50 63 70
Male 69 1 676 0 6.2 4.8 34 57 64 84 92 155
Hungary Female 2 305 0 0 0.42 5 4.8 6.5 7.6 7.3 8.3
Male 2 490 0 0 0.4 3.3 6.2 7.5 20 22 17
Iceland Female 0 3 0 0 0 4.3 4.4 0 4.6 0 0
Male 0 5 0 0 0 8.2 4.2 4.7 4.7 0 0
India Female 50 943 503 218 12 36 131 124 106 98 101 81
Male 44 766 1 010 620 14 26 143 171 229 281 317 305
Indonesia Female 11 081 122 592 0 41 27 121 131 124 151 179 114
Male 12 089 177 044 0 44 27 122 175 173 233 319 296
Iran (Islamic Republic of) Female 204 4 770 0 1.8 2.6 10 8.1 11 13 27 82
Male 146 5 071 0 2.2 1.2 7.2 13 15 15 24 69
Iraq Female 323 3 988 0 2.5 5.9 28 29 27 46 85 101
Male 262 3 695 0 3.6 3.4 18 28 35 51 80 119
Ireland Female 3 132 0 0 0.95 5 10 5.6 6.3 7.2 8.1
Male 4 158 0 0 1.2 6.3 9.7 8.5 7.2 6.9 14
Israel Female 14 120 0 2.8 0.45 2.8 5.6 3.3 4.7 2.6 5.5
Male 17 217 0 3.8 0.14 4.8 14 6.1 5.4 6 9.4
Italy Female
Male
Jamaica Female 4 16 0 3 0.44 0.38 2.2 0.55 4.5 1.8 0
Male 4 62 0 1.9 0.84 3.6 8.3 3.6 5.7 13 4.3
Japan Female 26 7 584 0 0.35 0.31 5.5 8.3 5.9 6.5 6.8 27
Male 23 11 982 0 0.29 0.26 6.3 8.8 8.7 11 18 55
* New cases only
* New cases only.
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0–14 > 15 Unknown 0–4 5–14 15–24 25–34 35–44 45–54 55–64 > 65
Notified cases by age group 
(rate per 100 000 population)
Notified cases by age
(Number)
Jordan Female 14 168 0 0.63 1.3 4.3 9.7 6.9 5.3 13 10
Male 16 187 0 0.4 1.6 5 8.6 6.4 7 14 16
Kazakhstan Female 235 5 792 0 6.4 14 103 119 84 60 53 64
Male 217 9 000 0 6.6 11 115 146 180 165 165 124
Kenya Female 4 069 31 036 0 51 39 158 288 307 271 200 249
Male 4 379 49 810 0 59 38 195 431 561 558 399 483
Kiribati Female 52 147 0 165 345 275 417 391 485 495 536
Male 43 172 0 185 237 399 189 633 715 963 870
Kuwait Female 2 325 0 0 0.83 15 42 24 15 13 29
Male 7 400 0 2.3 1.2 12 24 25 34 24 31
Kyrgyzstan* Female 202 2 414 0 9.7 32 142 130 88 70 113 151
Male 236 3 028 0 10 36 142 138 163 164 196 177
Lao People's Democratic Republic Female 47 1 508 0 2.9 4.7 20 49 66 115 162 202
Male 26 2 581 0 1.6 2.5 27 67 129 241 342 445
Latvia Female 15 197 0 11 11 17 38 33 26 15 8.1
Male 26 500 0 24 14 38 74 80 96 68 31
Lebanon Female 34 366 6.1 4.5 19 29 14 6.2 9.8 9.2
Male 22 251 5.5 2.2 8.1 13 16 9.9 14 11
Lesotho Female 196 3 543 56 64 45 255 677 917 709 406 357
Male 172 4 803 70 54 39 156 692 1 380 1 770 1 400 1 200
Liberia* Female 25 531 0 0 4.3 20 62 57 47 33 38
Male 21 1 126 0 1.1 2.8 49 99 114 113 71 205
Libya Female 42 413 0 3.1 5.5 16 19 16 21 25 25
Male 27 671 0 1.8 3.4 19 35 37 28 25 40
Lithuania Female 14 445 0 1.4 9.9 21 48 39 37 27 28
Male 8 1 014 0 2.6 4.3 25 61 127 123 126 82
Luxembourg Female 0 10 0 0 0 0 12 4.8 0 0 6.9
Male 0 14 0 0 0 8.4 4.9 12 2.2 3.1 5.9
Madagascar* Female
Male
Malawi Female 858 5 716 0 24 22 57 150 206 186 143 127
Male 969 8 724 0 30 23 55 229 341 321 274 273
Malaysia Female 354 8 434 0 7.9 10 62 70 69 72 99 119
Male 337 14 929 0 12 7.7 71 97 139 172 227 266
Maldives Female 10 49 11 27 34 27 13 18 75 173
Male 4 68 16 3.2 19 42 23 57 121 238
Mali Female 37 1 216 608 14 36 32 34 34 35
Male 32 2 519 1 234 23 62 69 94 113 102
Malta Female 0 12 0 0 0 11 27 3.3 3.7 0 2.3
Male 0 33 0 0 0 64 29 10 7.2 0 5.7
Marshall Islands Female 1 30 0 0 20 191 134 177 275 49 60
Male 1 25 0 0 18 101 158 98 220 185 0
Mauritania Female 67 695 12 3.4 12 45 57 65 64 86 74
Male 75 1 559 23 5.3 12 78 128 120 157 240 345
Mauritius Female 0 39 0 0 0 8 13 5.3 4.3 8.2 6
Male 0 87 0 0 0 13 22 19 22 16 10
Mexico Female 381 7 710 0 1.8 2.4 12 14 14 21 26 28
Male 407 12 698 0 3.1 1.9 15 23 27 38 43 56
Micronesia (Federated States of) Female 19 73 0 125 102 160 227 189 300 230 373
Male 18 77 0 184 55 226 232 272 188 263 51
Monaco Female
Male
Mongolia Female 193 1 733 37 56 222 198 105 110 127 151
Male 196 2 361 38 55 238 214 222 238 274 202
Montenegro Female 0 47 0 0 0 14 16 14 14 17 31
Male 0 66 0 0 0 18 15 26 24 28 54
Montserrat Female
Male
Morocco* Female 1 074 10 422 0 11 31 103 83 68 67 74 88
Male 1 002 15 637 0 12 27 134 157 123 104 114 134
Mozambique Female
Male
Myanmar Female 15 506 36 727 17 299 168 127 178 162 202 253 303
Male 20 795 65 260 47 383 228 147 317 384 449 540 656
Namibia* Female 431 3 241 0 135 75 269 517 543 378 356 459
Male 446 4 724 0 151 70 234 772 1 030 942 739 969
* New cases only
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Table A4.4
Notified new and relapse TB cases by age and sex, 2014
0–14 > 15 Unknown 0–4 5–14 15–24 25–34 35–44 45–54 55–64 > 65
Notified cases by age group 
(rate per 100 000 population)
Notified cases by age
(Number)
Nauru Female 0 6 0 0 0 110 279 0 536 0 0
Male 0 2 0 0 0 0 273 0 0 0 0
Nepal* Female 181 4 973 7 427 0.36 5.5 43 42 46 61 78 60
Male 164 10 629 11 903 0.34 4.7 69 100 116 156 224 206
Netherlands Female 21 290 0 1.4 1.6 5.1 8.1 4 3.6 2.3 2.6
Male 27 476 0 1.8 1.9 6.7 11 8.1 5 5 6.2
New Caledonia Female 0 10 0 0 0 9.7 5.5 0 5.9 8.2 37
Male 3 16 0 20 5.1 4.7 21 5.3 23 0 48
New Zealand Female 10 114 0 4 1.4 5.8 11 8.1 4.6 4.5 3.4
Male 9 164 0 3.8 0.98 9.1 13 10 6.2 7.1 11
Nicaragua* Female 19 603 0 26 28 26 30 30 32
Male 10 815 0 27 36 47 53 57 56
Niger* Female 46 1 733 0.2 1.5 17 42 45 53 53 57
Male 50 5 244 0.2 1.6 47 163 145 120 126 183
Nigeria Female 2 683 33 863 0 5.6 7.9 40 86 86 81 73 83
Male 2 780 52 028 0 6.3 7.3 43 119 144 144 136 166
Niue Female 0 0 0 0 0 0 0 0 0 0 0
Male 0 0 0 0 0 0 0 0 0 0 0
Northern Mariana Islands Female 0 10 0 0 0 21 52 57 33 95 116
Male 0 16 0 0 0 20 25 32 92 224 346
Norway Female 7 127 0 0.66 2 7.2 16 9.2 2.3 2 1.1
Male 6 163 0 0.62 1.6 12 17 7.8 4.1 1.6 2.9
Oman Female 4 149 0 2.2 0 11 17 14 17 17 18
Male 4 201 0 0.51 1.1 6.5 6.2 7.2 15 15 41
Pakistan Female 15 032 140 120 0 32 58 217 210 238 264 330 294
Male 12 213 141 052 0 33 38 166 181 225 297 415 386
Palau* Female 0 3 0 0 0 53 0 74 0 0 150
Male 1 10 0 0 46 0 132 245 79 348 179
Panama Female 62 482 0 23 6.2 35 38 31 32 31 37
Male 53 860 0 16 6.5 42 73 59 75 58 71
Papua New Guinea* Female
Male
Unknown 6 959 19 003
Paraguay Female 90 612 1 13 7.2 23 27 23 31 32 40
Male 97 1 442 4 15 6.9 40 61 60 73 101 93
Peru* Female 766 9 548 0 15 19 106 86 62 76 70 104
Male 793 16 268 0 14 20 179 146 129 106 129 190
Philippines Female 5 740 14 486 14 494 48 31 29 38 44 57 61 60
Male 6 451 32 479 23 928 52 32 53 78 106 144 162 148
Poland Female 33 2 057 0 1.2 1.2 6 8.1 9.4 11 13 21
Male 37 4 412 0 1.3 1.2 5.6 12 23 43 46 43
Portugal Female 18 791 0 3.2 2.2 15 25 17 15 13 16
Male 25 1 334 1 4.8 2.7 18 25 37 42 32 33
Puerto Rico Female 0 11 0 0 0 0.36 0.38 0.38 0.79 0.46 1.7
Male 0 33 0 0 0 0.35 1.2 0.83 4.1 5.6 3.6
Qatar Female 5 79 6.4 1.1 16 25 15 14 5.6 12
Male 1 375 5 1.5 0 24 30 23 23 25 36
Republic of Korea Female 94 16 287 0 1.4 3.4 44 66 50 49 61 178
Male 83 23 474 0 2.1 2.3 52 68 73 108 140 281
Republic of Moldova Female 53 1 099 0 13 19 52 73 86 60 52 37
Male 61 2 845 0 27 14 65 159 247 279 192 104
Romania Female 329 4 481 0 22 22 81 72 49 41 34 46
Male 310 9 741 0 24 18 101 110 129 158 138 95
Russian Federation Female 1 635 29 280 157 12 15 45 77 65 36 26 22
Male 1 560 69 153 555 12 14 59 157 197 142 103 54
Rwanda Female 168 1 762 0 41 49 61 55 54 51
Male 170 3 661 0 47 115 167 205 238 225
Saint Kitts and Nevis Female 0 2 0 0 0 0 0 27 29 0 0
Male 0 5 0 0 0 0 0 0 30 0 175
Saint Lucia Female 0 2 0 0 0 0 0 8.3 13 0
Male 0 4 0 0 0 0 0 16 8.7 14 0
Saint Vincent and the Grenadines Female 0 0 0 0 0 0 0 0 0 0 0
Male 0 5 0 0 0 0 11 13 14 22 28
Samoa Female 2 8 8.4 4.4 17 18 10 0 18 18
Male 1 12 7.8 0 5.1 8.2 28 22 34 70
San Marino Female
Male
* New cases only
* New cases only.
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Table A4.4
Notified new and relapse TB cases by age and sex, 2014
0–14 > 15 Unknown 0–4 5–14 15–24 25–34 35–44 45–54 55–64 > 65
Notified cases by age group 
(rate per 100 000 population)
Notified cases by age
(Number)
Sao Tome and Principe Female 4 51 0 14 8 44 66 93 201 175 209
Male 7 96 0 14 20 49 146 245 396 379 425
Saudi Arabia Female 42 988 0 0.77 1.1 11 13 5.9 9.2 14 23
Male 61 2 157 0 1.2 1.4 15 21 12 14 21 44
Senegal* Female 101 2 632 0 0.72 4.8
Male 105 6 440 0 1.2 4.5
Serbia Female 19 793 0 1.4 1.6 21 21 21 15 14 29
Male 22 984 0 0.86 1.5 22 19 25 30 29 38
Seychelles Female 0 6 0 0 0 0 27 14 15 23 26
Male 0 7 0 0 0 0 0 25 15 46 74
Sierra Leone Female 63 2 683 0.6 7 102 169 194 159 150 127
Male 72 4 635 0.8 8 134 280 376 419 292 267
Singapore Female 7 767 0 0.77 2 17 63 32 20 25 39
Male 10 1 387 0 5.1 0.97 24 51 40 50 80 152
Sint Maarten (Dutch part)* Female
Male
Slovakia Female 26 106 0 14 2.7 4.3 1.9 3.9 3 4.4 8.6
Male 18 170 0 8.9 1.8 2.6 2.7 7.5 12 11 13
Slovenia Female 0 60 0 0 0 2 4.4 3.5 2.6 7.5 15
Male 3 79 0 3.5 1 0 8 6.3 7 9.4 22
Solomon Islands Female 32 138 0 28 30 61 107 44 101 173 52
Male 30 145 0 40 17 80 75 45 104 191 103
Somalia Female 1 201 3 924 0 62 41 99 147 158 155 152 257
Male 1 582 6 196 0 92 45 167 223 230 255 303 498
South Africa Female 15 727 116 441 0 369 112 406 798 845 597 395 324
Male 16 250 157 748 0 393 101 295 920 1 440 1 140 1 080 764
South Sudan* Female
Male
Spain Female 136 1 777 0 5.9 3.2 10 13 9.8 7.1 5.5 7.8
Male 161 2 735 2 7.5 3.2 10 15 14 14 14 17
Sri Lanka Female 159 2 950 0 7.1 5.8 31 30 29 41 48 44
Male 154 5 717 0 6.9 5.5 29 55 64 108 128 127
Sudan* Female 943 6 336 226 13 11
Male 1 209 10 123 429 14 15
Suriname Female 5 43 0 8.6 6.3 18 31 28 27 4.7 9.5
Male 2 99 0 8 0 17 46 52 103 66 26
Swaziland Female 250 2 251 131 91 289 815 981 565 337 384
Male 252 2 830 130 91 174 830 1 610 1 280 1 130 790
Sweden Female 26 277 0 1.1 4.4 9.7 16 8 4.1 3.9 2.7
Male 27 305 0 1 4.4 13 15 8.5 4.9 1.9 3.7
Switzerland* Female 7 150 0.49 1.5 4.3 7.2 5.4 3.1 2.6 3.2
Male 4 262 0.93 0.49 14 9.8 9 5.1 4.3 5.1
Syrian Arab Republic Female 172 1 271 14 5.9 4.7 21 22 19 22 23 28
Male 225 1 755 44 11 4 21 33 31 32 37 42
Tajikistan Female 150 2 445 0 6.7 13 78 96 66 82 132 190
Male 184 3 028 0 12 13 106 123 99 97 124 164
Thailand* Female 62 9 662 0
Male 57 24 613 0
The Former Yugoslav Republic of Macedonia Female 7 96 0 3.6 4.2 11 19 7.4 6.2 8.3 14
Male 12 169 0 14 3.2 15 17 13 29 25 23
Timor-Leste* Female 201 1 457
Male 189 1 732
Togo Female 45 884 0 0.88 4.3 23 55 51 48 45 57
Male 35 1 561 0 0.87 3.2 27 74 119 152 127 107
Tokelau Female 0 0 0 0 0 0 0 0 0 0 0
Male 0 0 0 0 0 0 0 0 0 0 0
Tonga Female 0 7 0 0 0 30 15 0 0 63 28
Male 0 6 0 0 0 19 0 17 0 107 0
Trinidad and Tobago Female 5 67 0 4.2 3.3 4.3 15 9.5 18 14 13
Male 4 175 0 4.1 2.1 9.5 29 32 55 47 32
Tunisia Female 103 1 463 1.7 12 26 36 29 34 42 39
Male 92 1 476 1.2 10 23 37 36 37 41 51
Turkey Female 266 5 316 0 2.2 3 16 16 13 16 20 33
Male 284 7 242 0 2.3 3 16 20 22 32 41 49
Turkmenistan* Female
Male
* New cases only
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Table A4.4
Notified new and relapse TB cases by age and sex, 2014
0–14 > 15 Unknown 0–4 5–14 15–24 25–34 35–44 45–54 55–64 > 65
Notified cases by age group 
(rate per 100 000 population)
Notified cases by age
(Number)
Turks and Caicos Islands Female 0 0 0 0 0 0 0 0 0 0 0
Male 0 1 0 0 0 35 0 0 0 0 0
Tuvalu Female 8 226 298 163 371 273
Male 0 7 0 0 105 145 177 813 342
US Virgin Islands Female
Male
Uganda Female 1 606 14 169 20 16 84 189 197 202 136 127
Male 1 710 26 702 23 16 86 324 483 530 387 307
Ukraine Female 254 8 924 0 8.2 7.8 40 70 64 38 24 25
Male 278 22 245 0 8.7 7.9 52 145 209 163 103 57
United Arab Emirates Female 3 24 0 0.42 0.54 1.9 0.8 0 2.9 0 20
Male 4 29 0 1.2 0.25 0.37 0.25 0.1 0.33 2.7 13
United Kingdom of Great Britain and Northern 
Ireland Female 133 2 581 0 1.8 2.7 9.2 16 11 7.3 7 7.1
Male 141 3 767 0 2.7 2.2 11 23 19 12 11 11
United Republic of Tanzania Female 2 972 21 895 0 33 21 61 159 234 225 219 228
Male 3 491 33 213 0 35 26 72 224 363 411 388 467
United States of America Female 224 3 193 0 1.4 0.46 1.8 3 2.5 2.1 2.2 3
Male 231 5 298 0 1.3 0.48 2.4 3.6 3.7 4.1 5 6.4
Uruguay Female 24 250 0 12 4.1 23 25 15 13 13 16
Male 33 555 0 13 6.7 28 59 48 50 46 33
Uzbekistan Female 758 6 961 0 9.2 24 36 56 56 68 106 149
Male 1 155 9 471 0 16 34 47 74 105 128 159 187
Vanuatu Female 7 42 0 30 6.9 25 57 49 81 47 94
Male 8 55 0 28 9.5 46 57 35 86 155 151
Venezuela (Bolivarian Republic of) Female 197 2 379 0 6.4 3.7 17 22 18 18 28 34
Male 218 3 598 0 6.3 4.1 25 29 28 35 48 64
Viet Nam* Female 76 12 518 0.22 1 23 31 24 28 49 77
Male 68 37 267 0.27 0.81 35 76 110 154 189 250
Wallis and Futuna Islands* Female 0 0 0 0 0 0 0 0 0 0
Male 0 0 0 0 0 0 0 0 0 0
West Bank and Gaza Strip Female 1 13 0 0 0.18 0.62 0.61 0.45 1.3 2.4 4.3
Male 0 29 0 0 0 0.99 0.6 2.2 4 6.4 9.5
Yemen Female 497 4 394 0 0 15 38 53 70 82 81 94
Male 525 4 212 0 0 15 30 48 62 99 88 134
Zambia Female 1 294 13 024 36 36 160 391 471 417 277 239
Male 1 432 20 472 43 37 148 610 895 714 556 526
Zimbabwe Female 1 123 11 640 43 31 105 291 455 370 291 286
Male 1 167 15 723 48 30 99 374 719 652 523 523
WHO regions
African Region Female 43 928 389 667 803 32 21 98 215 237 208 170 164
Male 46 595 574 141 1 495 35 20 98 290 410 394 338 324
Region of the Americas Female 5 112 71 991 509 5.4 4.3 21 23 19 17 17 18
Male 5 377 126 342 1 426 6.1 4.1 31 40 36 35 36 38
Eastern Mediterranean Region Female 22 195 194 095 4 161 15 26 94 81 89 102 124 128
Male 19 833 204 948 3 784 16 18 77 76 85 111 153 180
European Region Female 4 834 86 060 158 5.6 7.1 25 37 28 19 17 17
Male 5 425 171 825 561 6.5 7.3 33 64 71 59 50 30
South-East Asia Region Female 84 057 786 056 7 444 24 37 126 127 116 119 128 97
Male 84 253 1 462 009 11 950 27 32 136 176 224 279 336 329
Western Pacific Region Female 14 019 330 042 14 494 7.5 9.6 43 40 34 37 52 70
Male 16 295 714 207 23 928 8.8 9.3 67 65 71 95 134 182
Unknown 6 959 19 003 0
Global Female 174 145 1 857 911 27 569 17 21 75 82 71 64 66 59
Male 177 778 3 253 472 43 144 19 18 85 115 133 144 162 160
Unknown 6 959 19 003 0
* New cases only
* New cases only.
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TABLE A4.5
Treatment outcomes by TB case type, 2013 and treatment outcomes for RR-/MDR-TB cases, 2012
* Relapses included in the previously treated cohort.
a All calculations are made before numbers are rounded, so the total of all outcomes may not always appear as 100%.
Table A4.5
Treatment outcomes by TB case type, 2013 and treatment outcomes for RR-/MDR-TB  cases, 2012
Failed
(%)a
Afghanistan 30 507 88 1 1 2 8 1 115 74 38 71
Albania 472 88 1 2 4 5 2 50
Algeria 7 020 91 0 2 3 3 130 59
American Samoa
Andorra 5 60 0 20 20 0 0 1 100 0
Angola 60 807 23 1 1 8 67 6 844 39 24 445 0 0
Anguilla 0 0 0 0
Antigua and Barbuda* 9 67 0 22 11 0 0 4 75 0
Argentina 8 474 51 0 5 8 36 782 40 554 32 89 34
Armenia 1 251 81 1 5 11 2 18 78 38 66 115 44
Aruba
Australia 1 264 85 0 4 1 9 6 83 26 77 16 75
Austria 617 72 0 8 14 6 16 62 20 60
Azerbaijan* 4 294 82 5 2 8 3 2 652 73 373 60
Bahamas 33 76 0 12 9 3 0 10 40 1 100
Bahrain
Bangladesh 184 077 93 0 4 1 1 6 327 86 68 75 505 72
Barbados* 4 100 0 0 0 0 0 2 100 0
Belarus 3 034 87 4 6 1 2 222 71 138 65 2 509 54
Belgium 878 79 0 6 10 5 72 72 35 71 18 61
Belize 121 36 0 14 12 39 3 67 25 12 0
Benin* 3 254 89 3 6 2 0 242 90 8 75
Bermuda 0 0 0
Bhutan 1 080 91 4 4 0 1 35 60 10 100
Bolivia (Plurinational State of)* 7 657 85 1 5 5 4 561 77 43 67
Bonaire, Saint Eustatius and Saba 0 0 0 0
Bosnia and Herzegovina 1 261 82 2 8 1 7 0 0 7 43
Botswana 7 254 73 1 8 3 16 124 60 4 083 71 63 70
Brazil 76 543 72 0 8 10 10 6 945 38 9 460 46 825 51
British Virgin Islands* 1 100 0 0 0 0 0 0 0
Brunei Darussalam 212 73 0 8 0 20 0 0 0
Bulgaria 1 903 85 1 9 4 1 2 50 4 75 44 66
Burkina Faso* 5 125 80 3 10 5 2 400 75 680 71 26 58
Burundi 7 547 91 1 6 2 0 80 84 977 87 36 92
Cabo Verde 302 88 1 1 8 2 12 42 24 83 0
Cambodia 35 536 93 1 2 1 3 1 701 90 110 79
Cameroon* 15 102 82 1 6 7 3 1 634 71 76 92
Canada
Cayman Islands 5 80 0 0 0 20 0 1 0 0
Central African Republic* 4 400 70 1 5 17 6 514 62 1 972 62 16 81
Chad* 9 127 74 1 4 17 3 722 53 0 0
Chile 2 401 47 0 6 5 42 38 5 187 13 9 56
China 841 999 95 0 1 1 3 7 847 90 4 649 82 1 906 42
China, Hong Kong SAR 4 600 67 0 16 3 14 29 31 21 62 24 62
China, Macao SAR 433 82 0 7 1 10 3 67 4 100 7 86
Colombia 11 902 71 1 9 8 11 708 42 1 489 45 99 48
Comoros* 67 94 0 1 3 1 3 67 4 50 0
Congo
Cook Islands* 2 50 0 0 50 0 0 0 1 100
Costa Rica 420 88 0 6 0 5 6 50 42 69 0
Croatia 516 44 0 13 1 42 6 17
Cuba 747 84 1 10 5 0 18 28 58 57 6 67
Curaçao 2 0 0 0 0 100 0 0 0
Cyprus 40 50 0 5 0 45 0
Czech Republic 468 69 0 21 7 4 29 83 0 3 33
Côte d'Ivoire* 23 796 80 2 11 6 2 1 503 64 0
Democratic People's Republic of Korea 97 665 92 3 3 2 1 7 247 83 0 50 86
Democratic Republic of the Congo* 112 439 87 1 4 3 5 1 164 66 134 64
Denmark 329 59 1 3 1 37 25 48 7 43
Djibouti 1 383 75 1 1 13 10
Dominica 3 100 0 0 0 0 0 2 100 1 100































* Relapses included in the previously treated cohort
a
 All calculations are made before numbers are rounded, so the total of all outcomes may not always appear as 100%.
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Ecuador 5 277 75 2 5 6 12 197 53 243 54
Egypt 7 876 86 1 3 4 5 307 72 7 29 52 63
El Salvador 2 176 93 0 5 2 0 17 76 203 69 10 100
Equatorial Guinea 1 152 62 2 7 30 0 59 53 259 57
Eritrea 2 862 89 1 6 3 2 107 77 147 79 1 100
Estonia 226 87 0 9 3 0 10 60 29 66 50 76
Ethiopia* 43 860 89 3 2 5 271 83
Fiji 248 77 1 8 7 6 14 64 4 75 0
Finland 265 53 0 12 0 35 6 17
France
French Polynesia* 44 93 0 5 2 0 8 88 0 0
Gabon 3 861 55 1 1 35 8 628 41
Gambia* 1 431 86 2 5 3 4
Georgia 3 098 80 2 3 10 5 779 69 31 68 623 48
Germany 4 029 67 0 11 3 19 192 60 60 47
Ghana 15 043 85 1 10 3 0 563 77 2 737 73 2 100
Greece
Greenland
Grenada 1 100 0 0 0 0 0 0
Guam 48 92 0 6 0 2 0 0 0
Guatemala* 2 978 84 1 7 8 1 36 67 243 62 39 69
Guinea 11 313 79 6 5 5 5 0 1 959 75 15 80
Guinea-Bissau 2 236 77 0 10 9 4 9 22 5 40
Guyana 680 67 2 11 19 1 106 47 139 63 0
Haiti* 16 557 81 1 5 10 3 483 75 2 857 71 62 76
Honduras* 1 924 89 1 6 4 0 185 81 263 72 5 40
Hungary 1 030 74 0 11 6 9 5 60 9 33
Iceland 11 91 0 9 0 0 0 0
India 1 243 905 88 1 4 6 1 171 712 66 44 027 76 14 051 46
Indonesia 325 582 88 0 2 5 4 1 521 64 2 438 49 432 54
Iran (Islamic Republic of) 10 884 87 2 8 2 1 305 82 284 66 62 48
Iraq 8 554 88 1 3 2 7 329 79 0 66 47
Ireland 346 59 0 5 2 34 26 62 8 12 4 100
Israel 305 84 0 6 4 6 0 14 71 13 92
Italy
Jamaica 104 77 0 3 8 12 0 16 81 0
Japan* 15 941 54 0 17 7 23 1 008 46 30 40
Jordan 327 88 2 3 5 1 22 86 0 12 50
Kazakhstan 14 456 89 3 5 2 1 464 63 340 59 7 213 73
Kenya* 81 255 86 0 6 5 3 8 445 78 31 755 79 197 83
Kiribati 394 86 0 8 5 1 16 88 0 0
Kuwait 703 82 0 1 4 13 0 0 4 75
Kyrgyzstan* 5 658 85 1 4 5 4 1 130 76 775 63
Lao People's Democratic Republic 3 937 87 1 7 3 2 46 50 13 38
Latvia 804 83 0 9 6 1 21 81 79 67 90 63
Lebanon 689 71 0 1 5 23 0 4 50 7 86
Lesotho* 9 119 70 1 14 8 6 1 619 62 7 683 66 146 64
Liberia 3 534 40 1 4 9 46 14 64 795 52
Libya 1 345 59 0 1 36 3 71 20 52 27
Lithuania 1 392 80 1 10 7 3 57 37 21 43 219 41
Luxembourg 38 0 0 3 0 97 0 0
Madagascar* 24 182 82 1 5 9 4 2 243 75
Malawi 17 779 82 1 10 2 6 19 63
Malaysia 23 346 76 0 9 5 11 654 46 1 510 51 74 30
Maldives 113 84 0 4 1 12 4 75 0 2 50
Mali 5 810 74 2 8 9 7 191 76 12 67
Malta 49 76 0 2 6 16 0 0
Marshall Islands 153 89 0 6 5 1 1 0 1 0 4 75
Mauritania 2 137 71 1 3 10 15 2 058 71 0 1 0
Mauritius 130 88 0 5 5 2 0 23 65 0
Mexico 20 708 80 1 8 6 4 638 55 1 230 48 133 74
Micronesia (Federated States of) 129 91 1 4 1 4 5 20 0 5 100
* Relapses included in the previously treated cohort
a
 All calculations are made before numbers are rounded, so the total of all outcomes may not always appear as 100%.
TABLE A4.5
Treatment outcomes by TB case type, 2013 and treatment outcomes for RR-/MDR-TB cases, 2012
* Relapses included in the previously treated cohort.
a All calculations are made before numbers are rounded, so the total of all outcomes may not always appear as 100%.
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Mongolia 4 220 89 4 2 3 2 395 79 5 60 179 61
Montenegro* 119 87 0 8 3 2 1 0 2 100 1 100
Montserrat
Morocco 29 144 89 1 2 8 0 770 66 70 33
Mozambique* 23 072 88 1 6 3 2 214 28
Myanmar* 135 614 87 2 4 5 1 7 147 71 443 79
Namibia* 8 418 86 2 6 4 1 2 192 71 4 343 81 208 68
Nauru 3 67 0 33 0 0 0 0 0
Nepal 33 877 91 1 3 2 3 456 74 238 76
Netherlands 816 88 0 3 2 6 12 75 17 76 11 73
New Caledonia* 47 60 40 1 100 0
New Zealand 269 84 0 7 2 7 5 80 0 4 25
Nicaragua* 1 438 84 2 3 8 2 72 69 10 90
Niger* 10 795 79 1 6 9 4 635 73 43 86
Nigeria* 91 997 86 1 6 5 2 8 404 83 7 481 80 154 62
Niue 0 0 0 0
Northern Mariana Islands 33 82 3 3 3 9 0 1 100 0
Norway 357 89 1 2 1 8 38 79 8 75 6 33
Oman 330 96 0 4 0 0 0 5 100 6 83
Pakistan 289 376 93 1 1 4 1 7 217 80 37 81 858 71
Palau* 8 88 0 0 12 0 0 1 0 0
Panama 1 456 80 1 7 12 0 92 48 222 68 12 42
Papua New Guinea* 3 617 67 3 4 17 10 587 57 85 55
Paraguay 2 254 68 1 8 5 19 162 48 181 34 7 57
Peru* 17 265 79 1 4 6 10 2 802 59 1 016 57 1 122 60
Philippines 216 250 90 1 2 4 3 2 924 86 1 798 43
Poland 7 011 59 0 9 8 24 199 42 31 13
Portugal 2 336 74 0 7 3 17 52 56 249 54 19 47
Puerto Rico* 49 73 0 22 2 2 0 10 60 1 0
Qatar 469 85 0 0 0 14 0 0 0
Republic of Korea 40 794 82 0 7 6 4 3 257 74 1 212 60
Republic of Moldova 3 889 80 3 9 7 1 357 39 247 52 856 59
Romania 15 188 85 2 7 6 0 925 45 250 58 638 34
Russian Federation 83 301 68 9 9 7 7 6 934 39 16 021 40
Rwanda 5 701 85 2 10 2 1 278 75 1 448 76 58 98
Saint Kitts and Nevis 0 0 0 0
Saint Lucia* 16 100 0 0 0 0 0 0 0
Saint Vincent and the Grenadines*
Samoa 23 83 0 13 4 0 0 1
San Marino
Sao Tome and Principe 147 73 5 13 7 1 0 30 60 5 80
Saudi Arabia 3 435 56 0 5 15 24 127 39 77 17 20 25
Senegal 13 180 87 1 5 5 2 329 74 826 44 29 76
Serbia 1 427 78 1 8 7 6 49 69 19 84 6 50
Seychelles 24 79 0 17 0 4 0 1 100 0
Sierra Leone* 7 795 87 1 3 5 4 324 71
Singapore 2 142 77 0 9 1 14 8 75 51 86 22 55
Sint Maarten (Dutch part)* 2 100 0 2 100 0 0
Slovakia 395 94 1 4 1 2 3 67 0 1 0
Slovenia 139 77 0 19 0 4 1 100 0
Solomon Islands 361 94 1 5 0 0 8 100 0 0
Somalia 12 994 86 1 4 2 7 312 43 195 69 0
South Africa 321 087 78 0 7 6 8 18 292 69 191 189 76 8 084 49
South Sudan 7 240 72 1 4 12 12 559 58 701 62
Spain 5 290 75 0 4 0 20 298 67 283 58
Sri Lanka 9 010 85 1 6 5 4 167 62 37 24 8 88
Sudan 17 396 82 1 4 10 3 514 71 52 62
Suriname 136 77 0 10 10 4 5 20 31 65 0
Swaziland 7 191 75 3 14 5 3 538 66 5 773 71
Sweden 597 90 0 4 1 5 34 82 12 83
Switzerland
* Relapses included in the previously treated cohort
a
 All calculations are made before numbers are rounded, so the total of all outcomes may not always appear as 100%.
TABLE A4.5
Treatment outcomes by TB case type, 2013 and treatment outcomes for RR-/MDR-TB cases, 2012
* Relapses included in the previously treated cohort.
a All calculations are made before numbers are rounded, so the total of all outcomes may not always appear as 100%.
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Syrian Arab Republic 2 739 80 1 2 17 1 112 75 1 100 7 0
Tajikistan 5 263 88 3 5 4 1 812 82 122 66 535 66
Thailand 65 867 81 1 7 5 6 1 812 66 7 665 67
The Former Yugoslav Republic of 
Macedonia 317 91 0 7 2 0 5 100 0 3 67
Timor-Leste 3 718 84 0 2 11 3 11 91 4 75
Togo 2 644 88 1 6 3 1 50 82 180 3 100
Tokelau
Tonga 10 90 0 10 0 0 0 0 0
Trinidad and Tobago 250 62 1 15 15 6 30 33 56 34 0
Tunisia 3 032 91 1 2 2 4 35 86 17 100 15 73
Turkey 13 170 86 0 5 3 6 239 38 32 53 291 66
Turkmenistan* 3 046 72 4 4 3 17 629 26 0
Turks and Caicos Islands 2 100 0 0 0 0 0 0 0
Tuvalu 18 78 11 11 0 0 0 0 2 100
US Virgin Islands
Uganda 44 605 75 1 8 12 4 2 572 67 16 762 73 41 80
Ukraine 29 726 71 9 10 9 1 9 149 55 7 553 44 5 556 34
United Arab Emirates 81 75 0 11 14 0 3 67 2 50 2 50
United Kingdom of Great Britain and 
Northern Ireland 7 293 82 0 5 5 9 496 75 78 54
United Republic of Tanzania 64 053 91 0 6 1 2 1 679 79 20 320 72 45 73
United States of America* 8 890 83 1 6 1 9 448 78 552 75 27 59
Uruguay 878 79 0 13 8 0 18 67 119 61 1 100
Uzbekistan 17 373 83 3 5 5 3 4 340 78 1 491 49
Vanuatu 123 85 4 7 3 0 0 0 0
Venezuela (Bolivarian Republic of) 6 481 81 0 6 11 1 237 59 581 80 21 52
Viet Nam 102 196 89 1 3 7 4 453 71 713 71
Wallis and Futuna Islands* 2 100 0 0 0
West Bank and Gaza Strip 33 91 3 3 3 0 0 0 0
Yemen 10 325 90 0 2 4 4 42 62
Zambia 39 899 85 0 5 4 5 4 984 80 100 27
Zimbabwe* 35 278 80 1 10 3 6 234 75
WHO regions
African Region 1 165 070 79 1 6 5 9 70 144 70 326 597 70 10 246 53
Region of the Americas 200 742 75 1 7 8 9 14 753 48 19 816 53 2 866 57
Eastern Mediterranean Region 431 622 91 1 2 4 3 11 281 76 681 60 1 271 65
European Region 243 828 76 5 7 6 6 30 305 58 9 529 47 37 701 49
South-East Asia Region 2 100 508 88 1 4 5 2 196 439 67 54 235 74 15 743 48
Western Pacific Region 1 298 402 92 1 2 2 4 18 523 81 10 756 73 6 176 51
Global 5 440 172 86 1 4 4 4 341 445 67 421 614 69 74 003 50
* Relapses included in the previously treated cohort
a
 All calculations are made before numbers are rounded, so the total of all outcomes may not always appear as 100%.
TABLE A4.5
Treatment outcomes by TB case type, 2013 and treatment outcomes for RR-/MDR-TB cases, 2012
* Relapses included in the previously treated cohort.
a All calculations are made before numbers are rounded, so the total of all outcomes may not always appear as 100%.
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Table A4.6
Measured percentage of TB cases with MDR-TBa, most recent year available
Year Source Coverage Percentage Year Source Coverage Percentage
Afghanistan
Albania 2012 Surveillance National 0.58 (<0.1–3.2) 2012 Surveillance National 0 (0–22)
Algeria 2002 Survey National 1.4 (0.60–2.7) 2002 Survey National 9.1 (1.1–29)
American Samoa




Argentina 2005 Survey National 2.2 (1.2–3.6) 2005 Survey National 15 (9.8–23)
Armenia 2007 Survey National 9.4 (7.0–12) 2007 Survey National 43 (38–49)
Aruba
Australia 2014 Surveillance National 1.7 (0.86–3.0) 2014 Surveillance National 10 (2.8–24)
Austria 2014 Surveillance National 2.7 (1.1–5.5) 2014 Surveillance National 37 (16–62)
Azerbaijan 2013 Survey National 13 (10–16) 2013 Survey National 28 (22–34)
Bahamas 2012 Surveillance National 3.7 (<0.1–19) 2013 Surveillance National 0 (0–71)
Bahrain 2012 Surveillance National 1.9 (0.39–5.4) 2012 Surveillance National 100 (2.5–100)
Bangladesh 2011 Survey National 1.4 (0.70–2.5) 2011 Survey National 29 (24–34)
Barbados 2014 Surveillance National 0 (0–71) 2014 Surveillance National 0 (0–0)
Belarus 2014 Surveillance National 34 (32–36) 2014 Surveillance National 69 (66–72)
Belgium 2013 Surveillance National 1.8 (0.71–3.6) 2013 Surveillance National 2.4 (<0.1–13)
Belize 2013 Surveillance National 100 (29–100)
Benin 2010 Survey National 0.5 (0.10–2.0) 2014 Surveillance National 4.8 (2.1–9.3)
Bermuda 2012 Surveillance National 0 (0–84) 2012 Surveillance National 0 (0–0)
Bhutan 2011 Survey National 35 (21–52)
Bolivia (Plurinational State of) 2014 Surveillance National 10 (7.7–13)
Bonaire, Saint Eustatius and Saba 2011 Surveillance National 100 (2.5–100)
Bosnia and Herzegovina 2013 Surveillance National 0 (0–0.57) 2013 Surveillance National 1.6 (<0.1–8.5)
Botswana 2008 Survey National 2.5 (1.5–3.5) 2008 Survey National 6.6 (2.4–11)
Brazil 2008 Survey Sub-national 1.4 (1.0–1.8) 2008 Survey Sub-national 7.5 (5.7–9.9)
British Virgin Islands
Brunei Darussalam 2014 Surveillance National 0.88 (<0.1–4.8) 2014 Surveillance National 0 (0–52)




Cambodia 2007 Survey National 1.4 (0.70–2.5) 2007 Survey National 11 (4.0–22)
Cameroon
Canada 2013 Surveillance National 1.4 (0.70–2.4) 2013 Surveillance National 4.6 (0.96–13)
Cayman Islands 2013 Surveillance National 0 (0–71) 2013 Surveillance National 0 (0–0)
Central African Republic 2009 Survey Sub-national 0.4 (0–2.5)
Chad
Chile 2014 Surveillance National 1.2 (0.68–2.1) 2014 Surveillance National 0.56 (<0.1–3.1)
China 2007 Survey National 5.7 (4.5–7.0) 2007 Survey National 26 (22–30)
China, Hong Kong SAR 2012 Surveillance National 0.97 (0.59–1.5) 2012 Surveillance National 2.6 (0.95–5.5)
China, Macao SAR 2014 Surveillance National 1.7 (0.48–4.4) 2014 Surveillance National 19 (5.4–42)
Colombia 2005 Survey National 2.4 (1.6–3.6) 2012 Surveillance National 13 (9.6–17)
Comoros
Congo
Cook Islands 2013 Surveillance National 0 (0–98) 2013 Surveillance National 0 (0–0)
Costa Rica 2006 Survey National 1.5 (0.42–3.8) 2012 Surveillance National 4.5 (0.12–23)
Croatia 2014 Surveillance National 0 (0–1.3) 2014 Surveillance National 6.9 (0.85–23)
Cuba 2012 Surveillance National 0.74 (<0.1–2.7) 2014 Surveillance National 4.2 (0.51–14)
Curaçao 2014 Surveillance National 0 (0–60) 2014 Surveillance National 0 (0–0)
Cyprus 2013 Surveillance National 0 (0–15) 2013 Surveillance National 100 (2.5–100)
Czech Republic 2013 Surveillance National 0 (0–1.3) 2013 Surveillance National 0 (0–31)
Côte d'Ivoire 2006 Survey National 2.5 (1.1–4.9)
Democratic People's Republic of Korea 2014 Survey Sub-national 1.9 (0.80–3.9) 2014 Survey Sub-national 15 (8.8–24)
Democratic Republic of the Congo
Denmark 2013 Surveillance National 0.51 (<0.1–2.8) 2013 Surveillance National 5 (0.13–25)
New TB cases Previously treated TB cases
a
 Empty rows indicate an absence of high-quality survey or surveillance data. In the absence of high-quality national data, high-quality sub-national data are used.
TABLE A4.6
Measured percentage of TB cases with MDR-TB,a most recent year available
a Empty rows indicate an absence of high-quality survey or surveillance data. In the absence of high-quality national data, high-quality sub-national data are used.
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Table A4.6
Measured percentage of TB cases with MDR-TBa, most recent year available
Year Source Coverage Percentage Year Source Coverage Percentage
New TB cases Previously treated TB cases
Djibouti
Dominica 2013 Surveillance National 0 (0–0) 2013 Surveillance National 0 (0–0)
Dominican Republic
Ecuador 2002 Survey National 4.9 (3.5–6.7) 2012 Surveillance National 26 (23–29)
Egypt 2011 Survey National 3.4 (1.9–4.9) 2013 Surveillance National 15 (12–18)
El Salvador 2001 Survey National 0.33 (<0.1–1.2) 2014 Surveillance National 0 (0–4.3)
Equatorial Guinea
Eritrea
Estonia 2014 Surveillance National 19 (14–27) 2014 Surveillance National 62 (42–79)
Ethiopia 2005 Survey National 1.6 (0.86–2.8) 2005 Survey National 12 (5.6–21)
Fiji 2006 Surveillance National 0 (0–8.2) 2006 Surveillance National 0 (0–98)
Finland 2014 Surveillance National 2.7 (0.73–6.7) 2014 Surveillance National 20 (0.51–72)
France 2009 Surveillance National 0.45 (0.24–0.77) 2009 Surveillance National 13 (7.4–21)
French Polynesia 2014 Surveillance National 0 (0–13) 2014 Surveillance National 0 (0–98)
Gabon
Gambia 2000 Survey National 0.48 (<0.1–2.6) 2000 Survey National 0 (0–18)
Georgia 2014 Surveillance National 12 (10–13) 2014 Surveillance National 39 (35–44)
Germany 2014 Surveillance National 2.9 (1.3–5.7) 2014 Surveillance National 17 (11–25)
Ghana
Greece 2010 Surveillance National 1.5 (<0.1–8.0) 2010 Surveillance National 9.1 (0.23–41)
Greenland
Grenada
Guam 2012 Surveillance National 0 (0–11) 2012 Surveillance National 0 (0–0)





Honduras 2004 Survey National 1.8 (0.76–3.4) 2004 Survey National 12 (5.8–22)
Hungary 2010 Surveillance National 2.5 (1.3–4.3) 2010 Surveillance National 8.1 (3.3–16)











Multiple surveys 1.9 (1.4–2.5) 2006, 2010 Multiple surveys 12 (8.1–17)
Iran (Islamic Republic of) 2014 Survey National 0.8 (0.30–1.4) 2014 Survey National 12 (6.2–19)
Iraq 2013 Survey National 1.1 (0.30–1.8) 2013 Survey National 20 (13–27)
Ireland 2014 Surveillance National 1.6 (0.20–5.8) 2014 Surveillance National 0 (0–26)
Israel 2014 Surveillance National 6.6 (3.5–11) 2014 Surveillance National 50 (6.8–93)
Italy 2012 Surveillance National 2.6 (1.4–4.6) 2013 Surveillance National 4.2 (1.7–8.4)
Jamaica 2013 Surveillance National 2.4 (<0.1–13) 2013 Surveillance National 0 (0–0)
Japan 2002 Surveillance National 0.7 (0.42–1.1) 2002 Surveillance National 9.8 (7.1–13)
Jordan 2009 Surveillance National 6.3 (2.4–13) 2009 Surveillance National 29 (3.7–71)
Kazakhstan 2013 Surveillance National 26 (25–27) 2013 Surveillance National 58 (57–59)
Kenya 2014 Surveillance National 14 (12–15)
Kiribati
Kuwait 2014 Surveillance National 2.2 (0.89–4.5) 2014 Surveillance National 0 (0–98)
Kyrgyzstan 2011 Survey National 26 (23–31) 2013 Surveillance National 55 (52–58)
Lao People's Democratic Republic
Latvia 2014 Surveillance National 8.2 (5.8–11) 2014 Surveillance National 30 (21–40)
Lebanon 2003 Survey National 1 (0.13–3.8) 2013 Surveillance National 29 (3.7–71)
Lesotho 2014 Survey National 3.2 (2.2–4.1) 2014 Survey National 7.3 (4.2–10)
Liberia
Libya
Lithuania 2014 Surveillance National 14 (12–16) 2014 Surveillance National 49 (43–55)
Luxembourg 2014 Surveillance National 0 (0–0) 2014 Surveillance National 0 (0–0)
Madagascar 2007 Survey National 0.49 (0.13–1.3) 2007 Survey National 3.9 (0.48–13)
Malawi 2011 Survey National 0.42 (0.14–0.97) 2011 Survey National 4.8 (3.2–6.9)
a
 Empty rows indicate an absence of high-quality survey or surveillance data. In the absence of high-quality national data, high-quality sub-national data are used.
TABLE A4.6
Measured percentage of TB cases with MDR-TB,a most recent year available
a Empty rows indicate an absence of high-quality survey or surveillance data. In the absence of high-quality national data, high-quality sub-national data are used.
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Table A4.6
Measured percentage of TB cases with MDR-TBa, most recent year available
Year Source Coverage Percentage Year Source Coverage Percentage
New TB cases Previously treated TB cases
Malaysia 2014 Surveillance National 0.4 (0.24–0.63) 2014 Surveillance National 1.1 (0.24–3.3)
Maldives
Mali
Malta 2012 Surveillance National 0 (0–25) 2014 Surveillance National 0 (0–98)
Marshall Islands 2014 Surveillance National 0 (0–8.0) 2014 Surveillance National 0 (0–41)
Mauritania
Mauritius 2014 Surveillance National 0 (0–3.2) 2014 Surveillance National 33 (0.84–91)
Mexico 2009 Survey National 2.4 (2.1–2.8) 2009 Survey National 6.5 (5.1–7.8)
Micronesia (Federated States of)
Monaco
Mongolia 2007 Survey National 1.4 (0.70–2.5) 2013 Surveillance National 34 (29–38)
Montenegro 2014 Surveillance National 0 (0–5.7) 2014 Surveillance National 40 (5.3–85)
Montserrat
Morocco 2014 Survey National 1 (0.30–1.7) 2014 Survey National 8.7 (4.8–13)
Mozambique 2007 Survey National 3.5 (2.2–4.8) 2007 Survey National 11 (0–25)
Myanmar 2013 Survey National 5 (3.1–6.8) 2013 Survey National 27 (15–39)
Namibia 2008 Survey National 3.8 (2.7–5.1) 2008 Survey National 16 (13–21)
Nauru
Nepal 2011 Survey National 2.2 (1.3–3.8) 2011 Survey National 15 (10–23)
Netherlands 2014 Surveillance National 0.92 (0.19–2.7) 2014 Surveillance National 13 (0.32–53)
New Caledonia 2014 Surveillance National 0 (0–28) 2014 Surveillance National 0 (0–84)
New Zealand 2012 Surveillance National 0.9 (0.11–3.2) 2012 Surveillance National 17 (2.1–48)
Nicaragua 2006 Survey National 0.63 (<0.1–2.2) 2010 Surveillance National 11 (6.2–17)
Niger
Nigeria 2010 Survey National 2.9 (2.1–4.0) 2010 Survey National 14 (10–19)
Niue
Northern Mariana Islands 2014 Surveillance National 5.3 (0.13–26) 2014 Surveillance National 0 (0–98)
Norway 2013 Surveillance National 2.2 (0.61–5.6) 2013 Surveillance National 5.9 (0.15–29)
Oman 2014 Surveillance National 2.6 (0.96–5.6) 2014 Surveillance National 0 (0–41)
Pakistan 2013 Survey National 3.7 (2.5–5.0) 2013 Survey National 18 (13–23)
Palau 2013 Surveillance National 0 (0–41) 2013 Surveillance National 0 (0–0)
Panama
Papua New Guinea 2014 Survey Sub-national 2.7 (1.1–4.3) 2014 Survey Sub-national 19 (8.5–30)
Paraguay 2008 Survey National 0.3 (0–1.7) 2008 Survey National 15 (6.1–28)
Peru 2014 Surveillance National 5.3 (4.9–5.7) 2014 Surveillance National 20 (19–22)
Philippines 2012 Survey National 2 (1.4–2.7) 2012 Survey National 21 (16–29)
Poland 2014 Surveillance National 0.44 (0.26–0.70) 2014 Surveillance National 4.4 (2.6–6.8)
Portugal 2012 Surveillance National 0.98 (0.51–1.7) 2012 Surveillance National 4.9 (1.6–11)
Puerto Rico 2014 Surveillance National 0 (0–9.3) 2014 Surveillance National 0 (0–0)
Qatar 2014 Surveillance National 1.3 (0.16–4.7)
Republic of Korea 2004 Survey National 2.7 (2.1–3.4) 2004 Survey National 14 (10–19)
Republic of Moldova 2012 Surveillance National 24 (21–26) 2012 Surveillance National 62 (59–65)
Romania 2004 Survey National 2.8 (1.8–4.2) 2004 Survey National 11 (8.0–15)
Russian Federation 2013 Oblasts 19 (14–25) 2013 Oblasts 49 (40–59)
Rwanda 2014 Surveillance National 2.2 (1.4–3.2) 2014 Surveillance National 5.1 (1.7–11)
Saint Kitts and Nevis
Saint Lucia 2013 Surveillance National 0 (0–0) 2013 Surveillance National 0 (0–0)
Saint Vincent and the Grenadines 2014 Surveillance National 0 (0–0)
Samoa 2013 Surveillance National 0 (0–28) 2013 Surveillance National 0 (0–0)
San Marino
Sao Tome and Principe 2012 Surveillance National 88 (47–100)
Saudi Arabia 2010 Survey National 1.8 (1.4–2.4) 2010 Survey National 16 (12–21)
Senegal 2014 Survey National 0.4 (0–0.80) 2014 Survey National 16 (9.3–23)
Serbia 2013 Surveillance National 0.85 (0.31–1.8) 2013 Surveillance National 4.7 (1.3–11)
Seychelles 2014 Surveillance National 0 (0–41) 2014 Surveillance National 0 (0–0)
Sierra Leone
Singapore 2014 Surveillance National 1.1 (0.54–1.9) 2014 Surveillance National 1.3 (<0.1–7.1)
Sint Maarten (Dutch part)
Slovakia 2012 Surveillance National 0 (0–2.6) 2012 Surveillance National 3.7 (<0.1–19)
a
 Empty rows indicate an absence of high-quality survey or surveillance data. In the absence of high-quality national data, high-quality sub-national data are used.
TABLE A4.6
Measured percentage of TB cases with MDR-TB,a most recent year available
a Empty rows indicate an absence of high-quality survey or surveillance data. In the absence of high-quality national data, high-quality sub-national data are used.
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Table A4.6
Measured percentage of TB cases with MDR-TBa, most recent year available
Year Source Coverage Percentage Year Source Coverage Percentage
New TB cases Previously treated TB cases
Slovenia 2014 Surveillance National 0 (0–4.1) 2014 Surveillance National 0 (0–41)
Solomon Islands 2014 Surveillance National 0 (0–0)
Somalia 2011 Survey National 5.2 (2.7–7.7) 2011 Survey National 41 (23–58)
South Africa 2002 Survey National 1.8 (1.4–2.3) 2002 Survey National 6.7 (5.4–8.2)
South Sudan
Spain 2001, 2005 Multiple surveys 0.22 (<0.1–0.80) 2001, 2005 Multiple surveys 7.1 (3.3–13)
Sri Lanka 2006 Survey National 0.18 (0–0.99) 2013 Surveillance National 0.58 (<0.1–2.1)
Sudan
Suriname
Swaziland 2009 Survey National 7.7 (4.8–11) 2009 Survey National 34 (28–39)
Sweden 2014 Surveillance National 3 (1.4–5.6) 2014 Surveillance National 11 (1.3–33)
Switzerland 2014 Surveillance National 3.1 (1.0–7.0) 2014 Surveillance National 14 (4.0–33)
Syrian Arab Republic 2003 Survey National 6.2 (3.9–9.3) 2011 Surveillance National 31 (21–44)
Tajikistan 2014 Surveillance National 8.1 (6.9–9.4) 2014 Surveillance National 52 (47–57)
Thailand 2012 Survey National 2 (1.4–2.8) 2012 Survey National 19 (14–25)
The Former Yugoslav Republic of 
Macedonia 2014 Surveillance National 1.4 (0.17–4.9) 2014 Surveillance National 0 (0–20)
Timor-Leste




Tunisia 2012 Survey National 0.8 (0–1.7) 2012 Survey National 12 (4.5–19)
Turkey 2013 Surveillance National 2.5 (2.1–3.0) 2013 Surveillance National 18 (15–21)
Turkmenistan 2013 Survey National 14 (11–17) 2013 Survey National 38 (30–45)
Turks and Caicos Islands
Tuvalu
US Virgin Islands
Uganda 2011 Survey National 1.4 (0.60–2.2) 2011 Survey National 12 (6.8–19)
Ukraine 2014 Survey National 22 (20–24) 2014 Survey National 56 (50–61)
United Arab Emirates 2013 Surveillance National 0 (0–52)
United Kingdom of Great Britain and 
Northern Ireland 2014 Surveillance National 1.2 (0.81–1.7) 2014 Surveillance National 3.6 (1.3–7.7)
United Republic of Tanzania 2007 Survey National 1.1 (0.50–2.0) 2007 Survey National 3.1 (0.90–7.9)
United States of America 2014 Surveillance National 1.1 (0.84–1.4) 2014 Surveillance National 7.4 (4.7–11)
Uruguay 2012 Surveillance National 0 (0–0.79) 2012 Surveillance National 2.4 (<0.1–13)
Uzbekistan 2011 Survey National 23 (18–29) 2011 Survey National 62 (52–71)
Vanuatu 2006 Surveillance National 0 (0–12)
Venezuela (Bolivarian Republic of)
Viet Nam 2012 Survey National 4 (2.5–5.4) 2012 Survey National 23 (17–30)
Wallis and Futuna Islands
West Bank and Gaza Strip
Yemen 2011 Survey National 1.7 (0.50–3.0) 2011 Survey National 15 (8.1–22)
Zambia 2008 Survey National 0.3 (<0.1–1.2) 2008 Survey National 8.1 (4.1–14)
Zimbabwe
a
 Empty rows indicate an absence of high-quality survey or surveillance data. In the absence of high-quality national data, high-quality sub-national data are used.
TABLE A4.6
Measured percentage of TB cases with MDR-TB,a most recent year available
a Empty rows indicate an absence of high-quality survey or surveillance data. In the absence of high-quality national data, high-quality sub-national data are used.
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TABLE A4.7
Drug susceptibility testing for TB cases, estimated MDR-TB among notified TB cases, RR-/MDR-TB cases detected, and 
enrolments on MDR-TB treatment, 2014
a Bacteriologically confirmed pulmonary or extrapulmonary cases.
b May be > 100% due to testing of extrapulmonary cases or inadequate linkages between laboratory and clinical registers.
c May be > 100% due to denominator only including pulmonary MDR-TB cases, or if estimates of MDR-TB are too low.
d May be > 100% due to enrolment of cases without laboratory confirmation of RR-/MDR-TB, or cases detected in previous calendar years.
Table A4.7
Drug susceptibility testing for TB cases, estimated MDR-TB among notified TB cases, RR-/MDR-TB cases detected,  
and enrolments on MDR-TB treatment, 2014
(Number) (%)b (Number) (%)b
Afghanistan 2 <0.1 184 8.5 1 100 (850–1 400) 88 8 88 100
Albania 21 13 8 38 1 (0–4.0) 3 >100 0 0
Algeria 509 7.1 178 32 170 (53–290) 65 38 56 86
American Samoa
Andorra 4 >100 1 100 0 (0–0) 2 0 0
Angola 29 0.13 278 6.4 1 500 (630–2 500) 307 20 614 >100
Anguilla 1 100 0 0 (0–0) 0 0
Antigua and Barbuda 0 0 0 0 (0–0) 0 0
Argentina 1 894 36 546 41 360 (240–480) 114 32 78 68
Armenia 343 96 50 17 160 (140–190) 111 69 120 >100
Aruba 0 (0–0) 2
Australia 954 >100 55 79 19 (10–29) 24 >100 23 96
Austria 314 81 20 62 23 (12–34) 50 >100 3 6
Azerbaijan 2 059 >100 3 901 >100 1 300 (1 100–1 500) 1 007 77 814 81
Bahamas 21 84 2 50 2 (0–5.0) 0 0 0
Bahrain
Bangladesh 12 573 12 4 959 51 4 800 (3 400–6 200) 994 21 945 95
Barbados 3 100 0 0 (0–3.0) 0 0
Belarus 1 990 97 877 84 1 700 (1 600–1 800) 1 282 75 1 903 >100
Belgium 506 95 53 73 13 (4.0–22) 12 92 10 83
Belize 2 6.1 2 12 19 (18–19) 0 0 1
Benin 81 2.6 185 82 28 (0–60) 25 89 16 64
Bermuda 0 0 0 (0–0) 0 0
Bhutan 380 84 44 62 37 (26–48) 61 >100 122 >100
Bolivia (Plurinational State of) 238 4.3 510 80 210 (120–290) 110 52 55 50
Bonaire, Saint Eustatius and Saba 0 0 0 (0–0) 0 0
Bosnia and Herzegovina 613 100 59 55 2 (0–5.0) 4 >100 3 75
Botswana 10 0.45 62 6.4 160 (100–210) 41 26 73 >100
Brazil 1 800 (1 400–2 100) 702 39 702 100
British Virgin Islands 0 0 0 (0–0) 0 0
Brunei Darussalam 126 84 7 100 1 (0–4.0) 1 100 1 100
Bulgaria 639 80 101 45 72 (53–91) 44 61 29 66
Burkina Faso 6 0.16 273 48 170 (74–280) 53 31 34 64
Burundi 289 6.8 60 21 140 (42–240) 48 34 49 >100
Cabo Verde 8 (4.0–13) 5 62 5 100
Cambodia 646 5.3 1 329 67 520 (260–790) 110 21 110 100
Cameroon 5 <0.1 866 55 630 (220–1 000) 126 20 91 72
Canada
Cayman Islands 0 0 0 (0–0) 0 0
Central African Republic 92 1.8 0 0 74 (0–180) 40 54 21 52
Chad 0 0 217 26 310 (120–500) 22 7.1 12 55
Chile 1 127 76 179 70 23 (11–34) 23 100 10 43
China 45 664 19 17 210 54 52 000 (42 000–61 000) 5 807 11 2 846 49
China, Hong Kong SAR 2 328 96 277 58 44 (27–60) 34 77 22 65
China, Macao SAR 260 >100 23 79 10 (3.0–17) 8 80 7 88
Colombia 3 484 49 535 48 360 (260–450) 187 52 173 93
Comoros 0 0 0 0 3 (1.0–5.0) 0 0 0
Congo 477 >100 200 (57–350) 24 12 0 0
Cook Islands 0 0 0 0 (0–2.0) 0 0
Costa Rica 0 0 1 5.3 7 (0–13) 1 14 1 100
Croatia 274 79 29 81 2 (0–6.0) 2 100 3 >100
Cuba 310 66 56 86 7 (0–14) 10 >100 10 100
Curaçao 4 100 0 0 (0–3.0) 0 0
Cyprus 17 55 1 33 3 (3.0–3.0) 0 0
Czech Republic 323 99 18 45 0 (0–0) 8 5 62
Côte d'Ivoire 658 48 580 (250–900) 471 81 313 66
Democratic People's Republic of Korea 81 0.23 364 2.3 3 800 (2 200–5 500) 197 5.2 212 >100
Democratic Republic of the Congo 545 0.72 6 135 75 2 800 (980–4 500) 442 16 436 99
Cases enrolled on 
MDR-TB treatment
(Number) (% of notified)d(Number)
Confirmed new 
TB casesa tested 
for RR-/MDR-TB
Notified previously 
treated TB cases 
tested for RR-/MDR-TB
Confirmeda 
RR-/MDR-TB casesEstimated MDR-TB among 
notified pulmonary cases (% of estimated)c
(footnotes sent by email)
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Table A4.7
Drug susceptibility testing for TB cases, estimated MDR-TB among notified TB cases, RR-/MDR-TB cases detected,  
and enrolments on MDR-TB treatment, 2014
(Number) (%)b (Number) (%)b
Cases enrolled on 
MDR-TB treatment
(Number) (% of notified)d(Number)
Confirmed new 
TB casesa tested 
for RR-/MDR-TB
Notified previously 
treated TB cases 
tested for RR-/MDR-TB
Confirmeda 
RR-/MDR-TB casesEstimated MDR-TB among 
notified pulmonary cases (% of estimated)c
Denmark 197 98 18 67 3 (0–6.0) 1 33
Djibouti 218 20 28 16 48 (20–75) 110 >100 60 55
Dominica 1 0 0 (0–0) 0 0
Dominican Republic 240 9.1 176 31 150 (95–210) 93 62 127 >100
Ecuador 1 016 28 720 >100 310 (250–380) 451 >100 179 40
Egypt 45 1.2 358 60 250 (180–320) 86 34 72 84
El Salvador 846 54 123 82 6 (0–16) 15 >100 15 100
Equatorial Guinea 2 0.29 5 5.5 28 (20–36) 7 25 4 57
Eritrea 52 (21–82) 22 42 24 >100
Estonia 175 >100 29 71 62 (48–75) 50 81 48 96
Ethiopia 2 405 6 7 682 1 300 (700–2 300) 503 39 557 >100
Fiji 12 11 3 7.5 0 (0–0) 1 0 0
Finland 212 >100 5 38 7 (1.0–14) 8 >100 9 >100
France 3 358 >100 332 >100 56 (34–77) 111 >100 111 100
French Polynesia 31 84 1 33 0 (0–0) 0 0
Gabon 58 2.7 2 0.22 210 (100–310) 59 28 0 0
Gambia 0 0 96 86 11 (0–41) 15 >100 9 60
Georgia 1 700 95 634 61 640 (590–700) 441 69 501 >100
Germany 273 10 127 42 140 (74–210) 90 64
Ghana 328 4.3 1 471 >100 400 (160–640) 93 23 14 15
Greece 120 34 12 34 9 (0–22) 4 44
Greenland
Grenada 0 (0–0) 0 0
Guam 34 >100 1 100 0 (0–0) 1 1 100
Guatemala 353 17 151 69 130 (95–170) 62 48 42 68
Guinea 114 1.8 181 38 230 (80–380) 105 46 124 >100
Guinea-Bissau 83 5.4 58 >100 45 (11–79) 25 56 17 68
Guyana 6 2.1 41 27 28 (18–38) 4 14 4 100
Haiti 91 7.9 450 (260–640) 91 20 91 100
Honduras 117 6.5 97 43 63 (30–96) 12 19 12 100
Hungary 339 >100 34 35 26 (14–37) 11 42 9 82
Iceland 6 >100 1 100 0 (0–0) 0 0
India 12 795 1.7 214 209 69 71 000 (57 000–85 000) 25 748 36 24 073 93
Indonesia 1 058 0.55 8 445 88 6 800 (5 200–8 400) 1 812 27 1 284 71
Iran (Islamic Republic of) 1 135 20 237 35 130 (79–180) 48 37 53 >100
Iraq 986 38 250 37 160 (110–210) 196 >100 58 30
Ireland 173 >100 13 68 3 (0–7.0) 2 67 2 100
Israel 257 >100 4 67 20 (11–30) 17 85 17 100
Italy 1 178 221 93
Jamaica 34 100 2 100 2 (0–6.0) 0 0 0
Japan 7 861 65 481 41 190 (140–250) 81 43 56 69
Jordan 72 62 4 15 21 (7.0–35) 9 43 9 100
Kazakhstan 9 597 >100 6 377 >100 4 900 (4 800–5 000) 5 877 >100 7 315 >100
Kenya 17 619 50 7 436 85 2 500 (1 200–3 800) 644 26 544 84
Kiribati 0 0 22 79 22 (15–29) 0 0 0
Kuwait 733 >100 1 100 11 (3.0–19) 9 82 9 100
Kyrgyzstan 2 000 (1 800–2 100) 1 267 63 1 157 91
Lao People's Democratic Republic 671 23 68 24 230 (160–300) 24 10 25 >100
Latvia 483 99 107 86 84 (66–100) 71 85 70 99
Lebanon 299 98 40 >100 10 (0–20) 10 100 5 50
Lesotho 461 18 79 5.1 340 (260–420) 148 44 152 >100
Liberia 40 (12–68) 0 0 0
Libya 31 (24–39) 0
Lithuania 968 >100 294 100 300 (270–340) 279 93 271 97
Luxembourg 16 >100 0 0 (0–0) 2 2 100
Madagascar 0 0 492 21 200 (5.0–380) 27 14 11 41
Malawi 40 0.72 615 31 140 (86–200) 106 76 64 60
Malaysia 5 171 37 298 16 99 (57–140) 319 >100 60 19
(footnotes sent by email)
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b May be > 100% due to testing of extrapulmonary cases or inadequate linkages between laboratory and clinical registers.
c May be > 100% due to denominator only including pulmonary MDR-TB cases, or if estimates of MDR-TB are too low.
d May be > 100% due to enrolment of cases without laboratory confirmation of RR-/MDR-TB, or cases detected in previous calendar years.
Data for all years can be downloaded from www.who.int/tb/data  GLOBAL TUBERCULOSIS REPORT 2015  n  187
Table A4.7
Drug susceptibility testing for TB cases, estimated MDR-TB among notified TB cases, RR-/MDR-TB cases detected,  
and enrolments on MDR-TB treatment, 2014
(Number) (%)b (Number) (%)b
Cases enrolled on 
MDR-TB treatment
(Number) (% of notified)d(Number)
Confirmed new 
TB casesa tested 
for RR-/MDR-TB
Notified previously 
treated TB cases 
tested for RR-/MDR-TB
Confirmeda 
RR-/MDR-TB casesEstimated MDR-TB among 
notified pulmonary cases (% of estimated)c
Maldives 3 3.3 2 2 (2.0–2.0) 0 0 0
Mali 294 7.7 12 3.6 130 (51–210) 40 31 33 82
Malta 24 >100 1 100 0 (0–0) 0 0
Marshall Islands 82 >100 7 41 0 (0–0) 0 0
Mauritania 8 0.59 52 (21–84) 8 15 11 >100
Mauritius 114 100 3 100 1 (0–3.0) 1 100 1 100
Mexico 42 0.32 1 282 73 500 (440–560) 201 40 206 >100
Micronesia (Federated States of) 63 >100 0 0 8 (4.0–11) 1 12 0 0
Monaco
Mongolia 1 043 58 1 664 >100 220 (190–250) 318 >100 294 92
Montenegro 63 100 5 50 4 (0–8.0) 2 50 2 100
Montserrat 0 (0–0) 0 0
Morocco 424 3.4 358 14 340 (210–470) 115 34 123 >100
Mozambique 886 3.6 906 22 2 100 (1 300–2 900) 544 26 482 89
Myanmar 10 295 24 15 166 >100 9 000 (6 500–12 000) 3 495 39 1 537 44
Namibia 580 (470–690) 350 60 327 93
Nauru 0 0 0 0 (0–0) 0 0
Nepal 2 292 14 1 071 26 1 200 (770–1 500) 406 34 349 86
Netherlands 463 >100 11 58 6 (0–12) 7 >100 6 86
New Caledonia 11 92 2 100 0 (0–0) 0 0
New Zealand 3 (0–6.0)
Nicaragua 9 0.62 68 20 50 (21–78) 19 38 20 >100
Niger 1 <0.1 86 14 260 (97–410) 46 18 47 >100
Nigeria 3 300 (2 500–4 200) 798 24 423 53
Niue 0 0 0 (0–0) 0 0
Northern Mariana Islands 19 100 4 >100 1 (0–4.0) 1 100 0 0
Norway 213 88 16 73 7 (1.0–14) 8 >100
Oman 271 >100 8 100 6 (1.0–11) 8 >100 8 100
Pakistan 361 0.29 11 685 72 12 000 (8 800–15 000) 3 243 27 2 662 82
Palau 6 86 0 0 (0–5.0) 1 1 100
Panama 158 22 46 26 45 (28–61) 31 69 20 65
Papua New Guinea 890 (540–1 200) 320 36 320 100
Paraguay 308 22 149 39 60 (18–100) 11 18 13 >100
Peru 12 949 73 3 375 83 2 000 (1 900–2 100) 1 463 73 1 671 >100
Philippines 4 415 4.7 20 196 67 11 000 (8 600–13 000) 3 000 27 2 680 89
Poland 4 016 95 420 66 52 (35–69) 49 94
Portugal 822 65 76 49 21 (11–31) 26 >100 22 85
Puerto Rico 40 >100 0 0 (0–4.0) 0 0
Qatar 465 >100 2 (0–7.0) 2 100 2 100
Republic of Korea 19 412 >100 4 299 54 1 800 (1 400–2 100) 1 172 65 856 73
Republic of Moldova 1 764 99 831 61 1 500 (1 400–1 600) 925 62 930 >100
Romania 5 751 73 2 171 64 650 (490–810) 578 89 648 >100
Russian Federation 31 250 84 13 925 28 39 000 (33 000–45 000) 15 585 40 21 904 >100
Rwanda 1 449 36 172 28 130 (83–180) 82 63 81 99
Saint Kitts and Nevis 0 0 0 0 (0–0) 0 0
Saint Lucia 6 >100 0 0 (0–0) 0 0
Saint Vincent and the Grenadines 4 100 1 100 0 (0–0) 0 0
Samoa 10 >100 0 0 0 (0–0) 0 0
San Marino
Sao Tome and Principe 5 7.1 2 11 18 (13–22) 2 11 2 100
Saudi Arabia 1 091 56 82 42 72 (58–86) 67 93 51 76
Senegal 3 694 40 1 335 >100 240 (150–330) 70 29 49 70
Serbia 630 70 54 37 18 (7.0–29) 14 78 13 93
Seychelles 7 100 0 0 (0–3.0) 0 0
Sierra Leone 290 (93–480) 0 0 0
Singapore 1 217 >100 93 61 20 (9.0–32) 16 80 16 100
Sint Maarten (Dutch part) 0 (0–0) 0 0
Slovakia 156 >100 38 81 2 (0–5.0) 7 >100 2 29
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a Bacteriologically confirmed pulmonary or extrapulmonary cases.
b May be > 100% due to testing of extrapulmonary cases or inadequate linkages between laboratory and clinical registers.
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Table A4.7
Drug susceptibility testing for TB cases, estimated MDR-TB among notified TB cases, RR-/MDR-TB cases detected,  
and enrolments on MDR-TB treatment, 2014
(Number) (%)b (Number) (%)b
Cases enrolled on 
MDR-TB treatment
(Number) (% of notified)d(Number)
Confirmed new 
TB casesa tested 
for RR-/MDR-TB
Notified previously 
treated TB cases 
tested for RR-/MDR-TB
Confirmeda 
RR-/MDR-TB casesEstimated MDR-TB among 
notified pulmonary cases (% of estimated)c
Slovenia 122 >100 7 100 0 (0–0) 0 0
Solomon Islands 9 6.2 2 18 10 (6.0–14) 0 0 0
Somalia 21 0.34 200 29 770 (510–1 000) 176 23 76 43
South Africa 6 200 (5 100–7 300) 18 734 >100 11 538 62
South Sudan 56 7.2 230 (95–360) 6 2.6 0 0
Spain 1 492 52 110 48 24 (9.0–39) 39 >100
Sri Lanka 1 209 28 669 >100 14 (0–45) 42 >100 11 26
Sudan 24 0.39 103 5.8 540 (230–860) 82 15 74 90
Suriname 88 88 13 81 5 (3.0–6.0) 9 >100 0 0
Swaziland 440 (320–560) 358 81 380 >100
Sweden 498 >100 23 53 15 (6.0–24) 18 >100 15 83
Switzerland 231 85 35 70 16 (6.0–27) 17 >100
Syrian Arab Republic 226 19 57 32 150 (100–190) 31 21 8 26
Tajikistan 2 432 100 800 64 880 (810–950) 902 >100 804 89
Thailand 4 370 13 2 209 38 2 200 (1 700–2 700) 506 23
The Former Yugoslav Republic of 
Macedonia 154 92 18 78 3 (0–6.0) 3 100 3 100
Timor-Leste 198 99 99 (87–110) 3 3 3 100
Togo 1 <0.1 18 11 77 (39–120) 9 12 1 11
Tokelau 0 (0–0) 0 0
Tonga 0 0 0 1 (0–1.0) 0 0 0
Trinidad and Tobago 43 34 15 29 10 (8.0–12) 0 0 1
Tunisia 1 009 96 43 59 19 (7.0–30) 14 74 14 100
Turkey 4 866 84 630 56 360 (320–410) 349 97 257 74
Turkmenistan 310 16 162 31 450 (390–520) 210 47 210 100
Turks and Caicos Islands 0 (0–0) 0 0
Tuvalu 0 0 0 0 1 (1.0–1.0) 0 0 0
US Virgin Islands
Uganda 1 958 7.5 737 18 1 000 (620–1 400) 255 26 213 84
Ukraine 13 833 97 9 707 69 13 000 (12 000–14 000) 7 735 60 8 201 >100
United Arab Emirates 26 70 3 60 1 (0–1.0) 1 100 1 100
United Kingdom of Great Britain and 
Northern Ireland 3 820 >100 209 46 59 (39–79) 63 >100 60 95
United Republic of Tanzania 9 506 40 882 34 600 (240–950) 516 86 143 28
United States of America 6 557 >100 322 70 110 (88–140) 108 98 107 99
Uruguay 370 69 35 39 2 (0–6.0) 2 100 2 100
Uzbekistan 11 956 >100 5 888 77 7 000 (6 100–7 900) 4 955 71 3 665 74
Vanuatu 0 0 0 0 0 (0–0) 0 0
Venezuela (Bolivarian Republic of) 266 7.5 186 34 150 (110–200) 26 17 26 100
Viet Nam 2 756 5.5 8 511 96 5 100 (3 900–6 300) 2 198 43 1 532 70
Wallis and Futuna Islands 0 0 (0–0) 0
West Bank and Gaza Strip 0 0 0 0 2 (1.0–2.0) 0 0 0
Yemen 996 34 62 24 140 (65–220) 53 38 50 94
Zambia 610 (260–960)
Zimbabwe 341 3 237 6.4 940 (430–1 500) 412 44 381 92
WHO regions
African Region 40 940 6.4 31 952 33 32 000 (15 000–49 000) 25 654 80 17 352 68
Region of the Americas 30 537 24 8 724 32 7 000 (4 700–9 300) 3 745 54 3 568 95
Eastern Mediterranean Region 8 404 4.6 13 703 52 15 000 (12 000–19 000) 4 348 29 3 423 79
European Region 111 021 95 48 463 52 73 000 (63 000–83 000) 42 341 58 49 144 >100
South-East Asia Region 45 056 3.8 247 336 67 99 000 (90 000–110 000) 33 264 34 28 536 86
Western Pacific Region 92 801 21 54 553 62 71 000 (47 000–94 000) 13 437 19 8 850 66
Global 328 759 12 404 731 58 300 000 (220 000–370 000) 122 789 41 110 873 90
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TABLE A4.7
Drug susceptibility testing for TB cases, estimated MDR-TB among notified TB cases, RR-/MDR-TB cases detected, and 
enrolments on MDR-TB treatment, 2014
a Bacteriologically confirmed pulmonary or extrapulmonary cases.
b May be > 100% due to testing of extrapulmonary cases or inadequate linkages between laboratory and clinical registers.
c May be > 100% due to denominator only including pulmonary MDR-TB cases, or if estimates of MDR-TB are too low.
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TABLE A4.8
HIV testing for TB patients, provision of CPT and ART to HIV-positive TB patients, and initiation of IPT for people  
newly enrolled in HIV care, 2014
a CPT = Cotrimoxazole preventive therapy.
b ART = Anti-retroviral therapy.
c Initiation of isoniazid preventive therapy (IPT) for people newly enrolled in HIV care.
Table A4.8
HIV testing for TB patients, provision of CPT and ART to HIV-positive TB patients, and initiation of IPT for people 
newly enrolled in HIV care, 2014
(Number) (%) (Number) (%) (Number) (%) (Number) (%)
Afghanistan 32 712 10 443 32 4 <0.1 7
Albania 408 41 10 2 4.9 2 100 2 100
Algeria 22 715
American Samoa
Andorra 6 0 0 0 0 0
Angola 55 206 27 699 50 2 827 10 2 827 100
Anguilla 1 1 100 1 100 1 100 1 100
Antigua and Barbuda 3 3 100 1 33 1 100 1 100 1
Argentina 10 038 1 580 16 447 28
Armenia 1 342 1 342 100 84 6.3 54 64 54 64 0
Aruba 2
Australia 1 343 1 069 80 17 1.6
Austria 582
Azerbaijan 7 539 7 004 93 148 2.1 101 68 296
Bahamas 50 28 56 10 36 4 40 8 80
Bahrain
Bangladesh 196 797 1 110 0.56 45 4.1 45 100 45 100 0
Barbados 5 2 40 2 100 0 0 2 100
Belarus 4 274 4 274 100 271 6.3 271 100 191 70 539
Belgium 959 497 52 38 7.6
Belize 87 63 72 25 40 25 100 25 100
Benin 3 977 3 828 96
Bermuda 0 0 0 0 0
Bhutan 1 082 703 65 7 1 0 0 7 100
Bolivia (Plurinational State of) 8 201 6 340 77 262 4.1 125 48 177 68
Bonaire, Saint Eustatius and Saba 0 0 0 0 0
Bosnia and Herzegovina 1 196 194 16 2
Botswana 6 019 5 496 91 3 280 60 3 132 95 2 546 78
Brazil 81 512 56 981 70 9 578 17
British Virgin Islands 0 0 0 0 0
Brunei Darussalam 198 198 100 0 0 0 0
Bulgaria 1 872 1 377 74 3 0.22 31
Burkina Faso 5 792 5 553 96 656 12 641 98 564 86
Burundi 7 309 6 654 91 901 14 873 97 611 68
Cabo Verde 292 290 99 27 9.3 24 89 25 93 214
Cambodia 43 738 35 635 81 953 2.7 938 98 938 98 901
Cameroon 26 517 23 006 87 8 565 37 7 679 90 5 955 70
Canada
Cayman Islands 0 0 0 0 0
Central African Republic 10 186 5 201 51 1 781 34
Chad 12 305 6 636 54 1 291 19 721 56
Chile 2 440 1 213 50 213 18 66 31
China 826 155 343 515 42 5 309 1.5 3 675 69
China, Hong Kong SAR 4 784 3 345 70 23 0.69
China, Macao SAR 394 355 90 6 1.7 4 67 5 83
Colombia 12 435 9 994 80 2 143 21 901 42 816 38
Comoros 150 1 0.67 1 100 1 100 1 100 1
Congo 10 194 1 313 13 386 29 104 27 94 24
Cook Islands 2 0 0 0 0 0
Costa Rica 469 442 94 41 9.3 41 100 41 100
Croatia 497
Cuba 742 736 99 87 12 4 4.6 72 83 1 300
Curaçao 5 5 100 1 20 1 100 1 100
Cyprus 41
Czech Republic 514 146 28 3 2.1
Côte d'Ivoire 23 750 22 108 93 5 292 24 1 259 24 1 095 21
Democratic People's Republic of Korea 110 290 0 0 0 0 0

















  Cotri  tive therapy
b
 ART = Anti-retroviral therapy
c
 Initiation of isoniazid preventive therapy (IPT) for people newly enrolled in HIV care
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Table A4.8
HIV testing for TB patients, provision of CPT and ART to HIV-positive TB patients, and initiation of IPT for people 
newly enrolled in HIV care, 2014















Djibouti 2 227 1 877 84 160 8.5 109 68
Dominica 1 0 0 0 0 0
Dominican Republic 4 605 3 377 73 782 23 370 47 667 85 945
Ecuador 5 352 4 729 88 637 13 0 0 637 100 287
Egypt 7 467 1 690 23 12 0.71 12 100 12 100
El Salvador 2 220 2 173 98 203 9.3 171 84 170 84 1 946
Equatorial Guinea 1 213 732 60 293 40 266 91
Eritrea 2 425 2 311 95 140 6.1 104 74 115 82
Estonia 246 238 97 24 10 19 79
Ethiopia 119 592 89 320 75 8 670 9.7 3 396 39 10 385
Fiji 385 281 73 11 3.9 11 100 11 100 1
Finland 259 2
France 4 845
French Polynesia 59 12 20 0 0 0 0
Gabon 6 299 2 504 40 648 26 511 79 511 79 0
Gambia 2 583 2 169 84 429 20 381 89 205 48
Georgia 3 850 2 591 67 57 2.2 56 98 56 98 106
Germany 4 488
Ghana 15 276 11 830 77 2 858 24 1 910 67 1 104 39
Greece 519
Greenland
Grenada 0 0 0
Guam 56 55 98 0 0 0 0
Guatemala 3 224 2 782 86 245 8.8 228 93 228 93
Guinea 11 734 7 383 63 1 815 25 1 768 97 1 353 75
Guinea-Bissau 2 288 1 510 66 561 37 282 50 149 27 448
Guyana 648 587 91 148 25 135 91 103 70 44
Haiti 15 963 13 968 88 2 588 19 1 630 63 1 396 54 22 038
Honduras 2 820 2 479 88 256 10 203 79 210 82 249
Hungary 851
Iceland 8 7 88 0 0 0 0
India 1 683 915 1 034 712 61 44 171 4.3 41 066 93 39 800 90
Indonesia 324 539 15 074 4.6 2 355 16 963 41 624 26
Iran (Islamic Republic of) 10 395 3 009 29 272 9 55 20 100 37 181
Iraq 8 341 3 925 47 0 0 0 0
Ireland 316 84 27 15 18 7 47
Israel 368 367 100 25 6.8
Italy
Jamaica 86 79 92 19 24 18 95
Japan 19 615 1 672 8.5 45 2.7
Jordan 405 379 94 0 0 0 0
Kazakhstan 15 718 15 435 98 625 4 487 78 472 76 805
Kenya 89 294 84 423 95 30 002 36 29 735 99 26 142 87
Kiribati 432 223 52 1 0.45 1 100 1 100 0
Kuwait 734 393 54 1 0.25 1 100 1 100
Kyrgyzstan 7 423 221 118 53 112 51 95
Lao People's Democratic Republic 4 350 3 390 78 715
Latvia 761 488 64 95 19 48 51 55 58
Lebanon 683 289 42 6 2.1 6 100 6 100 10
Lesotho 9 856 9 145 93 6 600 72 6 600 100 4 866 74
Liberia 2 726 2 801 100 402 14 214 53 112 28
Libya 1 185 1 142 96 54 4.7
Lithuania 1 607 1 135 71 36 3.2 0 0
Luxembourg 24
Madagascar 28 936 6 606 23 98 1.5 0 0 98 100
Malawi 17 723 16 445 93 8 844 54 7 995 90 8 162 92 135 013
Malaysia 24 711 21 698 88 1 468 6.8 109 7.4 453 31 2 063
Maldives 131 130 99 0 0 0 0
Mali 5 976 2 563 43 367 14 265 72 367 100
a
 CPT = Cotrimoxazole preventive therapy
b
 ART = Anti-retroviral therapy
c
 Initiation of isoniazid preventive therapy (IPT) for people newly enrolled in HIV care
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HIV testing for TB patients, provision of CPT and ART to HIV-positive TB patients, and initiation of IPT for people  
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a   Cotri  tive therapy.
b ART = Anti-retroviral therapy.
c Initiation of isoniazid preventive therapy (IPT) for people newly enrolled in HIV care.
Data for all years can be downloaded from www.who.int/tb/data  GLOBAL TUBERCULOSIS REPORT 2015  n  191
Table A4.8
HIV testing for TB patients, provision of CPT and ART to HIV-positive TB patients, and initiation of IPT for people 
newly enrolled in HIV care, 2014















Malta 46 35 76 6 17
Marshall Islands 153 95 62 0 0 0 0
Mauritania 2 438
Mauritius 127 122 96 15 12 15 100 15 100
Mexico 21 881 18 547 85 1 287 6.9 900 70 755 59 487
Micronesia (Federated States of) 189 117 62 0 0 0 0
Monaco
Mongolia 4 771 3 498 73 8 0.23 6 75 6 75 0
Montenegro 113 94 83 0 0 0 0
Montserrat 0
Morocco 30 724 14 413 47 351 2.4 351 100 351 100
Mozambique 58 270 55 943 96 29 337 52 27 504 94 23 801 81 94 252
Myanmar 141 957 56 133 40 6 412 11 4 666 73 2 319 36 2 997
Namibia 9 882 9 088 92 3 994 44 3 940 99 3 360 84
Nauru 8 0 0 0 0 0
Nepal 37 025 3 254 8.8 369 11 273 74 43
Netherlands 823 424 52 23 5.4
New Caledonia 29 13 45
New Zealand 302 220 73 2 0.91
Nicaragua 2 839 2 185 77 78 130
Niger 11 102 7 056 64 485 6.9 76 16 111 23
Nigeria 91 354 84 161 92 16 066 19 14 569 91 11 997 75 26 383
Niue 0 0 0 0 0
Northern Mariana Islands 26 26 100 0 0 0 0
Norway 325
Oman 358 358 100 3 0.84 3 100 3 100
Pakistan 316 577 10 715 3.4 90 0.84 90 100 90 100
Palau 14 11 79 0 0 0 0
Panama 1 528 1 520 99 123 8.1 0 0 117 95
Papua New Guinea 28 567 7 218 25 781 11 246 31 484 62
Paraguay 2 415 1 899 79 189 10 114 60 165 87 0
Peru 31 461 23 280 74 1 385 5.9 578 42 913 66 1 126
Philippines 267 436 53 354 20 108 0.2 20 19 53 49
Poland 6 698 13 0.19
Portugal 2 226 1 432 64 221 15
Puerto Rico 44 39 89 6 15 2 33 2 33
Qatar 465 460 99 0 0 0 0
Republic of Korea 43 088
Republic of Moldova 4 636 4 426 95 338 7.6 140 41
Romania 15 906 10 927 69 312 2.9 281 90 278 89 158
Russian Federation 136 168 67 425 5 251
Rwanda 6 024 5 944 99 1 497 25 1 473 98 1 297 87
Saint Kitts and Nevis 7 4 57 1 25 1 100 1 100
Saint Lucia 6 6 100 1 17 1 100 1 100 0
Saint Vincent and the Grenadines 6 3
Samoa 23 0 0 0 0 0
San Marino
Sao Tome and Principe 158 158 100 28 18 28 100 28 100 0
Saudi Arabia 3 336 1 781 53 63 3.5
Senegal 13 647 11 305 83 831 7.4 791 95 708 85 1 332
Serbia 1 832 127 6.9 8 6.3 8 100
Seychelles 13 13 100 1 7.7 0 0 1 100
Sierra Leone 12 721 11 048 87 1 305 12 816 63 887 68 1 339
Singapore 2 171 1 827 84 50 2.7
Sint Maarten (Dutch part) 0 0 0 0 0
Slovakia 336 308 92 0 0 0 0 0
Slovenia 144 110 76 0 0 0 0
Solomon Islands 346 45 13 0 0 0 0
Somalia 13 130 7 714 59 248 3.2 166 67 111 45 226
a
 CPT = Cotrimoxazole preventive therapy
b
 ART = Anti-retroviral therapy
c
 Initiation of isoniazid preventive therapy (IPT) for people newly enrolled in HIV care
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HIV testing for TB patients, provision of CPT and ART to HIV-positive TB patients, and initiation of IPT for people  
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b ART = Anti-retroviral therapy.
c Initiation of isoniazid preventive therapy (IPT) for people newly enrolled in HIV care.
192  n  GLOBAL TUBERCULOSIS REPORT 2015 Data for all years can be downloaded from www.who.int/tb/data
Table A4.8
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South Africa 318 193 295 136 93 179 756 61 155 017 86 141 755 79 551 787
South Sudan 8 856 5 892 67 752 13 713 95 463 62
Spain 5 048 3 191 63 233 7.3
Sri Lanka 9 473 7 418 78 21 0.28 18 86 18 86 9
Sudan 20 392 5 501 27 329 6 147 45
Suriname 158 154 97 44 29 27 61 32 73
Swaziland 5 616 5 430 97 3 972 73 3 904 98 3 123 79 1 188
Sweden 670
Switzerland 473
Syrian Arab Republic 3 576 0 0 0 0 0
Tajikistan 6 260 5 656 90 161 2.8 156 97 128 80 280
Thailand 71 618 50 670 71 6 831 13 4 359 64 4 691 69
The Former Yugoslav Republic of 
Macedonia 285 171 60 1 0.58 1 100 1 100 1
Timor-Leste 3 778 2 054 54 24 1.2 24 100 24 100
Togo 2 577 2 511 97 523 21 465 89 396 76
Tokelau 0
Tonga 13 13 100 0 0 0 0
Trinidad and Tobago 293 289 99 71 25 17 24 40 56
Tunisia 3 173 2 317 73 12 0.52 0 0 12 100 54
Turkey 13 378 9 344 70 45 0.48 13 29 28 62
Turkmenistan 2 887
Turks and Caicos Islands 3 1 33 1 100 1 100 1 100
Tuvalu 15 15 100 0 0 0 0
US Virgin Islands
Uganda 46 171 43 883 95 19 612 45 19 211 98 15 877 81
Ukraine 40 302 39 057 97 7 640 20 3 350 44 4 273 56 16 263
United Arab Emirates 61 42 69 2 4.8 2 100 1 50 0
United Kingdom of Great Britain and 
Northern Ireland 7 077 5 552 78
United Republic of Tanzania 63 151 57 612 91 20 055 35 19 388 97 16 564 83 23 124
United States of America 9 407 8 217 87 504 6.1
Uruguay 888 809 91 132 16 73 55 68 52
Uzbekistan 22 804 22 347 98 780 3.5 615 79 354 45 2 438
Vanuatu 112 48 43 0 0 0 0
Venezuela (Bolivarian Republic of) 6 615 4 613 70 482 10 166 34 398 83
Viet Nam 102 087 74 092 73 3 875 5.2 2 936 76 2 827 73
Wallis and Futuna Islands 0 0
West Bank and Gaza Strip 43 43 100 0 0 0 0
Yemen 9 693 1 133 12 22 1.9 0 0 0 0
Zambia 42 716 39 763 93 24 198 61 21 929 91 17 611 73
Zimbabwe 32 016 28 508 89 19 290 68 18 200 94 16 522 86 30 420
WHO regions
African Region 1 342 259 1 064 310 79 415 657 39 360 015 89 317 773 77 875 886
Region of the Americas 228 460 169 125 74 21 915 13 5 720 52 7 132 63 28 556
Eastern Mediterranean Region 465 677 67 624 15 1 629 2.4 686 67 943 63 478
European Region 329 270 205 859 63 16 445 8.2 5 452 53 6 279 58 21 014
South-East Asia Region 2 580 605 1 171 258 45 60 235 5.1 51 141 85 47 801 79 3 049
Western Pacific Region 1 375 572 552 040 40 12 657 2.3 4 271 59 8 453 68 3 680
Global 6 321 843 3 230 216 51 528 538 16 427 285 87 388 381 77 932 663
a
 CPT = Cotrimoxazole preventive therapy
b
 ART = Anti-retroviral therapy
c
 Initiation of isoniazid preventive therapy (IPT) for people newly enrolled in HIV care
TABLE A4.8
HIV testing for TB patients, provision of CPT and ART to HIV-positive TB patients, and initiation of IPT for people  
newly enrolled in HIV care, 2014
a T = Cotri oxazole reve tive therapy.
b   ti-r troviral therapy.
c Initiation of isoniazid preventive therapy (IPT) for people newly enrolled in HIV care.

